STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 118984

TO: Sean McGarry
Location: REM-2D19/2C18
Art Unit: 1635
Wednesday, April 07, 2004
Case Serial Number: 09/993731

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: (571)272-2527

paul.schulwitz@uspto.gov

Search Notes

Examiner McGarry,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2527

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 7, 2004, 16:08:41 ; Search time 8 Seconds
(without alignments)
1.822 Million cell updates/sec

Title: us-09-993-731-10
Perfect score: 2525
Sequence: 1 ctctgggctgtgccgtggcc.....cgcattctctctcccacaga 2525

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 169 seqs, 2887 residues

Total number of hits satisfying chosen parameters: 338

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 175 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	20.6	0.8	21	1	AX154056	ACCESSION:AX154056
	2	20.6	0.8	21	1	AX154057	ACCESSION:AX154057
	3	20.6	0.8	21	1	AX154058	ACCESSION:AX154058
c	4	20.4	0.8	25	1	A51712	ACCESSION:A51712
c	5	20.4	0.8	25	1	AR167591	ACCESSION:AR167591
c	6	20.4	0.8	25	1	AR178301	ACCESSION:AR178301
c	7	20.4	0.8	25	1	AX323383	ACCESSION:AX323383
c	8	20.4	0.8	25	1	AX686853	ACCESSION:AX686853
	9	19.4	0.8	21	1	AR084552	ACCESSION:AR084552
c	10	19.4	0.8	21	1	AR084564	ACCESSION:AR084564
c	11	19.4	0.8	21	1	AR084570	ACCESSION:AR084570
	12	19.4	0.8	21	1	AR084575	ACCESSION:AR084575
	13	19.2	0.8	24	1	AR010038	ACCESSION:AR010038
	14	19.2	0.8	24	1	AR034773	ACCESSION:AR034773
	15	19.2	0.8	24	1	AX023424	ACCESSION:AX023424
	16	18.4	0.7	21	1	AR084581	ACCESSION:AR084581
c	17	18.4	0.7	21	1	AR084594	ACCESSION:AR084594
c	18	18.4	0.7	21	1	AR097224	ACCESSION:AR097224
c	19	17.4	0.7	20	1	AR126724	ACCESSION:AR126724
	20	17.4	0.7	20	1	AX241159	ACCESSION:AX241159
	21	17.4	0.7	20	1	AX486754	ACCESSION:AX486754
	22	17.4	0.7	21	1	AX154328	ACCESSION:AX154328
c	23	16.8	0.7	20	1	AR122500	ACCESSION:AR122500
c	24	16.8	0.7	21	1	AR121232	ACCESSION:AR121232
c	25	16.4	0.6	18	1	AR342472	ACCESSION:AR342472
	26	16.4	0.6	20	1	AR232303	ACCESSION:AR232303
c	27	16	0.6	20	1	AR126726	ACCESSION:AR126726
	28	16	0.6	20	1	AR307962	ACCESSION:AR307962
	29	16	0.6	20	1	AR307963	ACCESSION:AR307963
c	30	15.4	0.6	17	1	BD255013	ACCESSION:BD255013
c	31	15.4	0.6	17	1	I26890	ACCESSION:I26890
c	32	15.4	0.6	17	1	I91631	ACCESSION:I91631
	33	15.4	0.6	17	1	AX216917	ACCESSION:AX216917
c	34	15.4	0.6	17	1	AX422231	ACCESSION:AX422231
	35	15.4	0.6	17	1	AX498864	ACCESSION:AX498864
	36	15.4	0.6	19	1	BD248462	ACCESSION:BD248462
c	37	15	0.6	17	1	BD255012	ACCESSION:BD255012
c	38	14.8	0.6	18	1	AR078620	ACCESSION:AR078620
	39	14.8	0.6	18	1	BD267702	ACCESSION:BD267702
c	40	14.8	0.6	18	1	AR215559	ACCESSION:AR215559
c	41	14.8	0.6	18	1	HUMO453L2B	ACCESSION:D50246
	42	14.4	0.6	16	1	BD167992	ACCESSION:BD167992
c	43	14.4	0.6	17	1	A34251	ACCESSION:A34251
	44	14.4	0.6	17	1	AR189954	ACCESSION:AR189954
c	45	14.4	0.6	17	1	AR221454	ACCESSION:AR221454
c	46	14.4	0.6	17	1	AR286297	ACCESSION:AR286297
	47	14.4	0.6	17	1	AR324934	ACCESSION:AR324934
c	48	14.4	0.6	17	1	AR398287	ACCESSION:AR398287
	49	14.4	0.6	17	1	AX216918	ACCESSION:AX216918
	50	14.4	0.6	17	1	AX216922	ACCESSION:AX216922
	51	14.4	0.6	17	1	AX263524	ACCESSION:AX263524
c	52	14.4	0.6	17	1	AX263525	ACCESSION:AX263525
	53	14.4	0.6	17	1	AX263532	ACCESSION:AX263532
c	54	14.4	0.6	17	1	AX263533	ACCESSION:AX263533
c	55	14.4	0.6	17	1	AX421707	ACCESSION:AX421707
c	56	14.4	0.6	17	1	AX422230	ACCESSION:AX422230
	57	14.4	0.6	17	1	AX498863	ACCESSION:AX498863
	58	14.4	0.6	17	1	AX498865	ACCESSION:AX498865
c	59	14.4	0.6	17	1	AX731832	ACCESSION:AX731832
	60	14.4	0.6	17	1	AX735884	ACCESSION:AX735884
c	61	14.4	0.6	18	1	BD088673	ACCESSION:BD088673
c	62	14	0.6	17	1	BD254134	ACCESSION:BD254134
c	63	14	0.6	17	1	BD254409	ACCESSION:BD254409
c	64	14	0.6	17	1	BD259401	ACCESSION:BD259401
	65	14	0.6	17	1	AX216654	ACCESSION:AX216654
	66	14	0.6	17	1	AX216926	ACCESSION:AX216926
	67	14	0.6	17	1	AX216927	ACCESSION:AX216927
c	68	14	0.6	17	1	AX422232	ACCESSION:AX422232
c	69	14	0.6	17	1	AX422233	ACCESSION:AX422233
c	70	14	0.6	17	1	AX759707	ACCESSION:AX759707
	71	13.8	0.5	17	1	A56661	ACCESSION:A56661
	72	13.8	0.5	17	1	A80382	ACCESSION:A80382
c	73	13.8	0.5	17	1	AR045385	ACCESSION:AR045385
c	74	13.8	0.5	17	1	AR045387	ACCESSION:AR045387
c	75	13.8	0.5	17	1	AR045389	ACCESSION:AR045389
c	76	13.8	0.5	17	1	AR045391	ACCESSION:AR045391
	77	13.8	0.5	17	1	AR111785	ACCESSION:AR111785
c	78	13.8	0.5	17	1	I52437	ACCESSION:I52437
c	79	13.8	0.5	17	1	I52439	ACCESSION:I52439
c	80	13.8	0.5	17	1	I52441	ACCESSION:I52441
c	81	13.8	0.5	17	1	I52443	ACCESSION:I52443
c	82	13.8	0.5	17	1	I57029	ACCESSION:I57029
	83	13.8	0.5	17	1	AR188352	ACCESSION:AR188352
	84	13.8	0.5	17	1	AR189953	ACCESSION:AR189953
c	85	13.8	0.5	17	1	AR286296	ACCESSION:AR286296
	86	13.8	0.5	17	1	AR324205	ACCESSION:AR324205
c	87	13.8	0.5	17	1	AR398286	ACCESSION:AR398286
c	88	13.8	0.5	17	1	AX215457	ACCESSION:AX215457
	89	13.8	0.5	17	1	AX216916	ACCESSION:AX216916
	90	13.8	0.5	17	1	AX216919	ACCESSION:AX216919
	91	13.8	0.5	17	1	AX216920	ACCESSION:AX216920
	92	13.8	0.5	17	1	AX216921	ACCESSION:AX216921
	93	13.8	0.5	17	1	AX217020	ACCESSION:AX217020
	94	13.8	0.5	17	1	AX263536	ACCESSION:AX263536
c	95	13.8	0.5	17	1	AX263537	ACCESSION:AX263537
	96	13.8	0.5	17	1	AX423701	ACCESSION:AX423701
c	97	13.8	0.5	17	1	AX474990	ACCESSION:AX474990
c	98	13.8	0.5	17	1	AX474991	ACCESSION:AX474991
c	99	13.8	0.5	17	1	AX475408	ACCESSION:AX475408
c	100	13.8	0.5	17	1	AX499051	ACCESSION:AX499051
c	101	13.8	0.5	17	1	AX674218	ACCESSION:AX674218
	102	13.8	0.5	17	1	AX688168	ACCESSION:AX688168
	103	13.8	0.5	17	1	AX688169	ACCESSION:AX688169
	104	13.8	0.5	17	1	AX728971	ACCESSION:AX728971
c	105	13.8	0.5	17	1	AX759206	ACCESSION:AX759206
	106	13.8	0.5	17	1	AX783324	ACCESSION:AX783324

c 107	13.4	0.5	15	1	A12051	ACCESSION:A12051
108	13.4	0.5	15	1	A12052	ACCESSION:A12052
109	13.4	0.5	15	1	AR053182	ACCESSION:AR053182
110	13.4	0.5	15	1	I28566	ACCESSION:I28566
111	13.4	0.5	15	1	I58728	ACCESSION:I58728
c 112	13.4	0.5	15	1	I61479	ACCESSION:I61479
c 113	13.4	0.5	15	1	AX635911	ACCESSION:AX635911
114	13.4	0.5	15	1	BD137831	ACCESSION:BD137831
115	13.4	0.5	16	1	BD268811	ACCESSION:BD268811
116	13.4	0.5	16	1	BD268813	ACCESSION:BD268813
c 117	13.4	0.5	16	1	I27472	ACCESSION:I27472
118	13.4	0.5	16	1	AX036054	ACCESSION:AX036054
119	13.4	0.5	16	1	AX036056	ACCESSION:AX036056
c 120	13	0.5	15	1	AX572366	ACCESSION:AX572366
c 121	13	0.5	16	1	AX572367	ACCESSION:AX572367
122	12.8	0.5	16	1	BD274528	ACCESSION:BD274528
c 123	12.8	0.5	16	1	AR234405	ACCESSION:AR234405
124	12.8	0.5	16	1	AR258892	ACCESSION:AR258892
125	12.8	0.5	16	1	AX046979	ACCESSION:AX046979
c 126	12.8	0.5	16	1	AX139183	ACCESSION:AX139183
c 127	12.8	0.5	16	1	AX255757	ACCESSION:AX255757
c 128	12.8	0.5	16	1	AX259673	ACCESSION:AX259673
c 129	12.8	0.5	16	1	AX259676	ACCESSION:AX259676
130	12.8	0.5	16	1	AX382376	ACCESSION:AX382376
c 131	12.8	0.5	16	1	BD013467	ACCESSION:BD013467
c 132	12.8	0.5	20	1	AR307962	ACCESSION:AR307962
c 133	12.4	0.5	14	1	A88025	ACCESSION:A88025
c 134	12.4	0.5	14	1	A89294	ACCESSION:A89294
c 135	12.4	0.5	14	1	A89466	ACCESSION:A89466
c 136	12.4	0.5	14	1	A89992	ACCESSION:A89992
137	12.4	0.5	14	1	AX239937	ACCESSION:AX239937
c 138	12.4	0.5	14	1	AX587251	ACCESSION:AX587251
c 139	12.4	0.5	14	1	BD065538	ACCESSION:BD065538
c 140	12.4	0.5	14	1	BD066807	ACCESSION:BD066807
c 141	12.4	0.5	14	1	BD066979	ACCESSION:BD066979
142	12.4	0.5	14	1	BD137809	ACCESSION:BD137809
143	12.4	0.5	14	1	BD137813	ACCESSION:BD137813
144	12.4	0.5	14	1	BD137826	ACCESSION:BD137826
145	12.4	0.5	14	1	BD137828	ACCESSION:BD137828
146	12.4	0.5	14	1	BD137835	ACCESSION:BD137835
147	12.4	0.5	14	1	BD201812	ACCESSION:BD201812
148	12.4	0.5	14	1	BD209448	ACCESSION:BD209448
c 149	12.4	0.5	15	1	A88206	ACCESSION:A88206
c 150	12.4	0.5	15	1	A90173	ACCESSION:A90173
c 151	12.4	0.5	15	1	AR056120	ACCESSION:AR056120
c 152	12.4	0.5	15	1	AR113878	ACCESSION:AR113878
153	12.4	0.5	15	1	I28075	ACCESSION:I28075
c 154	12.4	0.5	15	1	I52067	ACCESSION:I52067
c 155	12.4	0.5	15	1	I61647	ACCESSION:I61647
156	12.4	0.5	15	1	AR179965	ACCESSION:AR179965
c 157	12.4	0.5	15	1	AR180323	ACCESSION:AR180323
158	12.4	0.5	15	1	AX088088	ACCESSION:AX088088
159	12.4	0.5	15	1	AX088089	ACCESSION:AX088089
160	12.4	0.5	15	1	AX088090	ACCESSION:AX088090
161	12.4	0.5	15	1	AX088091	ACCESSION:AX088091
162	12.4	0.5	15	1	AX088092	ACCESSION:AX088092
163	12.4	0.5	15	1	AX164571	ACCESSION:AX164571
c 164	12.4	0.5	15	1	AX633220	ACCESSION:AX633220
c 165	12.4	0.5	15	1	AX636058	ACCESSION:AX636058
c 166	12.4	0.5	15	1	AX711168	ACCESSION:AX711168
167	12.4	0.5	15	1	BD061455	ACCESSION:BD061455
c 168	12.4	0.5	15	1	BD065719	ACCESSION:BD065719
169	12.4	0.5	15	1	BD104667	ACCESSION:BD104667
170	12.4	0.5	15	1	BD104785	ACCESSION:BD104785
c 171	11.8	0.5	16	1	BD167992	ACCESSION:BD167992
c 172	11.8	0.5	20	1	AR307963	ACCESSION:AR307963
c 173	11.8	0.5	24	1	AR010038	ACCESSION:AR010038
c 174	11.8	0.5	24	1	AR034773	ACCESSION:AR034773
c 175	11.8	0.5	24	1	AX023424	ACCESSION:AX023424

ALIGNMENTS

```
RESULT 1
AX154056
LOCUS       AX154056                 21 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 154 from Patent WO0138576.
ACCESSION   AX154056
VERSION     AX154056.1  GI:14535670
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cargill,M., Ireland,J.S. and Lander,E.S.
  TITLE     Human single nucleotide polymorphisms
  JOURNAL   Patent: WO 0138576-A 154 31-MAY-2001;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.8%;  Score 20.6;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 6.3;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1624 TCAGCTGTGCTCAGCAGGCCC 1644
              ||||||||||:||||||||||
Db          1 TCAGCTGTGCYCAGCAGGCCC 21


RESULT 2
AX154057
LOCUS       AX154057                 21 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 155 from Patent WO0138576.
ACCESSION   AX154057
VERSION     AX154057.1  GI:14535671
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cargill,M., Ireland,J.S. and Lander,E.S.
  TITLE     Human single nucleotide polymorphisms
  JOURNAL   Patent: WO 0138576-A 155 31-MAY-2001;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.8%;  Score 20.6;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 6.3;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1823 GGCCGGCGAGGTGGAGCTCTC 1843
              ||||||||||:||||||||||
Db          1 GGCCGGCGAGRTGGAGCTCTC 21


RESULT 3
AX154058
LOCUS       AX154058                 21 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 156 from Patent WO0138576.
ACCESSION   AX154058
VERSION     AX154058.1  GI:14535672
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cargill,M., Ireland,J.S. and Lander,E.S.
  TITLE     Human single nucleotide polymorphisms
  JOURNAL   Patent: WO 0138576-A 156 31-MAY-2001;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.8%;  Score 20.6;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 6.3;
  Matches   20;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1838 GCTCTCAGAGAGCGAGGACGA 1858
              ||||||||||:||||||||||
Db          1 GCTCTCAGAGRGCGAGGACGA 21


RESULT 4
A51712/c
LOCUS       A51712                    25 bp    DNA     linear   PAT 10-MAR-1997
DEFINITION  Sequence 18 from Patent WO9618744.
ACCESSION   A51712
VERSION     A51712.1  GI:2304516
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Crouzet,J., Scherman,D. and Wils,P.
  TITLE     PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN IMMOBILIZED
            OLIGONUCLEOTIDE
  JOURNAL   Patent: WO 9618744-A 18 20-JUN-1996;
            RHONE POULENC RORER SA (FR)
COMMENT     Other publication AU 4178996 960703
            Other publication FR 2728264 960621.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 5
AR167591/c
LOCUS       AR167591                  25 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 18 from patent US 6287762.
ACCESSION   AR167591
VERSION     AR167591.1  GI:17903380
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Crouzet,J., Scherman,D. and Wils,P.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: US 6287762-A 18 11-SEP-2001;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 6
AR178301/c
LOCUS       AR178301                  25 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 18 from patent US 6319672.
ACCESSION   AR178301
VERSION     AR178301.1  GI:20219439
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: US 6319672-A 18 20-NOV-2001;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 7
AX323383/c
LOCUS       AX323383                  25 bp    DNA     linear   PAT 07-JAN-2002
DEFINITION  Sequence 18 from Patent WO0192511.
ACCESSION   AX323383
VERSION     AX323383.1  GI:18094145
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: WO 0192511-A 18 06-DEC-2001;
            Aventis Pharma (FR)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="synthetic oligonucleotide"

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 8
AX686853/c
```

```
LOCUS       AX686853                25 bp    DNA     linear   PAT 29-MAR-2003
DEFINITION  Sequence 18 from Patent EP1281774.
ACCESSION   AX686853
VERSION     AX686853.1  GI:29372394
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Couzet,J., Scherman,D. and Wils,P.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: EP 1281774-A 18 05-FEB-2003;
            Aventis Pharma S.A. (FR)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 9
AR084552
LOCUS       AR084552                21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 41 from patent US 5981185.
ACCESSION   AR084552
VERSION     AR084552.1  GI:10011323
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 41 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGG 1791
              ||||||||||| ||||||||
Db          1 AGGAGGAGGAGGAGGAGGAGG 21


RESULT 10
AR084564/c
LOCUS       AR084564                21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 53 from patent US 5981185.
ACCESSION   AR084564
VERSION     AR084564.1  GI:10011335
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 53 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGG 1791
              ||||||||||| ||||||||
Db         21 AGGAGGAGGAGGAGGAGGAGG 1


RESULT 11
AR084570/c
LOCUS       AR084570                21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 59 from patent US 5981185.
ACCESSION   AR084570
VERSION     AR084570.1  GI:10011341
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 59 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGAG 1790
              ||||||||||||| |||||||
Db         21 GAGGAGGAGGAGGAGGAGGAG 1


RESULT 12
AR084575
LOCUS       AR084575                21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 64 from patent US 5981185.
ACCESSION   AR084575
VERSION     AR084575.1  GI:10011346
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 64 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGAG 1790
              ||||||||||||| |||||||
Db          1 GAGGAGGAGGAGGAGGAGGAG 21


RESULT 13
AR010038
LOCUS       AR010038                24 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 51 from patent US 5756684.
ACCESSION   AR010038
```

```
VERSION     AR010038.1  GI:3968843
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Johnson,E.M. and Bergemann,A.D.
  TITLE     Cloning and expression of PUR protein
  JOURNAL   Patent: US 5756684-A 51 26-MAY-1998;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 17;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
              ||||| |||||||||||| || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 14
AR034773
LOCUS       AR034773                 24 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 51 from patent US 5869622.
ACCESSION   AR034773
VERSION     AR034773.1  GI:5950378
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Johnson,E.M. and Bergemann,A.D.
  TITLE     Monoclonal antibodies to the pur protein
  JOURNAL   Patent: US 5869622-A 51 09-FEB-1999;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 17;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
              ||||| |||||||||||| || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 15
AX023424
LOCUS       AX023424                 24 bp    DNA     linear   PAT 15-SEP-2000
DEFINITION  Sequence 39 from Patent WO0014217.
ACCESSION   AX023424
VERSION     AX023424.1  GI:10183824
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lipford,G.B., Heeg,K. and Wagner,H.
  TITLE     G-motif oligonucleotides and uses thereof
  JOURNAL   Patent: WO 0014217-A 39 16-MAR-2000;
            LIPFORD GRAYSON B (DE) ; HEEG KLAUS (DE) ; WAGNER HERMANN (DE) ;
            CPG IMMUNOPHARMACEUTICALS GMBH (DE)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="synthetic, no natural origin"

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 17;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
              ||||| |||||||||||| || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 16
AR084581
LOCUS       AR084581                 21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 70 from patent US 5981185.
ACCESSION   AR084581
VERSION     AR084581.1  GI:10011352
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 70 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 16;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAG 1791
              ||||||||||| ||||||||
Db          1 GGAGGAGGAGGAGGAGGAG 20


RESULT 17
AR084594/c
LOCUS       AR084594                 21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 83 from patent US 5981185.
ACCESSION   AR084594
VERSION     AR084594.1  GI:10011365
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 83 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 16;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAG 1791
              ||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAG 2


RESULT 18
AR097224/c
LOCUS       AR097224                 21 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 5 from patent US 6071695.
ACCESSION   AR097224
VERSION     AR097224.1  GI:12805954
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Ozkaynak,E. and Oppermann,H.
  TITLE     Methods and products for identification of modulators of osteogenic
            protein-1 gene expression
  JOURNAL   Patent: US 6071695-A 5 06-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 16;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
              |||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 19
AR126724/c
LOCUS       AR126724                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 153 from patent US 6180353.
ACCESSION   AR126724
VERSION     AR126724.1  GI:14113317
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dean,N.M. and Cowsert,L.M.
  TITLE     Antisense modulation of daxx expression
  JOURNAL   Patent: US 6180353-A 153 30-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 22;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 TGAGGAGGAGGAGGCGGAG 1787
              |||||||||||||| ||||
Db         19 TGAGGAGGAGGAGGAGGAG 1


RESULT 20
AX241159
LOCUS       AX241159                  20 bp    DNA     linear   PAT 26-SEP-2001
DEFINITION  Sequence 397 from Patent WO0160975.
ACCESSION   AX241159
VERSION     AX241159.1  GI:15798034
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Roemer,T., Jiang,B., Boone,C. and Bussey,H.
  TITLE     Gene disruption methodologies for drug target discovery
  JOURNAL   Patent: WO 0160975-A 397 23-AUG-2001;
            Elitra Pharmaceuticals, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA primer"

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 22;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAG 1790
              |||||||||||| |||||||
Db         2 GGAGGAGGAGGAGGAGGAG 20


RESULT 21
AX486754
LOCUS       AX486754                  20 bp    DNA     linear   PAT 16-AUG-2002
DEFINITION  Sequence 4054 from Patent WO02053728.
ACCESSION   AX486754
VERSION     AX486754.1  GI:22320902
KEYWORDS    .
SOURCE      Candida albicans
  ORGANISM  Candida albicans
            Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
            Saccharomycetales; mitosporic Saccharomycetales; Candida.
REFERENCE   1
  AUTHORS   Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlsen,K.L.
  TITLE     Gene disruption methodologies for drug target discovery
  JOURNAL   Patent: WO 02053728-A 4054 11-JUL-2002;
            Elitra Pharmaceuticals, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Candida albicans"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:5476"

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 22;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAG 1790
              |||||||||||| |||||||
Db         2 GGAGGAGGAGGAGGAGGAG 20


RESULT 22
AX154328
LOCUS       AX154328                  21 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 426 from Patent WO0138576.
ACCESSION   AX154328
VERSION     AX154328.1  GI:14535942
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cargill,M., Ireland,J.S. and Lander,E.S.
  TITLE     Human single nucleotide polymorphisms
  JOURNAL   Patent: WO 0138576-A 426 31-MAY-2001;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 25;
  Matches   18;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGGAGGCGG 1785
              |||| |||||:||||||| ||
Db         1 AAGAGGAGGARGAGGAGGAGG 21


RESULT 23
AR122500/c
LOCUS       AR122500                  20 bp    DNA     linear   PAT 16-MAY-2001
```

```
DEFINITION  Sequence 54 from patent US 6165728.
ACCESSION   AR122500
VERSION     AR122500.1  GI:14106817
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of NCK-2 expression
  JOURNAL   Patent: US 6165728-A 54 26-DEC-2000;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 28;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1776 GAGGAGGCGGAGGAGGCGGC 1795
              ||||||| ||| ||||||||
Db         20 GAGGAGGTGGACGAGGCGGC 1


RESULT 24
AR121232/c
LOCUS       AR121232                  21 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 12 from patent US 6159710.
ACCESSION   AR121232
VERSION     AR121232.1  GI:14104808
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Fraser,N.W., Zabolotny,J.M. and Krummenacher,C.F.
  TITLE     Method and compositions for stabilizing unstable gene transcripts
  JOURNAL   Patent: US 6159710-A 12 12-DEC-2000;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 33;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGA 1789
              |||||||| ||||| |||||
Db         20 GAGGAGGAAGAGGCAGAGGA 1


RESULT 25
AR342472/c
LOCUS       AR342472                  18 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 22 from patent US 6576423.
ACCESSION   AR342472
VERSION     AR342472.1  GI:33737482
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Batra,S.K., Brand,R.E., Ringel,J., Faulmann,G., Lohr,M. and
            Varshney,G.C.
  TITLE     Specific mucin expression as a marker for pancreatic cancer
  JOURNAL   Patent: US 6576423-A 22 10-JUN-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 25;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        894 CTGCAGCAGACAGCCCTG 911
              ||||||||| ||||||||
Db         18 CTGCAGCAGGCAGCCCTG 1


RESULT 26
AR232303
LOCUS       AR232303                  20 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 93 from patent US 6455307.
ACCESSION   AR232303
VERSION     AR232303.1  GI:27274295
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   McKay,R., Freier,S.M. and Wyatt,J.
  TITLE     Antisense modulation of casein kinase 2-alpha prime expression
  JOURNAL   Patent: US 6455307-A 93 24-SEP-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 34;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1881 CTGGAGGAGGACGAGGAG 1898
              |||||||||| ||||||
Db          1 CTGGAGGAGGAGGAGGAG 18


RESULT 27
AR126726/c
LOCUS       AR126726                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 155 from patent US 6180353.
ACCESSION   AR126726
VERSION     AR126726.1  GI:14113319
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dean,N.M. and Cowsert,L.M.
  TITLE     Antisense modulation of daxx expression
  JOURNAL   Patent: US 6180353-A 155 30-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1756 CTGAAGATGAAGATGA 1771
              ||||||||||||||||
Db         16 CTGAAGATGAAGATGA 1


RESULT 28
AR307962
LOCUS       AR307962                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 173 from patent US 6551826.
ACCESSION   AR307962
VERSION     AR307962.1  GI:31698718
KEYWORDS    .
SOURCE      Unknown.
```

```
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Watt,A.T.
  TITLE     Antisense modulation of raidd expression
  JOURNAL   Patent: US 6551826-A 173 22-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1227 CTCCAGCATGTGCTGG 1242
              ||||||||||||||||
Db          1 CTCCAGCATGTGCTGG 16


RESULT 29
AR307963
LOCUS       AR307963                 20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 174 from patent US 6551826.
ACCESSION   AR307963
VERSION     AR307963.1  GI:31698719
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Watt,A.T.
  TITLE     Antisense modulation of raidd expression
  JOURNAL   Patent: US 6551826-A 174 22-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1227 CTCCAGCATGTGCTGG 1242
              ||||||||||||||||
Db          4 CTCCAGCATGTGCTGG 19


RESULT 30
BD255013/c
LOCUS       BD255013                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255013
VERSION     BD255013.1  GI:33064783
KEYWORDS    JP 2002541795-A/2806.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2806 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2806
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1879 AGCTGGAGGAGGACGAG 1895
              ||| |||||||||||||
Db         17 AGCAGGAGGAGGACGAG 1


RESULT 31
I26890/c
LOCUS       I26890                   17 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 113 from patent US 5561041.
ACCESSION   I26890
VERSION     I26890.1  GI:1606760
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Sidransky,D.
  TITLE     Nucleic acid mutation detection by analysis of sputum
  JOURNAL   Patent: US 5561041-A 113 01-OCT-1996;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1655 GCTGCAGAGGCAGGTCT 1671
              |||||| ||||||||||
Db         17 GCTGCACAGGCAGGTCT 1


RESULT 32
I91631/c
LOCUS       I91631                   17 bp    DNA     linear   PAT 01-DEC-1998
DEFINITION  Sequence 113 from patent US 5726019.
ACCESSION   I91631
VERSION     I91631.1  GI:3936101
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Sidransky,D.
  TITLE     Analysis of sputum by amplification and detection of mutant nucleic
            acid sequences
  JOURNAL   Patent: US 5726019-A 113 10-MAR-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 32;
```

```
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1655 GCTGCAGAGGCAGGTCT 1671
              ||||||  ||||||||||
Db         17 GCTGCACAGGCAGGTCT 1


RESULT 33
AX216917
LOCUS       AX216917                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2359 from Patent WO0159103.
ACCESSION   AX216917
VERSION     AX216917.1  GI:15526978
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2359 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1764 GAAGATGAGGAGGAGGA 1780
              |||||  ||||||||||
Db          1 GAAGAAGAGGAGGAGGA 17


RESULT 34
AX422231/c
LOCUS       AX422231                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 567 from Patent WO0188124.
ACCESSION   AX422231
VERSION     AX422231.1  GI:21525613
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 567 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1880 GCTGGAGGAGGACGAGG 1896
              |||||||||||||| ||
Db         17 GCTGGAGGAGGACGCGG 1


RESULT 35
AX498864
LOCUS       AX498864                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 171 from Patent EP1229046.
ACCESSION   AX498864
VERSION     AX498864.1  GI:23381157
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 171 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCAGTGG 2136
              ||||  ||||||||||||
Db          1 CCACCGGGCCGCAGTGG 17


RESULT 36
BD248462
LOCUS       BD248462                  19 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Alpha-2/delta gene.
ACCESSION   BD248462
VERSION     BD248462.1  GI:33058232
KEYWORDS    JP 2002526100-A/20.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Johns,M.A., Moldover,B. and Offord,J.D.
  TITLE     Alpha-2/delta gene
  JOURNAL   Patent: JP 2002526100-A 20 20-AUG-2002;
            WARNER LAMBERT CO
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002526100-A/20
            PD   20-AUG-2002
            PF   07-OCT-1999 JP 2000574561
            PR   07-OCT-1998 US    60/103322,30-OCT-1998 US    60/106473 PR
            29-DEC-1998 US    60/114088
            PI   MARGARET ANN JOHNS,BRIAN MOLDOVER,JAMES DAVID OFFORD PC
            C12N15/09,A61K31/711,A61K38/00,A61K48/00,A61P25/06,A61P25/08, PC
            A61P25/16,
            PC   A61P25/20,A61P25/22,A61P25/28,A61P25/30,A61P29/00,A61P35/00,
            PC   C07K14/47,
            PC   C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12P21/02,C12Q1/
            PC   02,C12Q1/68,
            PC   G01N33/15,G01N33/50,C12N15/00,C12N5/00,A61K37/02 CC
            Alpha-2/delta gene
            FH   Key             Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 44;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1075 TGAGGAAGCGGTTCATG 1091
              ||||||||||| |||||
Db          3 TGAGGAAGCGGATCATG 19


RESULT 37
BD255012/c
LOCUS       BD255012                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255012
VERSION     BD255012.1  GI:33064782
KEYWORDS    JP 2002541795-A/2805.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2805 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2805
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1883 GGAGGAGGACGAGGA 1897
              |||||||||||||||
Db         16 GGAGGAGGACGAGGA 2


RESULT 38
AR078620/c
LOCUS       AR078620                  18 bp    DNA     linear   PAT 31-AUG-2000
DEFINITION  Sequence 46 from patent US 5962672.
ACCESSION   AR078620
VERSION     AR078620.1  GI:10005366
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Coswert,L.M.
  TITLE     Antisense modulation of RhoB expression
  JOURNAL   Patent: US 5962672-A 46 05-OCT-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 49;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1251 CGGCTGCAGCAACAGCTG 1268
              |||||||| |||| ||||
Db         18 CGGCTGCATCAACTGCTG 1


RESULT 39
BD267702
LOCUS       BD267702                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Extracellular protease of Acremonium chrysogenum having CPC
            acetylhydrolase activity, and use thereof in gene inactivation for
            synthesizing deacetylated cepharosporin C and elevating
            cepharosporin yield.
ACCESSION   BD267702
VERSION     BD267702.1  GI:33077470
KEYWORDS    JP 2002541812-A/2.
SOURCE      Tritirachium album
  ORGANISM  Tritirachium album
            Eukaryota; Fungi; Ascomycota; mitosporic Ascomycota; Tritirachium.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Alvarez,J.V., Martin,S.G., Blanco,F.J.C., Garcia,S.C., Fierro,F.F.,
            Fuente,J.L.B., Garcia,B.D. and Martin,J.F.M.
  TITLE     Extracellular protease of Acremonium chrysogenum having CPC
            acetylhydrolase activity, and use thereof in gene inactivation for
            synthesizing deacetylated cepharosporin C and elevating
            cepharosporin yield
  JOURNAL   Patent: JP 2002541812-A 2 10-DEC-2002;
            ANTIBIOTICOS SAU
COMMENT     OS   Tritirachium album
            PN   JP 2002541812-A/2
            PD   10-DEC-2002
            PF   07-APR-2000 JP 2000611690
            PR   09-APR-1999 ES    P 9900731
            PI   JAVIER VELASCO ALVAREZ,SANTIAGO GUTIERREZ MARTIN, PI
            FRANCISCO JAVIER CASQUEIRO BLANCO,SONIA CAMPOY GARCIA, PI
            FRANCISCO FIERRO FIERRO,JOSE LUIS BARREDO FUENTE,BRUNO DIEZ  PI
            GARCIA,
            PI   JUAN FRANCISCO MARTIN MARTIN
            PC   C12N15/09,C12N1/15,C12N1/19,C12N1/21,C12P35/06//(C12P35/06, PC
              C12R1:645),
            PC   C12N15/00
            CC   Synthetic oligonucleotide deduced starting
            from the amino acid
            CC           sequence
            CC   (Pro-His-Val-Ala-Gly-Leu) of the active centre of protease T
            CC           of
            CC   Tritirachium album.
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Tritirachium album'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Tritirachium album"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:5558"

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 49;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1821 GAGGCCGGCGAGGTGGAG 1838
              |||||||||| |||| |
Db          1 GAGGCCGGCGACGTGGGG 18


RESULT 40
AR215559/c
LOCUS       AR215559                  18 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 107 from patent US 6410323.
ACCESSION   AR215559
```

```
VERSION     AR215559.1  GI:23313815
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Roberts,M.L. and Cowsert,L.M.
  TITLE     Antisense modulation of human Rho family gene expression
  JOURNAL   Patent: US 6410323-A 107 25-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 49;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1251 CGGCTGCAGCAACAGCTG 1268
              |||||||| |||| ||||
Db         18 CGGCTGCATCAACTGCTG 1


RESULT 41
HUMO453L2B/c
LOCUS       HUMO453L2B                18 bp    DNA     linear   STS 29-MAY-2002
DEFINITION  A PCR primer for D21S8 locus STS, location 21q22.1, sequence tagged
            site.
ACCESSION   D50246
VERSION     D50246.1  GI:801801
KEYWORDS    STS.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Tanahashi,H., Ito,T., Hattori,M., Ohira,M., Ohki,M., Tashiro,K. and
            Sakaki,Y.
  TITLE     Sixty new STSs (sequence-tagged sites) of human chromosome 21
  JOURNAL   DNA Res. 1 (2), 85-89 (1994)
  MEDLINE   96051984
   PUBMED   7584032
REFERENCE   2  (bases 1 to 18)
  AUTHORS   Sakaki,Y.
  TITLE     Direct Submission
  JOURNAL   Submitted (28-APR-1995) Yoshiyuki Sakaki, Institute of Medical
            Science, University of Tokyo, Human Genome Center; 4-6-1
            Shirokanedai Minato-ku, Tokyo 108, Japan
            (E-mail:sakaki@hgc.ims.u-tokyo.ac.jp, Tel:03-5449-5362,
            Fax:03-5449-5445)
COMMENT     Submitted (28-Apr-1995) to DDBJ by:
            Yoshiyuki Sakaki
            Human Genome Center
            Institute of Medical Science
            University of Tokyo
            4-6-1 Shirokanedai Minato-ku
            Tokyo, 108
            Japan
            Phone: 03-5449-5362
            Fax  : 03-5449-5445.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
                     /chromosome="21"

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 49;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1363 CTGAGGCTTACCAGAAGC 1380
              ||||||||  ||||||||
Db         18 CTGAGGCTCCCCAGAAGC 1


RESULT 42
BD167992
LOCUS       BD167992                  16 bp    DNA     linear   PAT 17-JAN-2003
DEFINITION  Method of constructing mutation DNA library and utilization
            thereof.
ACCESSION   BD167992
VERSION     BD167992.1  GI:27873804
KEYWORDS    WO 0226964-A/39.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Tsuji,T. and Yanagawa,H.
  TITLE     Method of constructing mutation DNA library and utilization thereof
  JOURNAL   Patent: WO 0226964-A 39 04-APR-2002;
            MITSUBISHI CHEMICAL CORP,TORU TSUJI,HIROSHI YANAGAWA
COMMENT     OS   Artificial Sequence
            PN   WO 0226964-A/39
            PD   04-APR-2002
            PF   26-SEP-2001 WO 2001JP008387
            PR   27-SEP-2000 JP 00P   293692,06-FEB-2001 JP 01P   029138 PI
            TORU TSUJI,HIROSHI YANAGAWA
            PC   C12N15/09,C12P21/02
            CC   Description of Artificial Sequence:Synthesized FH   Key
                 Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 41;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1866 GGCCTGACCCCGCAGC 1881
              |||||||||| |||||
Db          1 GGCCTGACCCTGCAGC 16


RESULT 43
A34251/c
LOCUS       A34251                    17 bp    DNA     linear   PAT 03-JUL-2002
DEFINITION  Synthetic sequencing primer.
ACCESSION   A34251
VERSION     A34251.1  GI:21694203
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Odink,K.G., Tarcsay,L., Brueggen,J., Wiesendanger,W., Cerletti,N.,
            Sorg,C., DeWolf-Peeters,C. and Delabie,J.
  TITLE     Novel cytokines
  JOURNAL   Patent: EP 0412050-A 11 06-FEB-1991;
            CIBA-GEIGY AG
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1899 CTTCAGGGCCACCTGG 1914
              |||||||||| |||||
```

```
Db         17 CTTCAGGGCCTCCTGG 2


RESULT 44
AR189954
LOCUS       AR189954                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 5442 from patent US 6346398.
ACCESSION   AR189954
VERSION     AR189954.1  GI:20235919
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 5442 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1301 CATGGTCATCTGTGAG 1316
              ||||||| ||||||||
Db          1 CATGGTCTTCTGTGAG 16


RESULT 45
AR221454/c
LOCUS       AR221454                  17 bp    DNA     linear   PAT 26-SEP-2002
DEFINITION  Sequence 4 from patent US 6426221.
ACCESSION   AR221454
VERSION     AR221454.1  GI:23328504
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of RIP2 expression
  JOURNAL   Patent: US 6426221-A 4 30-JUL-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1898 GCTTCAGGGCCACCTG 1913
              ||||||| |||||||||
Db         16 GCTTCACGGCCACCTG 1


RESULT 46
AR286297/c
LOCUS       AR286297                  17 bp    RNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 669 from patent US 6528640.
ACCESSION   AR286297
VERSION     AR286297.1  GI:29723893
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Synthetic ribonucleic acids with RNAse activity
  JOURNAL   Patent: US 6528640-A 669 04-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1266 CTGGAAGAGGCTGAGG 1281
              |||||||| |||||||
Db         17 CTGGAAGACGCTGAGG 2


RESULT 47
AR324934
LOCUS       AR324934                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2336 from patent US 6566127.
ACCESSION   AR324934
VERSION     AR324934.1  GI:33710742
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2336 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1301 CATGGTCATCTGTGAG 1316
              ||||||| ||||||||
Db          1 CATGGTCTTCTGTGAG 16


RESULT 48
AR398287/c
LOCUS       AR398287                  17 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 668 from patent US 6617438.
ACCESSION   AR398287
VERSION     AR398287.1  GI:40135974
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Oligoribonucleotides with enzymatic activity
  JOURNAL   Patent: US 6617438-A 668 09-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1266 CTGGAAGAGGCTGAGG 1281
              |||||||| |||||||
Db         17 CTGGAAGACGCTGAGG 2
```

```
RESULT 49
AX216918
LOCUS       AX216918                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2360 from Patent WO0159103.
ACCESSION   AX216918
VERSION     AX216918.1  GI:15526979
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2360 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGGA 1780
              |||| ||||||||||
Db          1 AAGAAGAGGAGGAGGA 16


RESULT 50
AX216922
LOCUS       AX216922                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2364 from Patent WO0159103.
ACCESSION   AX216922
VERSION     AX216922.1  GI:15526983
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2364 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1883 GGAGGAGGACGAGGAG 1898
              ||||||||| ||||||
Db          2 GGAGGAGGAAGAGGAG 17


RESULT 51
AX263524
LOCUS       AX263524                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 915 from Patent WO0173002.
ACCESSION   AX263524
VERSION     AX263524.1  GI:16512323
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 915 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
              | ||||||||||||||
Db          2 GGAGCAACAGCTGGAA 17


RESULT 52
AX263525/c
LOCUS       AX263525                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 916 from Patent WO0173002.
ACCESSION   AX263525
VERSION     AX263525.1  GI:16512324
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 916 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
              | ||||||||||||||
Db         16 GGAGCAACAGCTGGAA 1


RESULT 53
AX263532
LOCUS       AX263532                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 923 from Patent WO0173002.
ACCESSION   AX263532
VERSION     AX263532.1  GI:16512331
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
```

```
  JOURNAL   Patent: WO 0173002-A 923 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
              | ||||||||||||||
Db          2 GGAGCAACAGCTGGAA 17


RESULT 54
AX263533/c
LOCUS       AX263533                17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 924 from Patent WO0173002.
ACCESSION   AX263533
VERSION     AX263533.1  GI:16512332
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 924 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
              | ||||||||||||||
Db         16 GGAGCAACAGCTGGAA 1


RESULT 55
AX421707/c
LOCUS       AX421707                17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 43 from Patent WO0188124.
ACCESSION   AX421707
VERSION     AX421707.1  GI:21525089
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 43 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1880 GCTGGAGGAGGACGAG 1895
              |||||||||||||| |
Db         16 GCTGGAGGAGGACGCG 1


RESULT 56
AX422230/c
LOCUS       AX422230                17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 566 from Patent WO0188124.
ACCESSION   AX422230
VERSION     AX422230.1  GI:21525612
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 566 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1881 CTGGAGGAGGACGAGG 1896
              |||||||||||||| ||
Db         17 CTGGAGGAGGACGCGG 2


RESULT 57
AX498863
LOCUS       AX498863                17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 170 from Patent EP1229046.
ACCESSION   AX498863
VERSION     AX498863.1  GI:23381156
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 170 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCAGTG 2135
              |||| ||||||||||||
Db          2 CCACCGGGCCGCAGTG 17


RESULT 58
AX498865
```

```
LOCUS       AX498865                 17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 172 from Patent EP1229046.
ACCESSION   AX498865
VERSION     AX498865.1  GI:23381158
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 172 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2121 CACGGGGCCGCAGTGG 2136
              ||| ||||||||||||
Db          1 CACCGGGCCGCAGTGG 16


RESULT 59
AX731832/c
LOCUS       AX731832                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3466 from Patent WO03025175.
ACCESSION   AX731832
VERSION     AX731832.1  GI:30511175
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3466 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1383 CTGCGTTTTGCTGAGC 1398
              ||||||||||||||| |
Db         16 CTGCGTTTTGCTGATC 1


RESULT 60
AX735884
LOCUS       AX735884                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1474 from Patent WO03025177.
ACCESSION   AX735884
VERSION     AX735884.1  GI:30515161
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 1474 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 49;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2092 ATCTAGAAATTGTCCG 2107
              |||||||||||| |||
Db          2 ATCTAGAAATTGCCCG 17


RESULT 61
BD088673/c
LOCUS       BD088673                 18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD088673
VERSION     BD088673.1  GI:22634283
KEYWORDS    JP 2001321190-A/917.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 917 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/917
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 57;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2016 GTGAGGCAGGGCCACC 2031
              ||||||||| ||||||
Db         18 GTGAGGCAGAGCCACC 3


RESULT 62
BD254134/c
LOCUS       BD254134                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254134
VERSION     BD254134.1  GI:33063904
KEYWORDS    JP 2002541795-A/1927.
SOURCE      unidentified
```

```
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 1927 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/1927
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES            Location/Qualifiers
     source         1. .17
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2273 GCTGGAGACGCTGC 2286
              ||||||||||||||
Db         15 GCTGGAGACGCTGC 2


RESULT 63
BD254409/c
LOCUS       BD254409                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254409
VERSION     BD254409.1  GI:33064179
KEYWORDS    JP 2002541795-A/2202.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2202 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2202
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES            Location/Qualifiers
     source         1. .17
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1883 GGAGGAGGACGAGG 1896
              ||||||||||||||
Db         16 GGAGGAGGACGAGG 3


RESULT 64
BD259401/c
LOCUS       BD259401                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD259401
VERSION     BD259401.1  GI:33069171
KEYWORDS    JP 2002541795-A/7194.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 7194 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/7194
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES            Location/Qualifiers
     source         1. .17
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 CGGAGGAGGCGGCA 1796
              ||||||||||||||
Db         14 CGGAGGAGGCGGCA 1


RESULT 65
AX216654
LOCUS       AX216654                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2096 from Patent WO0159103.
ACCESSION   AX216654
VERSION     AX216654.1  GI:15526715
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
```

```
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2096 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
              ||||||||||||||
Db          2 GAGGAGGACGAGGA 15


RESULT 66
AX216926
LOCUS       AX216926                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2368 from Patent WO0159103.
ACCESSION   AX216926
VERSION     AX216926.1  GI:15526987
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2368 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
              ||||||||||||||
Db          4 GAGGAGGACGAGGA 17


RESULT 67
AX216927
LOCUS       AX216927                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2369 from Patent WO0159103.
ACCESSION   AX216927
VERSION     AX216927.1  GI:15526988
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2369 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
              ||||||||||||||
Db          3 GAGGAGGACGAGGA 16


RESULT 68
AX422232/c
LOCUS       AX422232                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 568 from Patent WO0188124.
ACCESSION   AX422232
VERSION     AX422232.1  GI:21525614
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 568 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1880 GCTGGAGGAGGACG 1893
              ||||||||||||||
Db         15 GCTGGAGGAGGACG 2


RESULT 69
AX422233/c
LOCUS       AX422233                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 569 from Patent WO0188124.
ACCESSION   AX422233
VERSION     AX422233.1  GI:21525615
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 569 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
```

```
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1880 GCTGGAGGAGGACG 1893
              ||||||||||||||
Db         14 GCTGGAGGAGGACG 1


RESULT 70
AX759707/c
LOCUS       AX759707                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 3028 from Patent WO03040369.
ACCESSION   AX759707
VERSION     AX759707.1  GI:32254323
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 3028 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1018 GCCAGCACTCCCAG 1031
              ||||||||||||||
Db         17 GCCAGCACTCCCAG 4


RESULT 71
A56661
LOCUS       A56661                   17 bp    DNA     linear   PAT 03-MAR-1998
DEFINITION  Sequence 28 from Patent EP0739898.
ACCESSION   A56661
VERSION     A56661.1  GI:3712706
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Peyman,A.D., Uhlmann,E.D., Breipohl,G.D. and Wallmeier,H.D.
  TITLE     Phosphonomonoester nucleic acids, methods for their preparation and
            their use
  JOURNAL   Patent: EP 0739898-A 28 30-OCT-1996;
            HOECHST AG (DE)
COMMENT     Other publication CZ 9600743 961016
            Other publication CN 1138588 961225
            Other publication PL 313207 960916
            Other publication JP 8259579 961008
            Other publication NO 961006 960916
            Other publication CA 2171589 960914
            Other publication AU 4802896 960926
            Other publication DE 19508923 960919.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              ||||||.||.|||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 72
A80382
LOCUS       A80382                   17 bp    DNA     linear   PAT 20-OCT-1999
DEFINITION  Sequence 28 from Patent EP0726274.
ACCESSION   A80382
VERSION     A80382.1  GI:6093109
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Peyman,A.D. and Uhlmann,E.D.
  TITLE     G-CAP STABILIZED OLIGONUCLEOTIDES
  JOURNAL   Patent: EP 0726274-A 28 14-AUG-1996;
            HOECHST AG (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
     exon            1. .17

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              ||||||.||.|||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 73
AR045385/c
LOCUS       AR045385                 17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 178 from patent US 5817796.
ACCESSION   AR045385
VERSION     AR045385.1  GI:5966850
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 178 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              |||||.|||.|||||||
Db         17 AGGAGAAGGAGGAGGAG 1


RESULT 74
AR045387/c
LOCUS       AR045387                 17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 180 from patent US 5817796.
ACCESSION   AR045387
VERSION     AR045387.1  GI:5966852
KEYWORDS    .
SOURCE      Unknown.
```

```
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 180 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              |||||||| |||||||
Db         17 AGGAGGAGAAGGAGGAG 1


RESULT 75
AR045389/c
LOCUS       AR045389                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 182 from patent US 5817796.
ACCESSION   AR045389
VERSION     AR045389.1  GI:5966854
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 182 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGA 1786
              ||||||||| ||| |||
Db         17 GAGGAGGAGAAGGAGGA 1


RESULT 76
AR045391/c
LOCUS       AR045391                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 184 from patent US 5817796.
ACCESSION   AR045391
VERSION     AR045391.1  GI:5966856
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 184 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAG 1787
              |||||||||||  ||||
Db         17 AGGAGGAGAAGGAGGAG 1


RESULT 77
AR111785
LOCUS       AR111785                  17 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 28 from patent US 6127346.
ACCESSION   AR111785
VERSION     AR111785.1  GI:12828633
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Peyman,A., Uhlmann,E., Breipohl,G. and Wallmeier,H.
  TITLE     Phosphonomonoester nucleic acids process for their preparation and
            their use
  JOURNAL   Patent: US 6127346-A 28 03-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              |||||| || |||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 78
I52437/c
LOCUS       I52437                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 178 from patent US 5646042.
ACCESSION   I52437
VERSION     I52437.1  GI:2473638
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 178 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              ||||| ||| |||||||
Db         17 AGGAGAAGGAGGAGGAG 1


RESULT 79
I52439/c
LOCUS       I52439                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 180 from patent US 5646042.
ACCESSION   I52439
VERSION     I52439.1  GI:2473640
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
```

```
  JOURNAL   Patent: US 5646042-A 180 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              ||||||||  |||||||
Db         17 AGGAGGAGAAGGAGGAG 1


RESULT 80
I52441/c
LOCUS       I52441                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 182 from patent US 5646042.
ACCESSION   I52441
VERSION     I52441.1  GI:2473642
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 182 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGA 1786
              |||||||||  ||| |||
Db         17 GAGGAGGAGAAGGAGGA 1


RESULT 81
I52443/c
LOCUS       I52443                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 184 from patent US 5646042.
ACCESSION   I52443
VERSION     I52443.1  GI:2473644
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 184 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAG 1787
              ||||||||||  ||||
Db         17 AGGAGGAGGAGAAGGAG 1


RESULT 82
I57029/c
LOCUS       I57029                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 30 from patent US 5650553.
ACCESSION   I57029
VERSION     I57029.1  GI:2477442
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Ecker,J., Rothenberg,M., Lehman,A. and Roman,G.
  TITLE     Plant genes for sensitivity to ethylene and pathogens
  JOURNAL   Patent: US 5650553-A 30 22-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1124 CCTCCAAGACCTGGGAG 1140
              || |||||||||||| |
Db         17 CCACCAAGACCTGGGTG 1


RESULT 83
AR188352
LOCUS       AR188352                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 3840 from patent US 6346398.
ACCESSION   AR188352
VERSION     AR188352.1  GI:20234317
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 3840 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1299 GCCATGGTCATCTGTGA 1315
              | |||||||  |||||||
Db          1 GGCATGGTCTTCTGTGA 17


RESULT 84
AR189953
LOCUS       AR189953                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 5441 from patent US 6346398.
ACCESSION   AR189953
VERSION     AR189953.1  GI:20235918
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 5441 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
```

/mol_type="unassigned DNA"

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1299 GCCATGGTCATCTGTGA 1315
              | |||||||| |||||||
Db          1 GGCATGGTCTTCTGTGA 17
```

RESULT 85
AR286296/c
LOCUS AR286296 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 668 from patent US 6528640.
ACCESSION AR286296
VERSION AR286296.1 GI:29723892
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNAse activity
JOURNAL Patent: US 6528640-A 668 04-MAR-2003;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1268 GGAAGAGGCTGAGGGCA 1284
              |||||| ||||||| ||
Db         17 GGAAGACGCTGAGGTCA 1
```

RESULT 86
AR324205
LOCUS AR324205 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1607 from patent US 6566127.
ACCESSION AR324205
VERSION AR324205.1 GI:33710013
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1607 20-MAY-2003;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1299 GCCATGGTCATCTGTGA 1315
              | |||||||| |||||||
Db          1 GGCATGGTCTTCTGTGA 17
```

RESULT 87
AR398286/c
LOCUS AR398286 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 667 from patent US 6617438.
ACCESSION AR398286
VERSION AR398286.1 GI:40135972
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 667 09-SEP-2003;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1268 GGAAGAGGCTGAGGGCA 1284
              |||||| ||||||| ||
Db         17 GGAAGACGCTGAGGTCA 1
```

RESULT 88
AX215457/c
LOCUS AX215457 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 899 from Patent WO0159103.
ACCESSION AX215457
VERSION AX215457.1 GI:15525500
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 899 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source 1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1772 GGAGGAGGAGGCGGAGG 1788
              || |||||||| |||||
Db         17 GGGGGAGGAGGGGGAGG 1
```

RESULT 89
AX216916
LOCUS AX216916 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2358 from Patent WO0159103.
ACCESSION AX216916
VERSION AX216916.1 GI:15526977
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 2358 16-AUG-2001;

```
           RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1762 ATGAAGATGAGGAGGAG 1778
              | ||||| |||||||||
Db          1 AGGAAGAAGAGGAGGAG 17


RESULT 90
AX216919
LOCUS       AX216919                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2361 from Patent WO0159103.
ACCESSION   AX216919
VERSION     AX216919.1  GI:15526980
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2361 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1764 GAAGATGAGGAGGAGGA 1780
              ||||| |||||||| ||
Db          1 GAAGAGGAGGAGGAAGA 17


RESULT 91
AX216920
LOCUS       AX216920                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2362 from Patent WO0159103.
ACCESSION   AX216920
VERSION     AX216920.1  GI:15526981
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2362 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGGAG 1781
              |||| |||||||| |||
Db          1 AAGAGGAGGAGGAAGAG 17


RESULT 92
AX216921
LOCUS       AX216921                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2363 from Patent WO0159103.
ACCESSION   AX216921
VERSION     AX216921.1  GI:15526982
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2363 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGA 1786
              |||||||||| | |||
Db          1 GAGGAGGAGGAAGAGGA 17


RESULT 93
AX217020
LOCUS       AX217020                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2462 from Patent WO0159103.
ACCESSION   AX217020
VERSION     AX217020.1  GI:15527081
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2462 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1759 AAGATGAAGATGAGGAG 1775
```

```
              |||||||||| ||| ||
Db          1 AAGATGAAGAAGAGAAG 17


RESULT 94
AX263536
LOCUS       AX263536                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 927 from Patent WO0173002.
ACCESSION   AX263536
VERSION     AX263536.1  GI:16512335
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 927 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGAG 1280
              |||||||||||  ||| |
Db          1 AGCTGGAAGAGTCTGGG 17


RESULT 95
AX263537/c
LOCUS       AX263537                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 928 from Patent WO0173002.
ACCESSION   AX263537
VERSION     AX263537.1  GI:16512336
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 928 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGAG 1280
              |||||||||||  ||| |
Db         17 AGCTGGAAGAGTCTGGG 1


RESULT 96
AX423701
LOCUS       AX423701                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 2037 from Patent WO0188124.
ACCESSION   AX423701
VERSION     AX423701.1  GI:21527083
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 2037 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAG 1787
              |||||||  |||||  |||
Db          1 AGGAGGAAGAGGCAGAG 17


RESULT 97
AX474990/c
LOCUS       AX474990                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 211 from Patent WO0224750.
ACCESSION   AX474990
VERSION     AX474990.1  GI:22214275
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 211 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1635 CAGCAGGCCCAGCGTGC 1651
              ||||||| ||| ||||
Db         17 CAGCAGGCTCAGGGTGC 1


RESULT 98
AX474991/c
LOCUS       AX474991                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 212 from Patent WO0224750.
ACCESSION   AX474991
VERSION     AX474991.1  GI:22214276
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 212 28-MAR-2002;
```

```
           Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1634 TCAGCAGGCCCAGCGTG 1650
              ||||||||| ||| |||
Db         17 TCAGCAGGCTCAGGGTG 1


RESULT 99
AX475408/c
LOCUS       AX475408                 17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 629 from Patent WO0224750.
ACCESSION   AX475408
VERSION     AX475408.1  GI:22214693
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 629 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1748 CAGTGTAGCTGAAGATG 1764
              || |||||||||| ||
Db         17 CATTGTAGCTGAAGTTG 1


RESULT 100
AX499051/c
LOCUS       AX499051                 17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 358 from Patent EP1229046.
ACCESSION   AX499051
VERSION     AX499051.1  GI:23381344
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 358 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1652 CCAGCTGCAGAGGCAGG 1668
              |||||| ||| ||||||
Db         17 CCAGCTCCAGCGGCAGG 1


RESULT 101
AX674218/c
LOCUS       AX674218                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 2663 from Patent WO03004526.
ACCESSION   AX674218
VERSION     AX674218.1  GI:29332566
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 2663 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1210 CAGCCATCTGTCAGAAC 1226
              ||||| ||||||||| |
Db         17 CAGCCCTCTGTCAGATC 1


RESULT 102
AX688168
LOCUS       AX688168                 17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 900 from Patent EP1281758.
ACCESSION   AX688168
VERSION     AX688168.1  GI:29410868
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 900 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1925 GGGGAGCAAGTGGAACC 1941
              |||||| | ||||||||
Db          1 GGGGAGTATGTGGAACC 17


RESULT 103
AX688169
LOCUS       AX688169                 17 bp    DNA     linear   PAT 31-MAR-2003
```

```
DEFINITION  Sequence 901 from Patent EP1281758.
ACCESSION   AX688169
VERSION     AX688169.1  GI:29410869
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 901 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1926 GGGAGCAAGTGGAACCG 1942
              ||||| | |||||||||
Db          1 GGGAGTATGTGGAACCG 17


RESULT 104
AX728971
LOCUS       AX728971                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 605 from Patent WO03025175.
ACCESSION   AX728971
VERSION     AX728971.1  GI:30508314
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 605 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        890 GAGCCTGCAGCAGACAG 906
              || ||||||| ||||||
Db          1 GATCCTGCAGGAGACAG 17


RESULT 105
AX759206/c
LOCUS       AX759206                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 2527 from Patent WO03040369.
ACCESSION   AX759206
VERSION     AX759206.1  GI:32253822
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 2527 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 GGAGGAGGACGAGGAGC 1899
              ||||||||| ||||| |
Db         17 GGAGGAGGAAGAGGATC 1


RESULT 106
AX783324
LOCUS       AX783324                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 1655 from Patent WO03050284.
ACCESSION   AX783324
VERSION     AX783324.1  GI:32951173
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 1655 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1916 CCGGCGGAAGGGGAGCA 1932
              |||||| |||| |||||
Db          1 CCGGCGAAAGGAGAGCA 17


RESULT 107
A12051/c
LOCUS       A12051                    15 bp    DNA     linear   PAT 09-DEC-1993
DEFINITION  Oligonucleotide.
ACCESSION   A12051
VERSION     A12051.1  GI:491254
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Epplen,J.T.
  TITLE     Process for the detection of restriction fragment length
            polymorphisms in eukaryotic genomes
  JOURNAL   Patent: EP 0266787-A 11 11-MAY-1988;
            Max-Planck-Gesellschaft zur Foerderung der Wissenschaften
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
```

/db_xref="taxon:32630"

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1772 GGAGGAGGAGGCGGA 1786
              ||||||||||| |||
Db         15 GGAGGAGGAGGAGGA 1
```

RESULT 108
A12052
LOCUS A12052 15 bp DNA linear PAT 09-DEC-1993
DEFINITION Oligonucleotide.
ACCESSION A12052
VERSION A12052.1 GI:489448
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Epplen,J.T.
TITLE Process for the detection of restriction fragment length polymorphisms in eukaryotic genomes
JOURNAL Patent: EP 0266787-A 12 11-MAY-1988;
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften
FEATURES Location/Qualifiers
source 1. .15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1772 GGAGGAGGAGGCGGA 1786
              ||||||||||| |||
Db          1 GGAGGAGGAGGAGGA 15
```

RESULT 109
AR053182
LOCUS AR053182 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 16 from patent US 5834184.
ACCESSION AR053182
VERSION AR053182.1 GI:5978044
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Harada,K., Martin,S.S. and Frankel,A.
TITLE In vivo selection of RNA-binding peptides
JOURNAL Patent: US 5834184-A 16 10-NOV-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1161 GCCCTGAAGAAGGCC 1175
              | ||||||||||||||
Db          1 GGCCTGAAGAAGGCC 15
```

RESULT 110
I28566
LOCUS I28566 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 19 from patent US 5571937.
ACCESSION I28566
VERSION I28566.1 GI:1819342
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Watanabe,K.A., Ren,W.-Y. and Weil,R.
TITLE Complementary DNA and toxins
JOURNAL Patent: US 5571937-A 19 05-NOV-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1765 AAGATGAGGAGGAGG 1779
              |||| ||||||||||
Db          1 AAGAGGAGGAGGAGG 15
```

RESULT 111
I58728
LOCUS I58728 15 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 19 from patent US 5652350.
ACCESSION I58728
VERSION I58728.1 GI:2477966
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Watanabe,K.A., Ren,W.-Y. and Weil,R.
TITLE Complementary DNA and toxins
JOURNAL Patent: US 5652350-A 19 29-JUL-1997;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1765 AAGATGAGGAGGAGG 1779
              |||| ||||||||||
Db          1 AAGAGGAGGAGGAGG 15
```

RESULT 112
I61479/c
LOCUS I61479 15 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 33 from patent US 5658780.
ACCESSION I61479
VERSION I61479.1 GI:2479427
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
TITLE Rel a targeted ribozymes
JOURNAL Patent: US 5658780-A 33 19-AUG-1997;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 13.4; DB 1; Length 15;

```
  Best Local Similarity   93.3%;  Pred. No. 52;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 GGCCGGCGAGGTGGA 1837
              ||||||  ||||||||
Db         15 GGCCGGTGAGGTGGA 1


RESULT 113
AX635911/c
LOCUS       AX635911                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3050 from Patent EP1260586.
ACCESSION   AX635911
VERSION     AX635911.1  GI:28471525
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 3050 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 52;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 GGCCGGCGAGGTGGA 1837
              ||||||  ||||||||
Db         15 GGCCGGTGAGGTGGA 1


RESULT 114
BD137831
LOCUS       BD137831                 15 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV).
ACCESSION   BD137831
VERSION     BD137831.1  GI:23232776
KEYWORDS    JP 2002504317-A/116.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Paul,P.S. and Zhang,Y.
  TITLE     Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV)
  JOURNAL   Patent: JP 2002504317-A 116 12-FEB-2002;
            IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC,AMERICAN CYANAMID CO
COMMENT     OS   Artificial Sequence
            PN   JP 2002504317-A/116
            PD   12-FEB-2002
            PF   08-FEB-1999 JP 2000530103
            PR   06-FEB-1998 US    09/019793
            PI   PREM S PAUL,YANJIN ZHANG
            PC   C12N15/09,A61K39/12,A61P31/14,C07K14/08,C12Q1/68//C07K16/10,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 52;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2027 CCACCCCCTTAACCC 2041
              ||||||||||| ||
Db          1 CCACCCCCTTAAACC 15


RESULT 115
BD268811
LOCUS       BD268811                 16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Vascular adhesion molecule and control of its function.
ACCESSION   BD268811
VERSION     BD268811.1  GI:33078579
KEYWORDS    JP 2002537837-A/6.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Imhof,B.A. and Lions,M.A.
  TITLE     Vascular adhesion molecule and control of its function
  JOURNAL   Patent: JP 2002537837-A 6 12-NOV-2002;
            RMF DICTAGENE SA
COMMENT     OS   Artificial Sequence
            PN   JP 2002537837-A/6
            PD   12-NOV-2002
            PF   13-MAR-2000 JP 2000603370
            PR   11-MAR-1999 EP   99200746.8
            PI   BEAT ALBEAT IMHOF,MICHEL AURRAND LIONS
            PC   C12N15/09,A61K38/00,A61K39/395,A61K39/395,A61K39/395,A61K39/
            PC   395,A61P9/00,
            PC   A61P29/00,A61P35/00,C07K14/47,C07K16/18,C12Q1/68,C12N15/00, PC
              A61K37/02
            CC   Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2243 CACCCTCCGCACTCG 2257
              |||||||| ||||||
Db          1 CACCCTCCTCACTCG 15


RESULT 116
BD268813
LOCUS       BD268813                 16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Vascular adhesion molecule and control of its function.
ACCESSION   BD268813
VERSION     BD268813.1  GI:33078581
KEYWORDS    JP 2002537837-A/8.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Imhof,B.A. and Lions,M.A.
  TITLE     Vascular adhesion molecule and control of its function
  JOURNAL   Patent: JP 2002537837-A 8 12-NOV-2002;
            RMF DICTAGENE SA
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2002537837-A/8
            PD   12-NOV-2002
            PF   13-MAR-2000 JP 2000603370
            PR   11-MAR-1999 EP   99200746.8
            PI   BEAT ALBEAT IMHOF,MICHEL AURRAND LIONS
            PC   C12N15/09,A61K38/00,A61K39/395,A61K39/395,A61K39/395,A61K39/
            PC   395,A61P9/00,
            PC   A61P29/00,A61P35/00,C07K14/47,C07K16/18,C12Q1/68,C12N15/00, PC
              A61K37/02
            CC   Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2243 CACCCTCCGCACTCG 2257
              ||||||||  ||||||
Db          1 CACCCTCCTCACTCG 15


RESULT 117
I27472/c
LOCUS       I27472                  16 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 13 from patent US 5565331.
ACCESSION   I27472
VERSION     I27472.1  GI:1818248
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Tessier-Lavigne,M., Serafini,T., Kennedy,T., Placzek,M., Jessell,T.
            and Dodd,J.
  TITLE     Nucleic acids encoding neural axon outgrowth modulators
  JOURNAL   Patent: US 5565331-A 13 15-OCT-1996;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 GAGAGCGAGGACGAC 1859
              ||||  ||||||||||
Db         16 GAGAACGAGGACGAC 2


RESULT 118
AX036054
LOCUS       AX036054                16 bp    DNA     linear   PAT 15-NOV-2000
DEFINITION  Sequence 6 from Patent WO0053749.
ACCESSION   AX036054
VERSION     AX036054.1  GI:11191593
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Imhof,B.A. and Aurrand-Lions,M.
  TITLE     Vascular adhesion molecules and modulation of their function
  JOURNAL   Patent: WO 0053749-A 6 14-SEP-2000;
            IMHOF BEAT ALBERT (CH) ; AURRAND LIONS MICHEL (CH) ; RMF DICTAGENE
            SA (CH)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2243 CACCCTCCGCACTCG 2257
              ||||||||  ||||||
Db          1 CACCCTCCTCACTCG 15


RESULT 119
AX036056
LOCUS       AX036056                16 bp    DNA     linear   PAT 15-NOV-2000
DEFINITION  Sequence 8 from Patent WO0053749.
ACCESSION   AX036056
VERSION     AX036056.1  GI:11191595
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Imhof,B.A. and Aurrand-Lions,M.
  TITLE     Vascular adhesion molecules and modulation of their function
  JOURNAL   Patent: WO 0053749-A 8 14-SEP-2000;
            IMHOF BEAT ALBERT (CH) ; AURRAND LIONS MICHEL (CH) ; RMF DICTAGENE
            SA (CH)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer used for detection JAM-2 transcript"

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2243 CACCCTCCGCACTCG 2257
              ||||||||  ||||||
Db          1 CACCCTCCTCACTCG 15


RESULT 120
AX572366/c
LOCUS       AX572366                15 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 406 from Patent WO02055741.
ACCESSION   AX572366
VERSION     AX572366.1  GI:26004456
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 406 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
```

Best Local Similarity 100.0%; Pred. No. 61;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1426 CCATCATCCACGT 1438
              |||||||||||||
Db         15 CCATCATCCACGT 3
```

```
RESULT 121
AX572367/c
LOCUS       AX572367                 16 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 407 from Patent WO02055741.
ACCESSION   AX572367
VERSION     AX572367.1  GI:26004457
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 407 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"
```

Query Match 0.5%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1426 CCATCATCCACGT 1438
              |||||||||||||
Db         16 CCATCATCCACGT 4
```

```
RESULT 122
BD274528
LOCUS       BD274528                 16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Diagnosis of glaucoma.
ACCESSION   BD274528
VERSION     BD274528.1  GI:33084296
KEYWORDS    JP 2002543802-A/3.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Garchon,H.
  TITLE     Diagnosis of glaucoma
  JOURNAL   Patent: JP 2002543802-A 3 24-DEC-2002;
            INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),
            INSITE VISION INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002543802-A/3
            PD   24-DEC-2002
            PF   04-MAY-2000 JP 2000616394
            PR   07-MAY-1999 US    60/133224
            PI   HENRI-JEAN GARCHON
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC   Oligonucleotide
            FH   Key             Location/Qualifiers
            FT   misc_binding    (1). .(16).
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
```

Query Match 0.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1116 GCACAGGTCCTCCAAG 1131
              ||||| |||||||| |
Db          1 GCACACGTCCTCCATG 16
```

```
RESULT 123
AR234405/c
LOCUS       AR234405                 16 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 59 from patent US 6458567.
ACCESSION   AR234405
VERSION     AR234405.1  GI:27277093
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Barber,J.R., Welch,P.J., Tritz,R., Yei,S. and Yu,M.
  TITLE     Hepatitis C Virus ribozymes
  JOURNAL   Patent: US 6458567-A 59 01-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"
```

Query Match 0.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        880 TCACCTTTGAGAGCCT 895
              |||||||||| || ||
Db         16 TCACCTTTGACAGACT 1
```

```
RESULT 124
AR258892
LOCUS       AR258892                 16 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 110 from patent US 6489307.
ACCESSION   AR258892
VERSION     AR258892.1  GI:27309332
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Phillips,M.I. and Zhang,Y.
  TITLE     Antisense compositions targeted to .beta.1-adrenoceptor-specific
            mRNA and methods of use
  JOURNAL   Patent: US 6489307-A 110 03-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"
```

Query Match 0.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1649 TGCCCAGCTGCAGAGG 1664
              |||| |||||| ||||
Db          1 TGCCGAGCTGCGGAGG 16
```

```
RESULT 125
AX046979
LOCUS       AX046979                 16 bp    DNA     linear   PAT 15-DEC-2000
DEFINITION  Sequence 3 from Patent WO0068429.
ACCESSION   AX046979
VERSION     AX046979.1  GI:11876407
KEYWORDS    .
SOURCE      synthetic construct
```

```
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Garchon,H.J.
  TITLE     Diagnosis of glaucoma
  JOURNAL   Patent: WO 0068429-A 3 16-NOV-2000;
            INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; (INSERM)
            (FR) ; INSITE VISION INCORPORATED (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide"

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 79;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1116 GCACAGGTCCTCCAAG 1131
              ||||| |||||||| |
Db          1 GCACACGTCCTCCATG 16


RESULT 126
AX139183/c
LOCUS       AX139183                 16 bp    DNA     linear   PAT 30-MAY-2001
DEFINITION  Sequence 31 from Patent EP1076099.
ACCESSION   AX139183
VERSION     AX139183.1  GI:14274856
KEYWORDS    .
SOURCE      Mycobacterium tuberculosis
  ORGANISM  Mycobacterium tuberculosis
            Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
            Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium
            tuberculosis complex.
REFERENCE   1
  AUTHORS   Suzuki,Y., Nishida,M. and Takenishi,S.
  TITLE     Kit for diagnosis of tubercle bacilli
  JOURNAL   Patent: EP 1076099-A 31 14-FEB-2001;
            NISSHINBO INDUSTRIES, INC. (JP) ; System Research Incorporation
            (JP)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Mycobacterium tuberculosis"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:1773"
                     /note="capture"

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 79;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1662 AGGCAGGTCTTGCAGC 1677
              ||||||||| |||| |
Db         16 AGGCAGGTCCTGCACC 1


RESULT 127
AX255757/c
LOCUS       AX255757                 16 bp    DNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 178 from Patent WO0170982.
ACCESSION   AX255757
VERSION     AX255757.1  GI:16074812
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 178 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)

FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 79;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1197 CCTGTGCAGAGGGCAG 1212
              |||| ||||| |||||
Db         16 CCTGCGCAGACGGCAG 1


RESULT 128
AX259673/c
LOCUS       AX259673                 16 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 36 from Patent WO0173118.
ACCESSION   AX259673
VERSION     AX259673.1  GI:16508769
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   French,D.J., Mcdowell,D.G. and Brown,T.
  TITLE     Hybridisation beacon and method of rapid sequence detection and
            discrimination
  JOURNAL   Patent: WO 0173118-A 36 04-OCT-2001;
            LGC (Teddington) Limited (GB)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Combined DNA/RNA
                     Molecule:PROBE~PROBE"

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 79;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1704 CAGCCCCAGGAGGCCC 1719
              || |||||||| ||||
Db         16 CACCCCCAGGACGCCC 1


RESULT 129
AX259676/c
LOCUS       AX259676                 16 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 39 from Patent WO0173118.
ACCESSION   AX259676
VERSION     AX259676.1  GI:16508772
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   French,D.J., Mcdowell,D.G. and Brown,T.
  TITLE     Hybridisation beacon and method of rapid sequence detection and
            discrimination
  JOURNAL   Patent: WO 0173118-A 39 04-OCT-2001;
            LGC (Teddington) Limited (GB)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Combined DNA/RNA
                     Molecule:PROBE~PROBE"
```

```
  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 79;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1704 CAGCCCCAGGAGGCCC 1719
              || |||||||| ||||
Db         16 CACCCCCAGGACGCCC 1


RESULT 130
AX382376
LOCUS       AX382376                 16 bp    DNA     linear   PAT 18-MAR-2002
DEFINITION  Sequence 110 from Patent WO0204623.
ACCESSION   AX382376
VERSION     AX382376.1  GI:19577149
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Phillips,M.I. and Zhang,Y.
  TITLE     Antisense compositions targeted to _g(b) 1? adrenoceptor-specific
            mrna and methods of use
  JOURNAL   Patent: WO 0204623-A 110 17-JAN-2002;
            University of Florida (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="SYNTHETIC OLIGONUCLEOTIDE"

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 79;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 TGCCCAGCTGCAGAGG 1664
              |||| |||||| ||||
Db          1 TGCCGAGCTGCGGAGG 16


RESULT 131
BD013467/c
LOCUS       BD013467                 16 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Diagnosis kit of tubercle bacillus.
ACCESSION   BD013467
VERSION     BD013467.1  GI:22553781
KEYWORDS    JP 2001103981-A/31.
SOURCE      Mycobacterium tuberculosis
  ORGANISM  Mycobacterium tuberculosis
            Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
            Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium
            tuberculosis complex.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Suzuki,S., Nishida,M. and Takenishi,S.
  TITLE     Diagnosis kit of tubercle bacillus
  JOURNAL   Patent: JP 2001103981-A 31 17-APR-2001;
            NISSHINBO IND INC,SYSTEM RESEARCH CO LTD
COMMENT     OS   Mycobacterium tuberculosis
            PN   JP 2001103981-A/31
            PD   17-APR-2001
            PF   26-JUL-2000 JP 2000225985
            PI   SADAHIKO SUZUKI,MICHIO NISHIDA,SOICHIRO TAKENISHI PC
            C12N15/09,C12N15/09,C12M1/00,C12Q1/68//(C12Q1/68,C12R1:32), PC
            (C12Q1/68,C12R1:325),(C12Q1/68,C12R1:33),C12N15/00,C12N15/00 CC
            capture
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Mycobacterium tuberculosis'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Mycobacterium tuberculosis"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:1773"

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 79;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1662 AGGCAGGTCTTGCAGC 1677
              ||||||||| |||| |
Db         16 AGGCAGGTCCTGCACC 1


RESULT 132
AR307962/c
LOCUS       AR307962                 20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 173 from patent US 6551826.
ACCESSION   AR307962
VERSION     AR307962.1  GI:31698718
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Watt,A.T.
  TITLE     Antisense modulation of raidd expression
  JOURNAL   Patent: US 6551826-A 173 22-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 20;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1227 CTCCAGCATGTGCTGG 1242
              |||||||| ||||||
Db         18 CTCCAGCACATGCTGG 3


RESULT 133
A88025/c
LOCUS       A88025                   14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 173 from Patent WO9833904.
ACCESSION   A88025
VERSION     A88025.1  GI:6736595
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 173 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1778 GGAGGCGGAGGAGG 1791
              ||||||||||||| |
Db         14 GGAGGCGGAGGATG 1


RESULT 134
A89294/c
LOCUS       A89294                   14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 1442 from Patent WO9833904.
```

```
ACCESSION   A89294
VERSION     A89294.1  GI:6737864
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 1442 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1426 CCATCATCCACGTG 1439
              ||||||||||||| |
Db         14 CCATCATCCACGGG 1


RESULT 135
A89466/c
LOCUS       A89466                    14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 1614 from Patent WO9833904.
ACCESSION   A89466
VERSION     A89466.1  GI:6738036
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 1614 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2010 GACCTTGTGAGGCA 2023
              ||||||||| ||||
Db         14 GACCTTGTGCGGCA 1


RESULT 136
A89992/c
LOCUS       A89992                    14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 173 from Patent EP0856579.
ACCESSION   A89992
VERSION     A89992.1  GI:6738506
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 173 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1778 GGAGGCGGAGGAGG 1791
              ||||||||||||| |
Db         14 GGAGGCGGAGGATG 1


RESULT 137
AX239937
LOCUS       AX239937                  14 bp    DNA     linear   PAT 26-SEP-2001
DEFINITION  Sequence 64 from Patent WO0164958.
ACCESSION   AX239937
VERSION     AX239937.1  GI:15797539
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Dempcy,R.O., Gall,A.A., Lokhov,S.G., Afonina,I.A., Singer,M.J.,
            Kutyavin,I.V. and Vermeulen,N.M.
  TITLE     Modified oligonucleotides for mismatch discrimination
  JOURNAL   Patent: WO 0164958-A 64 07-SEP-2001;
            Epoch Biosciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="probe sequence"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1520 CGGCAACGTGCTGG 1533
              |||| |||||||||
Db          1 CGGCTACGTGCTGG 14


RESULT 138
AX587251/c
LOCUS       AX587251                  14 bp    DNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 27 from Patent WO0236761.
ACCESSION   AX587251
VERSION     AX587251.1  GI:27656116
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   D'Andrea,A.D., Taniguchi,T., Timmers,C. and Grompe,M.
  TITLE     Methods and compositions for the diagnosis of cancer
            susceptibilities and defective dna repair mechanisms and treatment
            thereof
  JOURNAL   Patent: WO 0236761-A 27 10-MAY-2002;
            DANA FARBER CANCER INSTITUTE (US)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     misc_feature    1. .14
                     /note="Intron/Exon Junction of FANCD"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
```

```
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1432 TCCACGTGTCCCTG 1445
              ||||||||| ||||
Db         14 TCCACGTGTACCTG 1


RESULT 139
BD065538/c
LOCUS       BD065538                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065538
VERSION     BD065538.1  GI:22611141
KEYWORDS    JP 2001511000-A/173.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 173 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/173
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES            Location/Qualifiers
     source         1. .14
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1778 GGAGGCGGAGGAGG 1791
              ||||||||||||| |
Db         14 GGAGGCGGAGGATG 1


RESULT 140
BD066807/c
LOCUS       BD066807                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066807
VERSION     BD066807.1  GI:22612410
KEYWORDS    JP 2001511000-A/1442.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1442 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1442
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES            Location/Qualifiers
     source         1. .14
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1426 CCATCATCCACGTG 1439
              ||||||||||||| |
Db         14 CCATCATCCACGGG 1


RESULT 141
BD066979/c
LOCUS       BD066979                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066979
VERSION     BD066979.1  GI:22612582
KEYWORDS    JP 2001511000-A/1614.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1614 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1614
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES            Location/Qualifiers
     source         1. .14
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2010 GACCTTGTGAGGCA 2023
              ||||||||| ||||
Db         14 GACCTTGTGCGGCA 1


RESULT 142
BD137809
LOCUS       BD137809                  14 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV).
ACCESSION   BD137809
VERSION     BD137809.1  GI:23232754
KEYWORDS    JP 2002504317-A/94.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Paul,P.S. and Zhang,Y.
  TITLE     Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV)
  JOURNAL   Patent: JP 2002504317-A 94 12-FEB-2002;
```

```
            IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC,AMERICAN CYANAMID CO
COMMENT     OS   Artificial Sequence
            PN   JP 2002504317-A/94
            PD   12-FEB-2002
            PF   08-FEB-1999 JP 2000530103
            PR   06-FEB-1998 US    09/019793
            PI   PREM S PAUL,YANJIN ZHANG
            PC   C12N15/09,A61K39/12,A61P31/14,C07K14/08,C12Q1/68//C07K16/10,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2027 CCACCCCCTTAACC 2040
              ||||||| ||||||
Db          1 CCACCCCTTTAACC 14


RESULT 143
BD137813
LOCUS       BD137813                  14 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV).
ACCESSION   BD137813
VERSION     BD137813.1  GI:23232758
KEYWORDS    JP 2002504317-A/98.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Paul,P.S. and Zhang,Y.
  TITLE     Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV)
  JOURNAL   Patent: JP 2002504317-A 98 12-FEB-2002;
            IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC,AMERICAN CYANAMID CO
COMMENT     OS   Artificial Sequence
            PN   JP 2002504317-A/98
            PD   12-FEB-2002
            PF   08-FEB-1999 JP 2000530103
            PR   06-FEB-1998 US    09/019793
            PI   PREM S PAUL,YANJIN ZHANG
            PC   C12N15/09,A61K39/12,A61P31/14,C07K14/08,C12Q1/68//C07K16/10,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2027 CCACCCCCTTAACC 2040
              ||||||| ||||||
Db          1 CCACCCCTTTAACC 14


RESULT 144
BD137826
LOCUS       BD137826                  14 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV).
ACCESSION   BD137826
VERSION     BD137826.1  GI:23232771
KEYWORDS    JP 2002504317-A/111.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Paul,P.S. and Zhang,Y.
  TITLE     Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV)
  JOURNAL   Patent: JP 2002504317-A 111 12-FEB-2002;
            IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC,AMERICAN CYANAMID CO
COMMENT     OS   Artificial Sequence
            PN   JP 2002504317-A/111
            PD   12-FEB-2002
            PF   08-FEB-1999 JP 2000530103
            PR   06-FEB-1998 US    09/019793
            PI   PREM S PAUL,YANJIN ZHANG
            PC   C12N15/09,A61K39/12,A61P31/14,C07K14/08,C12Q1/68//C07K16/10,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2027 CCACCCCCTTAACC 2040
              ||||||| ||||||
Db          1 CCACCCCTTTAACC 14


RESULT 145
BD137828
LOCUS       BD137828.                 14 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV).
ACCESSION   BD137828
VERSION     BD137828.1  GI:23232773
KEYWORDS    JP 2002504317-A/113.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Paul,P.S. and Zhang,Y.
  TITLE     Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV)
  JOURNAL   Patent: JP 2002504317-A 113 12-FEB-2002;
            IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC,AMERICAN CYANAMID CO
COMMENT     OS   Artificial Sequence
            PN   JP 2002504317-A/113
            PD   12-FEB-2002
            PF   08-FEB-1999 JP 2000530103
            PR   06-FEB-1998 US    09/019793
            PI   PREM S PAUL,YANJIN ZHANG
            PC   C12N15/09,A61K39/12,A61P31/14,C07K14/08,C12Q1/68//C07K16/10,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
```

```
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2027 CCACCCCCTTAACC 2040
              ||||||| ||||||
Db          1 CCACCCCTTTAACC 14


RESULT 146
BD137835
LOCUS       BD137835                  14 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV).
ACCESSION   BD137835
VERSION     BD137835.1  GI:23232780
KEYWORDS    JP 2002504317-A/120.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Paul,P.S. and Zhang,Y.
  TITLE     Protein encoded by polynucleic acid of porcine reproductive and
            respiratory syndrome virus (PRRSV)
  JOURNAL   Patent: JP 2002504317-A 120 12-FEB-2002;
            IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC,AMERICAN CYANAMID CO
COMMENT     OS   Artificial Sequence
            PN   JP 2002504317-A/120
            PD   12-FEB-2002
            PF   08-FEB-1999 JP 2000530103
            PR   06-FEB-1998 US    09/019793
            PI   PREM S PAUL,YANJIN ZHANG
            PC   C12N15/09,A61K39/12,A61P31/14,C07K14/08,C12Q1/68//C07K16/10,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .14
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2027 CCACCCCCTTAACC 2040
              ||||||| ||||||
Db          1 CCACCCCTTTAACC 14


RESULT 147
BD201812
LOCUS       BD201812                  14 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD201812
VERSION     BD201812.1  GI:33011582
KEYWORDS    JP 2002509721-A/4838.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 4838 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/4838
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
   . source           1. .14
                      /organism="Homo sapiens"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:9606"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1701 CTGCAGCCCCAGGA 1714
              ||||||||| ||||
Db          1 CTGCAGCCCGAGGA 14


RESULT 148
BD209448
LOCUS       BD209448                  14 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD209448
VERSION     BD209448.1  GI:33019218
KEYWORDS    JP 2002512791-A/3038.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 3038 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/3038
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                   related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                          virus)'.
FEATURES              Location/Qualifiers
```

```
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1126 TCCAAGACCTGGGA 1139
              ||| ||||||||||
Db          1 TCCCAGACCTGGGA 14


RESULT 149
A88206/c
LOCUS       A88206                    15 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 354 from Patent WO9833904.
ACCESSION   A88206
VERSION     A88206.1  GI:6736776
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 354 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1307 CATCTGTGAGCAGC 1320
              |||||||||||  ||
Db         14 CATCTGTGAGCTGC 1


RESULT 150
A90173/c
LOCUS       A90173                    15 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 354 from Patent EP0856579.
ACCESSION   A90173
VERSION     A90173.1  GI:6738687
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 354 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1307 CATCTGTGAGCAGC 1320
              |||||||||||  ||
Db         14 CATCTGTGAGCTGC 1


RESULT 151
AR056120/c
LOCUS       AR056120                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 324 from patent US 5837542.
ACCESSION   AR056120
VERSION     AR056120.1  GI:5981697
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 324 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1122 GTCCTCCAAGACCT 1135
              ||||||||| ||||
Db         15 GTCCTCCAATACCT 2


RESULT 152
AR113878/c
LOCUS       AR113878                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 324 from patent US 6132967.
ACCESSION   AR113878
VERSION     AR113878.1  GI:14094200
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 324 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match              0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1122 GTCCTCCAAGACCT 1135
              ||||||||| ||||
Db         15 GTCCTCCAATACCT 2


RESULT 153
I28075
LOCUS       I28075                    15 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 247 from patent US 5567809.
ACCESSION   I28075
VERSION     I28075.1  GI:1818851
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Apple,R.J., Erlich,H.A., Griffith,R.L. and Scharf,S.J.
  TITLE     Methods and reagents for HLA DRbeta DNA typing
```

```
  JOURNAL   Patent: US 5567809-A 247 22-OCT-1996;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2125 GGGCCGCAGTGGAC 2138
              ||||||| ||||||
Db          2 GGGCCGCGGTGGAC 15


RESULT 154
I52067/c
LOCUS       I52067                  15 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 9 from patent US 5646020.
ACCESSION   I52067
VERSION     I52067.1  GI:2473268
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Swiggen,J.A. and Mamone,J.Anthony.
  TITLE     Hammerhead ribozymes for preferred targets
  JOURNAL   Patent: US 5646020-A 9 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
              || ||||||||||||
Db         15 GACGAGGACGAGGA 2


RESULT 155
I61647/c
LOCUS       I61647                  15 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 201 from patent US 5658780.
ACCESSION   I61647
VERSION     I61647.1  GI:2479595
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
  TITLE     Rel a targeted ribozymes
  JOURNAL   Patent: US 5658780-A 201 19-AUG-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1764 GAAGATGAGGAGGA 1777
              |||||||||| |||
Db         14 GAAGATGAGGGGGA 1


RESULT 156
AR179965
LOCUS       AR179965                15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 33 from patent US 6333152.
ACCESSION   AR179965
VERSION     AR179965.1  GI:20221998
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 33 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2022 CAGGGCCACCCCCT 2035
              || ||||||||||||
Db          1 CATGGCCACCCCCT 14


RESULT 157
AR180323/c
LOCUS       AR180323                15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 391 from patent US 6333152.
ACCESSION   AR180323
VERSION     AR180323.1  GI:20222356
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 391 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1997 GCGCCGCGTCCAGG 2010
              ||||||||||||  |
Db         14 GCGCCGCGTCCATG 1


RESULT 158
AX088088
LOCUS       AX088088                15 bp    DNA     linear   PAT 17-MAR-2001
DEFINITION  Sequence 23 from Patent WO0114531.
ACCESSION   AX088088
VERSION     AX088088.1  GI:13397013
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   May,G.D., Kmiec,E.B. and Rice,M.C.
  TITLE     Cell-free assay for plant gene targeting and conversion
  JOURNAL   Patent: WO 0114531-A 23 01-MAR-2001;
            The Samuel Roberts Noble Foundation, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
```

```
                     /db_xref="taxon:32630"
                     /note="Plasmid pTsm153"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1036 TGCGCTGCTTGGAG 1049
              | ||||||||||||
Db          1 TTCGCTGCTTGGAG 14


RESULT 159
AX088089
LOCUS       AX088089                 15 bp    DNA     linear   PAT 17-MAR-2001
DEFINITION  Sequence 24 from Patent WO0114531.
ACCESSION   AX088089
VERSION     AX088089.1  GI:13397014
KEYWORDS    .
SOURCE      Zea mays
  ORGANISM  Zea mays
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
            clade; Panicoideae; Andropogoneae; Zea.
REFERENCE   1
  AUTHORS   May,G.D., Kmiec,E.B. and Rice,M.C.
  TITLE     Cell-free assay for plant gene targeting and conversion
  JOURNAL   Patent: WO 0114531-A 24 01-MAR-2001;
            The Samuel Roberts Noble Foundation, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Zea mays"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:4577"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1036 TGCGCTGCTTGGAG 1049
              | ||||||||||||
Db          1 TTCGCTGCTTGGAG 14


RESULT 160
AX088090
LOCUS       AX088090                 15 bp    DNA     linear   PAT 17-MAR-2001
DEFINITION  Sequence 25 from Patent WO0114531.
ACCESSION   AX088090
VERSION     AX088090.1  GI:13397015
KEYWORDS    .
SOURCE      Musa sp.
  ORGANISM  Musa sp.
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Zingiberales; Musaceae;
            Musa.
REFERENCE   1
  AUTHORS   May,G.D., Kmiec,E.B. and Rice,M.C.
  TITLE     Cell-free assay for plant gene targeting and conversion
  JOURNAL   Patent: WO 0114531-A 25 01-MAR-2001;
            The Samuel Roberts Noble Foundation, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Musa sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:46838"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1036 TGCGCTGCTTGGAG 1049
              | ||||||||||||
Db          1 TTCGCTGCTTGGAG 14


RESULT 161
AX088091
LOCUS       AX088091                 15 bp    DNA     linear   PAT 17-MAR-2001
DEFINITION  Sequence 26 from Patent WO0114531.
ACCESSION   AX088091
VERSION     AX088091.1  GI:13397016
KEYWORDS    .
SOURCE      Nicotiana tabacum (common tobacco)
  ORGANISM  Nicotiana tabacum
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            asterids; lamiids; Solanales; Solanaceae; Nicotiana.
REFERENCE   1
  AUTHORS   May,G.D., Kmiec,E.B. and Rice,M.C.
  TITLE     Cell-free assay for plant gene targeting and conversion
  JOURNAL   Patent: WO 0114531-A 26 01-MAR-2001;
            The Samuel Roberts Noble Foundation, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Nicotiana tabacum"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:4097"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1036 TGCGCTGCTTGGAG 1049
              | ||||||||||||
Db          1 TTCGCTGCTTGGAG 14


RESULT 162
AX088092
LOCUS       AX088092                 15 bp    DNA     linear   PAT 17-MAR-2001
DEFINITION  Sequence 27 from Patent WO0114531.
ACCESSION   AX088092
VERSION     AX088092.1  GI:13397017
KEYWORDS    .
SOURCE      Nicotiana tabacum (common tobacco)
  ORGANISM  Nicotiana tabacum
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            asterids; lamiids; Solanales; Solanaceae; Nicotiana.
REFERENCE   1
  AUTHORS   May,G.D., Kmiec,E.B. and Rice,M.C.
  TITLE     Cell-free assay for plant gene targeting and conversion
  JOURNAL   Patent: WO 0114531-A 27 01-MAR-2001;
            The Samuel Roberts Noble Foundation, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Nicotiana tabacum"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:4097"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1036 TGCGCTGCTTGGAG 1049
              | ||||||||||||
Db          1 TTCGCTGCTTGGAG 14


RESULT 163
AX164571
LOCUS       AX164571                 15 bp    DNA     linear   PAT 22-JUN-2001
DEFINITION  Sequence 401 from Patent WO0138564.
ACCESSION   AX164571
VERSION     AX164571.1  GI:14545505
```

```
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Rouleau,G.A., Lafreniere,R.G., Rochefort,D., Cossette,P. and
            Ragsdale,D.
  TITLE     Loci for idiopathic generalized epilepsy, mutations thereof and
            method using same to assess, diagnose, prognose or treat epilepsy
  JOURNAL   Patent: WO 0138564-A 401 31-MAY-2001;
            McGill University (CA)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1759 AAGATGAAGATGAG 1772
              ||||||| ||||||
Db          2 AAGATGATGATGAG 15


RESULT 164
AX633220/c
LOCUS       AX633220                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 359 from Patent EP1260586.
ACCESSION   AX633220
VERSION     AX633220.1  GI:28468834
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 359 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1122 GTCCTCCAAGACCT 1135
              ||||||||| ||||
Db         15 GTCCTCCAATACCT 2


RESULT 165
AX636058/c
LOCUS       AX636058                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3197 from Patent EP1260586.
ACCESSION   AX636058
VERSION     AX636058.1  GI:28471672
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 3197 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1764 GAAGATGAGGAGGA 1777
              |||||||||| |||
Db         14 GAAGATGAGGGGGA 1


RESULT 166
AX711168/c
LOCUS       AX711168                  15 bp    RNA     linear   PAT 11-APR-2003
DEFINITION  Sequence 468 from Patent EP1288296.
ACCESSION   AX711168
VERSION     AX711168.1  GI:29787549
KEYWORDS    .
SOURCE      Herpes simplex virus unknown type
  ORGANISM  Herpes simplex virus unknown type
            Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
            Alphaherpesvirinae; Simplexvirus.
REFERENCE   1
  AUTHORS   Draper,K.G., Mcswiggen,J.A., Holecek,J.J., Dudycz,L.W.,
            Macejak,D.G. and Mamone,J.A.
  TITLE     Method and reagent for inhibiting HBV viral replication
  JOURNAL   Patent: EP 1288296-A 468 05-MAR-2003;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Herpes simplex virus unknown type"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:126283"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
              || ||||||||||||
Db         15 GACGAGGACGAGGA 2


RESULT 167
BD061455
LOCUS       BD061455                  15 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method for selectively separating living cell expressed with
            specific gene.
ACCESSION   BD061455
VERSION     BD061455.1  GI:22607061
KEYWORDS    JP 2001286285-A/17.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Ishibashi,K. and Tsuji,A.
  TITLE     Method for selectively separating living cell expressed with
            specific gene
  JOURNAL   Patent: JP 2001286285-A 17 16-OCT-2001;
            LABORATORY OF MOLECULAR BIOPHOTONICS
```

```
COMMENT     OS   Artificial Sequence
            PN   JP 2001286285-A/17
            PD   16-OCT-2001
            PF   28-APR-2000 JP 2000130793
            PI   KANAME ISHIBASHI,AKIHIKO TSUJI
            PC   C12N15/09,C12N1/02,C12N5/10,C12Q1/68,G01N33/48,G01N33/53, PC
           G01N33/566,
            PC   G01N33/58//(C12N1/02,C12R1:91),(C12Q1/68,C12R1:91),C12N15/00,
            PC   C12N5/00
            CC   Probe
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1160 AGCCCTGAAGAAGG 1173
              ||||||| ||||||
Db          1 AGCCCTGCAGAAGG 14


RESULT 168
BD065719/c
LOCUS       BD065719                  15 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065719
VERSION     BD065719.1  GI:22611322
KEYWORDS    JP 2001511000-A/354.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 354 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/354
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Unknown'.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1307 CATCTGTGAGCAGC 1320
              |||||||||| ||
Db         14 CATCTGTGAGCTGC 1


RESULT 169
BD104667
LOCUS       BD104667                  15 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104667
VERSION     BD104667.1  GI:22650241
KEYWORDS    WO 0192572-A/771.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 771 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/771
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
           MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:capture
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2125 GGGCCGCAGTGGAC 2138
              ||||||| ||||||
Db          2 GGGCCGCGGTGGAC 15


RESULT 170
BD104785
LOCUS       BD104785                  15 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104785
VERSION     BD104785.1  GI:22650359
KEYWORDS    WO 0192572-A/889.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 889 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/889
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
           MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:capture
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .15
```

```
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 78;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2125 GGGCCGCAGTGGAC 2138
              ||||||  |||||||
Db          2 GGGCCGAAGTGGAC 15


RESULT 171
BD167992/c
LOCUS       BD167992                  16 bp    DNA     linear   PAT 17-JAN-2003
DEFINITION  Method of constructing mutation DNA library and utilization
            thereof.
ACCESSION   BD167992
VERSION     BD167992.1  GI:27873804
KEYWORDS    WO 0226964-A/39.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Tsuji,T. and Yanagawa,H.
  TITLE     Method of constructing mutation DNA library and utilization thereof
  JOURNAL   Patent: WO 0226964-A 39 04-APR-2002;
            MITSUBISHI CHEMICAL CORP,TORU TSUJI,HIROSHI YANAGAWA
COMMENT     OS   Artificial Sequence
            PN   WO 0226964-A/39
            PD   04-APR-2002
            PF   26-SEP-2001 WO 2001JP008387
            PR   27-SEP-2000 JP 00P   293692,06-FEB-2001 JP 01P   029138 PI
            TORU TSUJI,HIROSHI YANAGAWA
            PC   C12N15/09,C12P21/02
            CC   Description of Artificial Sequence:Synthesized FH   Key
                 Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        761 GCTGCAGGCACAGGC 775
              ||||||||  |||||
Db         16 GCTGCAGGGTCAGGC 2


RESULT 172
AR307963/c
LOCUS       AR307963                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 174 from patent US 6551826.
ACCESSION   AR307963
VERSION     AR307963.1  GI:31698719
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Watt,A.T.
  TITLE     Antisense modulation of raidd expression
  JOURNAL   Patent: US 6551826-A 174 22-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 20;
  Best Local Similarity   86.7%;  Pred. No. 1.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1228 TCCAGCATGTGCTGG 1242
              |||||||  ||||||
Db         20 TCCAGCACATGCTGG 6


RESULT 173
AR010038/c
LOCUS       AR010038                  24 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 51 from patent US 5756684.
ACCESSION   AR010038
VERSION     AR010038.1  GI:3968843
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Johnson,E.M. and Bergemann,A.D.
  TITLE     Cloning and expression of PUR protein
  JOURNAL   Patent: US 5756684-A 51 26-MAY-1998;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 24;
  Best Local Similarity   69.6%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy        859 GCCTCTATCTCAACCTGGGCCTC 881
              |||||   |||  |||  |||||
Db         24 GCCTCCGCCTCCGCCTCCGCCTC 2


RESULT 174
AR034773/c
LOCUS       AR034773                  24 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 51 from patent US 5869622.
ACCESSION   AR034773
VERSION     AR034773.1  GI:5950378
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Johnson,E.M. and Bergemann,A.D.
  TITLE     Monoclonal antibodies to the pur protein
  JOURNAL   Patent: US 5869622-A 51 09-FEB-1999;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 24;
  Best Local Similarity   69.6%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy        859 GCCTCTATCTCAACCTGGGCCTC 881
              |||||   |||  |||  |||||
Db         24 GCCTCCGCCTCCGCCTCCGCCTC 2


RESULT 175
AX023424/c
LOCUS       AX023424                  24 bp    DNA     linear   PAT 15-SEP-2000
DEFINITION  Sequence 39 from Patent WO0014217.
ACCESSION   AX023424
VERSION     AX023424.1  GI:10183824
KEYWORDS    .
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lipford,G.B., Heeg,K. and Wagner,H.
  TITLE     G-motif oligonucleotides and uses thereof
  JOURNAL   Patent: WO 0014217-A 39 16-MAR-2000;
            LIPFORD GRAYSON B (DE) ; HEEG KLAUS (DE) ; WAGNER HERMANN (DE) ;
            CPG IMMUNOPHARMACEUTICALS GMBH (DE)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="synthetic, no natural origin"

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 24;
  Best Local Similarity   69.6%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy        859 GCCTCTATCTCAACCTGGGCCTC 881
              |||||   |||  |||  |||||
Db         24 GCCTCCGCCTCCGCCTCCGCCTC 2


Search completed: April  7, 2004, 16:08:50
Job time : 9 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 7, 2004, 16:11:44 ; Search time 8 Seconds
(without alignments)
2.766 Million cell updates/sec

Title: us-09-993-731-10
Perfect score: 2525
Sequence: 1 ctctgggctgtgccgtggcc.....cgcattctctctcccacaga 2525

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 247 seqs, 4382 residues

Total number of hits satisfying chosen parameters: 494

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 260 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		21	0.8	21	1	AAH62255	SLC1A6 polymorphis
2		21	0.8	21	1	AAH62254	NF-kappa-B inhibit
c 3		20.4	0.8	25	1	AAT32777	Triple helix-formi
c 4		20.4	0.8	25	1	AAT32789	Triple helix-formi
c 5		20.4	0.8	25	1	AAS19343	Oligonucleotide se
c 6		20	0.8	20	1	AAL61544	Human inhibitor-ka
c 7		20	0.8	20	1	AAL61563	Human inhibitor-ka
c 8		20	0.8	20	1	AAL61578	Human inhibitor-ka
c 9		20	0.8	20	1	AAL61546	Human inhibitor-ka
c 10		20	0.8	20	1	AAL61549	Human inhibitor-ka
c 11		20	0.8	20	1	AAL61554	Human inhibitor-ka
c 12		20	0.8	20	1	AAL61561	Human inhibitor-ka
c 13		20	0.8	20	1	AAL61564	Human inhibitor-ka
c 14		20	0.8	20	1	AAL61540	Human inhibitor-ka
c 15		20	0.8	20	1	AAL61545	Human inhibitor-ka
c 16		20	0.8	20	1	AAL61562	Human inhibitor-ka
c 17		20	0.8	20	1	AAL61580	Human inhibitor-ka
c 18		20	0.8	20	1	AAL61570	Human inhibitor-ka
c 19		20	0.8	20	1	AAL61571	Human inhibitor-ka
c 20		20	0.8	20	1	AAL61555	Human inhibitor-ka
c 21		20	0.8	20	1	AAL61550	Human inhibitor-ka
c 22		20	0.8	20	1	AAL61551	Human inhibitor-ka
c 23		20	0.8	20	1	AAL61566	Human inhibitor-ka
c 24		20	0.8	20	1	AAL61577	Human inhibitor-ka
c 25		20	0.8	20	1	AAL61581	Human inhibitor-ka
c 26		20	0.8	20	1	AAL61548	Human inhibitor-ka
c 27		20	0.8	20	1	AAL61567	Human inhibitor-ka
c 28		20	0.8	20	1	AAL61582	Human inhibitor-ka
c 29		20	0.8	20	1	AAL61539	Human inhibitor-ka
c 30		20	0.8	20	1	AAL61547	Human inhibitor-ka
c 31		20	0.8	20	1	AAL61574	Human inhibitor-ka
c 32		20	0.8	20	1	AAL61575	Human inhibitor-ka
c 33		20	0.8	20	1	AAL61584	Human inhibitor-ka
c 34		20	0.8	20	1	AAL61585	Human inhibitor-ka
c 35		20	0.8	20	1	AAL61552	Human inhibitor-ka
c 36		20	0.8	20	1	AAL61553	Human inhibitor-ka
c 37		20	0.8	20	1	AAL61556	Human inhibitor-ka
c 38		20	0.8	20	1	AAL61542	Human inhibitor-ka
c 39		20	0.8	20	1	AAL61559	Human inhibitor-ka
c 40		20	0.8	20	1	AAL61560	Human inhibitor-ka
c 41		20	0.8	20	1	AAL61576	Human inhibitor-ka
c 42		20	0.8	20	1	AAL61557	Human inhibitor-ka
c 43		20	0.8	20	1	AAL61573	Human inhibitor-ka
c 44		20	0.8	20	1	AAL61568	Human inhibitor-ka
c 45		20	0.8	20	1	AAL61538	Human inhibitor-ka
c 46		20	0.8	20	1	AAL61541	Human inhibitor-ka
c 47		20	0.8	20	1	AAL61572	Human inhibitor-ka
c 48		20	0.8	20	1	AAL61583	Human inhibitor-ka
c 49		20	0.8	20	1	AAL61543	Human inhibitor-ka
c 50		20	0.8	20	1	AAL61586	Human inhibitor-ka
c 51		20	0.8	20	1	AAL61558	Human inhibitor-ka
c 52		20	0.8	20	1	AAL61565	Human inhibitor-ka
c 53		20	0.8	20	1	AAL61569	Human inhibitor-ka
c 54		20	0.8	20	1	AAL61579	Human inhibitor-ka
55		19.4	0.8	21	1	AAH62253	NF-kappa-B inhibit
56		19.2	0.8	24	1	AAT99287	upTAR element dime
57		19.2	0.8	24	1	AAV31744	Nucleotide sequenc
58		19.2	0.8	24	1	AAX04092	upTAR element olig
59		19.2	0.8	24	1	AAZ99647	Nucleotide sequenc
60		18.4	0.7	20	1	AAQ55605	3' flanking sequen
c 61		18.4	0.7	21	1	AAT11643	WT1/EGR human TCC
c 62		18.4	0.7	21	1	AAA59901	Human OP-1 Wt-1/Eg
c 63		18.4	0.7	21	1	ABK99278	Hepatitis C virus
64		18.4	0.7	23	1	AAQ10661	HLA Class II locus
c 65		17.4	0.7	20	1	AAZ21462	Human BURB1 PCR pr
c 66		17.4	0.7	20	1	AAF73052	Human daxx inhibit
c 67		17.4	0.7	20	1	AAC92593	Human nucleolin ph
68		17.4	0.7	20	1	AAS23716	Primer A #30 used
69		17.4	0.7	20	1	ABZ29903	Candida albicans G
70		17.4	0.7	20	1	ADD71322	Nucleic acid detec
c 71		16.8	0.7	20	1	AAC92693	Human Nck-2 phosph
72		16.8	0.7	20	1	ABZ86362	Human oligonucleot
c 73		16.8	0.7	20	1	ADC49221	Hyaluronic acid sy
c 74		16.8	0.7	21	1	AAV64914	HSV-1 primer Exon
c 75		16.4	0.6	18	1	ABQ78582	RT-PCR primer used
76		16.4	0.6	20	1	ABS67915	Human casein kinas
c 77		16.4	0.6	20	1	ABT43400	Neuroblastoma-rela
c 78		16.4	0.6	20	1	ABT32545	Neuroblastoma-rela
c 79		16.4	0.6	20	1	ABZ81534	PKA regulatory sub
c 80		16	0.6	20	1	AAF73054	Human daxx inhibit
81		16	0.6	20	1	ABK99821	Mouse RAIDD antise
82		16	0.6	20	1	ABK99820	Mouse RAIDD antise
c 83		15.4	0.6	17	1	AAQ92210	p53 detection prob
c 84		15.4	0.6	17	1	AAF02815	Hammerhead ribozym
85		15.4	0.6	17	1	ABK02359	Human NOGO Amberzy
86		15.4	0.6	17	1	ABN00937	Human GDMLP-1 17-m
87		15.4	0.6	17	1	ABN08667	Human GDMLP-1 17-m
88		15.4	0.6	17	1	ABV78925	Human HTPL scannin
c 89		15.4	0.6	17	1	ABK17920	Human ERG hammerhe
c 90		15.4	0.6	17	1	ADB98963	LRP5 mutagenic PCR
91		15.4	0.6	19	1	AAA09296	Primer for human a
c 92		15.4	0.6	19	1	ADE30113	Mitogen activated
93		15.4	0.6	19	1	ADE30322	Mitogen activated
94		15	0.6	15	1	AAF52822	IGF-I oligonucleot
c 95		15	0.6	17	1	AAF02814	Hammerhead ribozym
c 96		14.8	0.6	18	1	AAZ22430	Antisense oligonuc
c 97		14.8	0.6	18	1	AAF94683	Rho B antisense ph
98		14.8	0.6	18	1	ABK50427	Acremonium chrysog
99		14.8	0.6	18	1	ADA27360	Human microsatelli
100		14.8	0.6	18	1	ADB78536	Probe sequence #39
c 101		14.6	0.6	15	1	AAD26693	Human GPR31 gene p
c 102		14.4	0.6	16	1	AAT76198	Human IL4 receptor
103		14.4	0.6	16	1	ABK67989	Mutant DNA library
104		14.4	0.6	17	1	AAX72692	Mouse flk-1 VEGF r
c 105		14.4	0.6	17	1	AAV93512	Human B-raf substr
106		14.4	0.6	17	1	ABK02360	Human NOGO Amberzy

	107	14.4	0.6	17	1	ABK02364	Human NOGO Amberzy
c	108	14.4	0.6	17	1	ABA78078	BRCA1 mutation cor
	109	14.4	0.6	17	1	ABA78077	BRCA1 mutation cor
c	110	14.4	0.6	17	1	ABA78070	BRCA1 mutation cor
	111	14.4	0.6	17	1	ABA78069	BRCA1 mutation cor
	112	14.4	0.6	17	1	ABN00936	Human GDMLP-1 17-m
	113	14.4	0.6	17	1	ABN02626	Human GDMLP-1 17-m
	114	14.4	0.6	17	1	ABN08666	Human GDMLP-1 17-m
	115	14.4	0.6	17	1	ABN06400	Human GDMLP-1 17-m
	116	14.4	0.6	17	1	ABN06399	Human GDMLP-1 17-m
	117	14.4	0.6	17	1	ABN02625	Human GDMLP-1 17-m
	118	14.4	0.6	17	1	ABN00938	Human GDMLP-1 17-m
	119	14.4	0.6	17	1	ABN08668	Human GDMLP-1 17-m
c	120	14.4	0.6	17	1	AAD45173	Human RIP2 DNA spe
	121	14.4	0.6	17	1	ABV78926	Human HTPL scannin
	122	14.4	0.6	17	1	ABV78924	Human HTPL scannin
c	123	14.4	0.6	17	1	ABK17396	Human ERG hammerhe
c	124	14.4	0.6	17	1	ABK17919	Human ERG hammerhe
c	125	14.4	0.6	17	1	ABT37829	Tumour suppression
c	126	14.4	0.6	17	1	ABZ64881	Human HER2 DNAzyme
c	127	14.4	0.6	18	1	AAA10553	Smad2 antisense ol
c	128	14.4	0.6	18	1	ABS60576	Human polymorphism
c	129	14.4	0.6	18	1	ABS60512	Human polymorphism
c	130	14.4	0.6	18	1	ABL43873	Human chromosome 1
	131	14.4	0.6	18	1	ABK50300	Yeast HIS biosynth
	132	14.4	0.6	20	1	AAL61564	Human inhibitor-ka
	133	14.2	0.6	20	1	AAL61584	Human inhibitor-ka
	134	14	0.6	15	1	AAF52821	IGF-I oligonucleot
	135	14	0.6	15	1	AAF45187	IGFBP2 oligonucleo
	136	14	0.6	15	1	AAF45186	IGFBP2 oligonucleo
c	137	14	0.6	15	1	AAF48301	IGFBP3 oligonucleo
c	138	14	0.6	15	1	AAF48302	IGFBP3 oligonucleo
	139	14	0.6	15	1	AAF52823	IGF-I oligonucleot
c	140	14	0.6	17	1	AAF01936	Hammerhead ribozym
c	141	14	0.6	17	1	AAF02211	Hammerhead ribozym
c	142	14	0.6	17	1	AAF07203	Hammerhead ribozym
	143	14	0.6	17	1	ABK02369	Human NOGO Amberzy
	144	14	0.6	17	1	ABK02096	Human NOGO DNAzyme
	145	14	0.6	17	1	ABK02368	Human NOGO Amberzy
	146	14	0.6	17	1	ABN02624	Human GDMLP-1 17-m
	147	14	0.6	17	1	ABN02623	Human GDMLP-1 17-m
c	148	14	0.6	17	1	ABK17922	Human ERG hammerhe
c	149	14	0.6	17	1	ABK17921	Human ERG hammerhe
c	150	14	0.6	17	1	ADB42705	Tumour suppression
	151	13.8	0.5	17	1	AAT44257	HSV-1 antisense co
	152	13.8	0.5	17	1	AAX33904	HSV-1 gene express
c	153	13.8	0.5	17	1	AAT81044	Human c-myb hammer
c	154	13.8	0.5	17	1	AAT81046	Human c-myb hammer
c	155	13.8	0.5	17	1	AAT81047	Human c-myb hammer
c	156	13.8	0.5	17	1	AAT81045	Human c-myb hammer
	157	13.8	0.5	17	1	AAX24211	Phosphonomonoester
c	158	13.8	0.5	17	1	AAT09036	Arabidopsis thalia
	159	13.8	0.5	17	1	AAX72691	Mouse flk-1 VEGF r
	160	13.8	0.5	17	1	AAX71090	Human KDR VEGF rec
	161	13.8	0.5	17	1	ABK02358	Human NOGO Amberzy
	162	13.8	0.5	17	1	ABK02361	Human NOGO Amberzy
	163	13.8	0.5	17	1	ABK02462	Human NOGO Amberzy
	164	13.8	0.5	17	1	ABK02363	Human NOGO Amberzy
c	165	13.8	0.5	17	1	ABK00899	Human NOGO Inozyme
	166	13.8	0.5	17	1	ABK02362	Human NOGO Amberzy
c	167	13.8	0.5	17	1	ABA78082	BRCA1 mutation cor
	168	13.8	0.5	17	1	ABA78081	BRCA1 mutation cor
c	169	13.8	0.5	17	1	ABN06620	Human GDMLP-1 17-m
	170	13.8	0.5	17	1	ABN02601	Human GDMLP-1 17-m
	171	13.8	0.5	17	1	ABN08090	Human GDMLP-1 17-m
c	172	13.8	0.5	17	1	ABN07862	Human GDMLP-1 17-m
c	173	13.8	0.5	17	1	ABN10746	Human GDMLP-1 17-m
c	174	13.8	0.5	17	1	ABN10748	Human GDMLP-1 17-m
c	175	13.8	0.5	17	1	ABN06619	Human GDMLP-1 17-m
	176	13.8	0.5	17	1	ABN08656	Human GDMLP-1 17-m
	177	13.8	0.5	17	1	ABN00935	Human GDMLP-1 17-m
c	178	13.8	0.5	17	1	ABN07863	Human GDMLP-1 17-m
c	179	13.8	0.5	17	1	ABQ63436	Human KTOM1a porti
c	180	13.8	0.5	17	1	ABQ63435	Human KTOM1a porti
c	181	13.8	0.5	17	1	ABQ63853	Human KTOM1a porti
c	182	13.8	0.5	17	1	ABV79112	Human HTPL scannin
	183	13.8	0.5	17	1	ABK19390	Human ERG Amberzym
c	184	13.8	0.5	17	1	ACC53896	Human tumour suppr
	185	13.8	0.5	17	1	ABT34968	Tumour suppression
c	186	13.8	0.5	17	1	ACA07741	NFKB sub-unit modu
	187	13.8	0.5	17	1	ADA99911	Human MDZ3 scannin
	188	13.8	0.5	17	1	ADA99912	Human MDZ3 scannin
c	189	13.8	0.5	17	1	ABZ61958	Human H-Ras DNAzym
c	190	13.8	0.5	17	1	ABZ64880	Human HER2 DNAzyme
c	191	13.8	0.5	17	1	ACD62072	HCV minus strand D
	192	13.8	0.5	17	1	ACD65403	HCV minus strand D
	193	13.8	0.5	17	1	ACD60541	HCV DNAzyme substr
c	194	13.8	0.5	17	1	ACD57266	HCV DNAzyme substr
c	195	13.8	0.5	17	1	ACC58685	Human ADAMTS14 gen
c	196	13.8	0.5	17	1	ADB42204	Tumour suppression
	197	13.8	0.5	20	1	AAL61574	Human inhibitor-ka
	198	13.6	0.5	15	1	ABL36309	Human lysosomal ac
	199	13.6	0.5	15	1	ABL36360	Human lysosomal ac
c	200	13.4	0.5	15	1	AAT54850	Mouse relA hammerh
	201	13.4	0.5	15	1	AAX56927	HIV-1 proviral DNA
	202	13.4	0.5	15	1	AAT45448	Bacteriophage lamb
	203	13.4	0.5	15	1	AAZ07075	Peptide nucleic ac
c	204	13.4	0.5	15	1	AAF46416	IGFBP2 oligonucleo
	205	13.4	0.5	15	1	AAF46437	IGFBP2 oligonucleo
	206	13.4	0.5	15	1	AAF45184	IGFBP2 oligonucleo
	207	13.4	0.5	15	1	AAF45921	IGFBP2 oligonucleo
	208	13.4	0.5	15	1	AAF45922	IGFBP2 oligonucleo
	209	13.4	0.5	15	1	AAF45185	IGFBP2 oligonucleo
c	210	13.4	0.5	15	1	ABZ66523	Human HER2 synthet
	211	13.4	0.5	15	1	ACD82534	Nucleic acid cloni
	212	13.4	0.5	15	1	ADA27359	Human microsatelli
c	213	13.4	0.5	16	1	AAQ24927	Homeo box consensu
	214	13.4	0.5	16	1	AAQ25457	Purine rich HIV ta
c	215	13.4	0.5	16	1	AAQ70682	Triplex forming ol
	216	13.4	0.5	16	1	AAA95296	Murine CRAM-2 codi
	217	13.4	0.5	16	1	AAA95300	Murine CRAM-1 mRNA
	218	13	0.5	13	1	ABF36090	Oligonucleotide SE
c	219	13	0.5	13	1	ABF36091	Oligonucleotide SE
c	220	13	0.5	13	1	ABN83902	SNP detection prob
	221	13	0.5	13	1	ABN83901	Nucleotide fragmen
	222	13	0.5	13	1	ABN83903	Polynucleotide pri
	223	13	0.5	14	1	AAV93815	Human B-raf target
c	224	13	0.5	15	1	AAX09469	Human biallelic po
	225	13	0.5	15	1	ABK10952	PCR primer ONde5 r
	226	13	0.5	15	1	AAS57269	Human CHRNB2 allel
c	227	13	0.5	15	1	AAF48303	IGFBP3 oligonucleo
c	228	13	0.5	15	1	AAF53010	IGF-I oligonucleot
c	229	13	0.5	15	1	AAF53012	IGF-I oligonucleot
c	230	13	0.5	15	1	AAF48300	IGFBP3 oligonucleo
	231	13	0.5	15	1	AAF52824	IGF-I oligonucleot
	232	13	0.5	15	1	AAF52820	IGF-I oligonucleot
c	233	13	0.5	15	1	AAF53011	IGF-I oligonucleot
	234	13	0.5	15	1	AAF45188	IGFBP2 oligonucleo
c	235	13	0.5	15	1	ABZ34164	HIV-1 reverse tran
	236	13	0.5	15	1	AAS99348	Aldehyde dehydroge
c	237	13	0.5	15	1	AAS95930	Human CALM1 gene a
c	238	13	0.5	16	1	ABZ34165	HIV-1 reverse tran
	239	12.8	0.5	15	1	AAD44136	PCR primer #4 desi
c	240	12.8	0.5	16	1	AAT90642	Hepatitis C virus
c	241	12.8	0.5	16	1	AAX09676	Human biallelic po
c	242	12.8	0.5	16	1	AAA13459	Hepatitis C virus
	243	12.8	0.5	16	1	AAC82114	Human ApoE probe S
c	244	12.8	0.5	16	1	AAF95038	Mutant capture oli
c	245	12.8	0.5	16	1	AAS56903	Validation ribozym
c	246	12.8	0.5	16	1	AAS15118	F HyBeacon probe f
c	247	12.8	0.5	16	1	AAS15115	F HyBeacon probe f
	248	12.8	0.5	16	1	ABK40654	Human beta1-adreno
c	249	12.8	0.5	16	1	ABS98338	Human multidrug re
c	250	12.8	0.5	16	1	ABX74378	Hepatitis C recogn
c	251	12.8	0.5	17	1	ABN08656	Human GDMLP-1 17-m
	252	12.8	0.5	20	1	AAL61563	Human inhibitor-ka

c 253	12.8	0.5	20	1	ABK99820	Mouse RAIDD antise
254	12.6	0.5	20	1	AAL61576	Human inhibitor-ka
255	12.6	0.5	20	1	AAL61565	Human inhibitor-ka
256	12.6	0.5	20	1	AAL61579	Human inhibitor-ka
257	12.2	0.5	20	1	AAL61581	Human inhibitor-ka
258	12.2	0.5	20	1	AAL61582	Human inhibitor-ka
259	12.2	0.5	20	1	AAL61575	Human inhibitor-ka
260	12	0.5	20	1	AAL61547	Human inhibitor-ka

ALIGNMENTS

RESULT 1
AAH62255
ID AAH62255 standard; DNA; 21 BP.
XX
AC AAH62255;
XX
DT 12-SEP-2001 (first entry)
XX
DE SLC1A6 polymorphism containing DNA fragment #156.
XX
KW Single nucleotide polymorphism; SNP; human; cancer; inflammation;
KW heart disease; paternity testing; forensic science; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Variation replace(11,G)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
PN WO200138576-A2.
XX
PD 31-MAY-2001.
XX
PF 17-NOV-2000; 2000WO-US031639.
XX
PR 24-NOV-1999; 99US-0167334P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Cargill M, Ireland JS, Lander ES;
XX
DR WPI; 2001-367705/38.
XX
PT New nucleic acid segments of the human genome, particularly from genes
PT including polymorphic sites,for phenotype correlation, forensics,
PT paternity testing, medicine and genetic analysis.
XX
PS Claim 1; Page 42; 80pp; English.
XX
CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which
CC contain single nucleotide polymorphisms (SNPs). A method is included in
CC the invention for analysing a nucleic acid sample, which consists of
CC determining the base occupying any one of the polymorphic sites given in
CC the SNP containing sequences. The nucleotide sequences can be used in the
CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart
CC diseases, diseases of the cardiovascular system, and infection by
CC microorganisms. The oligonucleotides are also useful in the manufacture
CC of a medicament for the treatment or prophylaxis of the diseases, and as
CC a pharmaceutical. SNP containing oligonucleotides are useful in
CC applications such as phenotype correlation, forensics, paternity testing,
CC medicine and genetic analysis
XX
SQ Sequence 21 BP; 6 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1838 GCTCTCAGAGAGCGAGGACGA 1858
||||||||||||||||||||
Db 1 GCTCTCAGAGAGCGAGGACGA 21

RESULT 2
AAH62254
ID AAH62254 standard; DNA; 21 BP.
XX
AC AAH62254;
XX
DT 12-SEP-2001 (first entry)
XX
DE NF-kappa-B inhibitor polymorphism containing DNA fragment #155.
XX
KW Single nucleotide polymorphism; SNP; human; cancer; inflammation;
KW heart disease; paternity testing; forensic science; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Variation replace(11,A)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
PN WO200138576-A2.
XX
PD 31-MAY-2001.
XX
PF 17-NOV-2000; 2000WO-US031639.
XX
PR 24-NOV-1999; 99US-0167334P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Cargill M, Ireland JS, Lander ES;
XX
DR WPI; 2001-367705/38.
XX
PT New nucleic acid segments of the human genome, particularly from genes
PT including polymorphic sites,for phenotype correlation, forensics,
PT paternity testing, medicine and genetic analysis.
XX
PS Claim 1; Page 42; 80pp; English.
XX
CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which
CC contain single nucleotide polymorphisms (SNPs). A method is included in
CC the invention for analysing a nucleic acid sample, which consists of
CC determining the base occupying any one of the polymorphic sites given in
CC the SNP containing sequences. The nucleotide sequences can be used in the
CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart
CC diseases, diseases of the cardiovascular system, and infection by
CC microorganisms. The oligonucleotides are also useful in the manufacture
CC of a medicament for the treatment or prophylaxis of the diseases, and as
CC a pharmaceutical. SNP containing oligonucleotides are useful in
CC applications such as phenotype correlation, forensics, paternity testing,
CC medicine and genetic analysis
XX
SQ Sequence 21 BP; 2 A; 6 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1823 GGCCGGCGAGGTGGAGCTCTC 1843
||||||||||||||||||||
Db 1 GGCCGGCGAGGTGGAGCTCTC 21

RESULT 3
AAT32777/c
ID AAT32777 standard; DNA; 25 BP.
XX
AC AAT32777;

```
XX
DT   18-FEB-1997  (first entry)
XX
DE   Triple helix-forming oligonucleotide.
XX
KW   Triple helix; triplex formation; Hoogsteen base pairing; plasmid;
KW   purification; double-stranded DNA; homopyrimidine; polypurine; ss.
XX
OS   Synthetic.
XX
PN   WO9618744-A2.
XX
PD   20-JUN-1996.
XX
PF   08-NOV-1995;   95WO-FR001468.
XX
PR   16-DEC-1994;   94FR-00015162.
XX
PA   (RHON ) RHONE POULENC RORER SA.
XX
PI   Crouzet J,  Scherman D,  Wils P;
XX
DR   WPI; 1996-300660/30.
XX
PT   Purificn. of double stranded DNA by triple helix formation - comprises
PT   hybridising immobilised oligo-nucleotide to specific sequence in target
PT   DNA.
XX
PS   Claim 12; Page 26; 34pp; French.
XX
CC   Double-stranded (ds) DNA can be purified from complex mixtures of nucleic
CC   acids, proteins, endotoxins, nucleases, etc. by passing the mixture over
CC   a support to which an oligonucleotide is covalently attached; the
CC   oligonucleotide is able to form a triple helix by hybridisation with a
CC   specific sequence present in the dsDNA. The present sequence is a
CC   preferred oligonucleotide which can form a triple-helix with the
CC   homopurine target sequence in AAT32776. The target sequence may be
CC   present naturally, e.g. in a plasmid origin of replication, or can be
CC   introduced artificially. The method is particularly suited to
CC   purification of plasmid DNA
XX
SQ   Sequence 25 BP; 2 A; 14 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 11;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 4
AAT32789/c
ID   AAT32789 standard; DNA; 25 BP.
XX
AC   AAT32789;
XX
DT   18-FEB-1997  (first entry)
XX
DE   Triple helix-forming oligonucleotide for purifying plasmid pXL2725.
XX
KW   Triple helix; triplex formation; Hoogsteen base pairing; plasmid;
KW   purification; double-stranded DNA; homopyrimidine; polypurine; pXL2725;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO9618744-A2.
XX
PD   20-JUN-1996.
XX
PF   08-NOV-1995;   95WO-FR001468.
XX
PR   16-DEC-1994;   94FR-00015162.
XX
PA   (RHON ) RHONE POULENC RORER SA.
XX
PI   Crouzet J,  Scherman D,  Wils P;
XX
DR   WPI; 1996-300660/30.
XX
PT   Purificn. of double stranded DNA by triple helix formation - comprises
PT   hybridising immobilised oligo-nucleotide to specific sequence in target
PT   DNA.
XX
PS   Example 7; Page 18; 34pp; French.
XX
CC   Double-stranded (ds) DNA can be purified from complex mixtures of nucleic
CC   acids, proteins, endotoxins, nucleases, etc. by passing the mixture over
CC   a support to which an oligonucleotide is covalently attached; the
CC   oligonucleotide is able to form a triple helix by hybridisation with a
CC   specific sequence present in the dsDNA. The method is particularly suited
CC   to purification of plasmid DNA. In an example, the present
CC   oligonucleotide was used for purifying plasmid pXL2725 (specially
CC   constructed by inserting a linker comprising a (GGA)25 homopurine
CC   sequence into plasmid pBKS+)
XX
SQ   Sequence 25 BP; 2 A; 14 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 11;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 5
AAS19343/c
ID   AAS19343 standard; DNA; 25 BP.
XX
AC   AAS19343;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Oligonucleotide sequence used to purify plasmid XL2725.
XX
KW   ss; DNA purification; triple helix; plasmid purification; XL2725.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   repeat_region   5. .25
FT                   /*tag=  a
FT                   /rpt_type= TANDEM
FT   repeat_unit     5. .7
FT                   /*tag=  b
FT                   /note= "CCT repeat type"
XX
PN   WO200192511-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US017122.
XX
PR   26-MAY-2000; 2000US-00580923.
XX
PA   (AVET ) AVENTIS PHARMA SA.
XX
PI   Crouzet J,  Scherman D,  Wils P,  Blanche F,  Cameron B;
XX
DR   WPI; 2002-097772/13.
XX
PT   Purifying double-stranded (ds) DNA from a solution containing dsDNA and
```

```
PT   other components, comprises passing the solution through a support
PT   comprising a covalently coupled oligonucleotide able to form a triple
PT   helix with the dsDNA.
XX
PS   Example 7.2; Page 20; 40pp; English.
XX
CC   This invention comprises a method of purifying double-stranded DNA from a
CC   solution containing the double-stranded DNA mixed with other components,
CC   comprising passing the solution through a support comprising a covalently
CC   coupled oligonucleotide capable of forming a triple helix with the double
CC   -stranded DNA by hybridisation with a specific sequence present in the
CC   double-stranded DNA. The method is useful for purifying double-stranded
CC   DNA contained in a solution and mixed with other components. The new
CC   method is a simple, rapid and effective method for DNA purification, and
CC   makes it possible to obtain especially high purities with high yields.
CC   The method enables DNA to be purified from complex mixtures comprising
CC   other nucleic acids, proteins, endotoxins, nucleases and the like. The
CC   supports may be readily recycled, and the DNAs obtained display improved
CC   properties to pharmaceutical safety. Further, the method entails only one
CC   step contrary to prior art. The present sequence represents an
CC   oligonucleotide used to purify the XL2725 plasmid using the method of the
CC   invention
XX
SQ   Sequence 25 BP; 2 A; 14 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 11;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 6
AAL61544/c
ID   AAL61544 standard; DNA; 20 BP.
XX
AC   AAL61544;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130469.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 5 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        981 GCCCGCTACAACCTGGGCAC 1000
              ||||||||||||||||||||
Db         20 GCCCGCTACAACCTGGGCAC 1


RESULT 7
AAL61563/c
ID   AAL61563 standard; DNA; 20 BP.
XX
AC   AAL61563;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130488.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
```

```
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1323 GGGGACCTCTTCTCCAAGGC 1342
              ||||||||||||||||||||
Db         20 GGGGACCTCTTCTCCAAGGC 1


RESULT 8
AAL61578/c
ID   AAL61578 standard; DNA; 20 BP.
XX
AC   AAL61578;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130503.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1621 CGCTCAGCTGTGCTCAGCAG 1640
              ||||||||||||||||||||
Db         20 CGCTCAGCTGTGCTCAGCAG 1


RESULT 9
AAL61546/c
ID   AAL61546 standard; DNA; 20 BP.
XX
AC   AAL61546;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130471.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
```

```
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1035 ATGCGCTGCTTGGAGGGTGC 1054
              ||||||||||||||||||||
Db         20 ATGCGCTGCTTGGAGGGTGC 1


RESULT 10
AAL61549/c
ID   AAL61549 standard; DNA; 20 BP.
XX
AC   AAL61549;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130474.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1085 GTTCATGGAGAGCGAGTGCT 1104
              ||||||||||||||||||||
Db         20 GTTCATGGAGAGCGAGTGCT 1


RESULT 11
AAL61554/c
ID   AAL61554 standard; DNA; 20 BP.
XX
AC   AAL61554;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130479.
```

```
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1213 CCATCTGTCAGAACCTCCAG 1232
             ||||||||||||||||||||
Db         20 CCATCTGTCAGAACCTCCAG 1


RESULT 12
AAL61561/c
ID   AAL61561 standard; DNA; 20 BP.
XX
AC   AAL61561;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130486.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1300 CCATGGTCATCTGTGAGCAG 1319
             ||||||||||||||||||||
```

```
Db         20 CCATGGTCATCTGTGAGCAG 1


RESULT 13
AAL61564/c
ID   AAL61564 standard; DNA; 20 BP.
XX
AC   AAL61564;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130489.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1328 CCTCTTCTCCAAGGCAGGAG 1347
              ||||||||||||||||||||
Db         20 CCTCTTCTCCAAGGCAGGAG 1


RESULT 14
AAL61540/c
ID   AAL61540 standard; DNA; 20 BP.
XX
AC   AAL61540;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130465.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
```

```
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        909 CTGTGCAACGATTACTTCAG 928
              ||||||||||||||||||||
Db         20 CTGTGCAACGATTACTTCAG 1


RESULT 15
AAL61545/c
ID   AAL61545 standard; DNA; 20 BP.
XX
AC   AAL61545;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130470.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 CACTCCCAGGCTATGCGCTG 1042
              ||||||||||||||||||||
Db         20 CACTCCCAGGCTATGCGCTG 1


RESULT 16
AAL61562/c
ID   AAL61562 standard; DNA; 20 BP.
XX
AC   AAL61562;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130487.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
```

```
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1310 CTGTGAGCAGCTAGGGGACC 1329
              ||||||||||||||||||||
Db         20 CTGTGAGCAGCTAGGGGACC 1


RESULT 17
AAL61580/c
ID   AAL61580 standard; DNA; 20 BP.
XX
AC   AAL61580;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130505.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1658 GCAGAGGCAGGTCTTGCAGC 1677
              ||||||||||||||||||||
Db         20 GCAGAGGCAGGTCTTGCAGC 1


RESULT 18
AAL61570/c
ID   AAL61570 standard; DNA; 20 BP.
XX
AC   AAL61570;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130495.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
```

```
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1463 CATGAAGGACCACCATGGGG 1482
              ||||||||||||||||||||
Db         20 CATGAAGGACCACCATGGGG 1


RESULT 19
AAL61571/c
ID   AAL61571 standard; DNA; 20 BP.
XX
AC   AAL61571;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130496.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1485 GTGCGCCACTATGAGGAGGA 1504
              ||||||||||||||||||||
Db         20 GTGCGCCACTATGAGGAGGA 1


RESULT 20
AAL61555/c
ID   AAL61555 standard; DNA; 20 BP.
XX
AC   AAL61555;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130480.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
```

```
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1223 GAACCTCCAGCATGTGCTGG 1242
              ||||||||||||||||||||
Db         20 GAACCTCCAGCATGTGCTGG 1


RESULT 21
AAL61550/c
ID   AAL61550 standard; DNA; 20 BP.
XX
AC   AAL61550;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130475.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 7 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1099 AGTGCTGCGTGGTTATTGCA 1118
              ||||||||||||||||||||
Db         20 AGTGCTGCGTGGTTATTGCA 1


RESULT 22
AAL61551/c
ID   AAL61551 standard; DNA; 20 BP.
XX
AC   AAL61551;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130476.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
```

```
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match              0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1112 TATTGCACAGGTCCTCCAAG 1131
              ||||||||||||||||||||
Db         20 TATTGCACAGGTCCTCCAAG 1


RESULT 23
AAL61566/c
ID   AAL61566 standard; DNA; 20 BP.
XX
AC   AAL61566;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130491.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match              0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1347 GACTTTCCCAGGGCAGCTGA 1366
              ||||||||||||||||||||
Db         20 GACTTTCCCAGGGCAGCTGA 1


RESULT 24
AAL61577/c
ID   AAL61577 standard; DNA; 20 BP.
XX
```

```
AC   AAL61577;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130502.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1583 CGATGCCTACGAGCTGCTGG 1602
              ||||||||||||||||||||
Db         20 CGATGCCTACGAGCTGCTGG 1
```

```
RESULT 25
AAL61581/c
ID   AAL61581 standard; DNA; 20 BP.
XX
AC   AAL61581;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130506.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1662 AGGCAGGTCTTGCAGCATCT 1681
              ||||||||||||||||||||
Db         20 AGGCAGGTCTTGCAGCATCT 1


RESULT 26
AAL61548/c
ID   AAL61548 standard; DNA; 20 BP.
XX
AC   AAL61548;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130473.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1072 CCATGAGGAAGCGGTTCATG 1091
              ||||||||||||||||||||
Db         20 CCATGAGGAAGCGGTTCATG 1


RESULT 27
AAL61567/c
ID   AAL61567 standard; DNA; 20 BP.
XX
AC   AAL61567;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130492.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
```

```
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1373 CCAGAAGCAGCTGCGTTTTG 1392
              ||||||||||||||||||||
Db         20 CCAGAAGCAGCTGCGTTTTG 1


RESULT 28
AAL61582/c
ID   AAL61582 standard; DNA; 20 BP.
XX
AC   AAL61582;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130507.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1664 GCAGGTCTTGCAGCATCTCC 1683
              ||||||||||||||||||||
Db         20 GCAGGTCTTGCAGCATCTCC 1


RESULT 29
AAL61539/c
ID   AAL61539 standard; DNA; 20 BP.
XX
AC   AAL61539;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130464.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
```

```
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        896 GCAGCAGACAGCCCTGTGCA 915
              ||||||||||||||||||||
Db         20 GCAGCAGACAGCCCTGTGCA 1


RESULT 30
AAL61547/c
ID   AAL61547 standard; DNA; 20 BP.
XX
AC   AAL61547;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130472.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1061 GTGTGCGCACACCATGAGGA 1080
              ||||||||||||||||||||
Db         20 GTGTGCGCACACCATGAGGA 1


RESULT 31
AAL61574/c
ID   AAL61574 standard; DNA; 20 BP.
XX
AC   AAL61574;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130499.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
```

```
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1526 CGTGCTGGAGGAGGCCAAGA 1545
              ||||||||||||||||||||
Db         20 CGTGCTGGAGGAGGCCAAGA 1


RESULT 32
AAL61575/c
ID   AAL61575 standard; DNA; 20 BP.
XX
AC   AAL61575;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130500.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1530 CTGGAGGAGGCCAAGACCTG 1549
              ||||||||||||||||||||
Db         20 CTGGAGGAGGCCAAGACCTG 1


RESULT 33
AAL61584/c
ID   AAL61584 standard; DNA; 20 BP.
XX
AC   AAL61584;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130509.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
```

```
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1690 TGCAGCTGAGGCTGCAGCCC 1709
              ||||||||||||||||||||
Db         20 TGCAGCTGAGGCTGCAGCCC 1


RESULT 34
AAL61585/c
ID   AAL61585 standard; DNA; 20 BP.
XX
AC   AAL61585;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130510.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1730 AACCAGACTGCGGGAGCTCA 1749
              ||||||||||||||||||||
Db         20 AACCAGACTGCGGGAGCTCA 1


RESULT 35
AAL61552/c
ID   AAL61552 standard; DNA; 20 BP.
XX
AC   AAL61552;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130477.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
```

```
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1182 CTGGGCTCCCAGAAGCCTGT 1201
              ||||||||||||||||||||
Db         20 CTGGGCTCCCAGAAGCCTGT 1


RESULT 36
AAL61553/c
ID   AAL61553 standard; DNA; 20 BP.
XX
AC   AAL61553;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130478.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1194 AAGCCTGTGCAGAGGGCAGC 1213
              ||||||||||||||||||||
Db         20 AAGCCTGTGCAGAGGGCAGC 1
```

```
RESULT 37
AAL61556/c
ID   AAL61556 standard; DNA; 20 BP.
XX
AC   AAL61556;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130481.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1234 ATGTGCTGGCAGTGGTCCGG 1253
              ||||||||||||||||||||
Db         20 ATGTGCTGGCAGTGGTCCGG 1

RESULT 38
AAL61542/c
ID   AAL61542 standard; DNA; 20 BP.
XX
AC   AAL61542;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130467.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
```

```
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        947 GGAGCAGAACCACCTTTACG 966
              ||||||||||||||||||||
Db         20 GGAGCAGAACCACCTTTACG 1


RESULT 39
AAL61559/c
ID   AAL61559 standard; DNA; 20 BP.
XX
AC   AAL61559;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130484.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1289 CCCTCAGGGTGCCATGGTCA 1308
              ||||||||||||||||||||
Db         20 CCCTCAGGGTGCCATGGTCA 1


RESULT 40
AAL61560/c
ID   AAL61560 standard; DNA; 20 BP.
XX
AC   AAL61560;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130485.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
```

```
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1297 GTGCCATGGTCATCTGTGAG 1316
              ||||||||||||||||||||
Db         20 GTGCCATGGTCATCTGTGAG 1


RESULT 41
AAL61576/c
ID   AAL61576 standard; DNA; 20 BP.
XX
AC   AAL61576;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130501.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1532 GGAGGAGGCCAAGACCTGGC 1551
              ||||||||||||||||||||
Db         20 GGAGGAGGCCAAGACCTGGC 1


RESULT 42
AAL61557/c
ID   AAL61557 standard; DNA; 20 BP.
XX
AC   AAL61557;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130482.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
```

```
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 9 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1238 GCTGGCAGTGGTCCGGCTGC 1257
              ||||||||||||||||||||
Db         20 GCTGGCAGTGGTCCGGCTGC 1


RESULT 43
AAL61573/c
ID   AAL61573 standard; DNA; 20 BP.
XX
AC   AAL61573;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130498.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1494 TATGAGGAGGAACTGAGGCT 1513
              ||||||||||||||||||||
Db         20 TATGAGGAGGAACTGAGGCT 1


RESULT 44
AAL61568/c
ID   AAL61568 standard; DNA; 20 BP.
XX
AC   AAL61568;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130493.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
```

```
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1392 GCTGAGCTGCTGGACAGACC 1411
              ||||||||||||||||||||
Db         20 GCTGAGCTGCTGGACAGACC 1


RESULT 45
AAL61538/c
ID   AAL61538 standard; DNA; 20 BP.
XX
AC   AAL61538;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130463.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        840 CTGAATGAGATGAGGACCCG 859
              ||||||||||||||||||||
Db         20 CTGAATGAGATGAGGACCCG 1


RESULT 46
AAL61541/c
ID   AAL61541 standard; DNA; 20 BP.
XX
AC   AAL61541;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130466.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
```

```
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match              0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        940 TCCTTGCGGAGCAGAACCAC 959
              ||||||||||||||||||||
Db         20 TCCTTGCGGAGCAGAACCAC 1


RESULT 47
AAL61572/c
ID   AAL61572 standard; DNA; 20 BP.
XX
AC   AAL61572;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130497.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match              0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1488 CGCCACTATGAGGAGGAACT 1507
              ||||||||||||||||||||
Db         20 CGCCACTATGAGGAGGAACT 1


RESULT 48
AAL61583/c
ID   AAL61583 standard; DNA; 20 BP.
XX
AC   AAL61583;
XX
```

```
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130508.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1680 CTCCATACCGTGCAGCTGAG 1699
              ||||||||||||||||||||
Db         20 CTCCATACCGTGCAGCTGAG 1

RESULT 49
AAL61543/c
ID   AAL61543 standard; DNA; 20 BP.
XX
AC   AAL61543;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130468.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        960 CTTTACGAGGACCTATTCCG 979
              ||||||||||||||||||||
Db         20 CTTTACGAGGACCTATTCCG 1


RESULT 50
AAL61586/c
ID   AAL61586 standard; DNA; 20 BP.
XX
AC   AAL61586;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130511.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1842 TCAGAGAGCGAGGACGACAC 1861
              ||||||||||||||||||||
Db         20 TCAGAGAGCGAGGACGACAC 1


RESULT 51
AAL61558/c
ID   AAL61558 standard; DNA; 20 BP.
XX
AC   AAL61558;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130483.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
```

```
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AGCAACAGCTGGAAGAGGCT 1277
              ||||||||||||||||||||
Db         20 AGCAACAGCTGGAAGAGGCT 1


RESULT 52
AAL61565/c
ID   AAL61565 standard; DNA; 20 BP.
XX
AC   AAL61565;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130490.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothicate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1342 CAGGAGACTTTCCCAGGGCA 1361
              ||||||||||||||||||||
Db         20 CAGGAGACTTTCCCAGGGCA 1


RESULT 53
AAL61569/c
ID   AAL61569 standard; DNA; 20 BP.
XX
AC   AAL61569;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130494.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
```

```
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches   .0;  Indels    0;  Gaps    0;

Qy       1414 GTGCTGAGCGGGCCATCATC 1433
              ||||||||||||||||||||
Db         20 GTGCTGAGCGGGCCATCATC 1


RESULT 54
AAL61579/c
ID   AAL61579 standard; DNA; 20 BP.
XX
AC   AAL61579;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130504.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1652 CCAGCTGCAGAGGCAGGTCT 1671
              ||||||||||||||||||||
Db         20 CCAGCTGCAGAGGCAGGTCT 1


RESULT 55
AAH62253
ID   AAH62253 standard; DNA; 21 BP.
XX
AC   AAH62253;
XX
DT   12-SEP-2001  (first entry)
XX
DE   NF-kappa-B inhibitor polymorphism containing DNA fragment #154.
XX
KW   Single nucleotide polymorphism; SNP; human; cancer; inflammation;
KW   heart disease; paternity testing; forensic science; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Variation       replace(11,T)
FT                    /*tag=  a
FT                    /standard_name= "single nucleotide polymorphism"
XX
PN   WO200138576-A2.
XX
PD   31-MAY-2001.
XX
PF   17-NOV-2000; 2000WO-US031639.
XX
PR   24-NOV-1999;   99US-0167334P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
PI   Cargill M,  Ireland JS,  Lander ES;
XX
DR   WPI; 2001-367705/38.
XX
PT   New nucleic acid segments of the human genome, particularly from genes
PT   including polymorphic sites,for phenotype correlation, forensics,
PT   paternity testing, medicine and genetic analysis.
```

```
XX
PS   Claim 1; Page 42; 80pp; English.
XX
CC   DNA sequences AAH62100 - AAH62688 represent segments of human genes which
CC   contain single nucleotide polymorphisms (SNPs). A method is included in
CC   the invention for analysing a nucleic acid sample, which consists of
CC   determining the base occupying any one of the polymorphic sites given in
CC   the SNP containing sequences. The nucleotide sequences can be used in the
CC   diagnosis or monitoring of diseases, such as cancer, inflammation, heart
CC   diseases, diseases of the cardiovascular system, and infection by
CC   microorganisms. The oligonucleotides are also useful in the manufacture
CC   of a medicament for the treatment or prophylaxis of the diseases, and as
CC   a pharmaceutical. SNP containing oligonucleotides are useful in
CC   applications such as phenotype correlation, forensics, paternity testing,
CC   medicine and genetic analysis
XX
SQ   Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1624 TCAGCTGTGCTCAGCAGGCCC 1644
              ||||||||||.||||||||||
Db          1 TCAGCTGTGCCCAGCAGGCCC 21


RESULT 56
AAT99287
ID   AAT99287 standard; DNA; 24 BP.
XX
AC   AAT99287;
XX
DT   15-APR-1998  (first entry)
XX
DE   upTAR element dimer oligonucleotide for binding human PUR-alpha.
XX
KW   PUR element; human; c-myc; inhibitor; hyperproliferative disease; ss;
KW   cancer; probe; hybridisation.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5672479-A.
XX
PD   30-SEP-1997.
XX
PF   07-JUN-1995;   95US-00486421.
XX
PR   28-AUG-1992;   92US-00938189.
PR   02-FEB-1993;   93US-00014943.
PR   06-JUN-1995;   95US-00470911.
XX
PA   (MOUN ) MOUNT SINAI SCHOOL MEDICINE.
XX
PI   Bergemann AD,  Johnson EM;
XX
DR   WPI; 1997-488859/45.
XX
PT   Assays for PUR protein ligands or modulators - using immobilised PUR
PT   protein or fragments, to treat hyper-proliferative diseases, e.g. cancer.
XX
PS   Example; Col 39; 64pp; English.
XX
CC   This oligonucleotide represents a dimer sequence of the upTAR element and
CC   was used as a competitor oligonucleotide in a gel shift assay for the
CC   binding of PUR protein to DNA. The PUR sequence can be used to identify
CC   chemical or biological compounds that bind to PUR or binding fragments of
CC   PUR. Inhibitors of PUR activity may be used to treat hyperproliferative
CC   diseases such as cancer
XX
SQ   Sequence 24 BP; 4 A; 4 C; 16 G; 0 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 18;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
              ||||| |||||||||||| || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 57
AAV31744
ID   AAV31744 standard; DNA; 24 BP.
XX
AC   AAV31744;
XX
DT   24-SEP-1998  (first entry)
XX
DE   Nucleotide sequence of a purine-rich oligonucleotide.
XX
KW   PUR-alpha gene; inhibition; viral infection; cancer; PUR element;
KW   hyperproliferative disease; ss.
XX
OS   Synthetic.
XX
PN   US5756684-A.
XX
PD   26-MAY-1998.
XX
PF   06-JUN-1995;   95US-00470911.
XX
PR   28-AUG-1992;   92US-00938189.
PR   02-FEB-1993;   93US-00014943.
XX
PA   (MOUN ) MOUNT SINAI SCHOOL MEDICINE.
XX
PI   Bergemann AD,  Johnson EM;
XX
DR   WPI; 1998-321632/28.
XX
PT   PUR protein and its fragments - that inhibit PUR protein binding to PUR
PT   element or other proteins.
XX
PS   Example 7.1.1; Col 33; 63pp; English.
XX
CC   This is the nucleotide sequence of a purine-rich oligonucleotide used as
CC   a competitor with the PUR element in the method of the invention,
CC   involving the use of the PUR protein and its fragments, which inhibit PUR
CC   protein binding to PUR element or other proteins. Inhibitors of PUR
CC   activity may be useful for treating viral infections and
CC   hyperproliferative diseases such as cancer
XX
SQ   Sequence 24 BP; 4 A; 4 C; 16 G; 0 T; 0 U; 0 Other;

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 18;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
              ||||| |||||||||||| || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 58
AAX04092
ID   AAX04092 standard; DNA; 24 BP.
XX
AC   AAX04092;
XX
DT   12-APR-1999  (first entry)
XX
DE   upTAR element oligonucleotide purine-rich probe.
XX
KW   PUR element; PUR-alpha; hyperproliferative disease; cancer; human;
```

KW monoclonal antibody; identification; characterisation; probe; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5869622-A.
XX
PD 09-FEB-1999.
XX
PF 07-JUN-1995; 95US-00486809.
XX
PR 28-AUG-1992; 92US-00938189.
PR 02-FEB-1993; 93US-00014943.
PR 06-JUN-1995; 95US-00470911.
XX
PA (MOUN) MOUNT SINAI SCHOOL MEDICINE.
XX
PI Bergemann AD, Johnson EM;
XX
DR WPI; 1999-152881/13.
XX
PT Monoclonal antibody specific for PUR protein - useful for treating
PT cancer.
XX
PS Example; Col 40; 64pp; English.
XX
CC The present invention describes a monoclonal antibody that specifically
CC binds to an epitope of the PUR protein. Antibodies that bind to the PUR
CC protein and neutralise PUR activity may be used to treat
CC hyperproliferative diseases such as cancer. PUR antibodies may be used
CC diagnostically to detect aberrant expression of the PUR protein and/or
CC mutations in the PUR gene. The present sequence represents an upTAR
CC element oligonucleotide purine-rich probe, which is used in an example
CC from the present invention
XX
SQ Sequence 24 BP; 4 A; 4 C; 16 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
||||| |||||||||||| || |||
Db 1 GGAGGCGGAGGCGGAGGCGGAGGC 24

RESULT 59
AAZ99647
ID AAZ99647 standard; DNA; 24 BP.
XX
AC AAZ99647;
XX
DT 12-JUL-2000 (first entry)
XX
DE Nucleotide sequence of non-G-motif oligonucleotide Pur-alpha-Ori.
XX
KW G-motif oligonucleotide; vaccine; Toxoplasmosis; viral infection;
KW antigen presenting cell activation; natural killer cell; septic shock;
KW cytotoxic T-lymphocyte; inflammation; autoimmune disease;
KW rheumatoid arthritis; Crohn's disease; sarcoidosis; multiple sclerosis;
KW Kawasaki syndrome; graft-versus-host disease; transplant rejection;
KW helper T cell response 1-mediated disease; Lyme arthritis;
KW Streptococcal induced arthritis; chronic inflammatory bowel disease;
KW psoriasis vulgaris; experimental allergic encephalomyelitis;
KW insulin-dependent diabetes mellitus; bacterial infection;
KW parasitic infection; Leishmaniasis; spontaneous abortion; tumour; ss.
XX
OS Synthetic.
XX
PN WO200014217-A2.
XX
PD 16-MAR-2000.
XX
PF 03-SEP-1999; 99WO-EP006502.
XX
PR 03-SEP-1998; 98EP-00116652.
XX
PA (CPGI-) CPG IMMUNOPHARMACEUTICALS GMBH.
XX
PI Wagner H, Lipford GB, Heeg K;
XX
DR WPI; 2000-256970/22.
XX
PT Compositions comprising G-motif oligonucleotides useful for treating e.g.
PT septic shock, rheumatoid arthritis, diabetes and human immunodeficiency
PT virus infections.
XX
PS Example 14; Page 32; 75pp; English.
XX
CC The present sequence represents a non-G-motif oligonucleotide of the
CC invention. The specification describes compositions comprising G-motif
CC oligonucleotides. The G-motif oligonucleotides inhibit activation of
CC antigen presenting cells by inhibiting the uptake of DNA by a cell, by
CC stimulating natural killer cells, or by co-stimulating cytotoxic T-
CC lymphocytes. The G-motif oligonucleotides may be used for the productions
CC of vaccines for treating septic shock, inflammation, autoimmune diseases
CC (e.g. rheumatoid arthritis, Crohn's disease, sarcoidosis, multiple
CC sclerosis, Kawasaki syndrome, graft-versus-host disease and transplant
CC rejection), helper T cell response 1-mediated diseases (e.g.
CC Streptococcal induced arthritis, Lyme arthritis, chronic inflammatory
CC bowel disease, psoriasis vulgaris, experimental allergic
CC encephalomyelitis, and insulin-dependent diabetes mellitus), bacterial
CC infections, parasitic infections (e.g. Leishmaniasis or Toxoplasmosis),
CC viral infections (e.g. Cytomegalovirus and human immunodeficiency virus
CC (HIV)-infections), spontaneous abortions and tumours. They may also be
CC used to induce proliferation of bone marrow cells, especially macrophage
CC precursor cells
XX
SQ Sequence 24 BP; 4 A; 4 C; 16 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
||||| |||||||||||| || |||
Db 1 GGAGGCGGAGGCGGAGGCGGAGGC 24

RESULT 60
AAQ55605
ID AAQ55605 standard; DNA; 20 BP.
XX
AC AAQ55605;
XX
DT 14-JUL-1994 (first entry)
XX
DE 3' flanking sequence primer for manipulation of cloned insert.
XX
KW Polymerase chain reaction; mutation; mutagenesis; alteration; deletion;
KW insertion; repetition; amplification; ss.
XX
OS Synthetic.
XX
PN US5279952-A.
XX
PD 18-JAN-1994.
XX
PF 09-AUG-1991; 91US-00743245.
XX
PR 09-AUG-1991; 91US-00743245.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Wu KC;
XX

```
DR   WPI; 1994-034337/04.
XX
PT   Construction of altered DNA molecules - using polymerase chain reaction
PT   to amplify a segment of a cloned segment of DNA obtd. by endonuclease
PT   cleavage.
XX
PS   Disclosure; Col 11; 24pp; English.
XX
CC   Synthetic flanking sequences (see AAQ55601) were used to illustrate the
CC   novel method; a direct repeat of a specific cloned region of DNA which
CC   lies between the flanking sequences can be constructed using primers
CC   having the sequences in AAQ55602-Q55605
XX
SQ   Sequence 20 BP; 7 A; 0 C; 13 G; 0 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   95.0%;  Pred. No. 16;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGA 1789
              ||||||||||||| ||||||
Db          1 GAGGAGGAGGAGGAGGAGGA 20


RESULT 61
AAT11643/c
ID   AAT11643 standard; DNA; 21 BP.
XX
AC   AAT11643;
XX
DT   16-APR-1996  (first entry)
XX
DE   WT1/EGR human TCC binding site.
XX
KW   Osteogenic protein; OP-1; reporter gene; screening; identification;
KW   intron; non-coding sequence; ss.
XX
OS   Homo sapiens.
XX
PN   WO9533831-A1.
XX
PD   14-DEC-1995.
XX
PF   07-JUN-1995;   95WO-US007349.
XX
PR   07-JUN-1994;   94US-00255250.
XX
PA   (CREA-) CREATIVE BIOMOLECULES INC.
XX
PI   Ozkaynak E,  Oppermann H;
XX
DR   WPI; 1996-040236/04.
XX
PT   Isolation of compounds to modulate OP-1 expression - by monitoring
PT   expression changes in a cell transformed to express osteogenic protein-1
PT   and having additional steroid binding site.
XX
PS   Disclosure; Page 58; 77pp; English.
XX
CC   The human and murine osteogenic protein-1 (OP-1) non-coding sequences can
CC   be used in the construction of expression vectors comprising a reporter
CC   gene which has the non-coding sequence lying contiguous to the reporter
CC   gene, the non-coding sequence being able to act on and affect expression
CC   of the reporter gene when bound to by candidate compounds. The method is
CC   used to identify compounds capable of modulating OP-1 expression. The
CC   vector may optionally comprise a second non-coding sequence and the non-
CC   coding sequence(s) used define at least one, preferably 1-6, WT1/EGR
CC   binding elements, at least one FTZ (Fushi-Tarazu) binding element or a
CC   steroid binding element
XX
SQ   Sequence 21 BP; 0 A; 14 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 18;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
              |||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 62
AAA59901/c
ID   AAA59901 standard; DNA; 21 BP.
XX
AC   AAA59901;
XX
DT   16-OCT-2000  (first entry)
XX
DE   Human OP-1 Wt-1/Egr-1 binding site.
XX
KW   Osteogenic protein-1; OP-1; morphogenic protein; human; osteoporosis;
KW   morphogen concentration; bone metabolism disease; ss.
XX
OS   Homo sapiens.
XX
PN   US6071695-A.
XX
PD   06-JUN-2000.
XX
PF   07-JUN-1995;   95US-00486343.
XX
PR   21-FEB-1992;   92US-00841646.
PR   01-NOV-1993;   93US-00147023.
PR   07-JUN-1994;   94US-00255250.
PR   23-MAY-1995;   95US-00449700.
PR   24-MAY-1995;   95US-00449699.
XX
PA   (CREA-) CREATIVE BIOMOLECULES INC.
XX
PI   Oppermann H,  Ozkaynak E;
XX
DR   WPI; 2000-422077/36.
XX
PT   Screening for compounds able to modulate osteogenic protein-1 (OP-1)
PT   expression by incubating a candidate compound with a nucleic acid with a
PT   reporter gene operatively associated with an OP-1 non-coding nucleic acid
PT   fragment.
XX
PS   Disclosure; Col 47; 33pp; English.
XX
CC   A method for screening a candidate compound for its ability to modulate
CC   the expression of osteogenic protein-1 (OP-1) uses a cell transfected
CC   with a nucleic acid sequence comprising a reporter gene and an upstream
CC   non-coding sequence from OP-1. OP-1 is a tissue morphogenic protein. The
CC   method is useful for screening compounds capable of stimulating or
CC   inhibiting transcription and/or translation of the OP-1 gene, as well as
CC   compounds which may be used as therapeutics for in vivo and ex vivo
CC   mammalian applications, e.g. morphogen expression inducing compounds for
CC   correcting and alleviating a diseased condition or to regenerate lost or
CC   damaged tissue. The compounds may also be used to maintain viability of
CC   the differentiated phenotype of cells in culture. Morphogen expression
CC   inhibiting compounds identified by the new method can be used to modulate
CC   the degree and/or timing of morphogen concentration. Compounds which up-
CC   regulate levels of circulating OP-1 in vivo can be used to correct bone
CC   metabolism diseases such as osteoporosis. This sequence represents the
CC   TCC binding sequence or Wt-1/Egr-1 binding site sequence contained in the
CC   upstream region of the osteogenic protein-1 (OP-1) gene. The DNA binding
CC   proteins Wt-1 and Egr-1 bind to and control transcription of DNA
CC   sequences at these sites
XX
SQ   Sequence 21 BP; 0 A; 14 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 18;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
                ||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 63
ABK99278/c
ID   ABK99278 standard; RNA; 21 BP.
XX
AC   ABK99278;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Hepatitis C virus (HCV) NS5B replicase RNA synthesis template #8.
XX
KW   Hepatitis C virus; HCV; NS5B replicase; ss; RNA polymerase.
XX
OS   Synthetic.
XX
PN   US2002064771-A1.
XX
PD   30-MAY-2002.
XX
PF   06-APR-2001; 2001US-00828034.
XX
PR   07-APR-2000; 2000US-0195852P.
XX
PA   (ZHON/) ZHONG W.
PA   (HONG/) HONG Z.
PA   (FERR/) FERRARI E.
XX
PI   Zhong W, Hong Z, Ferrari E;
XX
DR   WPI; 2002-582330/62.
XX
PT   Novel replicase complex comprising hepatitis C virus NS5B replicase, a 3
PT   nucleotide-long template to which a 2 nucleotide-long primer is annealed,
PT   and template and primer which do not form a stable duplex in the absence
PT   of HCV NS5B.
XX
PS   Example; Page 6; 17pp; English.
XX
CC   The invention relates to a replicase complex comprising a hepatitis C
CC   virus (HCV) NS5B replicase protein, a linear nucleic acid template and a
CC   complementary nucleic acid primer which is annealed to the 3' terminus of
CC   the template, where the template is at least three nucleotides and the
CC   primer is two or three nucleotides, and the template and primer do not
CC   form a stable duplex in solution in the absence of the HCV NS5B protein.
CC   The complex is useful for detecting HCV replicase activity and permits
CC   establishment of sensitive RNA-dependent RNA polymerase assays to screen
CC   and evaluate antiviral inhibitors and to improve the specificity and
CC   efficacy of the inhibitors. The complex is also useful in the development
CC   of a reliable system for determining kinetic and thermodynamic constants
CC   of HCV NS5B-catalysed nucleotide incorporation and investigation of
CC   mechanistic inhibitors for mis-incorporation or chain termination.
CC   Specifically, the short RNA template and primer pairs are useful in
CC   screening assays which are used for determining kinetic, thermodynamic
CC   and mechanistic properties of NS5B replication and ultimately in the
CC   development of inhibitors of NS5B. Newly identified inhibitors of
CC   replicase activity may be used for developing anti-HCV pharmaceuticals.
CC   Sequences ABK99271-ABK99296 represent HCV NS5B replicase RNA synthesis
CC   templates
XX
SQ   Sequence 21 BP; 0 A; 14 C; 0 G; 0 T; 7 U; 0 Other;

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 18;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
                ||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 64
AAQ10661
ID   AAQ10661 standard; DNA; 23 BP.
XX
AC   AAQ10661;
XX
DT   25-MAR-2003  (revised)
DT   29-APR-1991  (first entry)
XX
DE   HLA Class II locus-specific primer DQB E1.
XX
KW   Human leukocyte antigen; major histocompatibility complex; MHC;
KW   restriction fragment length polymorphic analysis; RFLP; tissue typing;
KW   allele; PCR; ss.
XX
OS   Synthetic.
XX
PN   EP414469-A.
XX
PD   27-FEB-1991.
XX
PF   20-AUG-1990;   90EP-00309107.
XX
PR   25-AUG-1989;   89US-00398217.
PR   11-SEP-1989;   89US-00405499.
PR   16-JAN-1990;   90US-00465863.
PR   11-JUL-1990;   90US-00551239.
XX
PA   (GENE-) GENETYPE AG.
PA   (JEAN-) GENETYPE AG.
PA   (SIMO/) SIMONS M J.
XX
PI   Simons MJ;
XX
DR   WPI; 1991-059664/09.
XX
PT   Detection of adjacent and non:adjacent locus, e.g. HLA alleles - by
PT   amplifying genomic DNA, for direct determination of haplotype.
XX
PS   Claim 29; Page 49; 53pp; English.
XX
CC   The primer is specific for nt 509-532 of HLA Class II DQw1va allele of
CC   the DQB1 locus. It is used in a method for the prodn. of RFLP fragments
CC   for an HLA locus, together with a second primer making up a locus-
CC   specific primer (LSP) pair. The primers pref. define a DNA sequence that
CC   contains all exons that encode allelic variability associated with the
CC   HLA locus together with at least one of the adjacent intron sequences.
CC   For Class II loci the variable exon is the second exon. The primers are
CC   pref. located so that a substantial portion of the amplified sequence
CC   corresponds to intron sequences. Direct deter- mination of the haplotype
CC   is possible, providing useful information for identity of individuals for
CC   e.g. paternity case and forensic investigations. See also AAQ10621-
CC   Q10669. (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ   Sequence 23 BP; 4 A; 7 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 23;
  Best Local Similarity   95.0%;  Pred. No. 23;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1274 GGCTGAGGGCAGAGACCCTC 1293
                ||||||||||||||||| |||
Db          2 GGCTGAGGGCAGAGACTCTC 21


RESULT 65
AAZ21462/c
ID   AAZ21462 standard; DNA; 20 BP.
XX
AC   AAZ21462;
XX
```

```
DT   02-DEC-1999  (first entry)
XX
DE   Human BURB1 PCR primer #4.
XX
KW   Human; BUB1; BUBR1; hBUB1; hBUBR1; mutation; mitosis; diagnosis;
KW   microsatellite instability; MIN; tumour; mismatch repair; CIN;
KW   chromosomal instability; detection; cell proliferative disorder;
KW   neoplasm; breast cancer; colorectal cancer; fibrotic disorder;
KW   benign hyperplasia; neoplasia; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9947638-A2.
XX
PD   23-SEP-1999.
XX
PF   16-MAR-1999;   99WO-US005692.
XX
PR   16-MAR-1998;   98US-0078196P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI   Vogelstein B,  Kinzler KW,  Cahill D,  Lengaver C;
XX
DR   WPI; 1999-562100/47.
XX
PT   Use of mitotic checkpoint genes for developing methods for the diagnosis
PT   and treatment of cell proliferative disorders or for increasing the
PT   proliferation of cells.
XX
PS   Example; Page 34; 56pp; English.
XX
CC   The present invention describes the use of mitotic check point genes
CC   (MCPGs) in the diagnosis and treatment of cell proliferative disorders. A
CC   method has been developed for diagnosing a cell proliferative disorder in
CC   a subject associated with a MCPG, by determining the presence of a mutant
CC   MCPG in the sample where the presence of a mutant MCPG in the sample is
CC   indicative of a cell proliferative disorder. The method can be used for
CC   diagnosing a cell proliferative disorder such as a neoplasm, e.g. breast
CC   or colorectal neoplasm. It can also be used for treating a cell
CC   proliferative disorder, e.g. a fibrotic disorder, benign hyperplasia or
CC   neoplasia, particularly colon or breast cancer. It can also be used for
CC   treating disorders associated with insufficient cell proliferation or
CC   undesirable cell degeneration. The present sequence represents a PCR
CC   primer used to amplify human BUBR1, in an example from the present
CC   invention. Loss of a MCPG is associated with the mutational inactivation
CC   of the human BUB1 gene
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 26;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1373 CCAGAAGCAGCTGCGTTTT 1391
              ||||||||||||| ||||||
Db         19 CCAGAAGCAGCTCCGTTTT 1

RESULT 66
AAF73052/c
ID   AAF73052 standard; DNA; 20 BP.
XX
AC   AAF73052;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:153.
XX
KW   Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
KW   Fas binding protein; CENP-C binding protein; dap6; EAP; cytostatic;
KW   antiinflammatory; death associated protein 6; Ets-1 associated protein;
KW   infection; inflammation; tumour formation; ss.
XX
OS   Homo sapiens.
XX
PN   US6180353-B1.
XX
PD   30-JAN-2001.
XX
PF   24-JAN-2000; 2000US-00490692.
XX
PR   24-JAN-2000; 2000US-00490692.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Cowsert LM;
XX
DR   WPI; 2001-217744/22.
XX
PT   Novel antisense compounds capable of modulating expression of daxx useful
PT   for diagnosis, prophylaxis and treatment of diseases associated with
PT   expression of daxx.
XX
PS   Claim 1; Col 49; 59pp; English.
XX
CC   The present invention describes an antisense compound (I) up to 30
CC   nucleobases in length, where (I) inhibits expression of daxx (also known
CC   as Fas binding protein, CENP-C binding protein, dap6 for death associated
CC   protein 6 and EAP for Ets-1 associated protein). (I) has cytostatic and
CC   antiinflammatory activity, and can be used in antisense therapy and as a
CC   modulator of daxx. (I) is useful for inhibiting the expression of daxx in
CC   cells or tissues in vitro. (I) can be utilised for diagnostics,
CC   therapeutics for the treatment of diseases associated with the expression
CC   of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
CC   tumour formation and as research reagent. The present sequence represents
CC   an inhibitory human daxx antisense phosphorothioate oligonucleotide which
CC   is used in the exemplification of the present invention
XX
SQ   Sequence 20 BP; 1 A; 13 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 26;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 TGAGGAGGAGGAGGCGGAG 1787
              ||||||||||||||| ||||
Db         19 TGAGGAGGAGGAGGAGGAG 1

RESULT 67
AAC92593/c
ID   AAC92593 standard; DNA; 20 BP.
XX
AC   AAC92593;
XX
DT   27-MAR-2001  (first entry)
XX
DE   Human nucleolin phosphorothioate antisense oligonucleotide, SEQ ID NO:43.
XX
KW   Human nucleolin; P92; C23; phosphoprotein; ribosome biogenesis;
KW   ribosome transport; cytokinesis; nucleogenesis; cell proliferation;
KW   cell growth; transcriptional repression; replication;
KW   signal transduction; chromatin decondensation; Ag-NOR family;
KW   nucleolin antibody; systemic connective tissue disease; SLE;
KW   systemic lupus erythematosus;
KW   scleroderma-like chronic graft versus host disease;
KW   expression inhibition; tumour formation; cancer; inflammation;
KW   immune disorder; phosphorothioate; antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   US6165786-A.
XX
PD   26-DEC-2000.
```

```
XX
PF   03-NOV-1999;   99US-00433699.
XX
PR   03-NOV-1999;   99US-00433699.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2001-079848/09.
XX
PT   Novel antisense compound targeted to human nucleolin which specifically
PT   hybridizes with and inhibits the expression of human nucleolin, useful
PT   for modulating the expression of nucleolin in cells.
XX
PS   Example 15; Col 41-42; 41pp; English.
XX
CC   Sequences AAC92560-C92639 represent antisense oligonucleotides targetted
CC   to the human nucleolin gene, which inhibit its expression. The antisense
CC   oligonucleotides were designed to target different regions of the human
CC   nucleolin mRNA, and were analysed for their effect on nucleolin mRNA
CC   levels by quantitative real-time PCR. Nucleolin (also known as P92 or
CC   C23) is the most abundant nucleolar phosphoprotein in actively growing
CC   cells. Nucleolin primarily participates in ribosome biogenesis and
CC   transport of ribosomal components, being able to transiently bind to pre-
CC   ribosomes in the nucleolus via a ribonucleoprotein consensus sequence.
CC   However, it has also been shown to be involved in cytokinesis,
CC   nucleogenesis, cell proliferation and growth, transcriptional repression,
CC   replication, signal transduction, and chromatin decondensation. Nucleolin
CC   is a member of the Ag-NOR (active ribosomal gene located in the nucleolar
CC   organiser region) family of proteins which are markers of active
CC   ribosomal genes, and whose expression is associated with the prediction
CC   of tumour growth rate. The presence of antibodies against nucleolin are
CC   associated with systemic connective tissue diseases such as systemic
CC   lupus erythematosus (SLE) and scleroderma-like chronic graft versus host
CC   disease. The oligonucleotides of the invention are useful for diagnosis,
CC   prevention and treatment of conditions associated with nucleolin
CC   expression, such as tumour formation, immune disorders and inflammation
XX
SQ   Sequence 20 BP; 4 A; 9 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 26;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1761 GATGAAGATGAGGAGGAGG 1779
             ||||||||||| |||||||
Db         19 GATGAAGATGATGAGGAGG 1


RESULT 68
AAS23716
ID   AAS23716 standard; DNA; 20 BP.
XX
AC   AAS23716;
XX
DT   04-DEC-2001  (first entry)
XX
DE   Primer A #30 used as probe for identifying C. albicans GRACE strain.
XX
KW   Gene identification; essential gene; GRACE; pathogenic fungus;
KW   gene replacement and conditional expression; fungal infection; probe; ss.
XX
OS   Candida albicans.
OS   Synthetic.
XX
PN   WO200160975-A2.
XX
PD   23-AUG-2001.
XX
PF   20-FEB-2001; 2001WO-US005551.
XX
PR   18-FEB-2000; 2000US-0183534P.
XX
PA   (ELIT-) ELITRA PHARM INC.
XX
PI   Roemer T,  Jiang B,  Boone C,  Bussey H;
XX
DR   WPI; 2001-489080/53.
XX
PT   Identifying genes essential to fungal metabolisms and identifying
PT   potential therapeutic agents that target these genes.
XX
PS   Disclosure; Page 306; 324pp; English.
XX
CC   The present invention relates to novel methods for constructing fungal
CC   strains useful for identification and validation of gene products as
CC   targets for therapeutic agents, for creating a collection of identified
CC   essential genes, and screening assays for the discovery of new drugs. The
CC   invention provides the GRACE (gene replacement and conditional
CC   expression) method for the construction of mutant organisms referred to
CC   as GRACE strains of the organism. The invention can be applied to any
CC   organism, particularly a pathogenic fungus e.g. Candida albicans,
CC   Aspergillus fumigatus and Cryptococcus neoformans. The methods are useful
CC   to identify agents that may be used in the treatment of fungal
CC   infections. AAS23687-AAS23747 represent primers A #1-61 used as probes
CC   for identifying C. albicans GRACE strains
XX
SQ   Sequence 20 BP; 6 A; 1 C; 13 G; 0 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 26;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAG 1790
             ||||||||||| |||||||
Db          2 GGAGGAGGAGGAGGAGGAG 20


RESULT 69
ABZ29903
ID   ABZ29903 standard; DNA; 20 BP.
XX
AC   ABZ29903;
XX
DT   30-JAN-2003  (first entry)
XX
DE   Candida albicans GRACE strain PCR primer SEQ ID NO 4054.
XX
KW   Fungus; yeast; tetracyclin; promoter; GRACE strain; biosynthesis;
KW   signal transduction; DNA replication; cell division; growth;
KW   proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX
OS   Candida albicans.
XX
PN   WO200253728-A2.
XX
PD   11-JUL-2002.
XX
PF   26-DEC-2001; 2001WO-US049486.
XX
PR   29-DEC-2000; 2000US-0259128P.
PR   20-FEB-2001; 2001US-00792024.
PR   22-AUG-2001; 2001US-0314050P.
XX
PA   (ELIT-) ELITRA PHARM INC.
XX
PI   Roemer T,  Jiang B,  Boone C,  Bussey H,  Ohlsen KL;
XX
DR   WPI; 2002-566694/60.
XX
PT   Constructing strains for identifying gene products as effective targets
PT   for therapeutic intervention, by inactivating in the strain one allele of
PT   a gene and placing other allele of the gene under conditional expression.
XX
PS   Claim 36; SEQ ID NO 4054; 167pp + Sequence Listing; English.
```

```
XX
CC   The invention relates to constructing (M1) a strain of diploid fungal
CC   cells in which both alleles of a gene are modified, comprising modifying
CC   one allele by insertion or replacement by a cassette having an
CC   expressible selectable marker and modifying other allele by
CC   recombination, of a promoter replacement fragment with a heterologous
CC   promoter, so that expression of the second allele is regulated by the
CC   promoter. (M1) is useful for constructing a strain of diploid fungal
CC   cells in which both alleles of a gene are modified. The diploid fungal
CC   cells having both alleles modified are useful for identifying a gene that
CC   is essential to the survival or growth of a fungus, a gene that
CC   contributes to the virulence and/or pathogenicity of a fungus, a gene
CC   that contributes to the resistance of a diploid fungus to an antifungal
CC   agent, an antifungal agent that inhibits the growth of a diploid fungus
CC   and for identifying a therapeutic agent for treatment of a mammalian
CC   disease. (M1) is useful for identifying a compound which modulates the
CC   activity of a gene product, preferably enzymatic activity, carbon
CC   compound catabolism, biosynthetic, transporter, transcriptional,
CC   translational, signal transduction, DNA replication and cell division
CC   activity. The method is useful for identifying a compound having the
CC   ability to inhibit growth or proliferation of C. albicans cells and for
CC   treating infection by C. albicans. The present sequence is that of a PCR
CC   primer used in the method of the invention. Note: The sequence data for
CC   this patent is not represented in the printed specification but is based
CC   on sequence information supplied to Derwent by the European Patent Office
XX
SQ   Sequence 20 BP; 6 A; 1 C; 13 G; 0 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 26;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAG 1790
              ||||||||||| |||||||
Db          2 GGAGGAGGAGGAGGAGGAG 20


RESULT 70
ADD71322
ID   ADD71322 standard; DNA; 20 BP.
XX
AC   ADD71322;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Nucleic acid detection method-related universal DNA sequence #2.
XX
KW   nucleic acid detection; nucleic acid quantitation; universal sequence;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2003078587-A2.
XX
PD   25-SEP-2003.
XX
PF   13-MAR-2003; 2003WO-US007818.
XX
PR   13-MAR-2002; 2002US-0364230P.
XX
PA   (SYGN ) SYNGENTA PARTICIPATIONS AG.
PA   (SHIL/) SHI L.
XX
PI   Shi L;
XX
DR   WPI; 2003-803888/75.
XX
PT   Detecting the presence of a target nucleic acid molecule in templates by
PT   combining a detection probe, a first oligonucleotide, second
PT   oligonucleotide, a primer and templates suspected of containing the
PT   target nucleic acid molecule.
XX
PS   Example 2; SEQ ID NO 9; 42pp; English.
XX
CC   The invention comprises a method for detecting a target nucleic acid
CC   molecule in a plurality of templates, the method involves combining a
CC   detection probe, a first oligonucleotide, second oligonucleotide, a
CC   primer and a plurality of templates suspected of containing the target
CC   nucleic acid molecule. The method of the invention is useful for
CC   detecting the presence of a target nucleic acid molecule in a plurality
CC   of templates. The method is also useful for quantitating a particular
CC   nucleic acid molecule in a sample. The invention provides a rapid,
CC   reliable and cost-effective method for detecting a particular nucleic
CC   acid molecule in a sample. The present DNA sequence represents a
CC   universal sequence that was used in an example of the invention.
XX
SQ   Sequence 20 BP; 7 A; 0 C; 13 G; 0 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 26;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAG 1790
              ||||||||||| |||||||
Db          1 GGAGGAGGAGGAGGAGGAG 19


RESULT 71
AAC92693/c
ID   AAC92693 standard; DNA; 20 BP.
XX
AC   AAC92693;
XX
DT   27-MAR-2001  (first entry)
XX
DE   Human Nck-2 phosphorothioate antisense oligonucleotide, SEQ ID NO:54.
XX
KW   Human Nck-2; adapter protein; Nck adapter protein; hNck-beta; Grb4;
KW   signal transduction; SH2 domain; SH3 domain; src homology domain;
KW   integrin signalling; receptor tyrosine kinase signalling;
KW   growth factor receptor signalling; PINCH; v-Abl; Ras; Sos;
KW   transcriptional activation; cancer; tumour; leukaemia; breast cancer;
KW   expression inhibition; phosphorothioate; antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   US6165728-A.
XX
PD   26-DEC-2000.
XX
PF   19-NOV-1999;   99US-00444053.
XX
PR   19-NOV-1999;   99US-00444053.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ward DT,  Cowsert LM;
XX
DR   WPI; 2001-090480/10.
XX
PT   Novel antisense compound which inhibits expression of human nck-2 useful
PT   for treating disease or condition associated with expression of nck-2,
PT   and as research reagents, kits and diagnostics.
XX
PS   Claim 1; Col 41-42; 38pp; English.
XX
CC   Sequences AAC92649-C92728 represent antisense oligonucleotides targetted
CC   to the human Nck-2 gene, which inhibit its expression. The antisense
CC   oligonucleotides were designed to target different regions of the human
CC   Nck-2 mRNA, and were analysed for their effect on Nck-2 mRNA levels by
CC   quantitative real-time PCR. Nck-2 (also known as Nck adapter protein,
CC   hNck-beta and Grb4), contains both SH2 and SH3 src homology domains and
CC   functions as an adapter protein in integrin-mediated and receptor
CC   tyrosine kinase-mediated signal transduction, particularly in growth
CC   factor receptor signalling. Moreover, Nck-2 participates in pathways that
CC   connect growth factor receptor signalling and integrin signalling via its
```

```
CC   interaction with PINCH, a LIM domain-containing adapter protein which is
CC   involved in integrin, growth factor and Wnt signalling pathways. Nck-2
CC   also interacts with EGF (epidermal growth factor) and PDGF (platelet-
CC   derived growth factor) receptors, inhibiting EGF- and PDGF-stimulated DNA
CC   synthesis in an SH2-dependent manner. Nck-2 is also able to interact with
CC   v-Abl, Ras and Sos proteins to induce transcriptional activation, and is
CC   therefore implicated in the development of cancer, particularly leukaemia
CC   and breast cancer. The oligonucleotides of the invention are useful for
CC   diagnosis, prevention and treatment of conditions associated with Nck-2
CC   expression, such as leukaemia and breast cancer
XX
SQ   Sequence 20 BP; 1 A; 12 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 34;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1776 GAGGAGGCGGAGGAGGCGGC 1795
              ||||||| ||| ||||||||
Db         20 GAGGAGGTGGACGAGGCGGC 1


RESULT 72
ABZ86362
ID   ABZ86362 standard; DNA; 20 BP.
XX
AC   ABZ86362;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Claim 15; SEQ ID NO 1604; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 34;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2134 TGGACGACCCAGGTGGCCAG 2153
              |||| |||||||||| ||||
Db          1 TGGAAGACCCAGGTGCCCAG 20


RESULT 73
ADC49221/c
ID   ADC49221 standard; DNA; 20 BP.
XX
AC   ADC49221;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Hyaluronic acid synthetase-1, HAS-1, PCR primer, SEQ ID 12.
XX
KW   Rabbit; hyaluronic acid synthetase; enzyme; HAS-2; HAS-3; joint disorder;
KW   articular disease; osteoarthritis; HAS-1; PCR; primer; ss.
XX
OS   Unidentified.
XX
PN   JP2003038185-A.
XX
PD   12-FEB-2003.
XX
PF   27-JUL-2001; 2001JP-00228543.
XX
PR   27-JUL-2001; 2001JP-00228543.
XX
PA   (UYHI-) UNIV HIROSHIMA.
XX
DR   WPI; 2003-508645/48.
XX
PT   Novel gene useful for nucleic acid sequencing, codes rabbit hyaluronic
PT   acid synthetase and has hyaluronic acid synthetase activity.
XX
PS   Example 1; SEQ ID NO 12; 31pp; Japanese.
XX
CC   The present invention relates to coding sequences (ADC49210 and ADC49212)
CC   for rabbit hyaluronic acid synthetase (HAS)-2 or HAS-3 (ADC49211 and
CC   ADC49213). The sequences of the invention can be used for treatment of
CC   joint disorders and articular diseases, such as osteoarthritis. The
CC   present sequence was used to illustrate the invention.
XX
SQ   Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 34;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2033 CCTTAACCCTCGGGACTACT 2052
              |||||||||| ||||| ||
Db         20 CCTTAACCCTCTGGACTCCT 1


RESULT 74
AAV64914/c
```

```
ID   AAV64914 standard; DNA; 21 BP.
XX
AC   AAV64914;
XX
DT   15-MAR-1999  (first entry)
XX
DE   HSV-1 primer Exon 2n.
XX
KW   HSV-1; latency associated transcript; LAT; LATin;
KW   gene transcript stabilisation; gene expression; gene therapy; PCR;
KW   primer; ss.
XX
OS   Synthetic.
OS   Human herpesvirus 1.
XX
PN   WO9848004-A1.
XX
PD   29-OCT-1998.
XX
PF   17-APR-1998;   98WO-US007691.
XX
PR   18-APR-1997;   97US-0044664P.
XX
PA   (WIST-) WISTAR INST ANATOMY & BIOLOGY.
XX
PI   Fraser NW,  Zabolotny JM,  Krummenacher CF;
XX
DR   WPI; 1998-609982/51.
XX
PT   Increasing expression of genes having unstable RNA transcripts,
PT   particularly for gene therapy - using a construct including gene flanked
PT   by intron fragments that include a hairpin next to the intron
PT   branchpoint.
XX
PS   Example 1; Page 23; 106pp; English.
XX
CC   This is the nucleotide sequence of primer Exon 2n, which was used with
CC   primer Exon 1 (see AAV64912) in RT-PCR to characterise the splice
CC   junctions of the latency associated transcript (LAT) of herpes simplex
CC   virus type 1 (see AAV64883-86). The invention relates to methods of
CC   stabilising unstable gene transcripts. A claimed polynucleotide
CC   comprises: a polynucleotide encoding a gene product; a 5'-sequence of an
CC   intron, including the splice donor and splice acceptor sites (see
CC   AAV64885-86), and a 3'-sequence of the same intron, including a hairpin
CC   structure (see AAV64887) next to the intron's branchpoint. A preferred
CC   intron is the 2.0 kb LAT of a herpes virus. Methods and compositions
CC   using the polynucleotide can be used in gene therapy and more generally
CC   as research reagents, markers of gene production, in therapeutic or
CC   diagnostic compositions, in drug screening and to identify transcripts
CC   produced only at selected stages of the cell cycle
XX
SQ   Sequence 21 BP; 0 A; 11 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 39;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGA 1789
              |||||||| ||||| |||||
Db         20 GAGGAGGAAGAGGCAGAGGA 1


RESULT 75
ABQ78582/c
ID   ABQ78582 standard; DNA; 18 BP.
XX
AC   ABQ78582;
XX
DT   25-NOV-2002  (first entry)
XX
DE   RT-PCR primer used to amplify CHYM cDNA.
XX
KW   Human; mucin 4; MUC4; peripheral blood monocyte; PBMC; tumour marker;
KW   pancreatic cancer; pancreatic adenocarcinoma; CHYM; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200259368-A1.
XX
PD   01-AUG-2002.
XX
PF   07-DEC-2001; 2001WO-US046887.
XX
PR   08-DEC-2000; 2000US-00733444.
XX
PA   (UYNE-) UNIV NEBRASKA.
XX
PI   Batra SK,  Brand RE,  Ringel J,  Paulamnn G,  Lohr M,  Varsheny GC;
XX
DR   WPI; 2002-643346/69.
XX
PT   Diagnosing pancreatic adenocarcinoma, particularly for the early
PT   detection of the pancreatic cancer, comprises employing primers or
PT   antibodies that are specific for the MUC4-encoding nucleic acid or MUC4
PT   protein, respectively.
XX
PS   Example 1; Page 29; 63pp; English.
XX
CC   PCR primers ABQ78581-82 were used to amplify human CHYM nucleic acids.
CC   Peripheral blood monocytes (PBMCs) isolated from pancreatic cancer
CC   patients are positive for mucin 4 (MUC4), while MUC4 expression is not
CC   observed in PBMCs isolated from normal patients or from patients
CC   suffering from chronic pancreatitis or other types of cancers. Expression
CC   of MUC4 can therefore be used as an indication of pancreatic cancer. The
CC   specification describes a method for detecting a MUC4-encoding nucleic
CC   acid or a MUC4 protein in a biological sample as a tumour marker for
CC   pancreatic cancer. The method comprises contacting a nucleic acid
CC   extracted from the sample with oligonucleotide primers that specifically
CC   hybridise to the MUC4 nucleic acid; or contacting a biological sample
CC   with an antibody (or its fragment) that has specific binding affinity for
CC   MUC4. The method is useful for diagnosing pancreatic cancer or pancreatic
CC   adenocarcinoma, particularly for early detection of pancreatic cancer
XX
SQ   Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 31;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        894 CTGCAGCAGACAGCCCTG 911
              |||||||| ||||||||
Db         18 CTGCAGCAGGCAGCCCTG 1


RESULT 76
ABS67915
ID   ABS67915 standard; DNA; 20 BP.
XX
AC   ABS67915;
XX
DT   29-NOV-2002  (first entry)
XX
DE   Human casein kinase 2-alpha prime antisense oligonucleotide #14.
XX
KW   Human; casein kinase 2-alpha prime; diabetes mellitus;
KW   hyperproliferative disorder; breast cancer; prostate cancer;
KW   liver cancer; infection; inflammation; tumour formation; cytostatic;
KW   antidiabetic; antiinflammatory; antimicrobial; phosphorothioate;
KW   antisense therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200262951-A2.
XX
PD   15-AUG-2002.
XX
```

```
PF   01-FEB-2002; 2002WO-US002772.
XX
PR   08-FEB-2001; 2001US-00780173.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Mckay R,  Freier SM,  Wyatt JR;
XX
DR   WPI; 2002-627539/67.
XX
PT   New antisense oligonucleotides targeted to nucleic acid encoding casein
PT   kinase 2-alpha prime, useful for diagnosing and/or treating a disease or
PT   condition associated with expression of casein kinase 2-alpha prime.
XX
PS   Claim 3; Page 96; 129pp; English.
XX
CC   The present invention relates to antisense oligonucleotides and methods
CC   for modulating the expression of human or mouse casein kinase 2-alpha
CC   prime. The antisense oligonucleotides are useful for inhibiting the
CC   expression of casein kinase 2-alpha prime, and for treating diseases or
CC   conditions associated with aberrant expression of casein kinase 2-alpha
CC   prime. Such diseases include diabetes mellitus, and hyperproliferative
CC   disorders (particularly cancers e.g. breast cancer, prostate cancer, or
CC   liver cancer). The antisense compounds are also useful for diagnostics,
CC   therapeutics, prophylaxis, e.g. to prevent or delay infection,
CC   inflammation or tumour formation, as research reagents and kits, and in
CC   distinguishing between functions of various members of a biological
CC   pathway. ABS67840-ABS67917 represent human or mouse casein kinase 2-alpha
CC   prime antisense oligonucleotides which comprise a phosphorothioate
CC   backbone
XX
SQ   Sequence 20 BP; 6 A; 1 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1881 CTGGAGGAGGACGAGGAG 1898
              ||||||||||| ||||||
Db          1 CTGGAGGAGGAGGAGGAG 18


RESULT 77
ABT43400/c
ID   ABT43400 standard; DNA; 20 BP.
XX
AC   ABT43400;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Neuroblastoma-related DNA sequence #315.
XX
KW   Neuroblastoma; prognosis; ds; oligonucleotide.
XX
OS   Unidentified.
XX
PN   WO2002103017-A1.
XX
PD   27-DEC-2002.
XX
PF   30-MAY-2002; 2002WO-JP005295.
XX
PR   31-MAY-2001; 2001JP-00163666.
PR   24-AUG-2001; 2001JP-00255260.
XX
PA   (CHIB-) CHIBA PREFECTURE.
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Nakagawara A;
XX
DR   WPI; 2003-167523/16.
XX
PT   Nucleic acids isolated from neuroblastoma showing enhanced expression in
PT   human neuroblastoma with good prognosis, useful in clarifying good/poor
PT   prognosis of neuroblastoma and providing genetic data.
XX
PS   Example 5; Page 25(1); 444pp; Japanese.
XX
CC   The invention comprises DNA sequences that show enhanced expression in
CC   human neuroblastoma with good prognosis. The DNA sequences of the
CC   invention are useful in clarifying good/poor prognosis of neuroblastoma.
CC   The present DNA sequence was used in the exemplification of the invention
XX
SQ   Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1545 ACCTGGCTGAACATTGCA 1562
              |||||||||||||| ||||
Db         19 ACCTGGCTGAACAATGCA 2


RESULT 78
ABT32545/c
ID   ABT32545 standard; DNA; 20 BP.
XX
AC   ABT32545;
XX
DT   08-MAY-2003  (first entry)
XX
DE   Neuroblastoma-related oligonucleotide #322.
XX
KW   Neuroblastoma; prognosis; spontaneous regression; primer; probe; ds;
KW   high malignancy.
XX
OS   Unidentified.
XX
PN   WO200297093-A1.
XX
PD   05-DEC-2002.
XX
PF   30-MAY-2002; 2002WO-JP005294.
XX
PR   30-MAY-2001; 2001JP-00162775.
PR   24-AUG-2001; 2001JP-00255226.
XX
PA   (CHIB-) CHIBA PREFECTURE.
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Nakagawara A;
XX
DR   WPI; 2003-140476/13.
XX
PT   Nucleic acids having higher expression in human neuroblastoma with poor
PT   prognosis for diagnostic prediction of neuroblastoma prognosis.
XX
PS   Example 5; Page 28; 111pp; Japanese.
XX
CC   The invention comprises nucleic acids that show increased expression in
CC   human neuroblastomas with poor prognosis over those with a good
CC   prognosis. The nucleic acids of the invention are useful as a tool for
CC   distinguishing neuroblastomas with a favourable prognosis (spontaneous
CC   regression) from neuroblastomas with a poor prognosis (high malignancy).
CC   The DNA sequences ABT32224 - ABT32571 represent oligonucleotides used in
CC   an example of the invention
XX
SQ   Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1545 ACCTGGCTGAACATTGCA 1562
              |||||||||||||| ||||
```

```
Db         19 ACCTGGCTGAACAATGCA 2


RESULT 79
ABZ81534/c
ID   ABZ81534 standard; DNA; 20 BP.
XX
AC   ABZ81534;
XX
DT   26-AUG-2003  (first entry)
XX
DE   PKA regulatory subunit RII beta antisense oligonucleotide ISIS #114459.
XX
KW   Human; cytostatic; antidiabetic; antisense therapy; phosphorothioate;
KW   protein kinase inhibitor; protein kinase A; PKA;
KW   regulatory subunit RII beta; cAMP-dependent protein kinase; diabetes;
KW   cancer; infection; inflammation; tumour; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Oligonucleotide has phosphorothioate backbone and
FT                   all cytidine nucleotides are 5-methylcytidine. Optionally
FT                   some nucleotides with 2'-methoxyethyl (2'-MOE wings)
FT                   modification"
XX
PN   WO2003010283-A2.
XX
PD   06-FEB-2003.
XX
PF   15-JUL-2002; 2002WO-US022629.
XX
PR   25-JUL-2001; 2001US-00915485.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Wyatt JR;
XX
DR   WPI; 2003-239434/23.
XX
PT   New antisense oligonucleotides targeted to nucleic acid encoding protein
PT   kinase A regulatory subunit RII beta, useful in treating diseases e.g.
PT   cancer associated with the aberrant expression of the protein kinase.
XX
PS   Claim 3; Page 74; 98pp; English.
XX
CC   The present invention relates to novel antisense oligonucleotides
CC   (ABZ81522-ABZ81593) which are targeted to human protein kinase A (PKA)
CC   regulatory subunit RII beta nucleotide sequence (ABZ81513), and which
CC   specifically hybridise with and inhibit the expression of the PKA
CC   regulatory subunit RII beta (PKA is also known as cAMP-dependent protein
CC   kinase). The antisense oligonucleotides are useful for modulating the
CC   expression of PKA regulatory subunit RII beta and for treating diseases
CC   or conditions associated with aberrant expression of PKA regulatory
CC   subunit RII beta, e.g. diabetes or cancer. The antisense compounds are
CC   also useful for diagnostics, therapeutics, prophylaxis, e.g. to prevent
CC   or delay infection, inflammation or tumour formation, as research
CC   reagents and kits, and in distinguishing between functions of various
CC   members of a biological pathway
XX
SQ   Sequence 20 BP; 0 A; 12 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAG 1787
              ||||||||||||||||| |
Db         20 GAGGAGGAGGAGGCGGCG 3


RESULT 80
AAF73054/c
ID   AAF73054 standard; DNA; 20 BP.
XX
AC   AAF73054;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:155.
XX
KW   Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
KW   Fas binding protein; CENP-C binding protein; dap6; EAP; cytostatic;
KW   antiinflammatory; death associated protein 6; Ets-1 associated protein;
KW   infection; inflammation; tumour formation; ss.
XX
OS   Homo sapiens.
XX
PN   US6180353-B1.
XX
PD   30-JAN-2001.
XX
PF   24-JAN-2000; 2000US-00490692.
XX
PR   24-JAN-2000; 2000US-00490692.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Cowsert LM;
XX
DR   WPI; 2001-217744/22.
XX
PT   Novel antisense compounds capable of modulating expression of daxx useful
PT   for diagnosis, prophylaxis and treatment of diseases associated with
PT   expression of daxx.
XX
PS   Claim 1; Col 49; 59pp; English.
XX
CC   The present invention describes an antisense compound (I) up to 30
CC   nucleobases in length, where (I) inhibits expression of daxx (also known
CC   as Fas binding protein, CENP-C binding protein, dap6 for death associated
CC   protein 6 and EAP for Ets-1 associated protein). (I) has cytostatic and
CC   antiinflammatory activity, and can be used in antisense therapy and as a
CC   modulator of daxx. (I) is useful for inhibiting the expression of daxx in
CC   cells or tissues in vitro. (I) can be utilised for diagnostics,
CC   therapeutics for the treatment of diseases associated with the expression
CC   of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
CC   tumour formation and as research reagent. The present sequence represents
CC   an inhibitory human daxx antisense phosphorothioate oligonucleotide which
CC   is used in the exemplification of the present invention
XX
SQ   Sequence 20 BP; 4 A; 6 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1756 CTGAAGATGAAGATGA 1771
              ||||||||||||||||
Db         16 CTGAAGATGAAGATGA 1


RESULT 81
ABK99821
ID   ABK99821 standard; DNA; 20 BP.
XX
AC   ABK99821;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Mouse RAIDD antisense oligonucleotide #75.
XX
KW   Antisense gene therapy; RAIDD; death domain; caspase recruitment domain;
```

KW CARD; hyperproliferative disorder; cancer; growth disorder; mouse;
KW metabolic disorder; infection; inflammation; tumour formation;
KW RIP associated ICH-1/CED-3-homologous protein with death domain;
KW receptor interacting protein; antisense oligonucleotide; ss.
XX
OS Mus musculus.
XX
PN WO200248314-A2.
XX
PD 20-JUN-2002.
XX
PF 29-OCT-2001; 2001WO-US050914.
XX
PR 01-NOV-2000; 2000US-00705267.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Zhang H, Freier SM, Watt AT;
XX
DR WPI; 2002-583496/62.
XX
PT Novel antisense compound that hybridizes and inhibits nucleic acid
PT encoding RAIDD which is an adaptor molecule containing both death domain
PT and caspase recruitment domains, for treating hyperproliferative
PT disorder.
XX
PS Example 16; Page 96; 144pp; English.
XX
CC The invention describes a compound (I) 8-50 nucleobases in length
CC targeted to a nucleic acid molecule (II) encoding RAIDD which is an
CC adaptor molecule containing both death domain (DD) and caspase
CC recruitment domains (CARD), where (I) specifically hybridises with and
CC inhibits expression of RAIDD, or specifically hybridises with at least an
CC 8-nucleobase portion of an active site on (II). (I) is useful for
CC inhibiting the expression of RAIDD (Receptor interacting protein (RIP)
CC associated ICH-1/CED-3-homologous protein with death domain) in cells or
CC tissues, and for treating an animal having a disease or condition
CC associated with RAIDD, where the disease or condition is a
CC hyperproliferative disorder such as cancer, or a growth or metabolic
CC disorder. (I) is also useful for diagnostics, therapeutics, prophylaxis,
CC as research reagents and kits, for distinguishing functions of various
CC members of a biological pathway, and in antisense gene therapy. (I) is
CC also useful prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. This sequence represents a mouse RAIDD
CC antisense oligonucleotide used to control expression of the RAIDD protein
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1227 CTCCAGCATGTGCTGG 1242
||||||||||||||||
Db 4 CTCCAGCATGTGCTGG 19

RESULT 82
ABK99820
ID ABK99820 standard; DNA; 20 BP.
XX
AC ABK99820;
XX
DT 21-OCT-2002 (first entry)
XX
DE Mouse RAIDD antisense oligonucleotide #74.
XX
KW Antisense gene therapy; RAIDD; death domain; caspase recruitment domain;
KW CARD; hyperproliferative disorder; cancer; growth disorder; mouse;
KW metabolic disorder; infection; inflammation; tumour formation;
KW RIP associated ICH-1/CED-3-homologous protein with death domain;
KW receptor interacting protein; antisense oligonucleotide; ss.
XX
OS Mus musculus.
XX
PN WO200248314-A2.
XX
PD 20-JUN-2002.
XX
PF 29-OCT-2001; 2001WO-US050914.
XX
PR 01-NOV-2000; 2000US-00705267.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Zhang H, Freier SM, Watt AT;
XX
DR WPI; 2002-583496/62.
XX
PT Novel antisense compound that hybridizes and inhibits nucleic acid
PT encoding RAIDD which is an adaptor molecule containing both death domain
PT and caspase recruitment domains, for treating hyperproliferative
PT disorder.
XX
PS Claim 3; Page 95; 144pp; English.
XX
CC The invention describes a compound (I) 8-50 nucleobases in length
CC targeted to a nucleic acid molecule (II) encoding RAIDD which is an
CC adaptor molecule containing both death domain (DD) and caspase
CC recruitment domains (CARD), where (I) specifically hybridises with and
CC inhibits expression of RAIDD, or specifically hybridises with at least an
CC 8-nucleobase portion of an active site on (II). (I) is useful for
CC inhibiting the expression of RAIDD (Receptor interacting protein (RIP)
CC associated ICH-1/CED-3-homologous protein with death domain) in cells or
CC tissues, and for treating an animal having a disease or condition
CC associated with RAIDD, where the disease or condition is a
CC hyperproliferative disorder such as cancer, or a growth or metabolic
CC disorder. (I) is also useful for diagnostics, therapeutics, prophylaxis,
CC as research reagents and kits, for distinguishing functions of various
CC members of a biological pathway, and in antisense gene therapy. (I) is
CC also useful prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. This sequence represents a mouse RAIDD
CC antisense oligonucleotide used to control expression of the RAIDD protein
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1227 CTCCAGCATGTGCTGG 1242
||||||||||||||||
Db 1 CTCCAGCATGTGCTGG 16

RESULT 83
AAQ92210/c
ID AAQ92210 standard; DNA; 17 BP.
XX
AC AAQ92210;
XX
DT 12-JAN-1996 (first entry)
XX
DE p53 detection probe, (codon 142 del 1 C).
XX
KW Primer; polymerase chain reaction; amplify; mutant; K-ras; PCR;
KW flanking region; amplification; probe; detection; sputum; diagnosis;
KW benign; malignant; neoplasm; lung; lung cancer; head; neck; ss.
XX
OS Synthetic.
XX
PN WO9513397-A1.
XX
PD 18-MAY-1995.
XX
PF 10-NOV-1994; 94WO-US012947.

```
XX
PR   12-NOV-1993;   93US-00152313.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS SCHOOL MED.
XX
PI   Sidransky D;
XX
DR   WPI; 1995-194114/25.
XX
PT   Detecting target nucleic acid in mammalian sputum - particularly for
PT   diagnosis of lung neoplasia involving mutation(s) in the K-ras oncogene
PT   or p53 tumour suppressor.
XX
PS   Example 1; Page 36; 122pp; English.
XX
CC   The sequences given in AAQ92112-211 are probes which were used in the
CC   detection of a mutant p53 gene sequence. The DNA to be detected is
CC   amplified using PCR and then these probes which are pref. labeled using
CC   32-P gamma-ATP are used to detect the mutant sequences. The primers and
CC   probes given in AAQ92098-219 are used in the method of the invention for
CC   detecting mammalian target DNA in sputum samples. Analysis of the target
CC   DNA is used to diagnose benign or malignant neoplasms of the lung. It is
CC   also useful for screening people at high risk or for monitoring progress
CC   of treatment of lung neoplasms. The method is based on the discovery that
CC   mutant target DNA associated with lung cancer is present at detectable
CC   levels in sputum. Cells shed into sputum from head and neck cancers may
CC   also be detected
XX
SQ   Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1655 GCTGCAGAGGCAGGTCT 1671
              |||||| ||||||||||
Db         17 GCTGCACAGGCAGGTCT 1


RESULT 84
AAF02815/c
ID   AAF02815 standard; DNA; 17 BP.
XX
AC   AAF02815;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #1110.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 81; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 0 A; 9 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1879 AGCTGGAGGAGGACGAG 1895
              ||| ||||||||||||||
Db         17 AGCAGGAGGAGGACGAG 1


RESULT 85
ABK02359
ID   ABK02359 standard; RNA; 17 BP.
XX
AC   ABK02359;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #31.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 131; 200pp; English.
XX
```

```
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 8 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1764 GAAGATGAGGAGGAGGA 1780
              ||||| ||||||||||||
Db          1 GAAGAAGAGGAGGAGGA 17


RESULT 86
ABN00937
ID   ABN00937 standard; DNA; 17 BP.
XX
AC   ABN00937;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:929.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 929; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGAG 1280
              ^ ||||| ||||||||||
Db          1 AGCTGAAAGAGGCTGAG 17


RESULT 87
ABN08667
ID   ABN08667 standard; DNA; 17 BP.
XX
AC   ABN08667;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8659.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
```

```
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8659; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GCTGGAGGAGGCCAAGA 1545
              ||||||||| |||||||
Db          1 GCTGGAGGAAGCCAAGA 17


RESULT 88
ABV78925
ID   ABV78925 standard; DNA; 17 BP.
XX
AC   ABV78925;
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 171.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1229046-A2.
XX
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 86; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
CC   mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC   useful for diagnosing a disorder caused by mutation in HTPL, and in
CC   therapy and manufacture of a medicament for treatment or prevention of
CC   such disorder associated with decreased expression or activity of human
CC   HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC   foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC   skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC   clinically useful diagnostic markers and potenial therapeutic agents for
CC   male infertility and cancer. The present oligonucleotide was used in an
CC   example from the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCAGTGG 2136
              |||| ||||||||||||
Db          1 CCACCGGGCCGCAGTGG 17


RESULT 89
ABK17920/c
ID   ABK17920 standard; RNA; 17 BP.
XX
AC   ABK17920;
XX
```

```
DT   09-APR-2002  (first entry)
XX
DE   Human ERG hammerhead ribozyme target sequence, Seq ID No 567.
XX
KW   Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW   ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW   vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW   tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW   neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW   angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW   Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW   Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW   amberzyme.
XX
OS   Homo sapiens.
XX
PN   WO200188124-A2.
XX
PD   22-NOV-2001.
XX
PF   16-MAY-2001; 2001WO-US015866.
XX
PR   16-MAY-2000; 2000US-00572021.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (GLAX ) GLAXO GROUP LTD.
XX
PI   Jarvis T,  Von Carlowitz I,  Mcswiggen JA,  Mclaughlin F,  Randi AM;
XX
DR   WPI; 2002-082995/11.
XX
PT   Novel polynucleotide which down regulates expression of Ets-related gene,
PT   useful for treating cancer, diabetic retinopathy, macular degeneration,
PT   arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS   Claim 4; Page 69; 149pp; English.
XX
CC   The invention relates to a nucleic acid molecule (I) which down regulates
CC   expression of an Ets-related gene (ERG). (I) is useful for treating
CC   conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC   tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC   vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC   Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC   syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC   treating a patient having a condition associated with the level of ERG,
CC   by contacting cells of the patient with (I) under conditions suitable for
CC   the treatment. The method comprises the use of one or more therapies
CC   under conditions suitable for the treatment. Leukaemia or tumour
CC   angiogenesis is treated by administering (I) to the patient in
CC   conjunction with one or more of other therapies such as radiation or
CC   chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC   cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC   ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC   cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC   diseases related to the expression of ERG, and as diagnostic tool to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of ERG RNA in a cell. (I) is useful for specifically
CC   targeting genes that share homology with ERG gene or ERG fusion genes.
CC   ABK17354-ABK22719 represent nucleic acids, including antisense and
CC   enzymatic nucleic acid molecules which regulate expression of ERG, and
CC   related PCR primers of the invention
XX
SQ   Sequence 17 BP; 1 A; 10 C; 3 G; 0 T; 3 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1880 GCTGGAGGAGGACGAGG 1896
              ||||||||||||||| ||
Db         17 GCTGGAGGAGGACGCGG 1

RESULT 90
ADB98963/c
ID   ADB98963 standard; DNA; 17 BP.
XX
AC   ADB98963;
XX
DT   04-DEC-2003  (first entry)
XX
DE   LRP5 mutagenic PCR primer #82.
XX
KW   Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW   bone mass modulation; osteoporosis; PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   WO200292000-A2.
XX
PD   21-NOV-2002.
XX
PF   13-MAY-2002; 2002WO-US014877.
XX
PR   11-MAY-2001; 2001US-0290071P.
PR   17-MAY-2001; 2001US-0291311P.
PR   01-FEB-2002; 2002US-0353058P.
PR   04-MAR-2002; 2002US-0361293P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (AMHP ) WYETH.
XX
PI   Allen K,  Anisowicz A,  Graham JR,  Morales A,  Yaworsky PJ,  Liu W;
XX
DR   WPI; 2003-129214/12.
XX
PT   New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT   diagnosing a HBM-like phenotype in a subject and for preparing a
PT   composition for modulating bone mass and/or lipid levels in a subject
PT   suffering from e.g. osteoporosis.
XX
PS   Disclosure; Page 53; 629pp; English.
XX
CC   The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC   LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC   cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC   level modulation. The invention is useful for diagnosing a HBM-like
CC   phenotype in a subject and for preparing a composition for modulating
CC   bone mass and/or lipid levels in a subject suffering from e.g.
CC   osteoporosis. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 42;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1349 CTTTCCCAGGGCAGCTG 1365
              ||||||||||||||| |
Db         17 CTTTCCCAGGGCAGCGG 1

RESULT 91
AAA09296
ID   AAA09296 standard; cDNA; 19 BP.
XX
AC   AAA09296;
XX
DT   10-AUG-2000  (first entry)
XX
DE   Primer for human alpha-2-delta-D gene.
XX
KW   alpha-2-delta-D; calcium channel; 12p13.3; gabapentin; cytostatic;
KW   anticonvulsant; antimigrane; antiparkinsonian; antidepressant; primer;
KW   ss.
```

```
XX
OS   Homo sapiens.
XX
PN   WO200020450-A2.
XX
PD   13-APR-2000.
XX
PF   07-OCT-1999;   99WO-US023519.
XX
PR   07-OCT-1998;   98US-0103322P.
PR   30-OCT-1998;   98US-0106473P.
PR   29-DEC-1998;   98US-0114088P.
XX
PA   (WARN ) WARNER LAMBERT CO.
XX
PI   Johns MA,  Moldover B,  Offord JD;
XX
DR   WPI; 2000-303744/26.
XX
PT   New human nucleic acids encoding the alpha2delta-C and alpha2delta-D
PT   proteins, useful in the treatment of epilepsy, migraine, chronic pain,
PT   anxiety, multiple sclerosis or cancer.
XX
PS   Claim 22; Page 76; 88pp; English.
XX
CC   The alpha-2-delta-D gene encodes a calcium channel subunit polypeptide.
CC   The gene has been mapped to chromosome 12p13.1. This gene and the related
CC   alpha-2-delta-C and -B genes are useful for protecting mammalian cells
CC   from abnormal calcium flux by introducing expression vectors containing
CC   the respective gene into mammalian cells. The antisense genes are also
CC   useful for treating or preventing epilepsy. The alpha-delta-2-A protein
CC   is a high-affinity binding target of the anti-convulsant drug gabapentin.
CC   Therefore, alpha-delta-2 proteins may also be targeted to treat seizure-
CC   related syndromes, migraine, ataxia, vestibular defects, chronic pain,
CC   sleep interference, anxiety, amyotropic lateral sclerosis (ALS), multiple
CC   sclerosis, mania, tremor, parkinsonism, substance abuse or addiction
CC   syndromes, mood, depression or cancer
XX
SQ   Sequence 19 BP; 5 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 57;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1075 TGAGGAAGCGGTTCATG 1091
              ||||||||||| |||||
Db          3 TGAGGAAGCGGATCATG 19


RESULT 92
ADE30113/c
ID   ADE30113 standard; RNA; 19 BP.
XX
AC   ADE30113;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:735.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition;
KW   mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW   cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW   immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW   antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW   inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW   psoriasis; inflammatory bowel disease; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS   Synthetic.
XX
PN   WO2003072590-A1.
XX
PD   04-SEP-2003.
XX
PF   28-JAN-2003; 2003WO-US002510.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N,  Haeberli P,  Chowrira B;
XX
DR   WPI; 2003-689980/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of mitogen-activated
PT   protein kinase genes.
XX
PS   Example 3; SEQ ID NO 735; 164pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of a mitogen-activated protein kinase
CC   (MAPK) genes by RNA interference. Also described: (1) a method for
CC   modulating expression of MAPK genes in cells, tissue explants or
CC   organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC   vectors that express siNA and cells containing these vectors. MAPK siNAs
CC   have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC   antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC   antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC   siNAs can be used to modulate the expression of MAPK genes, in cells,
CC   tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC   and II; a wide range of tumours, and inflammatory diseases (asthma,
CC   septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC   disease). They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents a MAPK siNA which is used
CC   in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 7 A; 4 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 57;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1301 CATGGTCATCTGTGAGC 1317
              ||||||||||||| |||
Db         19 CATGGTCATCTGTAAGC 3


RESULT 93
ADE30322
ID   ADE30322 standard; RNA; 19 BP.
XX
AC   ADE30322;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:944.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition;
KW   mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW   cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW   immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW   antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW   inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW   psoriasis; inflammatory bowel disease; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
```

OS Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
PF 28-JAN-2003; 2003WO-US002510.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Usman N, Haeberli P, Chowrira B;
XX
DR WPI; 2003-689980/65.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
PS Example 3; SEQ ID NO 944; 164pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNAs can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 4 A; 4 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 0.6%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 57;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1301 CATGGTCATCTGTGAGC 1317
              ||:||:||:|:|: |||
Db          1 CAUGGUCAUCUGUAAGC 17
```

RESULT 94
AAF52822
ID AAF52822 standard; DNA; 15 BP.
XX
AC AAF52822;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3782.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 85; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1232 GCATGTGCTGGCAGT 1246
              |||||||||||||||
Db          1 GCATGTGCTGGCAGT 15
```

RESULT 95
AAF02814/c
ID AAF02814 standard; DNA; 17 BP.
XX
AC AAF02814;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #1109.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.

```
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 81; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 0 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1883 GGAGGAGGACGAGGA 1897
              |||||||||||||||
Db         16 GGAGGAGGACGAGGA 2


RESULT 96
AAZ22430/c
ID   AAZ22430 standard; DNA; 18 BP.
XX
AC   AAZ22430;
XX
DT   25-NOV-1999  (first entry)
XX
DE   Antisense oligonucleotide directed against human RhoB mRNA.
XX
KW   Human; RhoB protein; antisense oligonucleotide; disease; RhoB expression;
KW   breast cancer; primer; phosphorothioate; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5962672-A.
XX
PD   05-OCT-1999.
XX
PF   18-SEP-1998;   98US-00156979.
XX
PR   18-SEP-1998;   98US-00156979.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Coswert LM;
XX
DR   WPI; 1999-571296/48.
XX
PT   Antisense inhibition of the gene encoding RhoB, useful for treating
PT   diseases associated with RhoB expression e.g. breast cancer.
XX
PS   Claim 3; Col 28; 24pp; English.
XX
CC   AAZ22392-Z22431 represent antisense oligonucleotides, which are 8-30
CC   nucleotides in length, and are targeted to the gene encoding human RhoB.
CC   The antisense oligonucleotides may be useful for treating diseases
CC   associated with the expression of RhoB, such as breast cancer. They may
CC   also have research and diagnostic applications
XX
SQ   Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1251 CGGCTGCAGCAACAGCTG 1268
              ||||||| |||| ||||
Db         18 CGGCTGCATCAACTGCTG 1


RESULT 97
AAF94683/c
ID   AAF94683 standard; DNA; 18 BP.
XX
AC   AAF94683;
XX
DT   23-MAY-2001  (first entry)
XX
DE   Rho B antisense phosphorothioate oligonucleotide SEQ ID 107.
XX
KW   Rho; GTP binding protein; phosphorothioate antisense oligonucleotide;
KW   RhoA; RhoB; RhoC; RhoG; Rac 1; cdc42; hyperproliferative condition;
KW   cancer; wound healing; clotting; ischaemia; reperfusion; reoxygenation;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200115739-A1.
XX
PD   08-MAR-2001.
XX
PF   18-AUG-2000; 2000WO-US022808.
XX
PR   31-AUG-1999;   99US-00387341.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Roberts ML,  Cowsert LM;
XX
DR   WPI; 2001-191677/19.
XX
PT   An antisense compound targeted to a nucleic acid molecule encoding a
PT   member of the human Rho family of small GTP binding proteins useful for
PT   treating e.g. cancer and ischemia.
XX
PS   Example 13; Page 65; 156pp; English.
XX
CC   This invention relates to an antisense compound targeted to a nucleic
CC   acid molecule encoding a member of the human Rho family of small GTP
CC   binding proteins, where the antisense compound inhibits the expression of
CC   the member of the human Rho family. The invention includes antisense
CC   oligonucleotides AAF94580 - AAF94637 which target a RhoA nucleotide
CC   sequence, AAF94645 - AAF94684 which target a RhoB nucleotide sequence,
CC   AAF94686 - AAF94725 which target a RhoC nucleotide sequence, AAF94727 -
CC   AAF94766 which target RhoG nucleotide sequence, AAF94769 - AAF94790 which
CC   target a Rac 1 nucleotide sequence and AAF94795 - AAF94809 which target
CC   cdc42 nucleotide sequence. The antisense compound is useful for treating
CC   hyperproliferative conditions, especially cancer, abnormal wound healing
CC   or clotting conditions and ischaemia/reperfusion or reoxygenation injury.
CC   The compound may also be used to diagnose the above conditions
XX
SQ   Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1251 CGGCTGCAGCAACAGCTG 1268
              ||||||||| |||| ||||
Db         18 CGGCTGCATCAACTGCTG 1
```

RESULT 98
ABK50427
ID ABK50427 standard; DNA; 18 BP.
XX
AC ABK50427;
XX
DT 30-JUL-2002 (first entry)
XX
DE Acremonium chrysogenum cephalosporin C (CPC) gene cahB PCR primer #1.
XX
KW Cephalosporin C-acetyl hydrolase; CPC-AH; cephalosporin C; CPC; primer;
KW cahB; 7-aminocephalosporanic acid; ss; PCR.
XX
OS Acremonium chrysogenum.
XX
PN WO200061767-A1.
XX
PD 19-OCT-2000.
XX
PF 07-APR-2000; 2000WO-ES000126.
XX
PR 09-APR-1999; 99ES-00000731.
XX
PA (ANTI) ANTIBIOTICOS SAU.
XX
PI Velasco Alvarez J, Gutierrez Martin S, Casqueiro Blanco FJ;
PI Campoy Garcia S, Fierro Fierro F, Barredo Fuente JL, Diez Garcia B;
PI Martin Martin JF;
XX
DR WPI; 2001-031587/04.
XX
PT Microbial production of cephalosporin C or its derivatives, useful as
PT intermediates for antibiotics, in cells transformed with a gene encoding
PT CPC (cephalosporin C)-acetylhydrolase.
XX
PS Example 2; Page 50; 64pp; Spanish.
XX
CC The invention relates to production of Acremonium chrysogenum
CC cephalosporin C-acetyl hydrolase (CPC-AH) and its utilisation in the
CC synthesis of deacetylated derivatives of cephalosporin C (CPC) and the
CC inactivation of the gene for increasing production of cephalosporin.
CC Derivatives and/or their synthesis intermediates can be synthesised by
CC growing a microbial host transformed with a DNA sequence that includes
CC the cahB gene encoding A. chrysogenum CPC-AH, under conditions where it
CC is either expressed or inactivated. The genes and proteins are used for
CC removal of acetyl groups, especially from the 3'-carbon of CPC or from 7-
CC aminocephalosporanic acid, to give deacetylated products useful as
CC intermediates for cephalosporin antibiotics. Inactivation of the gene
CC that expresses CPC increases production of cephalosporins by A.
CC chrysogenum. This sequence represents a PCR primer used to clone the cahB
CC gene encoding A. chrysogenum CPC-AH
XX
SQ Sequence 18 BP; 2 A; 4 C; 11 G; 1 T; 0 U; 0 Other;

```
  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1821 GAGGCCGGCGAGGTGGAG 1838
              |||||||||| |||| |
Db          1 GAGGCCGGCGACGTGGGG 18
```

RESULT 99
ADA27360
ID ADA27360 standard; DNA; 18 BP.
XX
AC ADA27360;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human microsatellite repeat M2_3_4.
XX
KW ds; HLA-related research; HLA class II-associated disease;
KW transplantation matching; recombination hot spot identification;
KW linkage disequilibrium study; human; microsatellite.
XX
OS Homo sapiens.
XX
PN US2003108940-A1.
XX
PD 12-JUN-2003.
XX
PF 06-DEC-2002; 2002US-00314405.
XX
PR 15-NOV-2000; 2000US-00713616.
XX
PA (INOK/) INOKO H.
XX
PI Inoko H, Tamiya G, Matsuzaka Y;
XX
DR WPI; 2003-616782/58.
XX
PT New oligonucleotide primer capable of specifically hybridizing to a DNA
PT having the sequence of the flanking regions of a microsatellite (e.g.
PT M249), useful for HLA-related research, e.g. transplantation matching.
XX
PS Example 2; Page 5; 20pp; English.
XX
CC The invention relates to an oligonucleotide primer capable of
CC specifically hybridising to a DNA having the sequence of the flanking
CC regions of a microsatellite selected from M2-4-9, M2-2-9, M2-2-12, M2-3-
CC 11, M2-2-20, M2-2-21, M2-2-22, M2-2-23, M2-2-24, M2-4-25, M2-4-26, M2-2-
CC 29, M2-2-32, M2-4-32, M2-4-33, M2-4-37, M2-3-22, M2-2-36, M2-5-11, M2-2-
CC 46, and M2-2-48. The primer is useful for determining the number of
CC repeat units of the microsatellite cited above. The primer is useful in
CC HLA-related research, such as genetic mapping of HLA class II-associated
CC diseases, transplantation matching, population genetics, and
CC identification of recombination hot spots as well as linkage
CC disequilibrium studies. The present sequence represents the human
CC microsatellite repeat M2_3_4.
XX
SQ Sequence 18 BP; 7 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

```
  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAG 1787
              |||||||| |||| ||||
Db          1 GAGGAGGAAGAGGAGGAG 18
```

RESULT 100
ADB78536
ID ADB78536 standard; DNA; 18 BP.
XX
AC ADB78536;
XX
DT 04-DEC-2003 (first entry)
XX
DE Probe sequence #39 related to the invention.
XX
KW human leukocyte antigen; HLA; probe; PCR; ss.
XX
OS Synthetic.
XX
PN WO2003027309-A2.
XX
PD 03-APR-2003.
XX

```
PF   24-SEP-2002; 2002WO-US030238.
XX
PR   24-SEP-2001; 2001US-0324421P.
XX
PA   (ONEL-) ONE LAMBDA.
XX
PI   Saito K,  Lee J,  Blair L;
XX
DR   WPI; 2003-363216/34.
XX
PT   Detecting the presence of a target nucleic acid sequence on a sample
PT   nucleic acid strand, useful for human leukocyte antigen tissue typing,
PT   comprises contacting a sample with a diagnostic probe under hybridizing
PT   conditions.
XX
PS   Example 4; Page 32; 62pp; English.
XX
CC   The present invention relates to the detecting of a target nucleic acid
CC   sequence on a sample nucleic acid strand. The methods are useful for
CC   detecting the presence or absence of target nucleic acid sequences on
CC   sample nucleic acid strands that are characteristic of pathogens or gene
CC   variations and mutations relating to human leukocyte antigen (HLA) or T-
CC   cell receptor gene sequences, e.g. for HLA tissue typing, detecting
CC   genetically inherited diseases or detecting infectious organisms in
CC   tissues. The diagnostic probes are useful for detecting the presence of
CC   particular target nucleotide sequences. The present invention provides
CC   improved methods of detecting sample/target nucleic acid sequences, where
CC   the use of diagnostic probes having increased specificity reduces the
CC   number of alleles detected, which increases the resolution of the method,
CC   and does so at a lower cost. The present sequence represents a probe of
CC   the invention.
XX
SQ   Sequence 18 BP; 1 A; 4 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 65;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1045 TGGAGGGTGCCCGGGAGT 1062
              ||||||| ||||||| ||
Db          1 TGGAGGGGGCCCGGGCGT 18


RESULT 101
AAD26693/c
ID   AAD26693 standard; DNA; 15 BP.
XX
AC   AAD26693;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human GPR31 gene polymorphism detecting ASO primer #16.
XX
KW   Human; G-protein coupled receptor 31; GPR31 protein; haplotyping;
KW   genotyping; gene therapy; cancer; polymorphism; ASO; primer;
KW   allele-specific oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO200190124-A2.
XX
PD   29-NOV-2001.
XX
PF   23-MAY-2001; 2001WO-US016908.
XX
PR   23-MAY-2000; 2000US-0206572P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bieglecki KM,  Duda A,  Kazemi A,  Lee HH,  Messer C;
XX
DR   WPI; 2002-089915/12.
XX
PT   Novel genetic variants of G-protein coupled receptor gene useful in
PT   studying expression and function of the protein, and for screening drugs
PT   to treat diseases e.g. cancer.
XX
PS   Claim 16; Page 13; 75pp; English.
XX
CC   The invention relates to genetic variants of human G-protein coupled
CC   receptor 31 (GPR31) gene. The invention also relates to compositions and
CC   methods for haplotyping and/or genotyping the GPR31 gene in an
CC   individual. Polynucleotides of the invention are useful in studying the
CC   expression and function of GPR31, and in expressing GPR31 protein for use
CC   in screening candidate drugs to treat diseases related to GPR31 activity
CC   and in studying the effect of the variation on the biological activity of
CC   GPR31 as well as on the binding affinity of candidate drugs targetting
CC   GPR31 for the treatment of cancer. They are also used in gene therapy.
CC   The haplotyping method is useful for improving the efficiency and
CC   reliability of several steps in the discovery and development of drugs
CC   for treating diseases associated with GPR31 activity e.g. cancer. This
CC   method is also useful for haplotyping GPR31 gene in an individual, which
CC   can also be used by the pharmaceutical research scientist to validate
CC   GPR31 as a candidate target for, and in design of clinical trials of
CC   candidate drugs, for treating a specific condition drugs or disease
CC   predicted to be associated with GPR31 activity. The present sequence is
CC   an allele specific oligonucleotide (ASO) primer used to detect human
CC   GPR31 gene polymorphisms
XX
SQ   Sequence 15 BP; 4 A; 3 C; 6 G; 1 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 14.6;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 44;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2106 CGCTTCCTGCTGGAC 2120
              |:||||||||||||
Db         15 CRCTTCCTGCTGGAC 1


RESULT 102
AAT76198/c
ID   AAT76198 standard; DNA; 16 BP.
XX
AC   AAT76198;
XX
DT   12-SEP-1997  (first entry)
XX
DE   Human IL4 receptor antisense oligonucleotide.
XX
KW   Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW   chronic obstructive pulmonary disease; bronchitis; interleukin; ss.
XX
OS   Synthetic.
XX
PN   WO9640162-A1.
XX
PD   19-DEC-1996.
XX
PF   06-JUN-1996;   96WO-US009306.
XX
PR   07-JUN-1995;   95US-00474497.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
XX
PI   Nyce JW,  Metzger WJ;
XX
DR   WPI; 1997-051871/05.
XX
PT   Treatment of airway diseases such as asthma - by topically applying
PT   adenosine-free antisense oligo:nucleotide to airway epithelium of
PT   subject.
XX
PS   Example 5; Page 30; 71pp; English.
XX
CC   A method for treating airway disease in a subject has been produced,
```

```
CC   which involves the topical administration of an essentially adenosine
CC   free antisense oligonucleotide (ON) to the airway epithelium of the
CC   subject. The present sequence is an antisense oligonucleotide specific
CC   for the human IL4 receptor. The method can be used to treat airway
CC   diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary
CC   disease, bronchitis and other airway diseases characterised by an
CC   inflammatory response. By eliminating adenosine from the antisense ON,
CC   its liberation upon antisense degradation is prevented, thereby
CC   preventing adenosine-induced bronchoconstriction in patients with hyper-
CC   reactive airways
XX
SQ   Sequence 16 BP; 0 A; 11 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 57;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 GATGAGGAGGAGGAGG 1782
              || |||||||||||||
Db         16 GAGGAGGAGGAGGAGG 1


RESULT 103
ABK67989
ID   ABK67989 standard; DNA; 16 BP.
XX
AC   ABK67989;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Mutant DNA library PCR primer #39.
XX
KW   Mutant DNA library; unit domain; clone; protein library; mutant protein;
KW   selective splicing; molecular engineering; DNA shuffling; evolution; PCR;
KW   primer; ss.
XX
OS   Synthetic.
XX
PN   WO200226964-A1.
XX
PD   04-APR-2002.
XX
PF   26-SEP-2001; 2001WO-JP008387.
XX
PR   27-SEP-2000; 2000JP-00293692.
PR   06-FEB-2001; 2001JP-00029138.
XX
PA   (MITU ) MITSUBISHI CHEM CORP.
XX
PI   Tsuji T,  Yanagawa H;
XX
DR   WPI; 2002-340012/37.
XX
PT   Constructing mutant DNA library comprises ligating unit domain DNAs in
PT   arbitrary combinations before mixing in specific manner as template for
PT   polymerase chain reaction to give clones, useful in producing protein
PT   library.
XX
PS   Example 2; Page 79; 89pp; Japanese.
XX
CC   The present invention relates to a new method of constructing a mutant
CC   DNA library. The method of the invention involves ligating unit domain
CC   DNAs in arbitrary combinations, mixing the ligated unit domains and
CC   performing polymerase chain reaction (PCR) by employing the ligated unit
CC   domain DNA mixture as a template to obtain a DNA library containing 2 or
CC   more clones. The method can be used for constructing a mutant DNA library
CC   which is for use in producing e.g. protein library, mutant proteins and
CC   artificial amino acid sequences with desirable functional properties with
CC   a combination of unit domains. The method can also be used for
CC   selectively splicing a library to yield mutant proteins with retention of
CC   function and smaller for wider application and in evolution molecular
CC   engineering in which the constructed mutant DNA library contains various
CC   DNA sequence including original sequences, exons and expression-
CC   regulating domains in structural DNAs. The method is easy and less error
CC   prone in DNA shuffling when constructing DNAs. The present nucleic acid
CC   sequence represent one of a collection (ABK67951-ABK68000) of PCR primers
CC   that were used in the methods of the invention for construction of a
CC   mutant DNA library, as describe above
XX
SQ   Sequence 16 BP; 2 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 57;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1866 GGCCTGACCCCGCAGC 1881
              |||||||||| |||||
Db          1 GGCCTGACCCTGCAGC 16


RESULT 104
AAX72692
ID   AAX72692 standard; RNA; 17 BP.
XX
AC   AAX72692;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #125.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 126; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 67;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1301 CATGGTCATCTGTGAG 1316
              ||:||:| :|:|:|||
Db          1 CAUGGUCUUCUGUGAG 16


RESULT 105
AAV93512/c
ID   AAV93512 standard; RNA; 17 BP.
XX
AC   AAV93512;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human B-raf substrate nucleotide position 1347.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 169; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 3 A; 6 C; 2 G; 0 T; 6 U; 0 Other;

  Query Match              0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1756 CTGAAGATGAAGATGA 1771
              |||| ||||||||||||
Db         17 CTGAGGATGAAGATGA 2


RESULT 106
ABK02360
ID   ABK02360 standard; RNA; 17 BP.
XX
AC   ABK02360;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #32.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 131; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
```

CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 9 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1765 AAGATGAGGAGGAGGA 1780
|||| ||||||||||
Db 1 AAGAAGAGGAGGAGGA 16

RESULT 107
ABK02364
ID ABK02364 standard; RNA; 17 BP.
XX
AC ABK02364;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Amberzyme #36.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 131; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 0 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1883 GGAGGAGGACGAGGAG 1898
||||||||| ||||||
Db 2 GGAGGAGGAAGAGGAG 17

RESULT 108
ABA78078/c
ID ABA78078 standard; DNA; 17 BP.
XX
AC ABA78078;
XX
DT 24-JAN-2002 (first entry)
XX
DE BRCA1 mutation correcting oligonucleotide SEQ ID NO: 924.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;

KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 100; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 1 A; 6 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAA 1271
| |||||||||||||||
Db 16 GGAGCAACAGCTGGAA 1

RESULT 109
ABA78077
ID ABA78077 standard; DNA; 17 BP.
XX
AC ABA78077;
XX
DT 24-JAN-2002 (first entry)
XX
DE BRCA1 mutation correcting oligonucleotide SEQ ID NO: 923.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 100; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAA 1271
| |||||||||||||||
Db 2 GGAGCAACAGCTGGAA 17

RESULT 110
ABA78070/c
ID ABA78070 standard; DNA; 17 BP.
XX
AC ABA78070;
XX
DT 24-JAN-2002 (first entry)
XX
DE BRCA1 mutation correcting oligonucleotide SEQ ID NO: 916.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;

KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 99; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 1 A; 6 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAA 1271
| ||||||||||||||
Db 16 GGAGCAACAGCTGGAA 1

RESULT 111
ABA78069
ID ABA78069 standard; DNA; 17 BP.
XX
AC ABA78069;
XX
DT 24-JAN-2002 (first entry)
XX
DE BRCA1 mutation correcting oligonucleotide SEQ ID NO: 915.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 99; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAA 1271
| ||||||||||||||
Db 2 GGAGCAACAGCTGGAA 17

RESULT 112
ABN00936
ID ABN00936 standard; DNA; 17 BP.
XX
AC ABN00936;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:928.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

```
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 928; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGA 1279
              ||||| ||||||||||
Db          2 AGCTGAAAGAGGCTGA 17


RESULT 113
ABN02626
ID   ABN02626 standard; DNA; 17 BP.
XX
AC   ABN02626;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2618.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2618; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
```

```
  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAGGA 1855
              ||||||||||||||| |
Db          1 TCTCAGAGAGCGAGCA 16


RESULT 114
ABN08666
ID   ABN08666 standard; DNA; 17 BP.
XX
AC   ABN08666;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8658.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8658; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GCTGGAGGAGGCCAAG 1544
              ||||||||| ||||||
Db          2 GCTGGAGGAAGCCAAG 17


RESULT 115
ABN06400
ID   ABN06400 standard; DNA; 17 BP.
XX
AC   ABN06400;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6392.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 6392; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
```

```
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 GCCCCGTGCTTCCAGA 1617
              ||||||||||| |||||
Db          1 GCCCCGTGCTCCCAGA 16


RESULT 116
ABN06399
ID   ABN06399 standard; DNA; 17 BP.
XX
AC   ABN06399;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6391.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 6391; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 GCCCCGTGCTTCCAGA 1617
              ||||||||||| |||||
Db          2 GCCCCGTGCTCCCAGA 17


RESULT 117
ABN02625
ID   ABN02625 standard; DNA; 17 BP.
XX
AC   ABN02625;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2617.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
```

PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 2617; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1840 TCTCAGAGAGCGAGGA 1855
||||||||||||||| |
Db 2 TCTCAGAGAGCGAGCA 17

RESULT 118
ABN00938
ID ABN00938 standard; DNA; 17 BP.
XX
AC ABN00938;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:930.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 930; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1265 GCTGGAAGAGGCTGAG 1280
|||| ||||||||||
Db 1 GCTGAAAGAGGCTGAG 16

RESULT 119
ABN08668
ID ABN08668 standard; DNA; 17 BP.
XX
AC ABN08668;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8660.

```
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8660; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1530 CTGGAGGAGGCCAAGA 1545
              ||||||||| |||||||
Db          1 CTGGAGGAAGCCAAGA 16
```

```
RESULT 120
AAD45173/c
ID   AAD45173 standard; DNA; 17 BP.
XX
AC   AAD45173;
XX
DT   27-DEC-2002  (first entry)
XX
DE   Human RIP2 DNA specific forward PCR primer.
XX
KW   Human; receptor interacting protein; RIP2; antisense; gene therapy; PCR;
KW   primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6426221-B1.
XX
PD   30-JUL-2002.
XX
PF   01-AUG-2001; 2001US-00920663.
XX
PR   01-AUG-2001; 2001US-00920663.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ward DT,  Cowsert LM;
XX
DR   WPI; 2002-673017/72.
XX
PT   New antisense oligonucleotide that targets regions of a nucleic acid
PT   encoding human receptor interacting protein (RIP)2, for treating diseases
PT   associated with RIP2 expression.
XX
PS   Example 13; Col 42; 35pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   encoding human receptor interacting protein (RIP)2 to inhibit its
CC   expression. Antisense compounds are used for treating diseases associated
CC   with RIP2 expression. They are also useful in antisense gene therapy. The
CC   present sequence is human RIP2 DNA specific PCR primer
XX
SQ   Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1898 GCTTCAGGGCCACCTG 1913
              |||||| |||||||||
Db         16 GCTTCACGGCCACCTG 1

RESULT 121
ABV78926
ID   ABV78926 standard; DNA; 17 BP.
XX
AC   ABV78926;
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 172.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1229046-A2.
XX
```

```
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 86; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
CC   mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC   useful for diagnosing a disorder caused by mutation in HTPL, and in
CC   therapy and manufacture of a medicament for treatment or prevention of
CC   such disorder associated with decreased expression or activity of human
CC   HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC   foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC   skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC   clinically useful diagnostic markers and potenial therapeutic agents for
CC   male infertility and cancer. The present oligonucleotide was used in an
CC   example from the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2121 CACGGGGCCGCAGTGG 2136
              ||| ||||||||||||
Db          1 CACCGGGCCGCAGTGG 16


RESULT 122
ABV78924
ID   ABV78924 standard; DNA; 17 BP.
XX
AC   ABV78924;
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 170.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
```

```
PN   EP1229046-A2.
XX
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 86; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
CC   mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC   useful for diagnosing a disorder caused by mutation in HTPL, and in
CC   therapy and manufacture of a medicament for treatment or prevention of
CC   such disorder associated with decreased expression or activity of human
CC   HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC   foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC   skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC   clinically useful diagnostic markers and potenial therapeutic agents for
CC   male infertility and cancer. The present oligonucleotide was used in an
CC   example from the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCAGTG 2135
              |||| ||||||||||||
Db          2 CCACCGGGCCGCAGTG 17


RESULT 123
ABK17396/c
ID   ABK17396 standard; RNA; 17 BP.
XX
AC   ABK17396;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human ERG hammerhead ribozyme target sequence, Seq ID No 43.
XX
KW   Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW   ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW   vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW   tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW   neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
```

KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberzyme.
XX
OS Homo sapiens.
XX
PN WO200188124-A2.
XX
PD 22-NOV-2001.
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 59; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1880 GCTGGAGGAGGACGAG 1895
||||||||||||||| |
Db 16 GCTGGAGGAGGACGCG 1

RESULT 124
ABK17919/c
ID ABK17919 standard; RNA; 17 BP.
XX
AC ABK17919;
XX
DT 09-APR-2002 (first entry)
XX
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 566.
XX
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberzyme.
XX
OS Homo sapiens.
XX
PN WO200188124-A2.
XX
PD 22-NOV-2001.
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 69; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1881 CTGGAGGAGGACGAGG 1896
||||||||||||||| ||
Db 17 CTGGAGGAGGACGCGG 2

RESULT 125

```
ABT37829/c
ID   ABT37829 standard; DNA; 17 BP.
XX
AC   ABT37829;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 3466.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A, Amson R, Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 439; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 7 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1383 CTGCGTTTTGCTGAGC 1398
              ||||||||||||||| |
Db         16 CTGCGTTTTGCTGATC 1


RESULT 126
ABZ64881/c
ID   ABZ64881 standard; RNA; 17 BP.
XX
AC   ABZ64881;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #338.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 139; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1266 CTGGAAGAGGCTGAGG 1281
              |||||||| |||||||
Db         17 CTGGAAGACGCTGAGG 2


RESULT 127
AAA10553/c
ID   AAA10553 standard; DNA; 18 BP.
XX
AC   AAA10553;
XX
DT   29-JUN-2000  (first entry)
XX
DE   Smad2 antisense oligonucleotide sequence #6 (ISIS# 27783).
XX
KW   Smad2; MADH2; MADR2; hMAD2; JV18-1; transcription factor; inflammation;
KW   chromosome 18q21; antisense compound; treat; prevent; infection; tumour;
KW   diagnostic reagent; research reagent; ss; cancer.
XX
```

OS Synthetic.
XX
PN US6037142-A.
XX
PD 14-MAR-2000.
XX
PF 23-FEB-1999; 99US-00255912.
XX
PR 23-FEB-1999; 99US-00255912.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowsert LM;
XX
DR WPI; 2000-269886/23.
XX
PT New antisense compound that inhibits human Smad2, useful e.g. for
PT treating or preventing infection, inflammation and tumors.
XX
PS Claim 11; Col 39; 31pp; English.
XX
CC This sequence represents an antisense nucleotide sequence targeting human
CC Smad2. Smad2 is also known as MADH2, MADR2, hMAD2 and JV18-1, and is a
CC member of a subgroup of Smad family transcription factors which are
CC cytosolic proteins regulated by transforming growth factor-beta (TGF-
CC beta) and activins. Smads exist as monomers in unstimulated cells as homo
CC - or heterodimerise and translocate to the nucleus and activate target
CC gene transcription upon ligand binding. The Smad2 gene is located on
CC chromosome 18q21. The invention relates to antisense compounds (see
CC AAA10548-A10587) targeted to the Smad2 nucleotide sequence. The antisense
CC oligonucleotide sequences inhibit Smad2 expression by hybridising to DNA
CC or RNA. The antisense nucleotides are used to treat or prevent diseases
CC associated with expression of Smad2, e.g. infection, inflammation and
CC tumours. The oligonucleotides can also be used as diagnostic or research
CC reagents
XX
SQ Sequence 18 BP; 0 A; 11 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1775 GGAGGAGGCGGAGGAG 1790
|||| ||||||||||
Db 18 GGAGCAGGCGGAGGAG 3

RESULT 128
ABS60576/c
ID ABS60576 standard; DNA; 18 BP.
XX
AC ABS60576;
XX
DT 05-NOV-2002 (first entry)
XX
DE Human polymorphism associated DNA sequence #325.
XX
KW Aminopeptidase P; XPNEP2; bradykinin receptor B1; ds; BDKRB1;
KW tachykinin receptor B1; TACR1; C1 esterase inhibitor; C1NH; kallikrein 1;
KW KLK1; bradykinin receptor B2; BDKRB2; gene therapy;
KW angiotensin converting enzyme 2; ACE2; protease inhibitor 4; PI4;
KW polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
KW cardiovascular disease; angina pectoris; hypertension; heart failure;
KW myocardial infarction; ventricular hypertrophy; vascular disease;
KW aneurysm; embolism; thrombosis; coronary artery disease; angioedaema;
KW arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
KW autoimmune disease; inflammatory arthritis; cancer; wound;
KW viral infection; bacterial infection; fungal infection; COPD;
KW Chronic obstructive pulmonary disease; enterocolitis.
XX
OS Homo sapiens.
XX
PN WO200261131-A2.
XX
PD 08-AUG-2002.
XX
PF 03-DEC-2001; 2001WO-US047235.
XX
PR 04-DEC-2000; 2000US-0251015P.
PR 23-JAN-2001; 2001US-0263678P.
PR 02-MAR-2001; 2001US-0273037P.
XX
PA (BRIM) BRISTOL-MYERS SQUIBB CO.
PA (TSUC/) TSUCHIHASHI Z.
PA (HUIL/) HUI L.
XX
PI Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH;
PI Swanson BN, Powell JR;
XX
DR WPI; 2002-619265/66.
XX
PT New isolated nucleic acid with at least one polymorphic position, useful
PT for detecting, diagnosing and treating disorders such as angioedema,
PT cancer, viral, bacterial or fungal infection, cardiovascular and
PT autoimmune diseases.
XX
PS Disclosure; Page 808; 977pp; English.
XX
CC The invention relates to an isolated nucleic acid from a human gene
CC encoding aminopeptidase P (XPNEP2), bradykinin receptor B1 (BDKRB1),
CC tachykinin receptor B1 (TACR1), C1 esterase inhibitor (C1NH), kallikrein
CC 1 (KLK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
CC 2 (ACE2) or protease inhibitor 4 (PI4), comprising at least one
CC polymorphic position. Also included are (1) a probe that hybridises to a
CC polymorphic position as provided in the detailed summary of single
CC nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising
CC obtaining the sample from one or more individuals and determining the
CC nucleic acid sequence at one or more polymorphic positions in a gene
CC encoding a protein selected from the group above; (3) constructing (M2)
CC haplotypes using the genes comprising grouping at least two nucleic acids
CC ; (4) identifying (M3) an individual at risk of developing a disorder
CC upon administration of an ACE inhibitor and/or vasopeptidase inhibitor
CC using the polymorphic data; (5) a library of nucleic acids, each of which
CC comprises one or more polymorphic positions within a gene encoding a
CC human protein selected from the group above; and (6) genotyping (M4) an
CC individual comprising obtaining a nucleic acid sample, determining the
CC nucleotide present in at least one polymorphic position, and comparing at
CC least one position with a known data set. The genes, (M1, M2, M3 and M4)
CC and compositions are useful for detecting, diagnosing, treating,
CC preventing various disorders such as angioedaema and diseases which
CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
CC disease, trachomas, and cardiovascular diseases like angina pectoris,
CC hypertension, heart failure, myocardial infarction, ventricular
CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
CC artery disease, arteriosclerosis and/or atherosclerosis, and
CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
CC obstructive pulmonary disease (COPD) and enterocolitis (many other
CC diseases and disorders are listed in the specification). The
CC polynucleotides are also useful for chromosome identification. Antibodies
CC against the proteins may be utilised for immunophenotyping of cell lines
CC and biological samples. The present sequence is included in the sequence
CC listing but is not referred to anywhere else in the specification
XX
SQ Sequence 18 BP; 1 A; 9 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1800 ACAGCGGAGAGCGAAG 1815
| ||||||||||||||
Db 18 AGAGCGGAGAGCGAAG 3

```
RESULT 129
ABS60512/c
ID   ABS60512 standard; DNA; 18 BP.
XX
AC   ABS60512;
XX
DT   05-NOV-2002  (first entry)
XX
DE   Human polymorphism associated DNA sequence #261.
XX
KW   Aminopeptidase P; XPNEP2; bradykinin receptor B1; ds; BDKRB1;
KW   tachykinin receptor B1; TACR1; C1 esterase inhibitor; C1NH; kallikrein 1;
KW   KLK1; bradykinin receptor B2; BDKRB2; gene therapy;
KW   angiotensin converting enzyme 2; ACE2; protease inhibitor 4; PI4;
KW   polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
KW   cardiovascular disease; angina pectoris; hypertension; heart failure;
KW   myocardial infarction; ventricular hypertrophy; vascular disease;
KW   aneurysm; embolism; thrombosis; coronary artery disease; angioedaema;
KW   arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
KW   autoimmune disease; inflammatory arthritis; cancer; wound;
KW   viral infection; bacterial infection; fungal infection; COPD;
KW   Chronic obstructive pulmonary disease; enterocolitis.
XX
OS   Homo sapiens.
XX
PN   WO200261131-A2.
XX
PD   08-AUG-2002.
XX
PF   03-DEC-2001; 2001WO-US047235.
XX
PR   04-DEC-2000; 2000US-0251015P.
PR   23-JAN-2001; 2001US-0263678P.
PR   02-MAR-2001; 2001US-0273037P.
XX
PA   (BRIM ) BRISTOL-MYERS SQUIBB CO.
PA   (TSUC/) TSUCHIHASHI Z.
PA   (HUIL/) HUI L.
XX
PI   Tsuchihashi Z,  Hui L,  Zerba KE,  Ma-Edmonds M,  Perrone MH;
PI   Swanson BN,  Powell JR;
XX
DR   WPI; 2002-619265/66.
XX
PT   New isolated nucleic acid with at least one polymorphic position, useful
PT   for detecting, diagnosing and treating disorders such as angioedema,
PT   cancer, viral, bacterial or fungal infection, cardiovascular and
PT   autoimmune diseases.
XX
PS   Disclosure; Page 798; 977pp; English.
XX
CC   The invention relates to an isolated nucleic acid from a human gene
CC   encoding aminopeptidase P (XPNEP2), bradykinin receptor B1 (BDKRB1),
CC   tachykinin receptor B1 (TACR1), C1 esterase inhibitor (C1NH), kallikrein
CC   1 (KLK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
CC   2 (ACE2) or protease inhibitor 4 (PI4), comprising at least one
CC   polymorphic position. Also included are (1) a probe that hybridises to a
CC   polymorphic position as provided in the detailed summary of single
CC   nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
CC   sequence; (2) analysing (M1) at least one nucleic acid sample comprising
CC   obtaining the sample from one or more individuals and determining the
CC   nucleic acid sequence at one or more polymorphic positions in a gene
CC   encoding a protein selected from the group above; (3) constructing (M2)
CC   haplotypes using the genes comprising grouping at least two nucleic acids
CC   ; (4) identifying (M3) an individual at risk of developing a disorder
CC   upon administration of an ACE inhibitor and/or vasopeptidase inhibitor
CC   using the polymorphic data; (5) a library of nucleic acids, each of which
CC   comprises one or more polymorphic positions within a gene encoding a
CC   human protein selected from the group above; and (6) genotyping (M4) an
CC   individual comprising obtaining a nucleic acid sample, determining the
CC   nucleotide present in at least one polymorphic position, and comparing at
CC   least one position with a known data set. The genes, (M1, M2, M3 and M4)
CC   and compositions are useful for detecting, diagnosing, treating,
CC   preventing various disorders such as angioedaema and diseases which
CC   involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
CC   disease, trachomas, and cardiovascular diseases like angina pectoris,
CC   hypertension, heart failure, myocardial infarction, ventricular
CC   hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
CC   artery disease, arteriosclerosis and/or atherosclerosis, and
CC   hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
CC   arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
CC   obstructive pulmonary disease (COPD) and enterocolitis (many other
CC   diseases and disorders are listed in the specification). The
CC   polynucleotides are also useful for chromosome identification. Antibodies
CC   against the proteins may be utilised for immunophenotyping of cell lines
CC   and biological samples. The present sequence is included in the sequence
CC   listing but is not referred to anywhere else in the specification
XX
SQ   Sequence 18 BP; 1 A; 9 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1800 ACAGCGGAGAGCGAAG 1815
              | ||||||||||||||
Db         18 AGAGCGGAGAGCGAAG 3


RESULT 130
ABL43873/c
ID   ABL43873 standard; DNA; 18 BP.
XX
AC   ABL43873;
XX
DT   11-APR-2002  (first entry)
XX
DE   Human chromosome 1p36-35 PCR primer SEQ ID NO:917.
XX
KW   Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001321190-A.
XX
PD   20-NOV-2001.
XX
PF   12-MAR-2001; 2001JP-00068285.
XX
PR   10-MAR-2000; 2000JP-00066716.
XX
PA   (RIKA ) RIKAGAKU KENKYUSHO.
PA   (GENO-) GENOTEX YG.
XX
DR   WPI; 2002-144136/19.
XX
PT   Arraying genome clones.
XX
PS   Claim 4; Page 23; 528pp; Japanese.
XX
CC   The present invention describes a method of arraying genome clones. The
CC   method comprises: (a) clones of the genomic libraries contained in
CC   multiwell plates numbered for discrimination are mixed in each of the
CC   multiwell plates; (b) a primer designed based on the chromosome marker
CC   sequence is added to the mixture to carry out an amplification reaction;
CC   (c) a signal corresponding to the marker is detected from the resultant
CC   amplified product to specify the discrimination Nos. of the multiwell
CC   plates containing the clones having said marker sequence; (d) the order
CC   of the markers is changed so that the same discrimination Nos. succeed to
CC   the maximum in the specified discrimination Nos. to array the multiwell
CC   plates; (e) the clones in the multiwell plates of the specified
CC   discrimination Nos. are mixed respectively in each wells of longitudinal
CC   and lateral directions; (f) the mixed clones are cultured and the
CC   resultant cultures are amplified by using the above primer; (g) signals
CC   are detected from the amplified products; (h) the clones in the multiwell
```

CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2016 GTGAGGCAGGGCCACC 2031
||||||||| ||||||
Db 18 GTGAGGCAGAGCCACC 3

RESULT 131
ABK50300
ID ABK50300 standard; DNA; 18 BP.
XX
AC ABK50300;
XX
DT 15-JUL-2002 (first entry)
XX
DE Yeast HIS biosynthetic gene PCR primer.
XX
KW Yeast; ss; PCR; heat shock protein 40; J domain; anti-HIV; virucide;
KW cytostatic; hepatotropic; antiinflammatory; transgenic; HSP; primer;
KW u-binding protein; UBP; chicken embryo orphan adenovirus infection;
KW San Nombre hantavirus infection; human immune deficiency virus infection;
KW cervical cancer; hepatitis; measles; HIS biosynthetic gene.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200219965-A2.
XX
PD 14-MAR-2002.
XX
PF 06-SEP-2001; 2001WO-US027554.
XX
PR 07-SEP-2000; 2000US-0230649P.
XX
PA (SCTE-) SCI & TECHNOLOGY CORP @UNM.
PA (BOEH) BOEHRINGER INGELHEIM INT GMBH.
XX
PI Moseley PL, Cotten M, Hjelle B, Panganiban A;
XX
DR WPI; 2002-383030/41.
XX
PT Method for inhibiting viral replication, useful for treating e.g. human
PT immune deficiency virus infection or measles, comprises administering a
PT heat shock protein inhibitor.
XX
PS Example 3; Page 79; 133pp; English.
XX
CC The invention relates to a method for inhibiting viral replication in a
CC cell or animal, where a heat-shock protein (HSP) is required for
CC replication, comprises administering an inhibitor of the heat shock
CC protein. Also included are a kit for the process comprising the
CC inhibitor, an applicator and instructions; an isolated nucleic acid that
CC is complementary (antisense) to a sequence that encodes the HSP; a vector
CC containing the antisense molecule; a non-human transgenic mammal
CC containing the antisense molecule; a method for inhibiting viral
CC replication in a cell by administering the antisense molecule, or its
CC fragments; a non-human transgenic mammal containing isolated nucleic acid
CC that encodes a viral particle u-binding protein (UBP) or its derivative
CC or fragment; a non-human transgenic mammal containing isolated nucleic
CC acid that encodes an inhibitor of HSP-dependent viral replication; a
CC method for inhibiting viral replication in a cell by administering the
CC inhibitor encoding nucleic acid; and a method for identifying compounds
CC that inhibit HSP-dependent viral replication. The method is used to treat
CC diseases caused by a wide variety of viruses for which replication is
CC dependent on HSP, especially chicken embryo orphan adenovirus, San Nombre
CC hantavirus and human immune deficiency virus, but also those responsible
CC for cervical cancer, hepatitis and measles. Also: (i) inhibition of HSP
CC function is used to identify agents that inhibit HSP-dependent
CC replication (potential therapeutic agents); (ii) expression of HSP
CC inhibitors in transgenic animals is used to produce virus-resistant
CC strains of livestock; and (iii) recombinant cells expressing nucleic acid
CC that encodes the inhibitor are useful therapeutically and for studying
CC HSP signalling pathways. The present sequence is a PCR primer used to
CC detect a deletion of the Yeast UBP gene in a yeast strain to be used for
CC expression of UBP constructs used for assaying the inhibition of human
CC immunodeficiency virus replication by UBP
XX
SQ Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1530 CTGGAGGAGGCCAAGA 1545
|| ||||||||||||
Db 2 CTAGAGGAGGCCAAGA 17

RESULT 132
AAL61564
ID AAL61564 standard; DNA; 20 BP.
XX
AC AAL61564;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130489.
XX
KW Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1. .5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003042360-A2.
XX
PD 22-MAY-2003.
XX
PF 05-NOV-2002; 2002WO-US035597.
XX
PR 13-NOV-2001; 2001US-00993731.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Watt AT;
XX
DR WPI; 2003-468635/44.
XX
PT New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases

```
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        775 CTGCCTTTGAGAAGAG 790
              ||||||| ||||||||
Db          4 CTGCCTTGGAGAAGAG 19


RESULT 133
AAL61584
ID   AAL61584 standard; DNA; 20 BP.
XX
AC   AAL61584;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130509.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1252 GGCTGCAGCAACAGCTGGA 1270
              ||||||||| |||||| |
Db          2 GGCTGCAGCCTCAGCTGCA 20


RESULT 134
AAF52821
ID   AAF52821 standard; DNA; 15 BP.
XX
AC   AAF52821;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #3781.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
```

```
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 85; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1232 GCATGTGCTGGCAG 1245
              ||||||||||||||
Db          2 GCATGTGCTGGCAG 15


RESULT 135
AAF45187
ID   AAF45187 standard; DNA; 15 BP.
XX
AC   AAF45187;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #26.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 3 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1782 GCGGAGGAGGCGGC 1795
              ||||||||||||||
Db          1 GCGGAGGAGGCGGC 14


RESULT 136
AAF45186
ID   AAF45186 standard; DNA; 15 BP.
XX
AC   AAF45186;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #25.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
```

```
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 3 A; 3 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1782 GCGGAGGAGGCGGC 1795
              ||||||||||||||
Db          2 GCGGAGGAGGCGGC 15


RESULT 137
AAF48301/c
ID   AAF48301 standard; DNA; 15 BP.
XX
AC   AAF48301;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1721.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 55; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCAG 2133
              ||||||||||||||
Db         15 CCACGGGGCCGCAG 2


RESULT 138
AAF48302/c
ID   AAF48302 standard; DNA; 15 BP.
XX
AC   AAF48302;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1722.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 55; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
```

```
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCAG 2133
              ||||||||||||||
Db         14 CCACGGGGCCGCAG 1


RESULT 139
AAF52823
ID   AAF52823 standard; DNA; 15 BP.
XX
AC   AAF52823;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #3783.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 85; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 3 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 58;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1233 CATGTGCTGGCAGT 1246
              ||||||||||||||
Db          1 CATGTGCTGGCAGT 14


RESULT 140
AAF01936/c
ID   AAF01936 standard; DNA; 17 BP.
XX
AC   AAF01936;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #231.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 61; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 81;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2273 GCTGGAGACGCTGC 2286
              ||||||||||||||
Db         15 GCTGGAGACGCTGC 2


RESULT 141
AAF02211/c
ID   AAF02211 standard; DNA; 17 BP.
XX
AC   AAF02211;
```

```
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #506.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 67; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 0 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 81;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1883 GGAGGAGGACGAGG 1896
             ||||||||||||||
Db         16 GGAGGAGGACGAGG 3


RESULT 142
AAF07203/c
ID   AAF07203 standard; DNA; 17 BP.
XX
AC   AAF07203;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3460.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 54; Page 135; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 1 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 81;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 CGGAGGAGGCGGCA 1796
             ||||||||||||||
Db         14 CGGAGGAGGCGGCA 1


RESULT 143
ABK02369
ID   ABK02369 standard; RNA; 17 BP.
XX
AC   ABK02369;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #41.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
```

PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 131; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 2 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1884 GAGGAGGACGAGGA 1897
||||||||||||||
Db 3 GAGGAGGACGAGGA 16

RESULT 144
ABK02096
ID ABK02096 standard; RNA; 17 BP.
XX
AC ABK02096;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO DNAzyme #8.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 112; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a DNAzyme molecule of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1884 GAGGAGGACGAGGA 1897
||||||||||||||

```
Db          2 GAGGAGGACGAGGA 15

RESULT 145
ABK02368
ID   ABK02368 standard; RNA; 17 BP.
XX
AC   ABK02368;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #40.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 131; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 7 A; 1 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 81;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
              ||||||||||||||
Db          4 GAGGAGGACGAGGA 17


RESULT 146
ABN02624
ID   ABN02624 standard; DNA; 17 BP.
XX
AC   ABN02624;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2616.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
```

```
PS   Disclosure; SEQ ID NO 2616; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match              0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 81;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAG 1853
              ||||||||||||||
Db          3 TCTCAGAGAGCGAG 16


RESULT 147
ABN02623
ID   ABN02623 standard; DNA; 17 BP.
XX
AC   ABN02623;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2615.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2615; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match              0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 81;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAG 1853
              ||||||||||||||
Db          4 TCTCAGAGAGCGAG 17


RESULT 148
ABK17922/c
ID   ABK17922 standard; RNA; 17 BP.
XX
AC   ABK17922;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human ERG hammerhead ribozyme target sequence, Seq ID No 569.
XX
KW   Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW   ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW   vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW   tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW   neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW   angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW   Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW   Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW   amberzyme.
XX
OS   Homo sapiens.
XX
PN   WO200188124-A2.
XX
PD   22-NOV-2001.
XX
```

PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 69; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1880 GCTGGAGGAGGACG 1893
||||||||||||||
Db 14 GCTGGAGGAGGACG 1

RESULT 149
ABK17921/c
ID ABK17921 standard; RNA; 17 BP.
XX
AC ABK17921;
XX
DT 09-APR-2002 (first entry)
XX
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 568.
XX
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberzyme.
XX
OS Homo sapiens.
XX
PN WO200188124-A2.
XX
PD 22-NOV-2001.
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 69; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 2 A; 8 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1880 GCTGGAGGAGGACG 1893
||||||||||||||
Db 15 GCTGGAGGAGGACG 2

RESULT 150
ADB42705/c
ID ADB42705 standard; DNA; 17 BP.
XX
AC ADB42705;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #3028.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;

KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 386; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1018 GCCAGCACTCCCAG 1031
              ||||||||||||||
Db         17 GCCAGCACTCCCAG 4
```

RESULT 151
AAT44257
ID AAT44257 standard; DNA; 17 BP.
XX
AC AAT44257;
XX
DT 22-JUL-1997 (first entry)
XX
DE HSV-1 antisense component of capped oligonucleotide.
XX
KW Antisense therapy; herpes simplex virus; HSV-1; guanosine;
KW nuclease resistance; stability; ss.
XX
OS Synthetic.
XX
PN DE19502912-A1.
XX
PD 01-AUG-1996.
XX
PF 31-JAN-1995; 95DE-01002912.
XX
PR 31-JAN-1995; 95DE-01002912.
XX
PA (FARH) HOECHST AG.
XX
PI Peyman A, Uhlmann E;
XX
DR WPI; 1996-355223/36.
XX
PT Oligo:nucleotide(s) with series of G residues at at least one end have
PT increased stability against nuclease and cell penetration, - are partic.
PT anti:sense sequences for treating and diagnosing cancer, viral diseases
PT etc.
XX
PS Claim 3; Page 13; 15pp; German.
XX
CC Ten- to 40-mer oligonucleotides which have a cap of 1-10 (esp. 4) G
CC residues on at least one end are provided; if caps are present at both
CC ends, they can be of the same or different lengths. A cap sequence
CC increases nuclease resistance of the oligonucleotide and also increases
CC cell penetration. The present sequence is that of a preferred
CC oligonucleotide, directed against HSV-1 sequences, which can be capped
CC for use in antiviral therapy
XX
SQ Sequence 17 BP; 4 A; 1 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1775 GGAGGAGGCGGAGGAGG 1791
              |||||| || |||||||
Db          1 GGAGGATGCTGAGGAGG 17
```

RESULT 152
AAX33904
ID AAX33904 standard; DNA; 17 BP.
XX
AC AAX33904;
XX
DT 30-JUN-1999 (first entry)
XX
DE HSV-1 gene expression inhibitor.
XX
KW Gene expression inhibitor; probe; nucleic acid detection; growth factor;
KW viral infection; therapy; HSV-1; cancer; restenosis; integrin;
KW cell-cell adhesion receptor; ss.
XX
OS Synthetic.
OS Human herpesvirus 1.
XX
PN AU9648028-A.
XX
PD 26-SEP-1996.
XX
PF 12-MAR-1996; 96AU-00048028.
XX
PR 13-MAR-1995; 95DE-01008923.
PR 24-NOV-1995; 95DE-01043865.
XX
PA (FARH) HOECHST AG.
XX
PI Peyman A, Uhlmann E, Breipohl G, Wallmeier H;
XX
DR WPI; 1996-455932/46.
XX
PT New phosphono:mono:ester oligo:nucleotide analogues - inhibitors of gene

```
PT   expression for treating viral infections, cancer, restenosis, etc.
XX
PS   Disclosure; Page 40; 129pp; English.
XX
CC   This sequence represents an inhibitor of HSV-1 gene expression, and is an
CC   example of an oligonucleotide analogue of the invention. The
CC   oligonucleotide analogues of the invention are used as inhibitors of gene
CC   expression (antisense oligonucleotides, ribozymes, sense oligonucleotides
CC   and triplex-forming oligonucleotides), as probes for the detection of
CC   nucleic acids, and as auxiliaries in molecular biology. As gene
CC   expression inhibitors they may be used for treating viral infections
CC   (especially where the virus is HSV-1, HSV-2, an influenza virus, VSV,
CC   hepatitis B or papilloma virus), cancer, restenosis, medical conditions
CC   mediated by integrins or cell-cell adhesion receptors, and medical
CC   conditions induced by growth factors (especially TNF-alpha)
XX
SQ   Sequence 17 BP; 4 A; 1 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              ||||||  || |||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 153
AAT81044/c
ID   AAT81044 standard; RNA; 17 BP.
XX
AC   AAT81044;
XX
DT   26-SEP-1997  (first entry)
XX
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 25).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 64; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              |||||  ||| |||||||
Db         17 AGGAGAAGGAGGAGGAG 1


RESULT 154
AAT81046/c
ID   AAT81046 standard; RNA; 17 BP.
XX
AC   AAT81046;
XX
DT   26-SEP-1997  (first entry)
XX
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 29).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 64; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGA 1786
              |||||||||  ||| |||
Db         17 GAGGAGGAGAAGGAGGA 1
```

```
RESULT 155
AAT81047/c
ID   AAT81047 standard; RNA; 17 BP.
XX
AC   AAT81047;
XX
DT   26-SEP-1997  (first entry)
XX
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 31).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 64; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAG 1787
              ||||||||||| ||||
Db         17 AGGAGGAGGAGAAGGAG 1


RESULT 156
AAT81045/c
ID   AAT81045 standard; RNA; 17 BP.
XX
AC   AAT81045;
XX
DT   26-SEP-1997  (first entry)
XX
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 28).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 64; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              ||||||||  |||||||
Db         17 AGGAGGAGAAGGAGGAG 1


RESULT 157
AAX24211
ID   AAX24211 standard; DNA; 17 BP.
XX
AC   AAX24211;
XX
DT   01-JUL-1999  (first entry)
XX
DE   Phosphonomonoester oligonucleotide analogue 28.
XX
KW   Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;
KW   ribozyme; diagnostic agent; detection; treatment; disease; virus;
KW   integrin; cell-cell adhesion receptor; TNF-alpha; ss.
XX
OS   Synthetic.
XX
PN   DE19508923-A1.
XX
PD   19-SEP-1996.
XX
PF   13-MAR-1995;   95DE-01008923.
XX
PR   13-MAR-1995;   95DE-01008923.
XX
PA   (FARH ) HOECHST AG.
```

```
XX
PI   Anuschirwan P,  Uhlmann E,  Breipohl G,  Wallmeier H;
XX
DR   WPI; 1996-425893/43.
XX
PT   New oligo:nucleotide analogues contg. phospho:mono:ester bridges - for
PT   therapeutic inhibition of gene expression, e.g. in cancer or viral
PT   infection, with good specificity and in vivo stability.
XX
PS   Disclosure; Page 23; 36pp; German.
XX
CC   This invention describes novel phosphonomonoester oligonucleotide
CC   analogues which act as inhibitors of gene expression (as sense/antisense,
CC   ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e.
CC   probes for detecting nucleic acid) or for treatment of diseases caused by
CC   viruses, influenced by integrins or cell-cell adhesion receptors, induced
CC   by factors such as TNF-alpha, or cancer or restenosis. The products of
CC   the invention satisfy the requirements of good in-vivo stability; ability
CC   to cross cellular and nuclear membranes, and specific binding to target
CC   nucleic acid better than known oligonucleotides
XX
SQ   Sequence 17 BP; 4 A; 1 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              |||||| || |||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 158
AAT09036/c
ID   AAT09036 standard; DNA; 17 BP.
XX
AC   AAT09036;
XX
DT   28-AUG-1996  (first entry)
XX
DE   Arabidopsis thaliana EIN2 (ethylene insensitive) locus primer PE7.
XX
KW   EIN2; ethylene insensitive; transformed plant; disease tolerance;
KW   ethylene insensitivity; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9535318-A1.
XX
PD   28-DEC-1995.
XX
PF   15-JUN-1995;   95WO-US007744.
XX
PR   17-JUN-1994;   94US-00261822.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Ecker J,  Rothenberg M,  Lehman A,  Roman G;
XX
DR   WPI; 1996-058366/06.
XX
PT   Plant sequences for ethylene insensitive loci and hook-less 1 allele(s) -
PT   confer disease tolerance and ethylene insensitivity when transformed into
PT   plants.
XX
PS   Example 2; Page 30; 144pp; English.
XX
CC   The present sequence is a primer for the A. thaliana EIN2 (ethylene
CC   insensitive) locus. When transformed into plants EIN2 genomic DNA, or
CC   cDNA sequences (obtd. from the EIN2 locus) confer disease tolerance and
CC   ethylene insensitivity, with minimal injury or reduction in the harvest
CC   yield of saleable material. The plants with disease tolerance may have
CC   extensive levels of infection, but little necrosis and few or no lesions.
CC   They may also have reduced necrotic and water soaking responses, and
CC   chlorophyll loss may be virtually absent
XX
SQ   Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1124 CCTCCAAGACCTGGGAG 1140
              || |||||||||||| |
Db         17 CCACCAAGACCTGGGTG 1


RESULT 159
AAX72691
ID   AAX72691 standard; RNA; 17 BP.
XX
AC   AAX72691;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #124.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 126; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 88;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1299 GCCATGGTCATCTGTGA 1315
              | ||:||:| :|:|:||
```

```
Db          1 GGCAUGGUCUUCUGUGA 17


RESULT 160
AAX71090
ID   AAX71090 standard; RNA; 17 BP.
XX
AC   AAX71090;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human KDR VEGF receptor hammerhead ribozyme substrate #102.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 100; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 88;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1299 GCCATGGTCATCTGTGA 1315
              | ||:||:| :|:|:||
Db          1 GGCAUGGUCUUCUGUGA 17


RESULT 161
ABK02358
ID   ABK02358 standard; RNA; 17 BP.
XX
AC   ABK02358;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #30.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 131; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
```

CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 8 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1762 ATGAAGATGAGGAGGAG 1778
| ||||| |||||||||
Db 1 AGGAAGAAGAGGAGGAG 17

RESULT 162
ABK02361
ID ABK02361 standard; RNA; 17 BP.
XX
AC ABK02361;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Amberzyme #33.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 131; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 8 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1764 GAAGATGAGGAGGAGGA 1780
||||| |||||||| ||
Db 1 GAAGAGGAGGAGGAAGA 17

RESULT 163
ABK02462
ID ABK02462 standard; RNA; 17 BP.
XX
AC ABK02462;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Amberzyme #134.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 133; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 10 A; 0 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 88;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1759 AAGATGAAGATGAGGAG 1775
||||:||||| ||| ||
Db 1 AAGAUGAAGAAGAGAAG 17

RESULT 164
ABK02363
ID ABK02363 standard; RNA; 17 BP.
XX
AC ABK02363;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Amberzyme #35.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 131; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an amberzyme molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 0 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;

```
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGA 1786
              ||||||||||| | |||
Db          1 GAGGAGGAGGAAGAGGA 17


RESULT 165
ABK00899/c
ID   ABK00899 standard; RNA; 17 BP.
XX
AC   ABK00899;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Inozyme #169.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 80; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 0 A; 14 C; 0 G; 0 T; 3 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGG 1788
              || |||||||| |||||
Db         17 GGGGGAGGAGGGGGAGG 1


RESULT 166
ABK02362
ID   ABK02362 standard; RNA; 17 BP.
XX
AC   ABK02362;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #34.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
```

```
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 131; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 8 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGGAG 1781
              |||| |||||||| |||
Db          1 AAGAGGAGGAGGAAGAG 17


RESULT 167
ABA78082/c
ID   ABA78082 standard; DNA; 17 BP.
XX
AC   ABA78082;
XX
DT   24-JAN-2002  (first entry)
XX
DE   BRCA1 mutation correcting oligonucleotide SEQ ID NO: 928.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200173002-A2.
XX
PD   04-OCT-2001.
XX
PF   27-MAR-2001; 2001WO-US009761.
XX
PR   27-MAR-2000; 2000US-0192176P.
PR   27-MAR-2000; 2000US-0192179P.
PR   01-JUN-2000; 2000US-0208538P.
PR   30-OCT-2000; 2000US-0244989P.
XX
PA   (UYDE ) UNIV DELAWARE.
XX
PI   Kmiec EB,  Gamper HB,  Rice MC;
XX
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
XX
PS   Claim 7; Page 100; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGAG 1280
              |||||||||| ||| |
Db         17 AGCTGGAAGAGTCTGGG 1


RESULT 168
ABA78081
ID   ABA78081 standard; DNA; 17 BP.
XX
AC   ABA78081;
XX
DT   24-JAN-2002  (first entry)
XX
DE   BRCA1 mutation correcting oligonucleotide SEQ ID NO: 927.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
```

OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 100; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGAG 1280
||||||||||| ||| |
Db 1 AGCTGGAAGAGTCTGGG 17

RESULT 169
ABN06620/c
ID ABN06620 standard; DNA; 17 BP.
XX
AC ABN06620;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6612.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 6612; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1221 CAGAACCTCCAGCATGT 1237
|||| ||||||| ||||
Db 17 CAGAGCCTCCAGGATGT 1

RESULT 170
ABN02601
ID ABN02601 standard; DNA; 17 BP.
XX
AC ABN02601;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2593.

```
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2593; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1293 CAGGGTGCCATGGTCAT 1309
              ||||||||||||||  ||
Db          1 CAGGGTGCCATGGAGAT 17
```

```
RESULT 171
ABN08090
ID   ABN08090 standard; DNA; 17 BP.
XX
AC   ABN08090;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8082.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8082; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
```

```
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1492 ACTATGAGGAGGAACTG 1508
              || | ||||||||||||
Db          1 ACCAGGAGGAGGAACTG 17


RESULT 172
ABN07862/c
ID   ABN07862 standard; DNA; 17 BP.
XX
AC   ABN07862;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7854.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7854; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 GTCTTGCAGCATCTCCA 1684
              ||| || ||||||||||
Db         17 GTCCTGTAGCATCTCCA 1


RESULT 173
ABN10746/c
ID   ABN10746 standard; DNA; 17 BP.
XX
AC   ABN10746;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10738.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10738; 214pp; English.
```

```
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1447 CCACCACACTGGGAGAC 1463
              | ||||||||||||| |
Db         17 CAACCACACTGGGAGCC 1

RESULT 174
ABN10748/c
ID   ABN10748 standard; DNA; 17 BP.
XX
AC   ABN10748;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10740.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10740; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 1 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1445 GGCCACCACACTGGGAG 1461
              | | ||||||||||||
Db         17 GCCAACCACACTGGGAG 1

RESULT 175
ABN06619/c
ID   ABN06619 standard; DNA; 17 BP.
XX
AC   ABN06619;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6611.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
```

```
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 6611; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match              0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1222 AGAACCTCCAGCATGTG 1238
              ||| ||||||| |||||
Db         17 AGAGCCTCCAGGATGTG 1


RESULT 176
ABN08656
ID   ABN08656 standard; DNA; 17 BP.
XX
AC   ABN08656;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8648.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-0024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8648; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match              0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1254 CTGCAGCAACAGCTGGA 1270
              |||||||  ||||||||
Db          1 CTGCAGCTGCAGCTGGA 17


RESULT 177
ABN00935
ID   ABN00935 standard; DNA; 17 BP.
XX
AC   ABN00935;
```

```
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:927.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 927; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1262 ACAGCTGGAAGAGGCTG 1278
              | ||||| |||||||||
Db          1 AGAGCTGAAAGAGGCTG 17


RESULT 178
ABN07863/c
ID   ABN07863 standard; DNA; 17 BP.
XX
AC   ABN07863;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7855.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7855; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
```

```
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1667 GGTCTTGCAGCATCTCC 1683
              |||| || |||||||||
Db         17 GGTCCTGTAGCATCTCC 1


RESULT 179
ABQ63436/c
ID   ABQ63436 standard; DNA; 17 BP.
XX
AC   ABQ63436;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 149.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 177; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1634 TCAGCAGGCCCAGCGTG 1650
              ||||||||| ||| |||
Db         17 TCAGCAGGCTCAGGGTG 1


RESULT 180
ABQ63435/c
ID   ABQ63435 standard; DNA; 17 BP.
XX
AC   ABQ63435;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 148.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 177; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
```

CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1635 CAGCAGGCCCAGCGTGC 1651
||||||| ||| ||||
Db 17 CAGCAGGCTCAGGGTGC 1

RESULT 181
ABQ63853/c
ID ABQ63853 standard; DNA; 17 BP.
XX
AC ABQ63853;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 566.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 231; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 6 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1748 CAGTGTAGCTGAAGATG 1764
|| |||||||||||| ||
Db 17 CATTGTAGCTGAAGTTG 1

RESULT 182
ABV79112/c
ID ABV79112 standard; DNA; 17 BP.
XX
AC ABV79112;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 358.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 110; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was

CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potenial therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 1 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1652 CCAGCTGCAGAGGCAGG 1668
||||||| ||| ||||||
Db 17 CCAGCTCCAGCGGCAGG 1

RESULT 183
ABK19390
ID ABK19390 standard; RNA; 17 BP.
XX
AC ABK19390;
XX
DT 09-APR-2002 (first entry)
XX
DE Human ERG Amberzyme target sequence Seq ID No 2037.
XX
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberzyme.
XX
OS Homo sapiens.
XX
PN WO200188124-A2.
XX
PD 22-NOV-2001.
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 127; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 7 A; 1 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1771 AGGAGGAGGAGGCGGAG 1787
||||||| ||||| |||
Db 1 AGGAGGAAGAGGCAGAG 17

RESULT 184
ACC53896/c
ID ACC53896 standard; DNA; 17 BP.
XX
AC ACC53896;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #2663.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Amson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 655; 798pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX

```
SQ   Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1210 CAGCCATCTGTCAGAAC 1226
              ||||| |||||||||  |
Db         17 CAGCCCTCTGTCAGATC 1


RESULT 185
ABT34968
ID   ABT34968 standard; DNA; 17 BP.
XX
AC   ABT34968;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 605.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 104; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       890 GAGCCTGCAGCAGACAG 906
             || ||||||| ||||||
Db         1 GATCCTGCAGGAGACAG 17


RESULT 186
ACA07741/c
ID   ACA07741 standard; RNA; 17 BP.
XX
AC   ACA07741;
XX
DT   03-JUN-2003  (first entry)
XX
DE   NFKB sub-unit modulating zinzyme substrate #140.
XX
KW   Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW   G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW   lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW   oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW   cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW   lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW   chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW   cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW   gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW   rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW   gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW   transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW   allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS   Homo sapiens.
XX
PN   US2002177568-A1.
XX
PD   28-NOV-2002.
XX
PF   23-MAY-2001; 2001US-00864785.
XX
PR   07-DEC-1992;   92US-00987132.
PR   18-MAY-1994;   94US-00245466.
PR   15-AUG-1994;   94US-00291932.
PR   23-DEC-1996;   96US-00777916.
XX
PA   (STIN/) STINCHCOMB D T.
PA   (MCSW/) MCSWIGGEN J.
PA   (DRAP/) DRAPER K G.
XX
PI   Stinchcomb DT,  Mcswiggen J,  Draper KG;
XX
DR   WPI; 2003-340953/32.
XX
PT   Novel enzymatic nucleic acid molecules which down regulates expression of
PT   a sequence encoding a subunit of nuclear factor kappa B useful for
PT   treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS   Claim 3; Page 39; 72pp; English.
XX
CC   The invention describes an enzymatic nucleic acid molecule (I) which down
CC   regulates expression of a sequence encoding a subunit of nuclear factor
CC   kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC   configuration. The enzymatic nucleic acid molecule is adapted to treat
CC   cancer and is useful for down-regulating REL-A activity in a cell, for
CC   treating a patient having a condition associated with the level of REL-A.
CC   (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC   the presence of a divalent cation, especially Mg^2^+. The enzymatic and
CC   antisense nucleic acid molecules are useful for treating breast, lung,
CC   prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC   cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC   multidrug resistant cancer. The method involves use of other drug
CC   therapies such as monoclonal antibodies, REL-A-specific inhibitors or
```

CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
SQ Sequence 17 BP; 2 A; 8 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1538 GGCCAAGACCTGGCTGA 1554
              |||| || |||||||||
Db         17 GGCCGAGGCCTGGCTGA 1
```

RESULT 187
ADA99911
ID ADA99911 standard; DNA; 17 BP.
XX
AC ADA99911;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ3 scanning oligonucleotide SEQ ID 900.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
DR WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS Example 8; SEQ ID NO 900; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1925 GGGGAGCAAGTGGAACC 1941
              |||||| | ||||||||
Db          1 GGGGAGTATGTGGAACC 17
```

RESULT 188
ADA99912
ID ADA99912 standard; DNA; 17 BP.
XX
AC ADA99912;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human MDZ3 scanning oligonucleotide SEQ ID 901.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
DR WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS Example 8; SEQ ID NO 901; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 88;

```
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1926 GGGAGCAAGTGGAACCG 1942
              ||||| | |||||||||
Db          1 GGGAGTATGTGGAACCG 17


RESULT 189
ABZ61958/c
ID   ABZ61958 standard; RNA; 17 BP.
XX
AC   ABZ61958;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #749.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 125; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 1 A; 6 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2019 AGGCAGGGCCACCCCCT 2035
              ||||||||| | |||||
Db         17 AGGCAGGGCAAGCCCCT 1


RESULT 190
ABZ64880/c
ID   ABZ64880 standard; RNA; 17 BP.
XX
AC   ABZ64880;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #337.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 139; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1268 GGAAGAGGCTGAGGGCA 1284
              |||||| ||||||| ||
Db         17 GGAAGACGCTGAGGTCA 1


RESULT 191
ACD62072/c
ID   ACD62072 standard; RNA; 17 BP.
XX
AC   ACD62072;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HCV minus strand DNAzyme substrate sequence #383.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
```

```
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 281; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        882 ACCTTTGAGAGCCTGCA 898
              ||||||||  ||  |||||
Db         17 ACCTTTGACAGACTGCA 1


RESULT 192
ACD65403
ID   ACD65403 standard; RNA; 17 BP.
XX
AC   ACD65403;
XX
DT   30-SEP-2003  (first entry)
XX
DE   HCV minus strand DNAzyme substrate sequence #2034.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 311; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 5 A; 5 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
```

```
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1872 ACCCCGCAGCTGGAGGA 1888
              |||| ||||| ||||||
Db          1 ACCCAGCAGCGGGAGGA 17


RESULT 193
ACD60541
ID   ACD60541 standard; RNA; 17 BP.
XX
AC   ACD60541;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #1895.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 267; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 88;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        881 CACCTTTGAGAGCCTGC 897
              ||||:::|| || |:||
Db          1 CACCUUUGACAGACUGC 17


RESULT 194
ACD57266/c
ID   ACD57266 standard; RNA; 17 BP.
XX
AC   ACD57266;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #244.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 238; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
```

```
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 0 A; 8 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1873 CCCCGCAGCTGGAGGAG 1889
              ||| ||||| |||||||
Db         17 CCCAGCAGCGGGAGGAG 1

RESULT 195
ACC58685/c
ID   ACC58685 standard; DNA; 17 BP.
XX
AC   ACC58685;
XX
DT   26-AUG-2003  (first entry)
XX
DE   Human ADAMTS14 gene exon 13 3' acceptor splice site.
XX
KW   A disintegrin and metalloproteinase with thrombospondin repeats;
KW   ADAMTS14; human; enzyme; neuroprotective; immunosuppressive; nootropic;
KW   antiinfertility; osteopathic; antiarthritic; antirheumatic;
KW   antiinflammatory; antiasthmatic; immunomodulator; antiallergic;
KW   cytostatic; antiulcer; vasotropic; antiarteriosclerotic; cardiant;
KW   anticonvulsant; antiparkinsonian; cerebroprotective; antimigraine;
KW   antidepressant; analgesic; ophthalmological; vulnerary; antidiabetic;
KW   dermatological; transgenic; chromosome 10q21.3; gene; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   intron          1. .12
FT                   /*tag=  a
FT                   /partial
FT   exon            13. .17
FT                   /*tag=  b
FT                   /partial
XX
PN   WO2003042379-A2.
XX
PD   22-MAY-2003.
XX
PF   08-NOV-2002; 2002WO-EP012534.
XX
PR   13-NOV-2001; 2001EP-00204335.
XX
PA   (UYLI-) UNIV LIEGE.
XX
PI   Colige A,  Lapiere C,  Nusgens B;
XX
DR   WPI; 2003-482347/45.
XX
PT   New isolated and purified A disintegrin and metalloproteinase with
PT   thrombospondin type I repeats polynucleotide, useful for manufacturing a
PT   medicament for the treatment of e.g. neurodegenerative, autoimmune, and
PT   cell proliferation diseases.
XX
PS   Disclosure; Page 39; 67pp; English.
XX
CC   The present sequence is that of the 3' acceptor splice site of exon 13 of
CC   a novel human A Disintegrin and Metalloproteinase with Thrombospondin
CC   type I repeats (ADAMTS) gene, denoted ADAMTS14, on chromosome 10q21.3. A
CC   cDNA sequence for ADAMTS14 is given in ACC58643. ADAMTS14 (see ABR42736)
CC   is an aminoprocollagen peptidase that functions in procollagen
CC   processing. ADAMTS14 polynucleotides, polypeptides, vectors, cells
CC   transfected by the vectors, and inhibitors directed against ADAMTS14 are
CC   used in the treatment and/or prevention of a range of diseases
XX
SQ   Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1271 AGAGGCTGAGGGCAGAG 1287
              | ||||||||| |||||
Db         17 ACAGGCTGAGGCCAGAG 1

RESULT 196
ADB42204/c
ID   ADB42204 standard; DNA; 17 BP.
XX
AC   ADB42204;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #2527.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 327; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
```

```
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nuclectides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 1 A; 9 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 GGAGGAGGACGAGGAGC 1899
              ||||||||| ||||| |
Db         17 GGAGGAGGAAGAGGATC 1


RESULT 197
AAL61574
ID   AAL61574 standard; DNA; 20 BP.
XX
AC   AAL61574;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130499.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         93 TGGCCTCGTCCAGCCCG 109
              ||||||| |||||| ||
Db          4 TGGCCTCCTCCAGCACG 20


RESULT 198
ABL36309
ID   ABL36309 standard; DNA; 15 BP.
XX
AC   ABL36309;
XX
DT   22-APR-2002  (first entry)
XX
DE   Human lysosomal acid phosphatase 2 (ACP2) allele-specific probe 11.
XX
KW   Human; ss; lysosomal acid phosphatase 2; ACP2; gene; chromosome 11;
KW   lysosome-specific enzyme; orthophosphoric monoester hydrolysis;
KW   Hodgkin's disease; HD; acid phosphatase deficiency;
KW   novel polymorphic site; ACP2 haplotype; ACP2 genotype; polymorphism;
KW   transgenic animal; primer; probe; primer-extension oligonucleotide; SNP;
KW   single nucleotide polymorphism.
XX
OS   Homo sapiens.
XX
PN   WO200194362-A2.
XX
PD   13-DEC-2001.
XX
PF   07-JUN-2001; 2001WO-US018457.
XX
PR   07-JUN-2000; 2000US-0210047P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Kliem SE,  Messer C,  Tanguay DA;
XX
DR   WPI; 2002-154563/20.
XX
PT   Novel genetic variants of acid phosphatase 2, lysosomal polypeptide gene
PT   useful in studying expression and function of the protein, and for
PT   screening drugs to treat diseases e.g. Hodgkin's disease.
XX
PS   Claim 17; Page 14; 109pp; English.
XX
CC   The invention comprises the human lysosomal acid phosphatase 2 (ACP2)
CC   nucleic acid and protein sequences. Specifically, the invention relates
CC   to the discovery of 22 novel polymorphic sites within the APC2 gene. The
CC   invention also comprises methods for haplotyping and genotyping the ACP2
CC   gene in an individual. The ACP2 gene (located on chromosome 11) encodes a
```

```
CC   lysosomal-specific enzyme that catalyses the hydrolysis of
CC   orthophosphoric monoesters to alcohol and phosphate. The ACP2 gene and
CC   protein are pharmaceutically important in the treatment of Hodgkin's
CC   disease (HD) and acid phosphatase deficiency. The novel ACP2 gene
CC   polymorphisms of the invention are useful in haplotyping the ACP2 gene.
CC   ACP2 haplotyping is useful in validating ACP2 as a target (and designing
CC   drugs) for treating an ACP2-related disease or condition (e.g. Hodgkin's
CC   disease and acid phosphatase deficiency). The ACP2 gene polymorphisms are
CC   useful for ACP2 genotyping, which can also be used to develop diagnostic
CC   tests and therapeutic treatments. The ACP2 protein and nucleic acids of
CC   the invention are useful in the production of a transgenic animal which
CC   expresses ACP2 protein. The ACP2 nucleic acids of the invention are
CC   useful in the production of allele-specific oligonucleotides designed to
CC   genotype each of the ACP2 polymorphisms. Nucleic acids ABL36299-ABL36320
CC   represent claimed ACP2 allele-specific probes. Nucleic acids ABL36321-
CC   ABL36364 represent claimed ACP2 allele-specific PCR primers. Nucleic
CC   acids ABL36365-ABL36408 represent claimed ACP2 primer-extension
CC   oligonucleotides
XX
SQ   Sequence 15 BP; 2 A; 6 C; 4 G; 2 T; 0 U; 1 Other;

  Query Match             0.5%;  Score 13.6;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 70;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1633 CTCAGCAGGCCCAG 1646
              ||||||:|||||||
Db          2 CTCAGCMGGCCCAG 15


RESULT 199
ABL36360
ID   ABL36360 standard; DNA; 15 BP.
XX
AC   ABL36360;
XX
DT   22-APR-2002  (first entry)
XX
DE   Human lysosomal acid phosphatase 2 (ACP2) allele-specific PCR primer 40.
XX
KW   Human; ss; lysosomal acid phosphatase 2; ACP2; gene; chromosome 11;
KW   lysosome-specific enzyme; orthophosphoric monoester hydrolysis;
KW   Hodgkin's disease; HD; acid phosphatase deficiency;
KW   novel polymorphic site; ACP2 haplotype; ACP2 genotype; polymorphism;
KW   transgenic animal; primer; probe; primer-extension oligonucleotide; SNP;
KW   single nucleotide polymorphism.
XX
OS   Homo sapiens.
XX
PN   WO200194362-A2.
XX
PD   13-DEC-2001.
XX
PF   07-JUN-2001; 2001WO-US018457.
XX
PR   07-JUN-2000; 2000US-0210047P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Kliem SE,  Messer C,  Tanguay DA;
XX
DR   WPI; 2002-154563/20.
XX
PT   Novel genetic variants of acid phosphatase 2, lysosomal polypeptide gene
PT   useful in studying expression and function of the protein, and for
PT   screening drugs to treat diseases e.g. Hodgkin's disease.
XX
PS   Claim 17; Page 14; 109pp; English.
XX
CC   The invention comprises the human lysosomal acid phosphatase 2 (ACP2)
CC   nucleic acid and protein sequences. Specifically, the invention relates
CC   to the discovery of 22 novel polymorphic sites within the APC2 gene. The
CC   invention also comprises methods for haplotyping and genotyping the ACP2
CC   gene in an individual. The ACP2 gene (located on chromosome 11) encodes a
CC   lysosomal-specific enzyme that catalyses the hydrolysis of
CC   orthophosphoric monoesters to alcohol and phosphate. The ACP2 gene and
CC   protein are pharmaceutically important in the treatment of Hodgkin's
CC   disease (HD) and acid phosphatase deficiency. The novel ACP2 gene
CC   polymorphisms of the invention are useful in haplotyping the ACP2 gene.
CC   ACP2 haplotyping is useful in validating ACP2 as a target (and designing
CC   drugs) for treating an ACP2-related disease or condition (e.g. Hodgkin's
CC   disease and acid phosphatase deficiency). The ACP2 gene polymorphisms are
CC   useful for ACP2 genotyping, which can also be used to develop diagnostic
CC   tests and therapeutic treatments. The ACP2 protein and nucleic acids of
CC   the invention are useful in the production of a transgenic animal which
CC   expresses ACP2 protein. The ACP2 nucleic acids of the invention are
CC   useful in the production of allele-specific oligonucleotides designed to
CC   genotype each of the ACP2 polymorphisms. Nucleic acids ABL36299-ABL36320
CC   represent claimed ACP2 allele-specific probes. Nucleic acids ABL36321-
CC   ABL36364 represent claimed ACP2 allele-specific PCR primers. Nucleic
CC   acids ABL36365-ABL36408 represent claimed ACP2 primer-extension
CC   oligonucleotides
XX
SQ   Sequence 15 BP; 5 A; 1 C; 6 G; 2 T; 0 U; 1 Other;

  Query Match             0.5%;  Score 13.6;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 70;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1492 ACTATGAGGAGGAA 1505
              |||||||||||||:
Db          1 ACTATGAGGAGGAR 14


RESULT 200
AAT54850/c
ID   AAT54850 standard; RNA; 15 BP.
XX
AC   AAT54850;
XX
DT   25-MAR-2003  (revised)
DT   07-APR-1997  (first entry)
XX
DE   Mouse relA hammerhead ribozyme target sequence (nt. position 326).
XX
KW   Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW   gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW   intercellular adhesion molecule; rel A; tumour necrosis factor;
KW   TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW   translocation; chronic myelogenous leukaemia; CML; cancer;
KW   Philadelphia chromosome; inflammation; autoimmune disease;
KW   atherosclerosis; myocardial infarction; stroke; restenosis;
KW   transplant rejection; rheumatoid arthritis; psoriasis;
KW   myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW   human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW   ss.
XX
OS   Mus musculus.
XX
PN   WO9523225-A2.
XX
PD   31-AUG-1995.
XX
PF   23-FEB-1995;   95WO-IB000156.
XX
PR   23-FEB-1994;   94US-00201109.
PR   29-MAR-1994;   94US-00218934.
PR   04-APR-1994;   94US-00222795.
PR   07-APR-1994;   94US-00224483.
PR   15-APR-1994;   94US-00227958.
PR   15-APR-1994;   94US-00228041.
PR   18-MAY-1994;   94US-00245736.
PR   06-JUL-1994;   94US-00271280.
PR   15-AUG-1994;   94US-00291932.
PR   16-AUG-1994;   94US-00291433.
PR   17-AUG-1994;   94US-00292620.
```

```
PR   19-AUG-1994;   94US-00293520.
PR   02-SEP-1994;   94US-00300000.
PR   08-SEP-1994;   94US-00303039.
PR   23-SEP-1994;   94US-00311486.
PR   23-SEP-1994;   94US-00311749.
PR   28-SEP-1994;   94US-00314397.
PR   03-OCT-1994;   94US-00316771.
PR   07-OCT-1994;   94US-00319492.
PR   11-OCT-1994;   94US-00321993.
PR   04-NOV-1994;   94US-00334847.
PR   10-NOV-1994;   94US-00337608.
PR   28-NOV-1994;   94US-00345516.
PR   16-DEC-1994;   94US-00357577.
PR   23-DEC-1994;   94US-00363233.
PR   30-JAN-1995;   95US-00380734.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Chowrira B,  Direnzo A,  Draper KG,  Dudycz LW;
PI   Grimm S,  Karpeisky A,  Kisich K,  Matulic-Adamic J,  Mcswiggen JA;
PI   Modak A,  Pavco P,  Beigleman L,  Sullivan SM,  Sweedler D,  Thompson JD;
PI   Tracz D,  Usman N,  Wincott FE,  Woolf T;
XX
DR   WPI; 1995-351090/45.
XX
PT   Ribozymes having modified bases and methods for producing them - for use
PT   in inhibiting disease related genes.
XX
PS   Claim 2; Page 225; 407pp; English.
XX
CC   The present sequence represents a preferred target sequence for an
CC   enzymatic nucleic acid (i.e. a ribozyme) which cleaves relA mRNA at the
CC   nucleotide base position indicated in the DE line. The relA gene product
CC   is a subunit of the transcriptional regulator NF-kappaB and is implicated
CC   specifically in the induction of inflammatory responses. Regions of the
CC   mRNA that do not form secondary folding structures and that contain
CC   potential hammerhead and hairpin ribozyme cleavage sites were identified
CC   by computer analysis. Ribozymes directed against these mRNA sequences
CC   were designed and synthesised with modifications that improve their
CC   nuclease resistance. The ribozymes are designed to cleave the target
CC   sequences and thereby inhibit relA expression, making them potentially
CC   useful for treating rheumatoid arthritis, restenosis and asthma as well
CC   as for increasing tolerance to transplanted tissues. The potential
CC   immunosuppressive properties of a ribozyme that cleaves relA mRNA means
CC   that uses are limited to local delivery, acute indications or ex vivo
CC   treatment. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ   Sequence 15 BP; 2 A; 9 C; 2 G; 0 T; 2 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 GGCCGGCGAGGTGGA 1837
              ||||| ||||||||
Db         15 GGCCGGTGAGGTGGA 1

RESULT 201
AAX56927
ID   AAX56927 standard; DNA; 15 BP.
XX
AC   AAX56927;
XX
DT   16-OCT-2003  (revised)
DT   15-JUL-1999  (first entry)
XX
DE   HIV-1 proviral DNA fragment 10.
XX
KW   DNA-targeting conjugate; anticancer drug; viral DNA-cleaving agent;
KW   viral DNA-binding agent; solid support; primer; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO9531434-A1.
XX
PD   23-NOV-1995.
XX
PF   12-MAY-1995;   95WO-US006379.
XX
PR   13-MAY-1994;   94US-00242664.
XX
PA   (SLOK ) SLOAN KETTERING INST CANCER RES.
PA   (ZWBI-) ZW BIOMEDICAL RES AG.
XX
PI   Watanabe KA,  Ren W,  Weil R;
XX
DR   WPI; 1996-010846/01.
XX
PT   Derivatised solid supports and reagents for oligo:nucleotide synthesis -
PT   and new oligo:nucleotide phosphoramidate conjugates.
XX
PS   Disclosure; Page 44; 68pp; English.
XX
CC   This invention describes novel derivatised solid supports of formula S'-L
CC   -Z-CH2CH2-R, where: S' = a solid support; L = a bond or an (in)organic
CC   linker; Z = SO2 or S-S; R = OH, an H-phosphonate, alkanephosphonate,
CC   phosphotriester, phosphite triester, phosphite diester, phosphorothioate,
CC   phosphorodithioate, phosphoramidate or phosphoramidite group, OR1, SR1,
CC   an optionally substituted or modified nucleotide (N'), or an
CC   oligonucleotide of formula (N')gR2; g = 1-200; R1 = a protecting group;
CC   R2 = an H-phosphonate, alkanephosphonate, phosphotriester, phosphite
CC   triester, phosphite diester, phosphorothioate, phosphorodithioate,
CC   phosphoramidate or phosphoramidite group, OH, OR1, SR1 or
CC   OP(OCH2CH2CN)OCH2CH2ZCH2CH2OR1. Also mentioned are compounds of formula
CC   R3CH2CH2ZCH2CH2R4, where: R3 = a protecting group; and R4 = OH or an H-
CC   phosphonate, alkanephosphonate, phosphotriester, phosphite triester,
CC   phosphite diester, phosphorothioate, phosphorodithioate, phosphoramidate
CC   or phosphoramidite group. Also claimed are new phosphoramidates, a
CC   process for preparing an oligonucleotide 5'-phosphate, a process for
CC   preparing a solid support useful for preparation of an oligonucleotide 3'
CC   -phosphate, a process for preparing an oligonucleotide 3'-phosphate and a
CC   process for preparing an oligonucleotide 3',5'-diphosphate. The
CC   oligonucleotide 3'- and/or 5'-phosphates may be used to prepare DNA-
CC   targeting conjugates, e.g. with anticancer drugs or viral (e.g. HIV) DNA-
CC   cleaving or -binding agents. The process for preparing oligonucleotide
CC   3',5'-diphosphates is simple and suitable for use in automatic DNA
CC   synthesisers. This sequence represents a fragment of the HIV-1 provirus
CC   genome, used to describe the method of the invention. (Updated on 16-OCT-
CC   2003 to standardise OS field)
XX
SQ   Sequence 15 BP; 6 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGG 1779
              |||| ||||||||||
Db          1 AAGAGGAGGAGGAGG 15

RESULT 202
AAT45448
ID   AAT45448 standard; RNA; 15 BP.
XX
AC   AAT45448;
XX
DT   05-AUG-1997  (first entry)
XX
DE   Bacteriophage lambda box B, RNA binding site.
XX
KW   Arginine rich; RNA; site; binding; box B; N protein; identification;
KW   screening; isolation; therapy; treatment; pathogenic; microorganism;
KW   disease; diagnosis; detection; ss.
XX
```

```
OS   Bacteriophage lambda.
XX
FH   Key             Location/Qualifiers
FT   stem_loop       1. .15
FT                   /*tag= a
XX
PN   WO9636692-A1.
XX
PD   21-NOV-1996.
XX
PF   08-MAY-1996;   96WO-US006513.
XX
PR   17-MAY-1995;   95US-00442461.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Harada K,  Martin SS,  Frankel A;
XX
DR   WPI; 1997-012071/01.
XX
PT   Screening for RNA-binding polypeptide(s) - by expressing an anti-
PT   termination protein fused to a test polypeptide and detecting expression
PT   of a reporter gene linked to a terminator.
XX
PS   Example 1; Fig 1A; 56pp; English.
XX
CC   Bacteriophage lambda N protein residues 1-19, is an arginine rich RNA
CC   binding peptide (RBP) specific to the bacteriophage lambda box B, RNA
CC   binding site, i.e. the present sequence. It was used in a novel screening
CC   method, which comprised the construction of a vector encoding a hybrid
CC   protein, in which the 19 residue amino-terminal RBP of the phage lambda N
CC   protein was replaced by an arginine rich putative RBP. A second vector
CC   encoding the phage lambda termination site Nut and a marker gene was
CC   constructed, into which oligonucleotides containing box A of the Nut site
CC   and the appropriate RNA hairpin in place of box B were cloned. Plasmids
CC   were transformed into E. coli, and the expression of the reporter gene
CC   determined, showing that anti-termination was observed only with specific
CC   peptide/RNA interactions. The method can be used to isolate RBP, useful
CC   in therapy to block the life cycle of pathogenic microorganisms including
CC   viruses, e.g. HIV, and bacteria. The RBP can also be used to treat
CC   mammalian diseases resulting from impairment or loss of a natural RBP, as
CC   lead compounds for the development of therapeutic compounds and in
CC   diagnosis, e.g. pathogenic microorganism detection
XX
SQ   Sequence 15 BP; 4 A; 4 C; 6 G; 0 T; 1 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 76;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1161 GCCCTGAAGAAGGCC 1175
              | ||:||||||||||
Db          1 GGCCUGAAGAAGGCC 15


RESULT 203
AAZ07075
ID   AAZ07075 standard; DNA; 15 BP.
XX
AC   AAZ07075;
XX
DT   07-OCT-1999  (first entry)
XX
DE   Peptide nucleic acid oligomer #5.
XX
KW   Peptide nucleic acid; PNA; polymer; solubility; modulation; synthesis;
KW   purification; analysis; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag= a
FT                   /note= "g is modified to Flu-OE-g where Flu is 5-(6)-
FT                   carboxyfluorescein, O is 8-amino-3,6-dioxaoctanoic acid
FT                   and E is an uncharged ether modifying moiety"
FT   modified_base   15
FT                   /*tag= b
FT                   /note= "g is modified to g-E-NH2, which is an amidated
FT                   uncharged ether modifying moiety"
XX
PN   WO9937670-A1.
XX
PD   29-JUL-1999.
XX
PF   19-JAN-1999;   99WO-US001024.
XX
PR   27-JAN-1998;   98US-0072772P.
PR   04-JAN-1999;   99US-00225048.
XX
PA   (BOST-) BOSTON PROBES INC.
XX
PI   Gildea BD,  Coull JM;
XX
DR   WPI; 1999-479032/40.
XX
PT   Branched compositions for improving the solubility of synthetic polymers
PT   or minimizing or eliminating polymer self-aggregation, particularly in
PT   peptide nucleic acids.
XX
PS   Example 12; Page 40; 81pp; English.
XX
CC   The present invention describes a branched composition (I) which is
CC   useful for improving the solubility of synthetic polymers (II) or aids in
CC   minimizing or eliminating self-aggregation of (II), where (II) is a
CC   nucleic acid (or analogue), peptide, peptide nucleic acid (PNA),
CC   polyamide, chimera or a linked polymer. Modification of (II) by (I) can
CC   facilitate synthesis, purification and analysis of many insoluble
CC   polymers, and particularly purine-rich PNA polymers labeled with
CC   hydrophobic labels. The products can be used in research, diagnostic and
CC   therapeutic applications. The present sequence represents a PNA used in
CC   the exemplification of the present invention
XX
SQ   Sequence 15 BP; 5 A; 0 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 GATGAGGAGGAGGAG 1781
              || ||||||||||||
Db          1 GAGGAGGAGGAGGAG 15


RESULT 204
AAF46416/c
ID   AAF46416 standard; DNA; 15 BP.
XX
AC   AAF46416;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1255.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
```

```
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 42; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 10 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1821 GAGGCCGGCGAGGTG 1835
              ||||||||.||||||
Db         15 GAGGCCGGGGAGGTG 1

RESULT 205
AAF46437
ID   AAF46437 standard; DNA; 15 BP.
XX
AC   AAF46437;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1276.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 42; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1651 CCCAGCTGCAGAGGC 1665
              ||||||||||||.||
Db          1 CCCAGCTGCAGATGC 15

RESULT 206
AAF45184
ID   AAF45184 standard; DNA; 15 BP.
XX
AC   AAF45184;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #23.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
```

```
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 4 A; 2 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1779 GAGGCGGAGGAGGCG 1793
              || ||||||||||||
Db          1 GAAGCGGAGGAGGCG 15


RESULT 207
AAF45921
ID   AAF45921 standard; DNA; 15 BP.
XX
AC   AAF45921;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #760.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 39; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1530 CTGGAGGAGGCCAAG 1544
              ||||||||| |||||
Db          1 CTGGAGGAGCCCAAG 15


RESULT 208
AAF45922
ID   AAF45922 standard; DNA; 15 BP.
XX
AC   AAF45922;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #761.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
```

```
PT   inflammation.
XX
PS   Example 6; Page 39; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 5 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1531 TGGAGGAGGCCAAGA 1545
              ||||||| ||||||
Db          1 TGGAGGAGCCCAAGA 15


RESULT 209
AAF45185
ID   AAF45185 standard; DNA; 15 BP.
XX
AC   AAF45185;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #24.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 4 A; 2 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1780 AGGCGGAGGAGGCGG 1794
              | ||||||||||||||
Db          1 AAGCGGAGGAGGCGG 15


RESULT 210
ABZ66523/c
ID   ABZ66523 standard; RNA; 15 BP.
XX
AC   ABZ66523;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 synthetic DNAzyme target #4.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 153; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
```

```
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 15 BP; 2 A; 7 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1267 TGGAAGAGGCTGAGG 1281
              ||||||| |||||||
Db         15 TGGAAGACGCTGAGG 1

RESULT 211
ACD82534
ID   ACD82534 standard; DNA; 15 BP.
XX
AC   ACD82534;
XX
DT   19-SEP-2003  (first entry)
XX
DE   Nucleic acid cloning associated adaptor molecule #235.
XX
KW   Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KW   internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
OS   Synthetic.
XX
PN   US2003044791-A1.
XX
PD   06-MAR-2003.
XX
PF   13-JUN-2001; 2001US-00880313.
XX
PR   13-JUN-2001; 2001US-00880313.
XX
PA   (FLEM/) FLEMINGTON E K.
XX
PI   Flemington EK;
XX
DR   WPI; 2003-521745/49.
XX
PT   New adaptor molecules, useful for cloning nucleic acid molecules that
PT   does not require the design and synthesis of oligonucleotides or PCR
PT   primers.
XX
PS   Claim 12; Fig 5; 100pp; English.
XX
CC   The invention describes adaptor molecules, where each end of the adaptor
CC   is compatible with a nucleic acid digested with a restriction enzyme or a
CC   nucleic acid comprising an end that is compatible with a nucleic acid
CC   digested with a restriction enzyme. The adaptor molecules, compositions,
CC   kits and arrays are useful for cloning nucleic acid molecules that does
CC   not require the design and synthesis of oligonucleotides or PCR primers.
CC   The adaptors, kits and arrays are also useful for ligating two ends of a
CC   single nucleic acid molecule, or ligating two or more nucleic acid
CC   molecules. The kits can also be used for performing internal deletion
CC   mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC   vehicle, making the cloning procedure more rapid and efficient, and less
CC   error-prone. This sequence represents a nucleic acid cloning associated
CC   adaptor molecule
XX
SQ   Sequence 15 BP; 3 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1247 GGTCCGGCTGCAGCA 1261
              | ||||||||||||||

Db          1 GATCCGGCTGCAGCA 15

RESULT 212
ADA27359
ID   ADA27359 standard; DNA; 15 BP.
XX
AC   ADA27359;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human microsatellite repeat M2_3_3.
XX
KW   ds; HLA-related research; HLA class II-associated disease;
KW   transplantation matching; recombination hot spot identification;
KW   linkage disequilibrium study; human; microsatellite.
XX
OS   Homo sapiens.
XX
PN   US2003108940-A1.
XX
PD   12-JUN-2003.
XX
PF   06-DEC-2002; 2002US-00314405.
XX
PR   15-NOV-2000; 2000US-00713616.
XX
PA   (INOK/) INOKO H.
XX
PI   Inoko H,  Tamiya G,  Matsuzaka Y;
XX
DR   WPI; 2003-616782/58.
XX
PT   New oligonucleotide primer capable of specifically hybridizing to a DNA
PT   having the sequence of the flanking regions of a microsatellite (e.g.
PT   M249), useful for HLA-related research, e.g. transplantation matching.
XX
PS   Example 2; Page 5; 20pp; English.
XX
CC   The invention relates to an oligonucleotide primer capable of
CC   specifically hybridising to a DNA having the sequence of the flanking
CC   regions of a microsatellite selected from M2-4-9, M2-2-9, M2-2-12, M2-3-
CC   11, M2-2-20, M2-2-21, M2-2-22, M2-2-23, M2-2-24, M2-4-25, M2-4-26, M2-2-
CC   29, M2-2-32, M2-4-32, M2-4-33, M2-4-37, M2-3-22, M2-2-36, M2-5-11, M2-2-
CC   46, and M2-2-48. The primer is useful for determining the number of
CC   repeat units of the microsatellite cited above. The primer is useful in
CC   HLA-related research, such as genetic mapping of HLA class II-associated
CC   diseases, transplantation matching, population genetics, and
CC   identification of recombination hot spots as well as linkage
CC   disequilibrium studies. The present sequence represents the human
CC   microsatellite repeat M2_3_3.
XX
SQ   Sequence 15 BP; 5 A; 0 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 76;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 GATGAGGAGGAGGAG 1781
              || ||||||||||||
Db          1 GAGGAGGAGGAGGAG 15

RESULT 213
AAQ24927/c
ID   AAQ24927 standard; DNA; 16 BP.
XX
AC   AAQ24927;
XX
DT   25-MAR-2003  (revised)
DT   19-NOV-1992  (first entry)
XX
DE   Homeo box consensus sequence primer (250).
```

XX
KW Single primer amplification; SPAR; ss.
XX
OS Synthetic.
XX
PN WO9207948-A1.
XX
PD 14-MAY-1992.
XX
PF 05-NOV-1991; 91WO-US008233.
XX
PR 06-NOV-1990; 90US-00610973.
PR 29-JUL-1991; 91US-00737919.
XX
PA (LUBR) LUBRIZOL CORP.
XX
PI Cardineau GA, Filner P;
XX
DR WPI; 1992-183683/22.
XX
PT Nucleic acid sequence single primer amplification - useful for genomic
PT variation analysis and polymorphism detection for restriction fragment
PT length data.
XX
PS Claim 16; Page 39; 65pp; English.
XX
CC The selected primer is used in practice of the single primer
CC amplification reaction (SPAR). (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 16 BP; 1 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 90;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1877 GCAGCTGGAGGAGGA 1891
||||||||||| ||||
Db 16 GCAGCTGGAGAAGGA 2

RESULT 214
AAQ25457
ID AAQ25457 standard; DNA; 16 BP.
XX
AC AAQ25457;
XX
DT 25-MAR-2003 (revised)
DT 07-DEC-1992 (first entry)
XX
DE Purine rich HIV target duplex sequence.
XX
KW Target; Human Immunodeficiency Virus; AIDS; triplex; hepatitis; herpes;
KW malignancy; ds.
XX
OS Synthetic.
XX
PN WO9209705-A1.
XX
PD 11-JUN-1992.
XX
PF 25-NOV-1991; 91WO-US008811.
XX
PR 23-NOV-1990; 90US-00617907.
PR 18-JAN-1991; 91US-00643382.
PR 08-APR-1991; 91US-00683420.
PR 17-APR-1991; 91US-00686544.
PR 17-APR-1991; 91US-00686546.
PR 17-APR-1991; 91US-00686547.
PR 27-SEP-1991; 91US-00766733.
XX
PA (GILE-) GILEAD SCI INC.
XX
PI Froehler B, Krawczyk S, Matteucci MD, Milligan J;
XX
DR WPI; 1992-217083/26.
XX
PT New oligomers contg. modified bases - which form a triplex with G-C
PT doublet in a DNA duplex, for treating and diagnosing HIV, hepatitis,
PT herpes malignancy and inflammation.
XX
PS Claim 11; Page 63; 77pp; English.
XX
CC The sequence depicts a HIV viral duplex sequence which contains a purine-
CC rich region concentrated on one chain of the duplex. The sequence may be
CC prepd. by standard DNA synthesis. The HIV duplex sequence is used as a
CC target for novel oligomers which are capable of forming a triplex at
CC physiological pH by coupling into the major groove of the DNA duplex.
CC Three such oligomers HIV141 -HIV143 are capable of forming a triplex with
CC this sequence. The oligomers are used in the diagnosis and therapy of HIV
CC infection. Similar oligomers may be used to target viral DNA duplexes
CC specific for hepatitis, herpes and malignancy. The triple helices form
CC under mild conditions thus assays may be carried out without subjecting
CC the test specimen to harsh conditions. The oligomer is able to inhibit
CC gene expression, as verified by in vitro systems See also AAQ25452-25501
CC and AAQ30226-448. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 16 BP; 7 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 90;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1765 AAGATGAGGAGGAGG 1779
|||| ||||||||||
Db 2 AAGAGGAGGAGGAGG 16

RESULT 215
AAQ70682/c
ID AAQ70682 standard; DNA; 16 BP.
XX
AC AAQ70682;
XX
DT 25-MAR-2003 (revised)
DT 15-MAR-1995 (first entry)
XX
DE Triplex forming oligonucleotide directed against Erb-B2 gene.
XX
KW Erb-B2; upstream region; regulatory element; gene expression; triplex;
KW antisense; inhibition; screening; identification; cancer; breast cancer;
KW carcinoma; breast cancer; erythroleukaemia; sarcoma; ss.
XX
OS Synthetic.
XX
PN WO9417086-A1.
XX
PD 04-AUG-1994.
XX
PF 10-JAN-1994; 94WO-US000348.
XX
PR 25-JAN-1993; 93US-00008897.
XX
PA (APOL-) APOLLON INC.
XX
PI Yoon K, Lu M;
XX
DR WPI; 1994-264018/32.
XX
PT Composition for decreasing gene transcription - comprises
PT oligo:nucleotide or deriv. complementary to target gene region.
XX
PS Claim 12; Page 43; 71pp; English.
XX
CC The Erb-B2 gene has a purine rich segment with substantial mirror
CC symmetry. This sequence, derived from the Erb-B2 gene is located 69

```
CC   nucleotides upstream of the transcriptional start site and is the
CC   potential site of H-DNA formation. The overexpression of Erb-B2 is
CC   particularly associated with breast cancer. This triplex forming
CC   oligonucleotide directed against Erb-B2 and its derivatives may be used
CC   in the treatment of breast cancer, erythroleukaemia and sarcoma and more
CC   generally any disease involving the expression of Erb-B2. (Updated on 25-
CC   MAR-2003 to correct PN field.)
XX
SQ   Sequence 16 BP; 1 A; 10 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1777 AGGAGGCGGAGGAGG 1791
              |||||| ||||||||
Db         16 AGGAGGTGGAGGAGG 2


RESULT 216
AAA95296
ID   AAA95296 standard; DNA; 16 BP.
XX
AC   AAA95296;
XX
DT   23-FEB-2001  (first entry)
XX
DE   Murine CRAM-2 coding sequence identification PCR primer #3.
XX
KW   Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;
KW   inflammation; cancer; wound; angiogenesis; mouse; JAM-3;
KW   confluency regulated adhesion molecule 2; CRAM-2; PCR primer; ss.
XX
OS   Mus sp.
XX
PN   WO200053749-A2.
XX
PD   14-SEP-2000.
XX
PF   13-MAR-2000; 2000WO-EP002219.
XX
PR   11-MAR-1999;   99EP-00200746.
XX
PA   (RMFD-) RMF DICTAGENE SA.
XX
PI   Imhof BA,  Aurrand-Lions M;
XX
DR   WPI; 2000-587436/55.
XX
PT   Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (CRAM-1 or
PT   CRAM-2) polypeptide, useful for treatment of tumors, inflammation
PT   reactions and modulating vascular permeability.
XX
PS   Example; Page 15; 59pp; English.
XX
CC   The present sequence is a PCR primer used during the identification of
CC   the murine confluency regulated adhesion molecule 2 (CRAM-2, also known
CC   as JAM-3) coding sequence. CRAM-2 is one of the vascular adhesion
CC   proteins of the immunoglobulin superfamily (Ig Sf). The CRAM-2 protein
CC   and coding sequence can be used in the treatment of cancer, inflammation,
CC   to modulate cell-cell interactions and angiogenesis, and in the
CC   modulation of wound healing
XX
SQ   Sequence 16 BP; 2 A; 9 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2243 CACCCTCCGCACTCG 2257
              ||||||||| ||||||
Db          1 CACCCTCCTCACTCG 15


RESULT 217
AAA95300
ID   AAA95300 standard; DNA; 16 BP.
XX
AC   AAA95300;
XX
DT   23-FEB-2001  (first entry)
XX
DE   Murine CRAM-1 mRNA transcript level PCR primer #2.
XX
KW   Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;
KW   inflammation; cancer; wound; angiogenesis; mouse; JAM-2;
KW   confluency regulated adhesion molecule 1; CRAM-1; PCR primer; ss.
XX
OS   Mus sp.
XX
PN   WO200053749-A2.
XX
PD   14-SEP-2000.
XX
PF   13-MAR-2000; 2000WO-EP002219.
XX
PR   11-MAR-1999;   99EP-00200746.
XX
PA   (RMFD-) RMF DICTAGENE SA.
XX
PI   Imhof BA,  Aurrand-Lions M;
XX
DR   WPI; 2000-587436/55.
XX
PT   Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (CRAM-1 or
PT   CRAM-2) polypeptide, useful for treatment of tumors, inflammation
PT   reactions and modulating vascular permeability.
XX
PS   Example; Page 16; 59pp; English.
XX
CC   The present sequence is a PCR primer used to determine the amount of
CC   murine confluency regulated adhesion molecule 1 (CRAM-1, also known as
CC   JAM-2) mRNA following assays differing in confluency. CRAM-1 is one of
CC   the vascular adhesion proteins of the immunoglobulin superfamily (Ig Sf).
CC   The CRAM-1 protein and coding sequence can be used in the treatment of
CC   cancer, inflammation, to modulate cell-cell interactions and
CC   angiogenesis, and in the modulation of wound healing
XX
SQ   Sequence 16 BP; 2 A; 9 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2243 CACCCTCCGCACTCG 2257
              ||||||||| ||||||
Db          1 CACCCTCCTCACTCG 15


RESULT 218
ABF36090
ID   ABF36090 standard; DNA; 13 BP.
XX
AC   ABF36090;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 136087 for detecting SNP TSC0033984.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
```

```
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 136087; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGG 1782
              |||||||||||||
Db          1 GAGGAGGAGGAGG 13


RESULT 219
ABF36091/c
ID   ABF36091 standard; DNA; 13 BP.
XX
AC   ABF36091;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 136088 for detecting SNP TSC0033984.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 136088; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 0 A; 9 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGG 1782
              |||||||||||||
Db          13 GAGGAGGAGGAGG 1


RESULT 220
ABN83902/c
ID   ABN83902 standard; DNA; 13 BP.
XX
AC   ABN83902;
XX
DT   06-SEP-2002  (first entry)
XX
DE   SNP detection probe following target binding and extension.
XX
KW   SNP; single nucleotide polymorphism; diagnostic; screening;
KW   gene expression analysis; probe; ss.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   misc_binding    1. .13
FT                   /*tag=  b
FT                   /bound_moiety= "SNP containing target nucleic acid"
FT                   /note= "binds to bases 13-1 of the SNP containing target
FT                   nucleic acid (see ABN83901) following binding and
FT                   extension of the probe"
FT   misc_feature    1. .7
FT                   /*tag=  a
FT                   /note= "original length of probe prior to binding and
FT                   extension"
XX
PN   EP1207209-A2.
XX
PD   22-MAY-2002.
XX
PF   08-OCT-2001; 2001EP-00123992.
XX
PR   09-NOV-2000; 2000US-00710983.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Amorese DA,  Sampson JR;
XX
DR   WPI; 2002-437468/47.
XX
PT   Detecting a target using an addressable array of probes linked to a
PT   substrate and observing the binding pattern is useful to determine single
```

```
PT   nucleotide polymorphisms in diagnostic, screening, and gene expression
PT   analysis.
XX
PS   Disclosure; Fig 3C; 17pp; English.
XX
CC   The invention relates to evaluating the presence of a target in an
CC   analyte, using an addressable array of probes linked to a substrate. The
CC   method comprises preparing a solution consisting of a buffer, target
CC   nucleic acid, DNA polymerase, deoxynucleotides and polynucleotide
CC   primers, then exposing the solution to the array so that the target
CC   hybridises, extending the bound probes, and observing a binding pattern
CC   on the array. The method is used to detect SNP's (single nucleotide
CC   polymorphisms) in diagnostic, screening, and gene expression analysis.
CC   The current sequence represents an SNP detection probe following target
CC   binding and extension
XX
SQ   Sequence 13 BP; 4 A; 3 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1623 CTCAGCTGTGCTC 1635
              |||||||||||||
Db         13 CTCAGCTGTGCTC 1


RESULT 221
ABN83901
ID   ABN83901 standard; DNA; 13 BP.
XX
AC   ABN83901;
XX
DT   06-SEP-2002  (first entry)
XX
DE   Nucleotide fragment representing an SNP detection target.
XX
KW   SNP; single nucleotide polymorphism; diagnostic; screening;
KW   gene expression analysis; ss.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   misc_binding    1. .13
FT                   /*tag=  a
FT                   /bound_moiety= "SNP detection probe"
FT                   /note= "binds to bases 13-1 of the SNP detection probe
FT                   following probe extension (see ABN83902)"
FT   misc_feature    7
FT                   /*tag=  b
FT                   /note= "location of SNP site"
XX
PN   EP1207209-A2.
XX
PD   22-MAY-2002.
XX
PF   08-OCT-2001; 2001EP-00123992.
XX
PR   09-NOV-2000; 2000US-00710983.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Amorese DA,  Sampson JR;
XX
DR   WPI; 2002-437468/47.
XX
PT   Detecting a target using an addressable array of probes linked to a
PT   substrate and observing the binding pattern is useful to determine single
PT   nucleotide polymorphisms in diagnostic, screening, and gene expression
PT   analysis.
XX
PS   Disclosure; Fig 3B; 17pp; English.
XX
CC   The invention relates to evaluating the presence of a target in an
CC   analyte, using an addressable array of probes linked to a substrate. The
CC   method comprises preparing a solution consisting of a buffer, target
CC   nucleic acid, DNA polymerase, deoxynucleotides and polynucleotide
CC   primers, then exposing the solution to the array so that the target
CC   hybridises, extending the bound probes, and observing a binding pattern
CC   on the array. The method is used to detect SNP's (single nucleotide
CC   polymorphisms) in diagnostic, screening, and gene expression analysis.
CC   The current sequence represents a nucleotide fragment representing an SNP
CC   detection target. The SNP located at position 7 of the fragment may be
CC   detected by a probe in the method of the invention
XX
SQ   Sequence 13 BP; 1 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1623 CTCAGCTGTGCTC 1635
              |||||||||||||
Db          1 CTCAGCTGTGCTC 13


RESULT 222
ABN83903
ID   ABN83903 standard; DNA; 13 BP.
XX
AC   ABN83903;
XX
DT   06-SEP-2002  (first entry)
XX
DE   Polynucleotide primer following extension of probe sequence.
XX
KW   SNP; single nucleotide polymorphism; diagnostic; screening;
KW   gene expression analysis; primer; ss.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   misc_binding    1. .13
FT                   /*tag=  b
FT                   /bound_moiety= "SNP detection probe"
FT                   /note= "binds to bases 13-1 of the SNP detection probe
FT                   (see ABN83902) following binding and extension of the
FT                   primer"
FT   misc_feature    1. .3
FT                   /*tag=  a
FT                   /note= "original length of primer following binding to
FT                   probe and extension"
XX
PN   EP1207209-A2.
XX
PD   22-MAY-2002.
XX
PF   08-OCT-2001; 2001EP-00123992.
XX
PR   09-NOV-2000; 2000US-00710983.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Amorese DA,  Sampson JR;
XX
DR   WPI; 2002-437468/47.
XX
PT   Detecting a target using an addressable array of probes linked to a
PT   substrate and observing the binding pattern is useful to determine single
PT   nucleotide polymorphisms in diagnostic, screening, and gene expression
PT   analysis.
XX
PS   Disclosure; Fig 3E; 17pp; English.
XX
CC   The invention relates to evaluating the presence of a target in an
CC   analyte, using an addressable array of probes linked to a substrate. The
```

CC method comprises preparing a solution consisting of a buffer, target
CC nucleic acid, DNA polymerase, deoxynucleotides and polynucleotide
CC primers, then exposing the solution to the array so that the target
CC hybridises, extending the bound probes, and observing a binding pattern
CC on the array. The method is used to detect SNP's (single nucleotide
CC polymorphisms) in diagnostic, screening, and gene expression analysis.
CC The current sequence represents a polynucleotide primer following
CC extension of the probe sequence. This primer may comprise one or more
CC labels that may provide a means for measuring the levels of extended DNA
CC present in the array
XX
SQ Sequence 13 BP; 1 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1623 CTCAGCTGTGCTC 1635
|||||||||||||
Db 1 CTCAGCTGTGCTC 13

RESULT 223
AAV93815
ID AAV93815 standard; RNA; 14 BP.
XX
AC AAV93815;
XX
DT 18-FEB-1999 (first entry)
XX
DE Human B-raf target sequence nucleotide position 2205.
XX
KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW screening; identification; synthesis; deprotection; purification; cancer;
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW restenosis; rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN WO9850530-A2.
XX
PD 12-NOV-1998.
XX
PF 05-MAY-1998; 98WO-US009249.
XX
PR 09-MAY-1997; 97US-0046059P.
PR 09-JUN-1997; 97US-0049002P.
PR 03-JUL-1997; 97US-0051718P.
PR 22-AUG-1997; 97US-0056808P.
PR 02-OCT-1997; 97US-0061321P.
PR 02-OCT-1997; 97US-0061324P.
PR 05-NOV-1997; 97US-0064866P.
PR 19-DEC-1997; 97US-0068212P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
PI Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;
PI Thompson J, Workman CT, Beaudry A, Sweedler D;
XX
DR WPI; 1999-009494/01.
XX
PT Identifying new catalytic nucleic acid that modulates selected processes
PT - especially ribozymes that cleave Raf RNA for treating cancer,
PT restenosis, and also new ribozymes and modified nucleoside triphosphates
PT used as antiviral agents and synthons.
XX
PS Claim 179; Page 175; 259pp; English.
XX
CC A method has been developed for the identification of a nucleic acid
CC capable of modulating a process in a biological system. The method
CC comprises: (a) introducing into the system a random library of nucleic
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence
CC of at least part of the SBDs in such systems. Nucleic acid molecules with
CC endonuclease activity and catalytic activity, from the present invention,
CC are used to modulate gene expression in plant and mammalian cells and to
CC cleave target nucleic acid, particularly for treating systemic diseases
CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC ascites and infection. They may also be used to detect genetic drift and
CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC with RNA-cleaving activity that modulate expression of the Raf gene, are
CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC generally any condition associated with the level of c-raf. Introduction
CC of sugar/phosphate modifications increases stability against nuclease and
CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC method, specifically for modulating the expression of a Raf gene
XX
SQ Sequence 14 BP; 1 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 0.5%; Score 13; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 77;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1593 GAGCTGCTGGCCC 1605
|||| :|| :|||||
Db 1 GAGCUGCUGGCCC 13

RESULT 224
AAX09469/c
ID AAX09469 standard; DNA; 15 BP.
XX
AC AAX09469;
XX
DT 24-MAR-1999 (first entry)
XX
DE Human biallelic polymorphic marker upstream primer #349.
XX
KW Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW detection; phenotypic typing; characteristic; infection; hereditary;
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW treatment; marker; primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9820165-A2.
XX
PD 14-MAY-1998.
XX
PF 05-NOV-1997; 97WO-US020313.
XX
PR 06-NOV-1996; 96US-0030455P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Lander ES, Wang D, Hudson T;
XX
DR WPI; 1998-286974/25.
XX
PT New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
PT testing or phenotypic typing for disease.
XX
PS Claim 15; Page 96; 310pp; English.
XX
CC AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC isolation of various biallelic polymorphic markers found in the human
CC genome (represented in AAX10269-X12937). These primers can be used in a
CC method for determining polymorphic forms in an individual for use in e.g.
CC forensics, paternity testing or for phenotypic typing for diseases such
CC as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial

```
CC   hypercholesterolemia, polycystic kidney disease, hereditary
CC   spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC   haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC   syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC   autoimmune diseases, inflammation, cancer, diseases of the nervous
CC   system, infection by pathogenic microorganisms, and characteristics such
CC   as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC   endurance, fertility, and susceptibility or receptivity to particular
CC   drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC   segments can also be used to produce medicaments for the treatment or
CC   prophylaxis of such diseases
XX
SQ   Sequence 15 BP; 1 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1925 GGGGAGCAAGTGG 1937
              |||||||||||||
Db         15 GGGGAGCAAGTGG 3


RESULT 225
ABK10952
ID   ABK10952 standard; DNA; 15 BP.
XX
AC   ABK10952;
XX
DT   06-JUN-2002  (first entry)
XX
DE   PCR primer ONde5 relating to invention of HIV-1 O-type specific antigen.
XX
KW   Human immunodeficiency virus type 1; HIV-1 O-type specific antigen; PCR;
KW   primer; ss.
XX
OS   Synthetic.
XX
PN   KR99080246-A.
XX
PD   05-NOV-1999.
XX
PF   14-APR-1998;   98KR-00013334.
XX
PR   14-APR-1998;   98KR-00013334.
XX
PA   (GREC ) KOREA GREEN CROSS CORP.
XX
PI   Kim SY,  Yoo SS,  Cho YS;
XX
DR   WPI; 2000-609488/58.
XX
PT   HIV-1 O-type specific antigen and process for preparing the same.
XX
PS   Disclosure; Page 3; 8pp; Korean.
XX
CC   The present invention relates to human immunodeficiency virus type 1 (HIV
CC   -1) O-type specific antigen and the polynucleotide sequence encoding it.
CC   The present sequence represents a PCR primer used in the methods of the
CC   present invention
XX
SQ   Sequence 15 BP; 4 A; 5 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1514 GCGCAGCGGCAAC 1526
              |||||||||||||
Db          2 GCGCAGCGGCAAC 14


RESULT 226
AAS57269
ID   AAS57269 standard; DNA; 15 BP.
XX
AC   AAS57269;
XX
DT   16-JAN-2002  (first entry)
XX
DE   Human CHRNB2 allele specific oligonucleotide (ASO) PCR primer #42.
XX
KW   Human; cholinergic receptor, nicotinic, beta polypeptide 2; neuronal;
KW   CHRNB2; memory disorder; Alzheimer's disease; epilepsy; learning;
KW   chromosome 1q21; schizophrenia; attention deficit/hyperactivity disorder;
KW   ADHD; autosomal dominant nocturnal frontal lobe epilepsy; ADNFLE; ss;
KW   allele specific oligonucleotide; ASO; PCR primer.
XX
OS   Homo sapiens.
XX
PN   WO200174833-A2.
XX
PD   11-OCT-2001.
XX
PF   03-APR-2001; 2001WO-US010666.
XX
PR   03-APR-2000; 2000US-0194155P.
PR   13-JUL-2000; 2000US-0217952P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Choi JY,  Kliem SE,  Koshy B,  Lee HH,  Sanchis A;
XX
DR   WPI; 2001-626374/72.
XX
PT   Genotyping cholinergic receptor, nicotinic, beta-polypeptide 2 gene of an
PT   individual involves determining for two copies of-the gene, the identity
PT   of nucleotide pair at polymorphic sites selected from PS1-24.
XX
PS   Claim 15; Page 15; 82pp; English.
XX
CC   The invention relates to genotyping/haplotyping the cholinergic receptor,
CC   nicotinic, beta-polypeptide 2 (neuronal) (CHRNB2) gene of an individual,
CC   comprising determining for the two copies of the CHRNB2 gene present in
CC   the individual, the identity of the nucleotide pair at one or more
CC   polymorphic sites selected from PS1-24. Also include are oligonucleotides
CC   for performing the method and the nucleotide sequence of the polymorphic
CC   variants of CHRNB2. The method is useful for detecting novel CHRNB2
CC   polymorphisms and for determining if an individual has a haplotype or
CC   haplotype pairs defined in the specification and to validate CHRNB2 as a
CC   candidate agent for treating a specific condition or disease predicted to
CC   be associated with CHRNB2 activity (e.g. a memory disorder, Alzheimer's
CC   disease, epilepsy, a learning disorder, schizophrenia, attention
CC   deficit/hyperactivity disorder, (ADHD) and autosomal dominant nocturnal
CC   frontal lobe epilepsy (ADNFLE)), and in the design of clinical trials of
CC   candidate drugs for treating a specific condition or disease predicted to
CC   be associated with CHRNB2 activity. The method is useful to screen for
CC   compounds targeting CHRNB2 to treat a specific conditions or disease
CC   associated with CHRNB2 activity. The polymorphic nucleic acids are useful
CC   in studying the expression and function of CHRNB2, and in expressing
CC   CHRNB2 protein for use in screening for candidate drugs to treat diseases
CC   related to CHRNB2 activity and are useful for therapeutic purposes. The
CC   CHRNB2 gene is located on chromosome 1q21. The present sequence is an
CC   allele specific oligonucleotide (ASO) PCR primer for performing the
CC   method of the invention
XX
SQ   Sequence 15 BP; 4 A; 2 C; 8 G; 0 T; 0 U; 1 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 92;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1778 GGAGGCGGAGGAGGC 1792
              |||| ||||||||:|
Db          1 GGAGACGGAGGAGKC 15
```

```
RESULT 227
AAF48303/c
ID   AAF48303 standard; DNA; 15 BP.
XX
AC   AAF48303;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1723.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 55; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCA 2132
              |||||||||||||
Db         13 CCACGGGGCCGCA 1


RESULT 228
AAF53010/c
ID   AAF53010 standard; DNA; 15 BP.
XX
AC   AAF53010;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #3970.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 86; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 9 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1886 GGAGGACGAGGAG 1898
              |||||||||||||
Db         15 GGAGGACGAGGAG 3


RESULT 229
AAF53012/c
ID   AAF53012 standard; DNA; 15 BP.
XX
AC   AAF53012;
XX
DT   30-MAR-2001  (first entry)
```

```
XX
DE   IGF-I oligonucleotide #3972.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 86; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1886 GGAGGACGAGGAG 1898
              |||||||||||||
Db         13 GGAGGACGAGGAG 1


RESULT 230
AAF48300/c
ID   AAF48300 standard; DNA; 15 BP.
XX
AC   AAF48300;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1720.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 55; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2121 CACGGGGCCGCAG 2133
              |||||||||||||
Db         15 CACGGGGCCGCAG 3


RESULT 231
AAF52824
ID   AAF52824 standard; DNA; 15 BP.
XX
AC   AAF52824;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #3784.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
```

```
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 85; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 3 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1234 ATGTGCTGGCAGT 1246
              |||||||||||||
Db          1 ATGTGCTGGCAGT 13


RESULT 232
AAF52820
ID   AAF52820 standard; DNA; 15 BP.
XX
AC   AAF52820;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #3780.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 85; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1232 GCATGTGCTGGCA 1244
              |||||||||||||
Db          3 GCATGTGCTGGCA 15


RESULT 233
AAF53011/c
ID   AAF53011 standard; DNA; 15 BP.
XX
AC   AAF53011;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGF-I oligonucleotide #3971.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
```

```
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 8; Page 86; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 10 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1886 GGAGGACGAGGAG 1898
              |||||||||||||
Db         14 GGAGGACGAGGAG 2


RESULT 234
AAF45188
ID   AAF45188 standard; DNA; 15 BP.
XX
AC   AAF45188;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #27.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 34; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 2 A; 4 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 CGGAGGAGGCGGC 1795
              |||||||||||||
Db          1 CGGAGGAGGCGGC 13


RESULT 235
ABZ34164/c
ID   ABZ34164 standard; DNA; 15 BP.
XX
AC   ABZ34164;
XX
DT   31-JAN-2003  (first entry)
XX
DE   HIV-1 reverse transcriptase mutation detection probe SEQ ID NO:406.
XX
KW   Human immunodeficiency virus; HIV; reverse transcriptase; RT; enzyme;
KW   detection; mutation; anti-HIV drug resistance; polymorphism; resistance;
KW   probe; ss.
XX
OS   Human immunodeficiency virus 1.
OS   Synthetic.
XX
PN   WO200255741-A2.
XX
PD   18-JUL-2002.
XX
PF   09-JAN-2002; 2002WO-EP000153.
XX
PR   11-JAN-2001; 2001EP-00870005.
PR   20-APR-2001; 2001EP-00870085.
PR   24-APR-2001; 2001US-0286102P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   De Smet K,  Stuyver L;
XX
```

```
DR   WPI; 2002-590680/63.
XX
PT   Detecting mutations associated with anti-HIV drug resistance comprises
PT   detecting at least one of the mutations in the HIV reverse transcriptase
PT   gene by using probes optimized to function together in a reverse-
PT   hybridization assay.
XX
PS   Claim 2; Page 26; 117pp; English.
XX
CC   The present invention describes a method for detecting mutations
CC   associated with anti-HIV drug resistance in a patient by detecting at
CC   least one of the mutations K103N/R, V106A/I/L, Y181C/I, M184V/I, Y188L,
CC   G190A/S/R, T215Y/F/D/S/A and/or Q151M/L in the reverse transcriptase (RT)
CC   of HIV strains in a biological sample using a specific set of probes
CC   optimised to function together in a reverse-hybridisation assay. The
CC   method and the nucleic acid sequences used in the method are useful for
CC   determining viral mutations and/or polymorphisms in the HIV RT gene
CC   associated with resistance. The probes are useful for the genetic
CC   detection, preferably in vitro detection of the mutations K103N/R,
CC   V106A/I/L, Y181C/I, Q151M/L, M184V/I, Y188L, G190A/S/R and/or
CC   T215Y/F/D/S/A in the RT of HIV strains in a biological sample, where the
CC   mutation is associated with anti-HIV drug resistance. The method provides
CC   a rapid, reliable and precise assay or determination and monitoring of
CC   antiviral drug resistance or mutations associated with drug resistance of
CC   viruses containing RT genes. ABZ33759 to ABZ34642 represent HIV RT
CC   sequences and probes which are used in the exemplification of the present
CC   invention
XX
SQ   Sequence 15 BP; 3 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1426 CCATCATCCACGT 1438
              |||||||||||||
Db         15 CCATCATCCACGT 3


RESULT 236
AAS99348
ID   AAS99348 standard; DNA; 15 BP.
XX
AC   AAS99348;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Aldehyde dehydrogenase 5 family, member A1, oligonucleotide #41.
XX
KW   Aldehyde dehydrogenase 5 family member A1; ALDH5A1;
KW   succinate-semialdehyde dehydrogenase; gene therapy; primer;
KW   antisense technology; allele specific oligonucleotide; ASO;
KW   4-hydroxybutyric aciduria; metabolic disease; transgenic animal; ss.
XX
OS   Synthetic.
XX
PN   WO200190119-A2.
XX
PD   29-NOV-2001.
XX
PF   21-MAY-2001; 2001WO-US016558.
XX
PR   19-MAY-2000; 2000US-0205849P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Kliem SE,  Koshy B,  Tanguay DA;
XX
DR   WPI; 2002-089912/12.
XX
PT   New genetic variants of human aldehyde dehydrogenase 5 family, member A1,
PT   ALDH5A1 gene for treating metabolic diseases and for expressing ALDH5A1
PT   protein useful in identifying drugs to treat 4-hydroxybutyric aciduria.
XX
PS   Claim 16; Page 14; 151pp; English.
XX
CC   The invention describes an isolated polynucleotide comprising a
CC   nucleotide sequence which is a polymorphic variant of a reference
CC   sequence for the aldehyde dehydrogenase 5 family, member A1 (succinate-
CC   semialdehyde dehydrogenase) (ALDH5A1) gene or its fragment. The
CC   polypeptide is useful for screening for drugs targeting it by contacting
CC   the ALDH5A1 polymorphic variant with a candidate agent and assaying for
CC   binding activity. The polypeptide and haplotypes are useful for
CC   identifying an association between a trait such as a clinical response to
CC   a drug targeting ALDH5A1 and a haplotype ALDH5A1 gene. Transgenic animals
CC   are also useful for studying expression of the ALDH5A1 isogenes in vivo,
CC   for in vivo screening and testing of drugs against ALDH5A1 protein and
CC   for testing the efficacy of therapeutic agents and compounds for 4-
CC   hydroxybutyric aciduria and metabolic diseases in a biological system.
CC   Antibodies are useful for diagnostic and prognostic formats and
CC   therapeutic methods, for immunoprecipitating the polypeptide from
CC   solution, for detecting ALDH5A1 protein isoforms in biological samples,
CC   frozen tissue sections, for use in immunocytochemical,
CC   immunohistochemical and immunofluorescence techniques. The polynucleotide
CC   is useful for gene therapy and antisense gene therapy. This sequence is
CC   an allele specific oligonucleotide (ASO) primer used to detect
CC   polymorphisms in the ALDH5A1 gene described in the method of the
CC   invention
XX
SQ   Sequence 15 BP; 2 A; 4 C; 8 G; 0 T; 0 U; 1 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 92;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 GAGGAGGCGGCAGCC 1799
              | ||||||||||||:|
Db          1 GCGGAGGCGGCAGYC 15


RESULT 237
AAS95930/c
ID   AAS95930 standard; DNA; 15 BP.
XX
AC   AAS95930;
XX
DT   26-FEB-2002  (first entry)
XX
DE   Human CALM1 gene allele-specific oligonucleotide #39.
XX
KW   Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
KW   haplotyping; SCYA3; Alzheimer's disease; drug screening;
KW   calcium-dependent signal transduction; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200179218-A2.
XX
PD   25-OCT-2001.
XX
PF   09-APR-2001; 2001WO-US011509.
XX
PR   12-APR-2000; 2000US-0196340P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bentivegna SC,  Chew A,  Choi JY,  Koshy B,  Stephens JC;
XX
DR   WPI; 2002-049190/06.
XX
PT   New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
PT   expressing CALM1 protein for use in screening for candidate drugs to
PT   treat diseases related to CALM1 activity such as Alzheimer's disease.
XX
PS   Claim 15; Page 13; 82pp; English.
XX
```

```
CC   The invention relates to an isolated polynucleotide comprising a sequence
CC   selected from a polymorphic variant of calmodulin 1 (CALM1). The
CC   polymorphic variant comprises an CALM1 isogene defined by a haplotype
CC   selected from haplotypes 1-21 given in the specification. The
CC   polymorphisms are useful for studying the biological function of CALM1 as
CC   well as in identifying drugs targeting this protein for the treatment of
CC   a disorder related to its abnormal expression or function. The
CC   polymorphic variants may also be used in screening for compounds
CC   targeting CALM1 to treat a specific condition or disease predicted to be
CC   associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
CC   pair of an individual is useful for improving the efficiency and
CC   reliability of several steps in the discovery and development of drugs
CC   for treating diseases associated with SCYA3 activity, e.g. Alzheimer's
CC   disease and diseases involving defects in calcium-dependent signal
CC   transduction. Haplotyping the CALM1 gene in an individual is also useful
CC   in the design of clinical trials of candidate drugs for treating a
CC   specific condition or disease predicted to be associated with CALM1
CC   activity. AAS95892-AAS96018 represent human CALM1 allele- specific
CC   oligonucleotides and PCR primers of the invention
XX
SQ   Sequence 15 BP; 1 A; 6 C; 5 G; 2 T; 0 U; 1 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 92;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1004 CCACTGGCGCGCGGG 1018
              |:||||||||| ||
Db         15 CSACTGGCGCGCAGG 1


RESULT 238
ABZ34165/c
ID   ABZ34165 standard; DNA; 16 BP.
XX
AC   ABZ34165;
XX
DT   31-JAN-2003  (first entry)
XX
DE   HIV-1 reverse transcriptase mutation detection probe SEQ ID NO:407.
XX
KW   Human immunodeficiency virus; HIV; reverse transcriptase; RT; enzyme;
KW   detection; mutation; anti-HIV drug resistance; polymorphism; resistance;
KW   probe; ss.
XX
OS   Human immunodeficiency virus 1.
OS   Synthetic.
XX
PN   WO200255741-A2.
XX
PD   18-JUL-2002.
XX
PF   09-JAN-2002; 2002WO-EP000153.
XX
PR   11-JAN-2001; 2001EP-00870005.
PR   20-APR-2001; 2001EP-00870085.
PR   24-APR-2001; 2001US-0286102P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   De Smet K,  Stuyver L;
XX
DR   WPI; 2002-590680/63.
XX
PT   Detecting mutations associated with anti-HIV drug resistance comprises
PT   detecting at least one of the mutations in the HIV reverse transcriptase
PT   gene by using probes optimized to function together in a reverse-
PT   hybridization assay.
XX
PS   Claim 2; Page 26; 117pp; English.
XX
CC   The present invention describes a method for detecting mutations
CC   associated with anti-HIV drug resistance in a patient by detecting at
CC   least one of the mutations K103N/R, V106A/I/L, Y181C/I, M184V/I, Y188L,
CC   G190A/S/R, T215Y/F/D/S/A and/or Q151M/L in the reverse transcriptase (RT)
CC   of HIV strains in a biological sample using a specific set of probes
CC   optimised to function together in a reverse-hybridisation assay. The
CC   method and the nucleic acid sequences used in the method are useful for
CC   determining viral mutations and/or polymorphisms in the HIV RT gene
CC   associated with resistance. The probes are useful for the genetic
CC   detection, preferably in vitro detection of the mutations K103N/R,
CC   V106A/I/L, Y181C/I, Q151M/L, M184V/I, Y188L, G190A/S/R and/or
CC   T215Y/F/D/S/A in the RT of HIV strains in a biological sample, where the
CC   mutation is associated with anti-HIV drug resistance. The method provides
CC   a rapid, reliable and precise assay or determination and monitoring of
CC   antiviral drug resistance or mutations associated with drug resistance of
CC   viruses containing RT genes. ABZ33759 to ABZ34642 represent HIV RT
CC   sequences and probes which are used in the exemplification of the present
CC   invention
XX
SQ   Sequence 16 BP; 4 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 13;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1426 CCATCATCCACGT 1438
              |||||||||||||
Db         16 CCATCATCCACGT 4


RESULT 239
AAD44136
ID   AAD44136 standard; DNA; 15 BP.
XX
AC   AAD44136;
XX
DT   13-DEC-2002  (first entry)
XX
DE   PCR primer #4 designed to bind human MMP CATR region.
XX
KW   Sequential consensus region-directed amplification; gene expression;
KW   disease diagnosis; gene analysis; human; matrix metalloproteinase; MMP;
KW   catalytic domain; CATR; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    11
FT                   /*tag=  a
FT                   /note= "This base is given as T in the sequence shown as
FT                   SEQ ID NO:30 in the sequence listing"
XX
PN   US6277571-B1.
XX
PD   21-AUG-2001.
XX
PF   30-SEP-1998;   98US-00163485.
XX
PR   03-OCT-1997;   97US-00943162.
PR   03-OCT-1997;   97US-0108152P.
XX
PA   (UYVI-) UNIV VIRGINIA COMMONWEALTH INTELLECTUAL.
XX
PI   Fillmore H,  Broaddus W,  Gillies G;
XX
DR   WPI; 2002-412824/44.
XX
PT   Sequential consensus region-directed amplification for sorting mixture of
PT   DNAs into 2 or more subsets or distinguishing gene expression patterns in
PT   2 samples, useful for disease diagnosis and gene analysis.
XX
PS   Example; Col 12; 19pp; English.
XX
CC   The invention relates to a method of sequential consensus region-directed
CC   amplification for sorting a mixture of DNAs into 2 or more subsets or
```

```
CC   distinguishing gene expression patterns in 2 samples. The methods, kits
CC   and oligonucleotides are useful for sorting a mixture of DNAs into 2 or
CC   more subsets or distinguishing gene expression patterns in 2 samples e.g.
CC   for disease diagnosis and gene analysis. The present sequence is a PCR
CC   primer designed to bind to human matrix metalloproteinase (MMP) catalytic
CC   domain (CATR). This primer is used to illustrate the method of the
CC   invention
XX
SQ   Sequence 15 BP; 5 A; 2 C; 4 G; 1 T; 0 U; 3 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 15;
  Best Local Similarity   78.6%;  Pred. No. 1e+02;
  Matches   11;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1852 AGGACGACACCGAT 1865
              ||||:||:|:||||
Db          2 AGGAYGAYAYCGAT 15


RESULT 240
AAT90642/c
ID   AAT90642 standard; RNA; 16 BP.
XX
AC   AAT90642;
XX
DT   07-APR-1998  (first entry)
XX
DE   Hepatitis C virus recognition sequence 52 for ribozyme cleavage.
XX
KW   Recognition sequence; HCV; ribozyme; 5' untranslated region;
KW   nucleocapsid coding region; hairpin ribozyme; RNA cleavage; treatment;
KW   HCV infection; HCV contamination; ss.
XX
OS   Hepatitis C virus.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1. .4
FT                   /*tag=  a
FT                   /note= "complementary to the CNR22 ribozyme"
FT   misc_feature    6
FT                   /*tag=  b
FT                   /note= "cleavage site corresponding to position 7763 of
FT                   the (-) strand, counting from 3' end"
FT   misc_feature    9. .16
FT                   /*tag=  c
FT                   /note= "complementary to the CNR22 ribozyme"
XX
PN   WO9732018-A2.
XX
PD   04-SEP-1997.
XX
PF   27-FEB-1997;   97WO-US003304.
XX
PR   29-FEB-1996;   96US-00608862.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Barber JR,  Welch PJ,  Tritz R,  Yei S,  Yu M;
XX
DR   WPI; 1997-470461/43.
XX
PT   Ribozyme(s) directed against hepatitis C virus - for prevention and
PT   treatment of viral infection, and detection of HCV contamination of
PT   blood.
XX
PS   Example 1; Page 18; 98pp; English.
XX
CC   AAT90621-650 represent recognition sequences found in the positive (-)
CC   strand of the Hepatitis C virus (HCV) RNA. The sequences are recognised
CC   by novel ribozymes which inhibit replication, infectivity or gene
CC   expression of HCV. The present sequence is located within the NS5 gene.
CC   Hairpin ribozymes of the present invention were designed based on
CC   sequences adjacent to the GUC sequence recognition feature. The ribozymes
CC   are directed against conserved regions of the genome and so should be
CC   active against many strains of HCV. The ribozymes, when optionally
CC   expressed from a vector, cleave the RNA of HCV and so are useful for
CC   treatment and prevention of HCV infection. They can also be used to
CC   detect HCV contamination of blood or for clinical diagnosis
XX
SQ   Sequence 16 BP; 5 A; 2 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        880 TCACCTTTGAGAGCCT 895
              ||||||||||  || ||
Db         16 TCACCTTTGACAGACT 1


RESULT 241
AAX09676/c
ID   AAX09676 standard; DNA; 16 BP.
XX
AC   AAX09676;
XX
DT   24-MAR-1999  (first entry)
XX
DE   Human biallelic polymorphic marker upstream primer #556.
XX
KW   Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW   detection; phenotypic typing; characteristic; infection; hereditary;
KW   autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW   treatment; marker; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9820165-A2.
XX
PD   14-MAY-1998.
XX
PF   05-NOV-1997;   97WO-US020313.
XX
PR   06-NOV-1996;   96US-0030455P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
PI   Lander ES,  Wang D,  Hudson T;
XX
DR   WPI; 1998-286974/25.
XX
PT   New isolated nucleic acid segments from the human genome - used for
PT   determining polymorphic forms for use in e.g. forensics, paternity
PT   testing or phenotypic typing for disease.
XX
PS   Claim 15; Page 219; 310pp; English.
XX
CC   AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC   isolation of various biallelic polymorphic markers found in the human
CC   genome (represented in AAX10269-X12937). These primers can be used in a
CC   method for determining polymorphic forms in an individual for use in e.g.
CC   forensics, paternity testing or for phenotypic typing for diseases such
CC   as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC   dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
CC   hypercholesterolemia, polycystic kidney disease, hereditary
CC   spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC   haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC   syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC   autoimmune diseases, inflammation, cancer, diseases of the nervous
CC   system, infection by pathogenic microorganisms, and characteristics such
CC   as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC   endurance, fertility, and susceptibility or receptivity to particular
CC   drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC   segments can also be used to produce medicaments for the treatment or
CC   prophylaxis of such diseases
```

```
XX
SQ   Sequence 16 BP; 1 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1354 CCAGGGCAGCTGAGGC 1369
              ||| |||||| |||||
Db         16 CCATGGCAGCAGAGGC 1


RESULT 242
AAA13459/c
ID   AAA13459 standard; RNA; 16 BP.
XX
AC   AAA13459;
XX
DT   17-JUL-2000  (first entry)
XX
DE   Hepatitis C virus hairpin ribozyme recognition sequence SEQ ID NO:59.
XX
KW   Hepatitis C virus; HCV; hairpin ribozyme; cleavage; recognition site;
KW   infection; virucide; hepatotropic; antiinflammatory;
KW   replication inhibitor; gene expression inhibitor; ss.
XX
OS   Hepatitis C virus.
XX
PN   US6043077-A.
XX
PD   28-MAR-2000.
XX
PF   20-OCT-1997;   97US-00954210.
XX
PR   29-FEB-1996;   97US-00608862.
PR   27-FEB-1997;   97WO-US003304.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Yei S,  Yu M,  Barber JR,  Welch PJ;
XX
DR   WPI; 2000-270342/23.
XX
PT   Ribozyme capable of inhibiting replication, infectivity or gene
PT   expression of hepatitis C virus, useful for treating or preventing
PT   hepatitis C virus infection.
XX
PS   Example 1; Col 13; 57pp; English.
XX
CC   The present invention describes ribozymes (I) capable of inhibiting
CC   replication, infectivity or gene expression of a hepatitis C virus (HCV),
CC   directed to target sequences AAA13438 to AAA13444, AAA13454 and AAA13465.
CC   (I) have virucide, hepatotropic and antiinflammatory activities. (I), or
CC   vectors comprising nucleotide sequences encoding (I), are useful for
CC   interfering with the replication or gene expression of HCV in a human
CC   cells. (I) are useful for diagnosis, prevention and treatment of HCV
CC   infection or disease in a mammals especially humans. Nucleotide sequences
CC   encoding (I) are useful for preventing hepatitis C viral infection in a
CC   cell. AAA13401 to AAA13405 represent examples of the briefest
CC   requirements for hairpin ribozyme; AAA13406 and AAA13407 represent PCR
CC   primers used in the amplification of the HCV capsid sequence; AAA13408 to
CC   AAA13467 represent HCV hairpin ribozyme recognition sites; and AAA13468
CC   to AAA13473 represent oligonucleotides used in the construction of HCV
CC   hairpin ribozymes, all these sequences are used in the exemplification of
CC   the present invention
XX
SQ   Sequence 16 BP; 5 A; 2 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        880 TCACCTTTGAGAGCCT 895
              ||||||||| || ||
Db         16 TCACCTTTGACAGACT 1


RESULT 243
AAC82114
ID   AAC82114 standard; DNA; 16 BP.
XX
AC   AAC82114;
XX
DT   07-MAR-2001  (first entry)
XX
DE   Human ApoE probe SEQ ID NO 3.
XX
KW   ApoE; early-onset glaucoma; intraocular; TIGR; promoter; ApoE4;
KW   trabecular meshwork inducible glucocorticoid response; apolipoprotein E;
KW   treatment; diagnosis; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200068429-A2.
XX
PD   16-NOV-2000.
XX
PF   04-MAY-2000; 2000WO-US012179.
XX
PR   07-MAY-1999;   99US-0133224P.
XX
PA   (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
PA   (INSI-) INSITE VISION INC.
XX
PI   Garchon H;
XX
DR   WPI; 2001-007406/01.
XX
PT   Assessing the risk of an individual for developing early-onset glaucoma,
PT   comprises assessing Apolipoprotein E alleles carrying a trabecular
PT   meshwork inducible glucocorticoid response gene mutation.
XX
PS   Disclosure; Page 18; 29pp; English.
XX
CC   This invention describes a novel method for assessing the risk for
CC   developing early-onset glaucoma and for developing glaucoma with a high
CC   intraocular pressure at the onset of disease in an individual having a
CC   mutation in a trabecular meshwork inducible glucocorticoid response
CC   (TIGR) gene, or in TIGR gene promoter. The method comprises assessing the
CC   apolipoprotein E (ApoE) allele, or allele of the ApoE gene promoter. The
CC   invention also describes (1) a kit for determining whether an individual
CC   is at risk of developing early-onset glaucoma comprising at least 1
CC   reagent that can be used to detect an ApoE4 allele in the individual; and
CC   (2) a kit for determining whether an individual is at risk of developing
CC   glaucoma with a high intraocular pressure at onset of disease, comprising
CC   at least 1 reagent that can be used to detect an ApoE4 allele in the
CC   individual, and/or at least 1 reagent that can be used to detect a T
CC   allele in the ApoE gene promoter. Identification of increased risk of
CC   glaucoma enables better treatment planning for affected individuals as
CC   well as for other family members who may be the affected individuals or
CC   disease gene carriers. The method provides a better and earlier means of
CC   diagnosis, so that preventative or palliative measures can be taken
CC   before significant damage to the optical nerve occurs
XX
SQ   Sequence 16 BP; 3 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1116 GCACAGGTCCTCCAAG 1131
              ||||| |||||||| |
Db          1 GCACACGTCCTCCATG 16


RESULT 244
```

```
AAF95038/c
ID   AAF95038 standard; DNA; 16 BP.
XX
AC   AAF95038;
XX
DT   23-MAY-2001  (first entry)
XX
DE   Mutant capture oligonucleotide #31.
XX
KW   Tubercle bacillus; drug sensitivity; drug resistance; rifampicin;
KW   streptomycin; kanamycin; isoniazid; ethambutol; rpoB gene; rrs gene;
KW   rpsL gene; inhA gene; katG gene; embB gene; probe; PCR primer; ss.
XX
OS   Mycobacterium tuberculosis.
XX
PN   EP1076099-A2.
XX
PD   14-FEB-2001.
XX
PF   02-AUG-2000; 2000EP-00306563.
XX
PR   03-AUG-1999;   99JP-00220357.
XX
PA   (NISN ) NISSHINBO IND INC.
PA   (SYST-) SYSTEM RES INC.
XX
PI   Suzuki Y,  Nishida M,  Takenishi S;
XX
DR   WPI; 2001-246696/26.
XX
PT   New oligonucleotides, nucleic acid probes and primers are useful for
PT   differentiating drug-resistance and determining infection with tubercle
PT   bacilli.
XX
PS   Claim 10; Page 27; 114pp; English.
XX
CC   The present invention relates to oligonucleotides based on nucleotide
CC   sequences obtained from both wild-type tubercle bacilli (wtTB) that are
CC   susceptible to a drug and mutant-type tubercle bacilli (mtTB) that are
CC   resistant to a drug. The drugs used in the present invention are
CC   rifampicin (RFP), streptomycin (SM), kanamycin (KM), isoniazid (INH) and
CC   ethambutol (EB). The rpoB gene is responsible for resistance to RFP; the
CC   rrs gene is responsible for resistance to SM and KM; the rpsL gene is
CC   responsible for resistance to SM; the inhA gene is responsible for
CC   resistance to INH; the katG gene is responsible for resistance to INH;
CC   and the embB gene is responsible for resistance to EB. The present
CC   invention also relates to nucleic acid probes having part of a nucleotide
CC   sequence of tubercle bacilli (TB) responsible for drug resistance and
CC   primers used to generate the probes. The present sequence is an
CC   oligonucleotide of the present invention. The oligonucleotides of the
CC   present invention can be used to enable the differentiation of drug
CC   resistance and the determination of infection with tubercle bacilli
CC   simultaneously
XX
SQ   Sequence 16 BP; 2 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1662 AGGCAGGTCTTGCAGC 1677
              ||||||||| |||| |
Db         16 AGGCAGGTCCTGCACC 1


RESULT 245
AAS56903/c
ID   AAS56903 standard; DNA; 16 BP.
XX
AC   AAS56903;
XX
DT   16-JAN-2002  (first entry)
XX
DE   Validation ribozyme DNA sequence #77.
XX
KW   Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;
KW   cytostatic; RNA cleavage; tumour suppressor; PCR primer; CHLR2; AF6; BR2;
KW   inhibitor dominant negative 4; breast basic conserved protein 1; BBC1;
KW   BR3; ID4; cancer; proliferative disorder; tumour proliferation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200170982-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US009559.
XX
PR   23-MAR-2000; 2000US-00536058.
XX
PA   (IMMU-) IMMUSOL INC.
PA   (BEGE/) BEGER C.
XX
PI   Beger C,  Barber J,  Wong-Staal F;
XX
DR   WPI; 2001-611503/70.
XX
PT   Novel polypeptides that are the regulators of BRCA-1, useful for treating
PT   cancer and diagnosing the presence of neoplastic cells in biological
PT   sample.
XX
PS   Disclosure; Fig 8; 97pp; English.
XX
CC   Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators,
CC   ribozyme target recognition RNA sequences, DNA fragments encoding the RNA
CC   and primers used in the methods of the invention. Hybridisation of
CC   ribozymes to their targets results in cleavage of the RNA target. The
CC   ribozymes can be used to cleave regulators of the tumour suppressor BRCA-
CC   1, resulting in upregulation or downregulation of BRCA-1 in a cell. The
CC   mRNA targets include those encoding the BRCA-1 regulator BR1, inhibitor
CC   dominant negative 4 (ID4), breast basic conserved protein 1 (BBC1),
CC   CHLR2, AF6, BR2 and BR3. Regulation of BRCA-1 is useful for treating and
CC   diagnosing cancer and other proliferative disorders. The severity of an
CC   incidence of cancer can be lessened by regulating tumour proliferation
CC   through modulation of BRCA-1 expression. The sequences of the invention
CC   are useful in the development of anti-cancer drugs
XX
SQ   Sequence 16 BP; 1 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1197 CCTGTGCAGAGGGCAG 1212
              |||| ||||| |||||
Db         16 CCTGCGCAGACGGCAG 1


RESULT 246
AAS15118/c
ID   AAS15118 standard; DNA; 16 BP.
XX
AC   AAS15118;
XX
DT   16-JAN-2002  (first entry)
XX
DE   F HyBeacon probe for human CYP2D6, 2D64E.
XX
KW   Human; ss; CYP2D6; cytochrome P450; SNP; single nucleotide polymorphism;
KW   hybridisation beacon; 2D64E; F HyBeacon probe; DNA-RNA hybrid.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    6
```

```
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "U is covalently linked to a HEX fluorophore"
FT   misc_RNA        6
FT                   /*tag=  a
FT                   /label= RNA
FT   modified_base   16
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "The 3' end of the probe is blocked with an
FT                   octanediol group"
XX
PN   WO200173118-A2.
XX
PD   04-OCT-2001.
XX
PF   28-MAR-2001; 2001WO-GB001430.
XX
PR   29-MAR-2000; 2000GB-00007622.
PR   02-NOV-2000; 2000GB-00026749.
XX
PA   (LGCT-) LGC TEDDINGTON LTD.
XX
PI   French DJ,  Mcdowell DG,  Brown T;
XX
DR   WPI; 2001-616532/71.
XX
PT   A hybridization beacon which is a single stranded oligonucleotide labeled
PT   with a fluorophore is useful to discriminate between polymorphic variants
PT   of target oligonucleotides.
XX
PS   Example; Page 27; 84pp; English.
XX
CC   The invention relates to a hybridisation beacon which is an
CC   oligonucleotide having substantially no secondary structure, and formed
CC   of nucleotides, one of which is labeled with a reporter, and no
CC   associated quencher. The beacon is used to detect, identify or quantify a
CC   target sequence in a sample, and to differentiate between homozygous and
CC   heterozygous polynucleotide targets. The present sequence is an F-Q
CC   HyBeacon probe targetting the a human gene for cytochrome P450, CYP2D6
CC   which is known to contain several single nucleotide polymorphisms (SNP)
CC   and is used to demonstrate the use of the hybridisation beacons of the
CC   invention in detecting the SNPs
XX
SQ   Sequence 16 BP; 0 A; 3 C; 10 G; 2 T; 1 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1704 CAGCCCCAGGAGGCCC 1719
              || |||||||| ||||
Db         16 CACCCCCAGGACGCCC 1


RESULT 247
AAS15115/c
ID   AAS15115 standard; DNA; 16 BP.
XX
AC   AAS15115;
XX
DT   16-JAN-2002  (first entry)
XX
DE   F HyBeacon probe for human CYP2D6, 2D64C*.
XX
KW   Human; ss; CYP2D6; cytochrome P450; SNP; single nucleotide polymorphism;
KW   hybridisation beacon; 2D64C*; F HyBeacon probe; DNA-RNA hybrid.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   6
```

```
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "U is covalently linked to a FAM fluorophore"
FT   misc_RNA        6
FT                   /*tag=  a
FT                   /label= RNA
FT   modified_base   16
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "The 3' end of the probe is blocked with a
FT                   phosphate group"
XX
PN   WO200173118-A2.
XX
PD   04-OCT-2001.
XX
PF   28-MAR-2001; 2001WO-GB001430.
XX
PR   29-MAR-2000; 2000GB-00007622.
PR   02-NOV-2000; 2000GB-00026749.
XX
PA   (LGCT-) LGC TEDDINGTON LTD.
XX
PI   French DJ,  Mcdowell DG,  Brown T;
XX
DR   WPI; 2001-616532/71.
XX
PT   A hybridization beacon which is a single stranded oligonucleotide labeled
PT   with a fluorophore is useful to discriminate between polymorphic variants
PT   of target oligonucleotides.
XX
PS   Example; Page 27; 84pp; English.
XX
CC   The invention relates to a hybridisation beacon which is an
CC   oligonucleotide having substantially no secondary structure, and formed
CC   of nucleotides, one of which is labeled with a reporter, and no
CC   associated quencher. The beacon is used to detect, identify or quantify a
CC   target sequence in a sample, and to differentiate between homozygous and
CC   heterozygous polynucleotide targets. The present sequence is an F-Q
CC   HyBeacon probe targetting the a human gene for cytochrome P450, CYP2D6
CC   which is known to contain several single nucleotide polymorphisms (SNP)
CC   and is used to demonstrate the use of the hybridisation beacons of the
CC   invention in detecting the SNPs
XX
SQ   Sequence 16 BP; 0 A; 3 C; 10 G; 2 T; 1 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1704 CAGCCCCAGGAGGCCC 1719
              || |||||||| ||||
Db         16 CACCCCCAGGACGCCC 1


RESULT 248
ABK40654
ID   ABK40654 standard; DNA; 16 BP.
XX
AC   ABK40654;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Human beta1-adrenoceptor antisense oligonucleotide #76.
XX
KW   ss; antisense; beta1 adrenoceptor; beta1-AR; vasotropic; hypotensive;
KW   cardiant; hypertension; hypertrophy; cardiac ischaemia;
KW   cardiovascular disease; cardiac dysfunction.
XX
OS   Homo sapiens.
XX
PN   WO200204623-A2.
XX
```

PD 17-JAN-2002.
XX
PF 11-JUL-2001; 2001WO-US021759.
XX
PR 11-JUL-2000; 2000US-00614034.
XX
PA (UYFL) UNIV FLORIDA.
XX
PI Phillips MI, Zhang Y;
XX
DR WPI; 2002-164644/21.
XX
PT Novel antisense oligonucleotides that specifically bind to mRNA encoding
PT beta 1-adrenoreceptor polypeptide, useful for treating cardiac
PT dysfunction, hypertension, hypertrophy and other cardiovascular diseases
PT in humans.
XX
PS Claim 48; Page 19; 186pp; English.
XX
CC The invention relates to an isolated antisense oligonucleotide of 9-35
CC nucleotides in length, which specifically binds to a portion of an mRNA
CC expressed from a gene encoding a mammalian beta1-adrenoceptor (AR)
CC polypeptide and alters the translation of the mRNA into the beta1-AR
CC polypeptide in a host cell expressing the mRNA. Also included are a
CC recombinant vector comprising the antisense oligonucleotide, and a host
CC cell comprising the vector. A composition comprising the antisense
CC oligonucleotides is useful in the manufacture of a medicament for use in
CC treating or ameliorating hypertension, hypertrophy and cardiac ischaemia
CC in a mammal. A composition comprising the antisense oligonucleotides is
CC also useful for reducing the level of beta1-AR polypeptide, the
CC transcription of beta1-AR polypeptide-specific mRNA in a mammalian host
CC cell, particularly human cell, and for decreasing blood pressure in a
CC mammal, where the antisense oligonucleotide is operably linked to a
CC promoter capable of expressing the oligonucleotide in the cell. A
CC composition comprising a selected nucleic acid segment that comprises a
CC full-length, or is a full length beta1-adrenoceptor antisense
CC polynucleotide operatively linked to a promoter capable of expressing the
CC polynucleotide in a cell is also useful for reducing the level of beta_1-
CC adrenoceptor polypeptide in a mammalian host cell. The antisense
CC oligonucleotide is also useful for other cardiovascular diseases and
CC cardiac dysfunction in humans. The present sequence is a beta1-AR mRNA
CC targetting antisense oligonucleotide of the invention
XX
SQ Sequence 16 BP; 2 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 TGCCCAGCTGCAGAGG 1664
||||.||||||.||||
Db 1 TGCCGAGCTGCGGAGG 16

RESULT 249
ABS98338/c
ID ABS98338 standard; DNA; 16 BP.
XX
AC ABS98338;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human multidrug resistance associated protein 3 PCR primer #4.
XX
KW Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW multidrug resistance associated protein 3; cancer; prostate;
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW altered drug metabolism; cardiovascular function; colorectal tumour;
KW central nervous system; pulmonary; immunological.
XX
OS Homo sapiens.
XX
PN WO200257410-A2.
XX
PD 25-JUL-2002.
XX
PF 28-NOV-2001; 2001WO-US044838.
XX
PR 28-NOV-2000; 2000US-00724389.
XX
PA (DNAS-) DNA SCI LAB INC.
XX
PI Guida M, Hall J;
XX
DR WPI; 2002-698522/75.
XX
PT Isolated nucleic acid molecules having polymorphisms in known human genes
PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT for locating, identifying and characterizing the genes responsible for
PT disorder-related traits.
XX
PS Example 24; Page 150; 714pp; English.
XX
CC This invention relates to the sequence of an isolated nucleic acid
CC molecule comprising at least one base variation from that of a known
CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
CC transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl
CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC The polymorphisms in the human genes cited in the invention are useful as
CC genetic linkage markers for locating and characterising the genes that
CC are responsible for specific traits within the genome and eventually
CC identifying the genes responsible for a variety of disorder-related
CC traits as a result of their e.g., overexpression, constitutive
CC expression, mutation or underexpression, which may be used in diagnosing
CC and/or treating the disorders. The nucleic acid molecules comprising the
CC polymorphic sequences contained in CYP4501A1, CYPP4501A2, CYP4502E1,
CC ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC metabolism. The polymorphic sequences contained in CYP4501A1, CYPP4501A2,
CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC used to screen for altered cardiovascular function, in COX2 for altered
CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC nervous system function, in FLAP and HNMT for altered pulmonary,
CC immunological or haematological function, in KLK2 for altered serine
CC protease activity in the prostate, in LTF for altered immunological or
CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC peripheral nervous system function. The present sequence represents a PCR
CC primer used to amplify the sequences of the invention
XX
SQ Sequence 16 BP; 1 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;

```
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1353 CCCAGGGCAGCTGAGG 1368
              | ||||||||| |||||
Db         16 CACAGGGCAGATGAGG 1


RESULT 250
ABX74378/c
ID   ABX74378 standard; RNA; 16 BP.
XX
AC   ABX74378;
XX
DT   24-MAR-2003  (first entry)
XX
DE   Hepatitis C recognition sequence for ribozyme CN22.
XX
KW   Hairpin ribozyme; ss; hepatitis C infection; HCV; gene therapy; virucide.
XX
OS   Hepatitis C virus.
XX
PN   US6458567-B1.
XX
PD   01-OCT-2002.
XX
PF   01-NOV-1999;   99US-00431419.
XX
PR   29-FEB-1996;   96US-00608862.
PR   20-OCT-1997;   97US-00954210.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Barber JR,  Welch PJ,  Tritz R,  Yei S,  Yu M;
XX
DR   WPI; 2003-155536/15.
XX
PT   New ribozyme having the ability to inhibit replication, infectivity or
PT   gene expression of a Hepatitis C Virus (HCV), useful for treating or
PT   preventing HCV infection.
XX
PS   Example 1; Col 12; 48pp; English.
XX
CC   The invention relates to a new ribozyme with the ability to inhibit
CC   replication, infectivity or gene expression of a Hepatitis C Virus (HCV)
CC   by cleaving the positive strand genomic RNA of HCV at a sequence having
CC   16 bp. Also included are a nucleic acid encoding the ribozyme, a host
CC   cell containing the ribozyme or vector, a vector comprising a promoter
CC   operably linked to the nucleic acid, producing a ribozyme, interfering
CC   with HCV replication or gene expression in a cell infected in a cell
CC   culture with HCV or a composition comprising the ribozyme and a carrier
CC   or diluent. The ribozyme is useful for treating or preventing HCV
CC   infection. The present sequence is an HCV -ve strand recognition sequence
CC   for a ribozyme of the invention
XX
SQ   Sequence 16 BP; 5 A; 2 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        880 TCACCTTTGAGAGCCT 895
              |||||||||| || ||
Db         16 TCACCTTTGACAGACT 1


RESULT 251
ABN08656/c
ID   ABN08656 standard; DNA; 17 BP.
XX
AC   ABN08656;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8648.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8648; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1652 CCAGCTGCAGAGGCAG 1667
              ||||||||||  ||||
```

```
Db         16 CCAGCTGCAGCTGCAG 1


RESULT 252
AAL61563
ID   AAL61563 standard; DNA; 20 BP.
XX
AC   AAL61563;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130488.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 20;
  Best Local Similarity   87.5%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        777 GCCTTTGAGAAGAGCT 792
              ||||| ||||||||| |
Db          1 GCCTTGGAGAAGAGGT 16


RESULT 253
ABK99820/c
ID   ABK99820 standard; DNA; 20 BP.
XX
AC   ABK99820;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Mouse RAIDD antisense oligonucleotide #74.
XX
KW   Antisense gene therapy; RAIDD; death domain; caspase recruitment domain;
KW   CARD; hyperproliferative disorder; cancer; growth disorder; mouse;
KW   metabolic disorder; infection; inflammation; tumour formation;
KW   RIP associated ICH-1/CED-3-homologous protein with death domain;
KW   receptor interacting protein; antisense oligonucleotide; ss.
XX
OS   Mus musculus.
XX
PN   WO200248314-A2.
XX
PD   20-JUN-2002.
XX
PF   29-OCT-2001; 2001WO-US050914.
XX
PR   01-NOV-2000; 2000US-00705267.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Zhang H,  Freier SM,  Watt AT;
XX
DR   WPI; 2002-583496/62.
XX
PT   Novel antisense compound that hybridizes and inhibits nucleic acid
PT   encoding RAIDD which is an adaptor molecule containing both death domain
PT   and caspase recruitment domains, for treating hyperproliferative
PT   disorder.
XX
PS   Claim 3; Page 95; 144pp; English.
XX
CC   The invention describes a compound (I) 8-50 nucleobases in length
CC   targeted to a nucleic acid molecule (II) encoding RAIDD which is an
CC   adaptor molecule containing both death domain (DD) and caspase
CC   recruitment domains (CARD), where (I) specifically hybridises with and
CC   inhibits expression of RAIDD, or specifically hybridises with at least an
CC   8-nucleobase portion of an active site on (II). (I) is useful for
CC   inhibiting the expression of RAIDD (Receptor interacting protein (RIP)
CC   associated ICH-1/CED-3-homologous protein with death domain) in cells or
CC   tissues, and for treating an animal having a disease or condition
CC   associated with RAIDD, where the disease or condition is a
CC   hyperproliferative disorder such as cancer, or a growth or metabolic
CC   disorder. (I) is also useful for diagnostics, therapeutics, prophylaxis,
CC   as research reagents and kits, for distinguishing functions of various
CC   members of a biological pathway, and in antisense gene therapy. (I) is
CC   also useful prophylactically, e.g. to prevent or delay infection,
CC   inflammation or tumour formation. This sequence represents a mouse RAIDD
CC   antisense oligonucleotide used to control expression of the RAIDD protein
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 20;
  Best Local Similarity   87.5%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1227 CTCCAGCATGTGCTGG 1242
```

```
                ||||||||  ||||||
Db         18 CTCCAGCACATGCTGG 3


RESULT 254
AAL61576
ID   AAL61576 standard; DNA; 20 BP.
XX
AC   AAL61576;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130501.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.6;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        498 GTCTGGCCTTGGCCTGCTC 516
              | | || |||||||| |||
Db          1 GCCAGGTCTTGGCCTCCTC 19


RESULT 255
AAL61565
ID   AAL61565 standard; DNA; 20 BP.
XX
AC   AAL61565;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130490.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
```

```
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match              0.5%;  Score 12.6;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        212 GCCCCGGGCCAGTCTCCGG 230
              |||| |||  ||||||| |
Db          2 GCCCTGGGAAAGTCTCCTG 20


RESULT 256
AAL61579
ID   AAL61579 standard; DNA; 20 BP.
XX
AC   AAL61579;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130504.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match              0.5%;  Score 12.6;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1866 GGCCTGACCCCGCAGCTGG 1884
              | |||| | | ||||||||
Db          2 GACCTGCCTCTGCAGCTGG 20


RESULT 257
AAL61581
ID   AAL61581 standard; DNA; 20 BP.
XX
AC   AAL61581;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130506.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
```

```
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.2;  DB 1;  Length 20;
  Best Local Similarity   82.4%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1120 AGGTCCTCCAAGACCTG 1136
              || | || |||||||||
Db          1 AGATGCTGCAAGACCTG 17


RESULT 258
AAL61582
ID   AAL61582 standard; DNA; 20 BP.
XX
AC   AAL61582;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130507.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Claim 3; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.2;  DB 1;  Length 20;
  Best Local Similarity   82.4%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1120 AGGTCCTCCAAGACCTG 1136
              || | || |||||||||
Db          3 AGATGCTGCAAGACCTG 19


RESULT 259
AAL61575
ID   AAL61575 standard; DNA; 20 BP.
XX
AC   AAL61575;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130500.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
```

```
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 75; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12.2;  DB 1;  Length 20;
  Best Local Similarity   82.4%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        500 CTGGCCTTGGCCTGCTC 516
              | || |||||||| |||
Db          1 CAGGTCTTGGCCTCCTC 17


RESULT 260
AAL61547
ID   AAL61547 standard; DNA; 20 BP.
XX
AC   AAL61547;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130472.
XX
KW   Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
KW   ikappab r; antisense; immune response; infection; inflammation; therapy;
KW   tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidine residues
FT                    are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003042360-A2.
XX
PD   22-MAY-2003.
XX
PF   05-NOV-2002; 2002WO-US035597.
XX
PR   13-NOV-2001; 2001US-00993731.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468635/44.
XX
PT   New antisense oligonucleotides targeted to nucleic acids encoding
PT   inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT   associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT   immune response or infection.
XX
PS   Example 15; Page 74; 108pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC   IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC   polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC   inhibit its expression. Antisense compounds of the invention are useful
CC   for treating diseases or conditions associated with the expression of
CC   inhibitor-kappa B-R such as a heightened immune response involving
CC   increased cytokine expression, or a result of infection (e.g. bacterial,
CC   viral or parasitic). They are useful for diagnostics, therapeutics,
CC   prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC   formation, as research reagents and kits and in distinguishing between
CC   functions of various members of a biological pathway. They are also
CC   useful in antisense therapy. The present sequence is an oligonucleotide
CC   targetted to human inhibitor-kappa B-R DNA
XX
SQ   Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1061 GTGTGCGCACAC 1072
              ||||||||||||
Db          9 GTGTGCGCACAC 20


Search completed: April  7, 2004, 16:11:53
Job time : 9 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 7, 2004, 16:15:32 ; Search time 2 Seconds
(without alignments)
4.447 Million cell updates/sec

Title: us-09-993-731-10
Perfect score: 2525
Sequence: 1 ctctgggctgtgccgtggcc.....cgcattctctctcccacaga 2525

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 101 seqs, 1761 residues

Total number of hits satisfying chosen parameters: 202

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 110 summaries

Database : rnidb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20.4	0.8	25	1	US-08-860-038-18	Sequence 18, Appl
c	2	20.4	0.8	25	1	US-09-580-923-18	Sequence 18, Appl
	3	19.4	0.8	21	1	US-08-863-639A-41	Sequence 41, Appl
c	4	19.4	0.8	21	1	US-08-863-639A-53	Sequence 53, Appl
c	5	19.4	0.8	21	1	US-08-863-639A-59	Sequence 59, Appl
	6	19.4	0.8	21	1	US-08-863-639A-64	Sequence 64, Appl
	7	19.2	0.8	24	1	US-08-486-421-51	Sequence 51, Appl
	8	19.2	0.8	24	1	US-08-470-911-51	Sequence 51, Appl
	9	19.2	0.8	24	1	US-08-486-809-51	Sequence 51, Appl
	10	18.4	0.7	21	1	US-08-863-639A-70	Sequence 70, Appl
c	11	18.4	0.7	21	1	US-08-863-639A-83	Sequence 83, Appl
c	12	18.4	0.7	21	1	US-08-486-343A-5	Sequence 5, Appli
c	13	18.4	0.7	21	1	PCT-US95-07349-5	Sequence 5, Appli
c	14	17.4	0.7	20	1	US-09-433-699-43	Sequence 43, Appl
c	15	17.4	0.7	20	1	US-09-490-692-153	Sequence 153, App
c	16	16.8	0.7	20	1	US-09-444-053-54	Sequence 54, Appl
c	17	16.8	0.7	21	1	US-09-403-267-12	Sequence 12, Appl
c	18	16.4	0.6	18	1	US-09-733-444-22	Sequence 22, Appl
	19	16.4	0.6	20	1	US-09-780-173A-93	Sequence 93, Appl
c	20	16	0.6	20	1	US-09-490-692-155	Sequence 155, App
	21	16	0.6	20	1	US-09-705-267A-173	Sequence 173, App
	22	16	0.6	20	1	US-09-705-267A-174	Sequence 174, App
c	23	15.4	0.6	17	1	US-08-152-313-113	Sequence 113, App
c	24	15.4	0.6	17	1	US-08-579-223-113	Sequence 113, App
	25	15.4	0.6	17	1	US-09-866-108A-929	Sequence 929, App
	26	15.4	0.6	17	1	US-09-866-108A-8659	Sequence 8659, Ap
c	27	15.4	0.6	17	1	PCT-US94-12947A-113	Sequence 113, App
c	28	14.8	0.6	18	1	US-09-156-979-46	Sequence 46, Appl
c	29	14.8	0.6	18	1	US-09-387-341-107	Sequence 107, App
	30	14.4	0.6	17	1	US-08-584-040-5442	Sequence 5442, Ap
c	31	14.4	0.6	17	1	US-09-920-663-4	Sequence 4, Appli
c	32	14.4	0.6	17	1	US-09-474-432B-669	Sequence 669, App
	33	14.4	0.6	17	1	US-09-371-772B-2336	Sequence 2336, Ap
c	34	14.4	0.6	17	1	US-09-476-387-668	Sequence 668, App
	35	14.4	0.6	17	1	US-09-866-108A-928	Sequence 928, App
	36	14.4	0.6	17	1	US-09-866-108A-930	Sequence 930, App
	37	14.4	0.6	17	1	US-09-866-108A-2617	Sequence 2617, Ap
	38	14.4	0.6	17	1	US-09-866-108A-2618	Sequence 2618, Ap
	39	14.4	0.6	17	1	US-09-866-108A-6391	Sequence 6391, Ap
	40	14.4	0.6	17	1	US-09-866-108A-6392	Sequence 6392, Ap
	41	14.4	0.6	17	1	US-09-866-108A-8658	Sequence 8658, Ap
	42	14.4	0.6	17	1	US-09-866-108A-8660	Sequence 8660, Ap
c	43	14.4	0.6	18	1	US-09-255-912-14	Sequence 14, Appl
	44	14	0.6	17	1	US-09-866-108A-2615	Sequence 2615, Ap
	45	14	0.6	17	1	US-09-866-108A-2616	Sequence 2616, Ap
c	46	13.8	0.5	17	1	US-08-373-124A-178	Sequence 178, App
c	47	13.8	0.5	17	1	US-08-373-124A-180	Sequence 180, App
c	48	13.8	0.5	17	1	US-08-373-124A-182	Sequence 182, App
c	49	13.8	0.5	17	1	US-08-373-124A-184	Sequence 184, App
c	50	13.8	0.5	17	1	US-08-261-822A-30	Sequence 30, Appl
c	51	13.8	0.5	17	1	US-08-435-628-178	Sequence 178, App
c	52	13.8	0.5	17	1	US-08-435-628-180	Sequence 180, App
c	53	13.8	0.5	17	1	US-08-435-628-182	Sequence 182, App
c	54	13.8	0.5	17	1	US-08-435-628-184	Sequence 184, App
	55	13.8	0.5	17	1	US-08-613-417A-28	Sequence 28, Appl
	56	13.8	0.5	17	1	US-08-594-452-28	Sequence 28, Appl
	57	13.8	0.5	17	1	US-09-258-408-28	Sequence 28, Appl
	58	13.8	0.5	17	1	US-09-196-132-28	Sequence 28, Appl
	59	13.8	0.5	17	1	US-08-584-040-3840	Sequence 3840, Ap
	60	13.8	0.5	17	1	US-08-584-040-5441	Sequence 5441, Ap
c	61	13.8	0.5	17	1	US-09-474-432B-668	Sequence 668, App
	62	13.8	0.5	17	1	US-09-371-772B-1607	Sequence 1607, Ap
c	63	13.8	0.5	17	1	US-09-476-387-667	Sequence 667, App
	64	13.8	0.5	17	1	US-09-866-108A-927	Sequence 927, App
	65	13.8	0.5	17	1	US-09-866-108A-2593	Sequence 2593, Ap
c	66	13.8	0.5	17	1	US-09-866-108A-6611	Sequence 6611, Ap
c	67	13.8	0.5	17	1	US-09-866-108A-6612	Sequence 6612, Ap
c	68	13.8	0.5	17	1	US-09-866-108A-7854	Sequence 7854, Ap
c	69	13.8	0.5	17	1	US-09-866-108A-7855	Sequence 7855, Ap
	70	13.8	0.5	17	1	US-09-866-108A-8082	Sequence 8082, Ap
	71	13.8	0.5	17	1	US-09-866-108A-8648	Sequence 8648, Ap
c	72	13.8	0.5	17	1	US-09-866-108A-10738	Sequence 10738, A
c	73	13.8	0.5	17	1	US-09-866-108A-10740	Sequence 10740, A
c	74	13.8	0.5	17	1	PCT-US95-07744A-30	Sequence 30, Appl
	75	13.4	0.5	15	1	US-08-242-664-19	Sequence 19, Appl
	76	13.4	0.5	15	1	US-08-484-138-19	Sequence 19, Appl
c	77	13.4	0.5	15	1	US-08-291-932A-33	Sequence 33, Appl
	78	13.4	0.5	15	1	US-08-442-461D-16	Sequence 16, Appl
	79	13.4	0.5	15	1	PCT-US91-03680-19	Sequence 19, Appl
	80	13.4	0.5	15	1	PCT-US95-06379-19	Sequence 19, Appl
	81	13.4	0.5	15	1	5217867-3	Patent No. 5217867
c	82	13.4	0.5	16	1	US-08-152-019A-13	Sequence 13, Appl
c	83	12.8	0.5	16	1	US-08-954-210-59	Sequence 59, Appl
c	84	12.8	0.5	16	1	US-09-431-419A-59	Sequence 59, Appl
	85	12.8	0.5	16	1	US-09-614-034-110	Sequence 110, App
c	86	12.8	0.5	17	1	US-09-866-108A-8648	Sequence 8648, Ap
c	87	12.8	0.5	20	1	US-09-705-267A-173	Sequence 173, App
	88	12.4	0.5	14	1	US-08-793-660B-22	Sequence 22, Appl
	89	12.4	0.5	14	1	US-10-032-307-64	Sequence 64, Appl
	90	12.4	0.5	15	1	US-08-050-073-247	Sequence 247, App
c	91	12.4	0.5	15	1	US-08-166-664-9	Sequence 9, Appli
c	92	12.4	0.5	15	1	US-08-291-932A-201	Sequence 201, App
c	93	12.4	0.5	15	1	US-08-292-620A-324	Sequence 324, App
c	94	12.4	0.5	15	1	US-09-071-845-324	Sequence 324, App
	95	12.4	0.5	15	1	US-09-081-646-33	Sequence 33, Appl
c	96	12.4	0.5	15	1	US-09-081-646-391	Sequence 391, App
	97	12	0.5	13	1	US-08-687-551-10	Sequence 10, Appl
c	98	12	0.5	15	1	US-08-291-932A-16	Sequence 16, Appl
	99	12	0.5	15	1	US-08-291-932A-249	Sequence 249, App
c	100	12	0.5	15	1	US-08-585-684B-2053	Sequence 2053, Ap
	101	12	0.5	15	1	US-08-271-882B-30	Sequence 30, Appl
c	102	12	0.5	15	1	US-09-038-073-2053	Sequence 2053, Ap
	103	12	0.5	15	1	US-09-275-850-21	Sequence 21, Appl
c	104	11.8	0.5	20	1	US-09-705-267A-174	Sequence 174, App
c	105	11.8	0.5	24	1	US-08-486-421-51	Sequence 51, Appl
c	106	11.8	0.5	24	1	US-08-470-911-51	Sequence 51, Appl

c 107	11.8	0.5	24	1	US-08-486-809-51	Sequence 51, Appl
108	11.6	0.5	18	1	US-09-156-979-46	Sequence 46, Appl
109	11.6	0.5	18	1	US-09-387-341-107	Sequence 107, App
110	11.2	0.4	17	1	US-09-866-108A-7854	Sequence 7854, Ap

ALIGNMENTS

```
RESULT 1
US-08-860-038-18/c
; Sequence 18, Application US/08860038
; Patent No. 6287762
;  GENERAL INFORMATION:
;    APPLICANT:  CROUZET, Joel
;    APPLICANT:  SCHERMAN, Daniel
;    APPLICANT:  WILS, Pierre
;    TITLE OF INVENTION:  PURIFICATION OF A TRIPLE HELIX FORMATION
;    TITLE OF INVENTION:  WITH AN IMMOBILIZED OLIGONUCLEOTIDE
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rhone-Poulenc Rorer Inc.
;      STREET:  500 Arcola Road, Mailstop 3C43
;      CITY:  Collegeville
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19426
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/860,038
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 94/15162
;      FILING DATE:  16-DEC-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO FR95/01468
;      FILING DATE:  08-NOV-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Savitzky Esq., Martin F.
;      REGISTRATION NUMBER:  29,699
;      REFERENCE/DOCKET NUMBER:  ST94090-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (610) 454-3816
;      TELEFAX:  (610) 454-3808
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotide"
US-08-860-038-18

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 7.8;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 2
US-09-580-923-18/c
; Sequence 18, Application US/09580923
; Patent No. 6319672
; GENERAL INFORMATION:
;  APPLICANT:  Crouzet, Joel
;  APPLICANT:  Scherman, Daniel
;  APPLICANT:  Wils, Pierre
;  APPLICANT:  Cameron, Beatrice
;  APPLICANT:  Blanche, Francis
;  TITLE OF INVENTION:  PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
;  TITLE OF INVENTION:  IMMOBILIZED OLIGONUCLEOTIDE
;  FILE REFERENCE:  03804.0138-01
;  CURRENT APPLICATION NUMBER: US/09/580,923
;  CURRENT FILING DATE:  2000-05-26
;  PRIOR APPLICATION NUMBER:  08/860,038
;  PRIOR FILING DATE:  1997-06-09
;  PRIOR APPLICATION NUMBER:  PCT/FR95/01468
;  PRIOR FILING DATE:  1995-11-08
;  NUMBER OF SEQ ID NOS:  36
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-09-580-923-18

  Query Match             0.8%;  Score 20.4;  DB 1;  Length 25;
  Best Local Similarity   95.5%;  Pred. No. 7.8;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              ||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4


RESULT 3
US-08-863-639A-41
; Sequence 41, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  41:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-41

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 6.9;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGG 1791
              ||||||||||||  ||||||||
Db          1 AGGAGGAGGAGGAGGAGGAGG 21


RESULT 4
US-08-863-639A-53/c
; Sequence 53, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  53:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-53

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 6.9;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGAGG 1791
              ||||||||||||  ||||||||
Db         21 AGGAGGAGGAGGAGGAGGAGG 1


RESULT 5
US-08-863-639A-59/c
; Sequence 59, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  59:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-59

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 6.9;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGAG 1790
              ||||||||||||  ||||||||
Db         21 GAGGAGGAGGAGGAGGAGGAG 1


RESULT 6
US-08-863-639A-64
; Sequence 64, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
```

```
;       REGISTRATION NUMBER:  20,532
;       REFERENCE/DOCKET NUMBER:  11859-1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (626) 796-4000
;       TELEFAX:  (626) 795-6321
;   INFORMATION FOR SEQ ID NO:  64:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  21 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-64

  Query Match             0.8%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 6.9;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGAG 1790
                ||||||||||||| |||||||
Db          1 GAGGAGGAGGAGGAGGAGGAG 21


RESULT 7
US-08-486-421-51
; Sequence 51, Application US/08486421
; Patent No. 5672479
;  GENERAL INFORMATION:
;    APPLICANT:  Johnson, Edward M.
;    APPLICANT:  Bergemann, Andrew D.
;    TITLE OF INVENTION:  CLONING AND EXPRESSION OF PUR PROTEIN
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,421
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/470,911
;      FILING DATE:  06-JUN-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Coruzzi, Laura A.
;      REGISTRATION NUMBER:  30,742
;      REFERENCE/DOCKET NUMBER:  6923-053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  51:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-486-421-51

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
                ||||| |||||||||||| || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 8
US-08-470-911-51
; Sequence 51, Application US/08470911
; Patent No. 5756684
;  GENERAL INFORMATION:
;    APPLICANT:  Johnson, Edward M.
;    APPLICANT:  Bergemann, Andrew D.
;    TITLE OF INVENTION:  CLONING AND EXPRESSION OF PUR PROTEIN
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/470,911
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Coruzzi, Laura A.
;      REGISTRATION NUMBER:  30,742
;      REFERENCE/DOCKET NUMBER:  6923-053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  51:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-470-911-51

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
                ||||| |||||||||||| || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 9
US-08-486-809-51
; Sequence 51, Application US/08486809
; Patent No. 5869622
;  GENERAL INFORMATION:
;    APPLICANT:  Johnson, Edward M.
;    APPLICANT:  Bergemann, Andrew D.
;    TITLE OF INVENTION:  CLONING AND EXPRESSION OF PUR PROTEIN
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/486,809
;       FILING DATE:  07-JUN-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/470,911
;       FILING DATE:  06-JUN-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Coruzzi, Laura A.
;       REGISTRATION NUMBER:  30,742
;       REFERENCE/DOCKET NUMBER:  6923-053
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (212) 790-9090
;       TELEFAX:  (212) 869-9741/8864
;       TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  51:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  24 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-486-809-51

  Query Match             0.8%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 12;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGGCGGC 1795
             ||||| |||||||||||  || |||
Db          1 GGAGGCGGAGGCGGAGGCGGAGGC 24


RESULT 10
US-08-863-639A-70
; Sequence 70, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  70:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-70

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 11;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
             |||||||||| ||||||||
Db          1 GGAGGAGGAGGAGGAGGAGG 20


RESULT 11
US-08-863-639A-83/c
; Sequence 83, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  83:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-83

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 11;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
             |||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 12
US-08-486-343A-5/c
; Sequence 5, Application US/08486343A
; Patent No. 6071695
;  GENERAL INFORMATION:
;    APPLICANT:  OZKAYNAK, ENGIN
```

```
;    APPLICANT:  OPPERMANN, HERMANN
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR MODULATING
;    TITLE OF INVENTION:  MORPHOGENIC PROTEIN EXPRESSION
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
;      ADDRESSEE:  INC.
;      STREET:  45 SOUTH STREET
;      CITY:  HOPKINTON
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  07148
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,343A
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PITCHER, Edmund R
;      REGISTRATION NUMBER:  27,829
;      REFERENCE/DOCKET NUMBER:  CRP-091CP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617)-248-7000
;      TELEFAX:  (617)-248-7100
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..21
;      OTHER INFORMATION:  /note= "WT1/EGR HUMAN TCC BINDING
;      OTHER INFORMATION:  SITE"
US-08-486-343A-5

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 11;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
             ||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 13
PCT-US95-07349-5/c
; Sequence 5, Application PC/TUS9507349
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR MODULATING
;    TITLE OF INVENTION:  MORPHOGEN EXPRESSION
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
;      ADDRESSEE:  INC.
;      STREET:  45 SOUTH STREET
;      CITY:  HOPKINTON
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  07148
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/07349
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/938,021
;      FILING DATE:  28-AUG-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KELLEY, ROBIN D
;      REGISTRATION NUMBER:  34,637
;      REFERENCE/DOCKET NUMBER:  CRP-091PC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (508)-435-9001
;      TELEFAX:  (508)-435-0992
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..21
;      OTHER INFORMATION:  /note= "WT1 HUMAN TCC BINDING SITE"
PCT-US95-07349-5

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 11;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
             ||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 14
US-09-433-699-43/c
; Sequence 43, Application US/09433699B
; Patent No. 6165786
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF NUCLEOLIN EXPRESSION
;  FILE REFERENCE: RTS-0109
;  CURRENT APPLICATION NUMBER: US/09/433,699B
;  CURRENT FILING DATE: 1999-11-03
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 43
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-433-699-43

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 14;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1761 GATGAAGATGAGGAGGAGG 1779
             ||||||||||| |||||||
Db         19 GATGAAGATGATGAGGAGG 1


RESULT 15
US-09-490-692-153/c
; Sequence 153, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
;  FILE REFERENCE: RTS-0120
```

```
;  CURRENT APPLICATION NUMBER: US/09/490,692
;  CURRENT FILING DATE: 2000-01-24
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 153
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-153

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 14;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 TGAGGAGGAGGAGGCGGAG 1787
              ||||||||||||||| ||||
Db         19 TGAGGAGGAGGAGGAGGAG 1


RESULT 16
US-09-444-053-54/c
; Sequence 54, Application US/09444053A
; Patent No. 6165728
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF NCK-2 EXPRESSION
;  FILE REFERENCE: RTS-0122
;  CURRENT APPLICATION NUMBER: US/09/444,053A
;  CURRENT FILING DATE: 1999-11-19
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 54
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-444-053-54

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 18;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1776 GAGGAGGCGGAGGAGGCGGC 1795
              ||||||| ||| ||||||||
Db         20 GAGGAGGTGGACGAGGCGGC 1


RESULT 17
US-09-403-267-12/c
; Sequence 12, Application US/09403267
; Patent No. 6159710
;  GENERAL INFORMATION:
;    APPLICANT:  Wistar Institute of Anatomy, and Biology
;    APPLICANT:  Fraser, Nigel W.
;    APPLICANT:  Zabolotny, Janice M.
;    APPLICANT:  Krummenacher, Claude F.
;    TITLE OF INVENTION:  Method and Compositions for Stabilizing
;    TITLE OF INVENTION:  Unstable Gene Transcripts
;    NUMBER OF SEQUENCES:  40
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Howson and Howson
;      STREET:  Spring House Corporate Cntr., P.O. Box 457
;      CITY:  Spring House
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19477
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/403,267
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/044,664
;      FILING DATE:  18-APR-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bak, Mary E.
;      REGISTRATION NUMBER:  31,215
;      REFERENCE/DOCKET NUMBER:  WST78APCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-540-9200
;      TELEFAX:  215-540-5818
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "probe/primer Exon 2n"
US-09-403-267-12

  Query Match             0.7%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 21;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGA 1789
              |||||||| ||||| |||||
Db         20 GAGGAGGAAGAGGCAGAGGA 1


RESULT 18
US-09-733-444-22/c
; Sequence 22, Application US/09733444
; Patent No. 6576423
; GENERAL INFORMATION:
;  APPLICANT: Batra, Surinder K.
;  APPLICANT:  Brandt, Randall E.
;  APPLICANT:  Ringel, J"erg
;  APPLICANT:  Faulmann, Grit
;  APPLICANT:  L"hr, Matthias
;  APPLICANT:  Varshney, Grish C.
;  APPLICANT:  University of Nebraska Board of Regents
;  TITLE OF INVENTION: Specific Mucin Expression as a Marker
;  TITLE OF INVENTION:  for Pancreatic Cancer
;  FILE REFERENCE: UNMC 63155
;  CURRENT APPLICATION NUMBER: US/09/733,444
;  CURRENT FILING DATE:  2000-12-08
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-733-444-22

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 15;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        894 CTGCAGCAGACAGCCCTG 911
              ||||||||| ||||||||
Db         18 CTGCAGCAGGCAGCCCTG 1


RESULT 19
US-09-780-173A-93
; Sequence 93, Application US/09780173A
; Patent No. 6455307
```

; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASEIN KINASE 2-ALPHA PRIME EXPRESSION
; FILE REFERENCE: RTS-0165
; CURRENT APPLICATION NUMBER: US/09/780,173A
; CURRENT FILING DATE: 2001-02-08
; NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-780-173A-93

Query Match 0.6%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1881 CTGGAGGAGGACGAGGAG 1898
||||||||||| ||||||
Db 1 CTGGAGGAGGAGGAGGAG 18

RESULT 20
US-09-490-692-155/c
; Sequence 155, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTS-0120
; CURRENT APPLICATION NUMBER: US/09/490,692
; CURRENT FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 155
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-155

Query Match 0.6%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1756 CTGAAGATGAAGATGA 1771
||||||||||||||||
Db 16 CTGAAGATGAAGATGA 1

RESULT 21
US-09-705-267A-173
; Sequence 173, Application US/09705267A
; Patent No. 6551826
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RAIDD EXPRESSION
; FILE REFERENCE: RTS-0211
; CURRENT APPLICATION NUMBER: US/09/705,267A
; CURRENT FILING DATE: 2000-11-01
; NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 173
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-705-267A-173

Query Match 0.6%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1227 CTCCAGCATGTGCTGG 1242
||||||||||||||||
Db 1 CTCCAGCATGTGCTGG 16

RESULT 22
US-09-705-267A-174
; Sequence 174, Application US/09705267A
; Patent No. 6551826
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RAIDD EXPRESSION
; FILE REFERENCE: RTS-0211
; CURRENT APPLICATION NUMBER: US/09/705,267A
; CURRENT FILING DATE: 2000-11-01
; NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-705-267A-174

Query Match 0.6%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1227 CTCCAGCATGTGCTGG 1242
||||||||||||||||
Db 4 CTCCAGCATGTGCTGG 19

RESULT 23
US-08-152-313-113/c
; Sequence 113, Application US/08152313
; Patent No. 5561041
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
; TITLE OF INVENTION: ANALYSIS OF SPUTUM
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Jubas & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/152,313
; FILING DATE: 12-NOV-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wetherell, Jr., Ph.D., John R.,
; REGISTRATION NUMBER: 31,678
; REFERENCE/DOCKET NUMBER: PD-2912
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 455-5100

```
;       TELEFAX:  (619) 455-5110
;   INFORMATION FOR SEQ ID NO:  113:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  1..17
US-08-152-313-113

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 20;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1655 GCTGCAGAGGCAGGTCT 1671
              |||||| ||||||||||
Db         17 GCTGCACAGGCAGGTCT 1


RESULT 24
US-08-579-223-113/c
; Sequence 113, Application US/08579223
; Patent No. 5726019
;  GENERAL INFORMATION:
;     APPLICANT:  Sidransky, David
;     TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;     TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;     NUMBER OF SEQUENCES:  128
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Spensley Horn Jubas & Lubitz
;       STREET:  1880 Century Park East, Suite 500
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  USA
;       ZIP:  90067
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/579,223
;       FILING DATE:  28-DEC-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/152,313
;       FILING DATE:  12-NOV-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Wetherell, Jr., Ph.D., John R.,
;       REGISTRATION NUMBER:  31,678
;       REFERENCE/DOCKET NUMBER:  PD-2912
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (619) 455-5100
;       TELEFAX:  (619) 455-5110
;   INFORMATION FOR SEQ ID NO:  113:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  1..17
US-08-579-223-113

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 20;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1655 GCTGCAGAGGCAGGTCT 1671
              |||||| ||||||||||
Db         17 GCTGCACAGGCAGGTCT 1


RESULT 25
US-09-866-108A-929
; Sequence 929, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 929
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-929

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 20;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGAG 1280
              ||||| ||||||||||||
Db          1 AGCTGAAAGAGGCTGAG 17


RESULT 26
US-09-866-108A-8659
; Sequence 8659, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
```

```
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8659
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8659

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 20;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GCTGGAGGAGGCCAAGA 1545
              ||||||||| |||||||
Db          1 GCTGGAGGAAGCCAAGA 17


RESULT 27
PCT-US94-12947A-113/c
; Sequence 113, Application PC/TUS9412947A
;  GENERAL INFORMATION:
;    APPLICANT:  The Johns Hopkins University School of Medicine
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION BY
;    TITLE OF INVENTION:  ANALYSIS OF SPUTUM
;    NUMBER OF SEQUENCES:  128
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12947A
;      FILING DATE:  10-NOV-1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Haile, Ph.D., Lisa A.
;      REGISTRATION NUMBER:  P-38,347
;      REFERENCE/DOCKET NUMBER:  FD-2912
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-5100
;      TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  113:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..17
PCT-US94-12947A-113

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 20;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1655 GCTGCAGAGGCAGGTCT 1671
              ||||||| ||||||||||
Db         17 GCTGCACAGGCAGGTCT 1


RESULT 28
US-09-156-979-46/c
; Sequence 46, Application US/09156979
; Patent No. 5962672
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RhoB EXPRESSION
;  FILE REFERENCE: RTS-0013
;  CURRENT APPLICATION NUMBER: US/09/156,979
;  CURRENT FILING DATE: 1998-09-18
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 46
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-156-979-46

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 30;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1251 CGGCTGCAGCAACAGCTG 1268
              |||||||| |||| ||||
Db         18 CGGCTGCATCAACTGCTG 1


RESULT 29
US-09-387-341-107/c
; Sequence 107, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
;  APPLICANT: Roberts, M. Luisa
;  APPLICANT: Cowsert, Lex M.
;  TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
;  TITLE OF INVENTION: Expression
;  FILE REFERENCE: ISPH-0404
;  CURRENT APPLICATION NUMBER: US/09/387,341
;  CURRENT FILING DATE: 1999-08-31
;  EARLIER APPLICATION NUMBER: 09/156,424
;  EARLIER FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 09/156,979
;  EARLIER FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 09/156,807
;  EARLIER FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 09/161,015
;  EARLIER FILING DATE: 1998-09-25
;  NUMBER OF SEQ ID NOS: 233
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 107
;   LENGTH: 18
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-09-387-341-107

  Query Match             0.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 30;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1251 CGGCTGCAGCAACAGCTG 1268
              ||||||||  ||||  ||||
Db         18 CGGCTGCATCAACTGCTG 1


RESULT 30
US-08-584-040-5442
; Sequence 5442, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5442:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5442

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 30;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1301 CATGGTCATCTGTGAG 1316
              ||:||:| :|:|:|||
Db          1 CAUGGUCUUCUGUGAG 16


RESULT 31
US-09-920-663-4/c
; Sequence 4, Application US/09920663
; Patent No. 6426221
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RIP2 EXPRESSION
;  FILE REFERENCE: RTS-0233
;  CURRENT APPLICATION NUMBER: US/09/920,663
;  CURRENT FILING DATE:  2001-08-01
;  NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-09-920-663-4

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1898 GCTTCAGGGCCACCTG 1913
              ||||||  |||||||||
Db         16 GCTTCACGGCCACCTG 1


RESULT 32
US-09-474-432B-669/c
; Sequence 669, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleoti
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 669
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-669

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1266 CTGGAAGAGGCTGAGG 1281
              ||||||||  |||||||
Db         17 CTGGAAGACGCTGAGG 2
```

```
RESULT 33
US-09-371-772B-2336
; Sequence 2336, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2336
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2336

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 30;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1301 CATGGTCATCTGTGAG 1316
              ||:||:| :|:|:|||
Db          1 CAUGGUCUUCUGUGAG 16


RESULT 34
US-09-476-387-668/c
; Sequence 668, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 668
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-668

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1266 CTGGAAGAGGCTGAGG 1281
              |||||||| |||||||
Db         17 CTGGAAGACGCTGAGG 2


RESULT 35
US-09-866-108A-928
; Sequence 928, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 928
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-928

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGA 1279
              ||||| ||||||||||
Db          2 AGCTGAAAGAGGCTGA 17


RESULT 36
US-09-866-108A-930
; Sequence 930, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
```

```
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 930
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-930

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1265 GCTGGAAGAGGCTGAG 1280
                |||| ||||||||||
Db          1 GCTGAAAGAGGCTGAG 16


RESULT 37
US-09-866-108A-2617
; Sequence 2617, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2617
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2617

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAGGA 1855
                ||||||||||||||| |
Db          2 TCTCAGAGAGCGAGCA 17


RESULT 38
US-09-866-108A-2618
; Sequence 2618, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2618
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2618

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
```

Best Local Similarity 93.8%; Pred. No. 30;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1840 TCTCAGAGAGCGAGGA 1855
              ||||||||||||||| |
Db          1 TCTCAGAGAGCGAGCA 16
```

RESULT 39
US-09-866-108A-6391
; Sequence 6391, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6391
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6391

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 30;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1602 GCCCCGTGCTTCCAGA 1617
              |||||||||| ||||||
Db          2 GCCCCGTGCTCCCAGA 17
```

RESULT 40
US-09-866-108A-6392
; Sequence 6392, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6392
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6392

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 30;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1602 GCCCCGTGCTTCCAGA 1617
              |||||||||| ||||||
Db          1 GCCCCGTGCTCCCAGA 16
```

RESULT 41
US-09-866-108A-8658
; Sequence 8658, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8658
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8658

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GCTGGAGGAGGCCAAG 1544
              ||||||||| ||||||
Db          2 GCTGGAGGAAGCCAAG 17


RESULT 42
US-09-866-108A-8660
; Sequence 8660, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8660
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8660

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 30;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1530 CTGGAGGAGGCCAAGA 1545
              |||||||| |||||||
Db          1 CTGGAGGAAGCCAAGA 16


RESULT 43
US-09-255-912-14/c
; Sequence 14, Application US/09255912
; Patent No. 6037142
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD2 EXPRESSION
;  FILE REFERENCE: RTS-0044
;  CURRENT APPLICATION NUMBER: US/09/255,912
;  CURRENT FILING DATE: 1999-02-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 14
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-255-912-14

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAG 1790
              |||| ||||||||||||
Db         18 GGAGCAGGCGGAGGAG 3


RESULT 44
US-09-866-108A-2615
; Sequence 2615, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2615
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2615

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAG 1853
             ||||||||||||||
Db          4 TCTCAGAGAGCGAG 17


RESULT 45
US-09-866-108A-2616
; Sequence 2616, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2616
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2616

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAG 1853
             ||||||||||||||
Db          3 TCTCAGAGAGCGAG 16


RESULT 46
US-08-373-124A-178/c
; Sequence 178, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  178:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-178

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
             ||||| ||| |||||||
Db         17 AGGAGAAGGAGGAGGAG 1


RESULT 47
US-08-373-124A-180/c
; Sequence 180, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
```

```
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  180:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-180

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              ||||||||  |||||||
Db         17 AGGAGGAGAAGGAGGAG 1


RESULT 48
US-08-373-124A-182/c
; Sequence 182, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  182:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-182

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGA 1786
              |||||||||  ||| |||
Db         17 GAGGAGGAGAAGGAGGA 1


RESULT 49
US-08-373-124A-184/c
; Sequence 184, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
```

```
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/373,124A
;       FILING DATE:  January 13, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  184:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-184

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAG 1787
              ||||||||||| ||||
Db         17 AGGAGGAGGAGAAGGAG 1

RESULT 50
US-08-261-822A-30/c
; Sequence 30, Application US/08261822A
; Patent No. 5650553
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker, Joseph R. et al.
;    TITLE OF INVENTION:  Plant Genes for Sensitivity to Ethylene
;    TITLE OF INVENTION:  and Pathogens
;    NUMBER OF SEQUENCES:  82
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & No. 5650553ris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/261,822A
;      FILING DATE:  17-JUN-1994
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Beardell, Lori Y.
;      REGISTRATION NUMBER:  34,293
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
US-08-261-822A-30

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1124 CCTCCAAGACCTGGGAG 1140
              || |||||||||||| |
Db         17 CCACCAAGACCTGGGTG 1

RESULT 51
US-08-435-628-178/c
; Sequence 178, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  178:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
```

US-08-435-628-178

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 38;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1774 AGGAGGAGGCGGAGGAG 1790
              ||||| ||| |||||||
Db         17 AGGAGAAGGAGGAGGAG 1
```

RESULT 52
US-08-435-628-180/c
; Sequence 180, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 180:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-180

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 38;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1774 AGGAGGAGGCGGAGGAG 1790
              ||||||| |||||||
Db         17 AGGAGGAGAAGGAGGAG 1
```

RESULT 53
US-08-435-628-182/c
; Sequence 182, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 182:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-182

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 38;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1770 GAGGAGGAGGAGGCGGA 1786
              ||||||||| ||| |||
Db         17 GAGGAGGAGAAGGAGGA 1
```

RESULT 54

```
US-08-435-628-184/c
; Sequence 184, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  184:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-184

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAG 1787
                ||||||||||  ||||
Db         17 AGGAGGAGGAGAAGGAG 1


RESULT 55
US-08-613-417A-28
; Sequence 28, Application US/08613417A
; Patent No. 5874553
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Phosphonomonoester nucleic acids,
;    TITLE OF INVENTION:  process for their preparation, and their use
;    NUMBER OF SEQUENCES:  33
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0. Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/613,417A
;      FILING DATE:
;      CLASSIFICATION:  514
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  yes
;    FEATURE:
;      NAME/KEY:  exon
;      LOCATION:  1..17
US-08-613-417A-28

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
                ||||||  ||  |||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 56
US-08-594-452-28
; Sequence 28, Application US/08594452
; Patent No. 6013639
;  GENERAL INFORMATION:
;    APPLICANT:  PEYMAN, Anuschirwan
;    APPLICANT:  UHLMANN, Eugen
;    TITLE OF INVENTION:  G CAP-STABILIZED OLIGONUCLEOTIDES
;    NUMBER OF SEQUENCES:  105
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  3000 K Street, N.W., Suite 500
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20007-5109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/594,452
;      FILING DATE:  31-JAN-1996
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DE 195 02 912.7
;      FILING DATE:  31-JAN-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SANDERCOCK, Colin G.
;      REGISTRATION NUMBER:  31,298
;      REFERENCE/DOCKET NUMBER:  18748/264/HOCE
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)672-5300
;      TELEFAX:  (202)672-5399
;      TELEX:  904136
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
```

```
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-594-452-28

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              ||||||  ||  |||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 57
US-09-258-408-28
; Sequence 28, Application US/09258408
; Patent No. 6121434
;  GENERAL INFORMATION:
;    APPLICANT:  PEYMAN, Anuschirwan
;    APPLICANT:  UHLMANN, Eugen
;    TITLE OF INVENTION:  G CAP-STABILIZED OLIGONUCLEOTIDES
;    NUMBER OF SEQUENCES:  105
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  3000 K Street, N.W., Suite 500
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20007-5109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/258,408
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/594,452
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  SANDERCOCK, Colin G.
;      REGISTRATION NUMBER:  31,298
;      REFERENCE/DOCKET NUMBER:  18748/264/HOCE
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)672-5300
;      TELEFAX:  (202)672-5399
;      TELEX:  904136
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-258-408-28

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              ||||||  ||  |||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 58
US-09-196-132-28
; Sequence 28, Application US/09196132
; Patent No. 6127346
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Phosphonomonoester nucleic acids,
;    TITLE OF INVENTION:  process for their preparation, and their use
;    NUMBER OF SEQUENCES:  33
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0. Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/196,132
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/613,417
;      FILING DATE:
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  yes
;    FEATURE:
;      NAME/KEY:  exon
;      LOCATION:  1..17
US-09-196-132-28

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 GGAGGAGGCGGAGGAGG 1791
              ||||||  ||  |||||||
Db          1 GGAGGATGCTGAGGAGG 17


RESULT 59
US-08-584-040-3840
; Sequence 3840, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
```

```
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  3840:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-3840

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 38;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1299 GCCATGGTCATCTGTGA 1315
              | ||:||:| :|:|:||
Db          1 GGCAUGGUCUUCUGUGA 17


RESULT 60
US-08-584-040-5441
; Sequence 5441, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5441:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5441

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 38;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1299 GCCATGGTCATCTGTGA 1315
              | ||:||:| :|:|:||
Db          1 GGCAUGGUCUUCUGUGA 17


RESULT 61
US-09-474-432B-668/c
; Sequence 668, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 668
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-668

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1268 GGAAGAGGCTGAGGGCA 1284
              ||||||  ||||||| ||
Db         17 GGAAGACGCTGAGGTCA 1


RESULT 62
US-09-371-772B-1607
; Sequence 1607, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
```

```
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1607
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1607

  Query Match              0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 38;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1299 GCCATGGTCATCTGTGA 1315
              | ||:||:| :|:|:||
Db          1 GGCAUGGUCUUCUGUGA 17


RESULT 63
US-09-476-387-667/c
; Sequence 667, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 667
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-667

  Query Match              0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1268 GGAAGAGGCTGAGGGCA 1284
              |||||| ||||||| ||
Db         17 GGAAGACGCTGAGGTCA 1


RESULT 64
US-09-866-108A-927
; Sequence 927, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 927
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-927

  Query Match              0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1262 ACAGCTGGAAGAGGCTG 1278
              | ||||| |||||||||
Db          1 AGAGCTGAAAGAGGCTG 17


RESULT 65
US-09-866-108A-2593
; Sequence 2593, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2593
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-2593

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1293 CAGGGTGCCATGGTCAT 1309
             ||||||||||||||  ||
Db          1 CAGGGTGCCATGGAGAT 17


RESULT 66
US-09-866-108A-6611/c
; Sequence 6611, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6611
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-6611

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1222 AGAACCTCCAGCATGTG 1238
             ||| ||||||| |||||
Db         17 AGAGCCTCCAGGATGTG 1


RESULT 67
US-09-866-108A-6612/c
; Sequence 6612, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6612
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-6612

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1221 CAGAACCTCCAGCATGT 1237
             |||| ||||||| ||||
Db         17 CAGAGCCTCCAGGATGT 1


RESULT 68
US-09-866-108A-7854/c
; Sequence 7854, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
```

```
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7854
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7854

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 GTCTTGCAGCATCTCCA 1684
              ||| || ||||||||||
Db         17 GTCCTGTAGCATCTCCA 1


RESULT 69
US-09-866-108A-7855/c
; Sequence 7855, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7855
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7855

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1667 GGTCTTGCAGCATCTCC 1683
              |||| || ||||||||||
Db         17 GGTCCTGTAGCATCTCC 1


RESULT 70
US-09-866-108A-8082
; Sequence 8082, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8082
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8082

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
```

```
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1492 ACTATGAGGAGGAACTG 1508
              || | ||||||||||||
Db          1 ACCAGGAGGAGGAACTG 17


RESULT 71
US-09-866-108A-8648
; Sequence 8648, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8648
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-8648

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1254 CTGCAGCAACAGCTGGA 1270
              |||||||  ||||||||
Db          1 CTGCAGCTGCAGCTGGA 17


RESULT 72
US-09-866-108A-10738/c
; Sequence 10738, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10738
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-10738

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1447 CCACCACACTGGGAGAC 1463
              | |||||||||||||| |
Db         17 CAACCACACTGGGAGCC 1


RESULT 73
US-09-866-108A-10740/c
; Sequence 10740, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10740
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10740

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1445 GGCCACCACACTGGGAG 1461
              | | ||||||||||||||
Db         17 GCCAACCACACTGGGAG 1


RESULT 74
PCT-US95-07744A-30/c
; Sequence 30, Application PC/TUS9507744A
;  GENERAL INFORMATION:
;    APPLICANT:  Trustees of The University of Pennsylvania
;    TITLE OF INVENTION:  Plant Genes for Sensitivity to Ethylene
;    TITLE OF INVENTION:  and Pathogens
;    NUMBER OF SEQUENCES:  82
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & Norris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/07744A
;      FILING DATE:  15-JUNE-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/261,822
;      FILING DATE:  June 17, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Beardell, Lori Y.
;      REGISTRATION NUMBER:  34,293
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
PCT-US95-07744A-30

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 38;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1124 CCTCCAAGACCTGGGAG 1140
              || |||||||||||| |
Db         17 CCACCAAGACCTGGGTG 1


RESULT 75
US-08-242-664-19
; Sequence 19, Application US/08242664
; Patent No. 5571937
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/242,664
;      FILING DATE:  May 12, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-242-664-19

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 31;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGG 1779
              |||| ||||||||||
Db          1 AAGAGGAGGAGGAGG 15


RESULT 76
US-08-484-138-19
; Sequence 19, Application US/08484138
; Patent No. 5652350
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
```

```
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,138
;      FILING DATE:  June 7, 1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-Z/JPW/MJG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-484-138-19

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 31;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGG 1779
             |||| ||||||||||
Db          1 AAGAGGAGGAGGAGG 15


RESULT 77
US-08-291-932A-33/c
; Sequence 33, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-33

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 31;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 GGCCGGCGAGGTGGA 1837
             |||||| ||||||||
Db         15 GGCCGGTGAGGTGGA 1


RESULT 78
US-08-442-461D-16
; Sequence 16, Application US/08442461D
; Patent No. 5834184
;  GENERAL INFORMATION:
;    APPLICANT:  Harada, Kazuo
;    APPLICANT:  Martin, Shelley S.
;    APPLICANT:  Frankel, Alan
;    TITLE OF INVENTION:  In Vivo Selection of RNA-Binding
;    TITLE OF INVENTION:  Peptides
;    NUMBER OF SEQUENCES:  35
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/442,461D
;      FILING DATE:  17-MAY-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  02307U-060500US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  both
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA
US-08-442-461D-16

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 31;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1161 GCCCTGAAGAAGGCC 1175
```

```
                    | ||:||||||||||
Db          1 GGCCUGAAGAAGGCC 15


RESULT 79
PCT-US91-03680-19
; Sequence 19, Application PC/TUS9103680
;  GENERAL INFORMATION:
;    APPLICANT:  Matteucci, Mark D.
;    APPLICANT:  Krawczyk, Steven
;    TITLE OF INVENTION:  SEQUENCE-SPECIFIC NONPHOTOACTIVATED
;    TITLE OF INVENTION:  CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
;    TITLE OF INVENTION:  DUPLEX DNA
;    NUMBER OF SEQUENCES:  158
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Morrison & Foerster
;      STREET:  545 Middlefield Road, Suite 200
;      CITY:  Menlo Park
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/03680
;      FILING DATE:  19910524
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murashige, Kate H.
;      REGISTRATION NUMBER:  29,959
;      REFERENCE/DOCKET NUMBER:  4610-0011.40
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-327-7250
;      TELEFAX:  415-327-2951
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
PCT-US91-03680-19

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 31;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGG 1779
                ||||  ||||||||||
Db          1 AAGAGGAGGAGGAGG 15


RESULT 80
PCT-US95-06379-19
; Sequence 19, Application PC/TUS9506379
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/06379
;      FILING DATE:  May 13, 1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-278-0400
;      TELEFAX:  212-391-0526
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US95-06379-19

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 31;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGG 1779
                ||||  ||||||||||
Db          1 AAGAGGAGGAGGAGG 15


RESULT 81
5217867-3
;Patent No. 5217867
;    APPLICANT: EVANS, RONALD M.;HOLLENBERG, STANLEY M.
;    TITLE OF INVENTION: RECEPTORS THEIR IDENTIFICATION,
;CHARACTERIZATION, PREPARATION AND USE
;    NUMBER OF SEQUENCES: 4
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/278,614
;      FILING DATE: 30-NOV-1988
;SEQ ID NO:3:
;      LENGTH: 15
5217867-3

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 31;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1469 GGACCACCATGGGGC 1483
                | ||||||||||||||
Db          1 GTACCACCATGGGGC 15


RESULT 82
US-08-152-019A-13/c
; Sequence 13, Application US/08152019A
; Patent No. 5565331
;  GENERAL INFORMATION:
;    APPLICANT:  Tessier-Lavigne, Marc
;    APPLICANT:  Serafini, Tito
;    APPLICANT:  Kennedy, Timothy
;    APPLICANT:  Placzek, Marysia
;    APPLICANT:  Jessell, Thomas
;    APPLICANT:  Dodd, Jane
;    TITLE OF INVENTION:  NEURAL AXON OUTGROWTH MODULATORS
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
;      STREET:  4 Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
```

```
;       COUNTRY:  USA
;       ZIP:  94111-4187
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/152,019A
;       FILING DATE:  12-NOV-1993
;       CLASSIFICATION:  514
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Osman, Richard Aron
;       REGISTRATION NUMBER:  36,627
;       REFERENCE/DOCKET NUMBER:  A-59012/RAO
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 781-1989
;       TELEFAX:  (415) 398-3249
;       TELEX:  910 277299 FHT UR
;   INFORMATION FOR SEQ ID NO:  13:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
US-08-152-019A-13

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 38;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 GAGAGCGAGGACGAC 1859
              |||| ||||||||||
Db         16 GAGAACGAGGACGAC 2


RESULT 83
US-08-954-210-59/c
; Sequence 59, Application US/08954210
; Patent No. 6043077
;  GENERAL INFORMATION:
;     APPLICANT:  Barber, Jack R.
;     APPLICANT:  Welch, Peter J.
;     APPLICANT:  Tritz, Richard
;     APPLICANT:  Yei, Soonpin
;     APPLICANT:  Yu, Mang
;     TITLE OF INVENTION:  HEPATITIS C VIRUS RIBOZYMES
;     NUMBER OF SEQUENCES:  73
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  SEED and BERRY LLP
;       STREET:  6300 Columbia Center, 701 Fifth Avenue
;       CITY:  Seattle
;       STATE:  Washington
;       COUNTRY:  USA
;       ZIP:  98104-7092
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/954,210
;       FILING DATE:  20-OCT-1997
;       CLASSIFICATION:  514
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  McMasters, David D.
;       REGISTRATION NUMBER:  33,963
;       REFERENCE/DOCKET NUMBER:  480124.403C1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (206) 622-4900
;       TELEFAX:  (206) 682-6031
;   INFORMATION FOR SEQ ID NO:  59:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-954-210-59

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        880 TCACCTTTGAGAGCCT 895
              |||||||||| || ||
Db         16 TCACCTTTGACAGACT 1


RESULT 84
US-09-431-419A-59/c
; Sequence 59, Application US/09431419A
; Patent No. 6458567
; GENERAL INFORMATION:
;  APPLICANT: Barber, Jack R.
;  APPLICANT:  Welch, Peter J.
;  APPLICANT:  Tritz, Richard
;  APPLICANT:  Yei, Soonpin
;  APPLICANT:  Yu, Mang
;  TITLE OF INVENTION: HEPATITIS C VIRUS RIBOZYMES
;  FILE REFERENCE: 480124.403C3
;  CURRENT APPLICATION NUMBER: US/09/431,419A
;  CURRENT FILING DATE:  1999-11-01
;  NUMBER OF SEQ ID NOS: 73
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 59
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Hepatitis C Virus
US-09-431-419A-59

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        880 TCACCTTTGAGAGCCT 895
              |||||||||| || ||
Db         16 TCACCTTTGACAGACT 1


RESULT 85
US-09-614-034-110
; Sequence 110, Application US/09614034
; Patent No. 6489307
; GENERAL INFORMATION:
;  APPLICANT: PHILLIPS, M. IAN
;  APPLICANT:  ZHANG, YUAN
;  TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
;  TITLE OF INVENTION:  METHODS OF USE
;  FILE REFERENCE: 4300.013900
;  CURRENT APPLICATION NUMBER: US/09/614,034
;  CURRENT FILING DATE:  2000-07-11
;  PRIOR APPLICATION NUMBER: 09/152,717
;  PRIOR FILING DATE: 1998-09-14
;  PRIOR APPLICATION NUMBER: PCT/US99/21007
;  PRIOR FILING DATE: 1999-09-14
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 110
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-614-034-110
```

Query Match 0.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 48;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1649 TGCCCAGCTGCAGAGG 1664
              |||| |||||| ||||
Db          1 TGCCGAGCTGCGGAGG 16
```

RESULT 86
US-09-866-108A-8648/c
; Sequence 8648, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8648

Query Match 0.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 57;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1652 CCAGCTGCAGAGGCAG 1667
              |||||||||| ||||
Db         16 CCAGCTGCAGCTGCAG 1
```

RESULT 87
US-09-705-267A-173/c
; Sequence 173, Application US/09705267A
; Patent No. 6551826
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RAIDD EXPRESSION
; FILE REFERENCE: RTS-0211
; CURRENT APPLICATION NUMBER: US/09/705,267A
; CURRENT FILING DATE: 2000-11-01
; NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 173
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-705-267A-173

Query Match 0.5%; Score 12.8; DB 1; Length 20;
Best Local Similarity 87.5%; Pred. No. 83;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1227 CTCCAGCATGTGCTGG 1242
              |||||||| ||||||
Db         18 CTCCAGCACATGCTGG 3
```

RESULT 88
US-08-793-660B-22
; Sequence 22, Application US/08793660B
; Patent No. 6214614
; GENERAL INFORMATION:
; APPLICANT: MULLER, Rolf
; TITLE OF INVENTION: CELL CYCLE REGULATED REPRESSOR
; TITLE OF INVENTION: AND DNA ELEMENT
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
; STREET: 130 Water Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/793,660B
; FILING DATE: 09-SEP-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 96/06943
; FILING DATE: 07-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 95/06466
; FILING DATE: 29-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 94/17366
; FILING DATE: 26-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Lowen, Cara Z.
; REGISTRATION NUMBER: 38,227
; REFERENCE/DOCKET NUMBER: 47211
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-523-3400
; TELEFAX: 617-523-6440
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-793-660B-22

Query Match 0.5%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 38;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1913 GGGCCGGCGGAAGG 1926
              |||| |||||||||
Db          1 GGGCTGGCGGAAGG 14


RESULT 89
US-10-032-307-64
; Sequence 64, Application US/10032307
; Patent No. 6683173
; GENERAL INFORMATION:
;  APPLICANT: Dempcy, Robert O.
;  APPLICANT:  Gall, Alexander A.
;  APPLICANT:  Lokhov, Sergey G.
;  APPLICANT:  Afonina, Irina A.
;  APPLICANT:  Singer, Michael J.
;  APPLICANT:  Kutyavin, Igor V.
;  APPLICANT:  Vermeulen, Nicolaas M.J.
;  APPLICANT:  Epoch Biosciences, Inc.
;  TITLE OF INVENTION: T-m Leveling Methods
;  FILE REFERENCE: 17682A-003630US
;  CURRENT APPLICATION NUMBER: US/10/032,307
;  CURRENT FILING DATE:  2001-12-21
;  PRIOR APPLICATION NUMBER: US 09/054,830
;  PRIOR FILING DATE: 1998-04-03
;  PRIOR APPLICATION NUMBER: US 09/054,832
;  PRIOR FILING DATE: 1998-04-03
;  PRIOR APPLICATION NUMBER: US 09/431,385
;  PRIOR FILING DATE: 1999-11-01
;  PRIOR APPLICATION NUMBER: US 60/186,046
;  PRIOR FILING DATE: 2000-03-01
;  PRIOR APPLICATION NUMBER: US 09/640,953
;  PRIOR FILING DATE: 2000-08-16
;  PRIOR APPLICATION NUMBER: US 09/724,959
;  PRIOR FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 09/796,988
;  PRIOR FILING DATE: 2001-02-28
;  NUMBER OF SEQ ID NOS: 90
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 64
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:probe sequence
US-10-032-307-64

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 38;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1520 CGGCAACGTGCTGG 1533
              |||| |||||||||
Db          1 CGGCTACGTGCTGG 14


RESULT 90
US-08-050-073-247
; Sequence 247, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  247:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-247

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2125 GGGCCGCAGTGGAC 2138
              ||||||| ||||||
Db          2 GGGCCGCGGTGGAC 15


RESULT 91
US-08-166-664-9/c
; Sequence 9, Application US/08166664
; Patent No. 5646020
;  GENERAL INFORMATION:
;    APPLICANT:  James A. McSwiggen
;    APPLICANT:  J. Anthony Mamone
;    TITLE OF INVENTION:  HAMMERHEAD RIBOZYMES FOR
;    TITLE OF INVENTION:  PREFERRED TARGETS
;    NUMBER OF SEQUENCES:  21
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/166,664
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/884,074
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/062
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
```

```
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  9:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-166-664-9

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
                || ||||||||||
Db         15 GACGAGGACGAGGA 2


RESULT 92
US-08-291-932A-201/c
; Sequence 201, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  201:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-201

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1764 GAAGATGAGGAGGA 1777
                ||||||||| |||
Db         14 GAAGATGAGGGGGA 1

RESULT 93
US-08-292-620A-324/c
; Sequence 324, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  324:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-324

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1122 GTCCTCCAAGACCT 1135
                ||||||||| ||||
Db         15 GTCCTCCAATACCT 2
```

```
RESULT 94
US-09-071-845-324/c
; Sequence 324, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  324:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-324

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1122 GTCCTCCAAGACCT 1135
              ||||||||| ||||
Db         15 GTCCTCCAATACCT 2


RESULT 95
US-09-081-646-33
; Sequence 33, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 33
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-33

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2022 CAGGGCCACCCCCT 2035
              || ||||||||||||
Db          1 CATGGCCACCCCCT 14


RESULT 96
US-09-081-646-391/c
; Sequence 391, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 391
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-391

  Query Match             0.5%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1997 GCGCCGCGTCCAGG 2010
              |||||||||||| |
Db         14 GCGCCGCGTCCATG 1


RESULT 97
US-08-687-551-10
; Sequence 10, Application US/08687551
; Patent No. 5856435
;  GENERAL INFORMATION:
;    APPLICANT:  BAZILE, Didier
;    APPLICANT:  EMILE, Carole
;    APPLICANT:  HELENE, Claude
;    APPLICANT:  SPENLEHAUER, Gilles
;    TITLE OF INVENTION:  NUCLEIC ACID-CONTAINING COMPOSITION, ITS
;    TITLE OF INVENTION:  PREPARATION AND USE
;    NUMBER OF SEQUENCES:  16
```

```
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rhone-Poulenc Rorer Inc.
;      STREET:  500 Arcola Rd. 3C43
;      CITY:  Collegeville
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19426
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/687,551
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 94/01381
;      FILING DATE:  08-FEB-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/FR95/00098
;      FILING DATE:  27-JAN-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Smith Ph.D., Julie K.
;      REGISTRATION NUMBER:  38,619
;      REFERENCE/DOCKET NUMBER:  ST94007-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (610)454-3839
;      TELEFAX:  (610)454-3808
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "oligonucleotide"
US-08-687-551-10

  Query Match             0.5%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 36;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1791 GCGGCAGCCACA 1802
             ||||||||||||
Db          1 GCGGCAGCCACA 12


RESULT 98
US-08-291-932A-16/c
; Sequence 16, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-16

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 55;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1189 CCCAGAAGCCTG 1200
             ||||||||||||
Db         12 CCCAGAAGCCTG 1


RESULT 99
US-08-291-932A-249
; Sequence 249, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
```

```
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  208/157
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  249:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-291-932A-249

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   83.3%;  Pred. No. 55;
  Matches   10;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1741 GGGAGCTCAGTG 1752
             ||||||:|||:|
Db          1 GGGAGCUCAGUG 12


RESULT 100
US-08-585-684B-2053/c
; Sequence 2053, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2053:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2053

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 55;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1656 CTGCAGAGGCAG 1667
             ||||||||||||
Db         13 CTGCAGAGGCAG 2


RESULT 101
US-08-271-882B-30
; Sequence 30, Application US/08271882B
; Patent No. 6017696
;  GENERAL INFORMATION:
;    APPLICANT:  Michael J. Heller
;    APPLICANT:  Eugene Tu
;    APPLICANT:  Glen A. Evans
;    APPLICANT:  Ronald G. Sosnowski
;    TITLE OF INVENTION:  SELF-ADDRESSABLE
;    TITLE OF INVENTION:  SELF-ASSEMBLING
;    TITLE OF INVENTION:  MICROELECTRONIC SYSTEMS AND
;    TITLE OF INVENTION:  DEVICES FOR
;    TITLE OF INVENTION:  MOLECULAR BIOLOGICAL ANALYSIS
;    TITLE OF INVENTION:  AND DIAGNOSTICS
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/271,882B
;      FILING DATE:  July 7, 1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/146,504
;      FILING DATE:  No. 6017696ember 1, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murphy, David B.
;      REGISTRATION NUMBER:  31,125
;      REFERENCE/DOCKET NUMBER:  207/263
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic
;      TYPE:  acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-271-882B-30

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 55;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1791 GCGGCAGCCACA 1802
             ||||||||||||
Db          3 GCGGCAGCCACA 14
```

```
RESULT 102
US-09-038-073-2053/c
; Sequence 2053, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2053:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2053

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 55;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1656 CTGCAGAGGCAG 1667
              ||||||||||||
Db         13 CTGCAGAGGCAG 2


RESULT 103
US-09-275-850-21
; Sequence 21, Application US/09275850A
; Patent No. 6261774
; GENERAL INFORMATION:
;  APPLICANT:  Pagratis, Nikos
;  APPLICANT:  Gold, Larry
;  APPLICANT:  Shtatland, Timur
;  APPLICANT:  Javornik, Brenda
;  TITLE OF INVENTION:  Truncation SELEX Method
;  FILE REFERENCE:  NEX 79
;  CURRENT APPLICATION NUMBER: US/09/275,850A
;  CURRENT FILING DATE:  1999-03-24
;  NUMBER OF SEQ ID NOS:  351
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 21
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: E. coli
US-09-275-850-21

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   91.7%;  Pred. No. 55;
  Matches   11;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1255 TGCAGCAACAGC 1266
              :|||||||||||
Db          1 UGCAGCAACAGC 12


RESULT 104
US-09-705-267A-174/c
; Sequence 174, Application US/09705267A
; Patent No. 6551826
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RAIDD EXPRESSION
;  FILE REFERENCE: RTS-0211
;  CURRENT APPLICATION NUMBER: US/09/705,267A
;  CURRENT FILING DATE:  2000-11-01
;  NUMBER OF SEQ ID NOS: 177
; SEQ ID NO 174
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-705-267A-174

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 20;
  Best Local Similarity   86.7%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1228 TCCAGCATGTGCTGG 1242
              ||||||| ||||||
Db         20 TCCAGCACATGCTGG 6


RESULT 105
US-08-486-421-51/c
; Sequence 51, Application US/08486421
; Patent No. 5672479
;  GENERAL INFORMATION:
;    APPLICANT:  Johnson, Edward M.
;    APPLICANT:  Bergemann, Andrew D.
;    TITLE OF INVENTION:  CLONING AND EXPRESSION OF PUR PROTEIN
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,421
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/470,911
;      FILING DATE:  06-JUN-1995
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Coruzzi, Laura A.
;      REGISTRATION NUMBER:  30,742
;      REFERENCE/DOCKET NUMBER:  6923-053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  51:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-486-421-51

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 24;
  Best Local Similarity   69.6%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy        859 GCCTCTATCTCAACCTGGGCCTC 881
              |||||   |||  |||  |||||
Db         24 GCCTCCGCCTCCGCCTCCGCCTC 2


RESULT 106
US-08-470-911-51/c
; Sequence 51, Application US/08470911
; Patent No. 5756684
;  GENERAL INFORMATION:
;    APPLICANT:  Johnson, Edward M.
;    APPLICANT:  Bergemann, Andrew D.
;    TITLE OF INVENTION:  CLONING AND EXPRESSION OF PUR PROTEIN
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/470,911
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Coruzzi, Laura A.
;      REGISTRATION NUMBER:  30,742
;      REFERENCE/DOCKET NUMBER:  6923-053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  51:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-470-911-51

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 24;
  Best Local Similarity   69.6%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy        859 GCCTCTATCTCAACCTGGGCCTC 881
              |||||   |||  |||  |||||
Db         24 GCCTCCGCCTCCGCCTCCGCCTC 2


RESULT 107
US-08-486-809-51/c
; Sequence 51, Application US/08486809
; Patent No. 5869622
;  GENERAL INFORMATION:
;    APPLICANT:  Johnson, Edward M.
;    APPLICANT:  Bergemann, Andrew D.
;    TITLE OF INVENTION:  CLONING AND EXPRESSION OF PUR PROTEIN
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,809
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/470,911
;      FILING DATE:  06-JUN-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Coruzzi, Laura A.
;      REGISTRATION NUMBER:  30,742
;      REFERENCE/DOCKET NUMBER:  6923-053
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  51:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-486-809-51

  Query Match             0.5%;  Score 11.8;  DB 1;  Length 24;
  Best Local Similarity   69.6%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy        859 GCCTCTATCTCAACCTGGGCCTC 881
              |||||   |||  |||  |||||
Db         24 GCCTCCGCCTCCGCCTCCGCCTC 2


RESULT 108
US-09-156-979-46
; Sequence 46, Application US/09156979
; Patent No. 5962672
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RhoB EXPRESSION
;  FILE REFERENCE: RTS-0013
;  CURRENT APPLICATION NUMBER: US/09/156,979
;  CURRENT FILING DATE: 1998-09-18
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 46
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-156-979-46

  Query Match 0.5%; Score 11.6; DB 1; Length 18;
  Best Local Similarity 77.8%; Pred. No. 98;
  Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 2286 CAGCAGTGGGTGAAGCTG 2303
         ||||||| | || ||| |
Db 1 CAGCAGTTGATGCAGCCG 18

RESULT 109
US-09-387-341-107
; Sequence 107, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsert, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; CURRENT FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; EARLIER FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 107
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-09-387-341-107

  Query Match 0.5%; Score 11.6; DB 1; Length 18;
  Best Local Similarity 77.8%; Pred. No. 98;
  Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 2286 CAGCAGTGGGTGAAGCTG 2303
         ||||||| | || ||| |
Db - 1 CAGCAGTTGATGCAGCCG 18

RESULT 110
US-09-866-108A-7854
; Sequence 7854, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7854
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7854

  Query Match 0.4%; Score 11.2; DB 1; Length 17;
  Best Local Similarity 81.2%; Pred. No. 99;
  Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2275 TGGAGACGCTGCAGCA 2290
         |||||| ||| ||| |
Db 1 TGGAGATGCTACAGGA 16

Search completed: April 7, 2004, 16:15:35
Job time : 3 secs

OM nucleic - nucleic search, using sw model

Run on: April 7, 2004, 16:18:19 ; Search time 4 Seconds
(without alignments)
4.147 Million cell updates/sec

Title: us-09-993-731-10
Perfect score: 2525
Sequence: 1 ctctgggctgtgccgtggcc.....cgcattctctctcccacaga 2525

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 186 seqs, 3285 residues

Total number of hits satisfying chosen parameters: 372

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 175 summaries

Database : rnpbdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20.4	0.8	25	1	US-10-275-071-18	Sequence 18, Appl
c	2	20	0.8	20	1	US-09-993-731-36	Sequence 36, Appl
c	3	20	0.8	20	1	US-09-993-731-37	Sequence 37, Appl
c	4	20	0.8	20	1	US-09-993-731-38	Sequence 38, Appl
c	5	20	0.8	20	1	US-09-993-731-39	Sequence 39, Appl
c	6	20	0.8	20	1	US-09-993-731-40	Sequence 40, Appl
c	7	20	0.8	20	1	US-09-993-731-41	Sequence 41, Appl
c	8	20	0.8	20	1	US-09-993-731-42	Sequence 42, Appl
c	9	20	0.8	20	1	US-09-993-731-43	Sequence 43, Appl
c	10	20	0.8	20	1	US-09-993-731-44	Sequence 44, Appl
c	11	20	0.8	20	1	US-09-993-731-45	Sequence 45, Appl
c	12	20	0.8	20	1	US-09-993-731-46	Sequence 46, Appl
c	13	20	0.8	20	1	US-09-993-731-47	Sequence 47, Appl
c	14	20	0.8	20	1	US-09-993-731-48	Sequence 48, Appl
c	15	20	0.8	20	1	US-09-993-731-49	Sequence 49, Appl
c	16	20	0.8	20	1	US-09-993-731-50	Sequence 50, Appl
c	17	20	0.8	20	1	US-09-993-731-51	Sequence 51, Appl
c	18	20	0.8	20	1	US-09-993-731-52	Sequence 52, Appl
c	19	20	0.8	20	1	US-09-993-731-53	Sequence 53, Appl
c	20	20	0.8	20	1	US-09-993-731-54	Sequence 54, Appl
c	21	20	0.8	20	1	US-09-993-731-55	Sequence 55, Appl
c	22	20	0.8	20	1	US-09-993-731-56	Sequence 56, Appl
c	23	20	0.8	20	1	US-09-993-731-57	Sequence 57, Appl
c	24	20	0.8	20	1	US-09-993-731-58	Sequence 58, Appl
c	25	20	0.8	20	1	US-09-993-731-59	Sequence 59, Appl
c	26	20	0.8	20	1	US-09-993-731-60	Sequence 60, Appl
c	27	20	0.8	20	1	US-09-993-731-61	Sequence 61, Appl
c	28	20	0.8	20	1	US-09-993-731-62	Sequence 62, Appl
c	29	20	0.8	20	1	US-09-993-731-63	Sequence 63, Appl
c	30	20	0.8	20	1	US-09-993-731-64	Sequence 64, Appl
c	31	20	0.8	20	1	US-09-993-731-65	Sequence 65, Appl
c	32	20	0.8	20	1	US-09-993-731-66	Sequence 66, Appl
c	33	20	0.8	20	1	US-09-993-731-67	Sequence 67, Appl
c	34	20	0.8	20	1	US-09-993-731-68	Sequence 68, Appl
c	35	20	0.8	20	1	US-09-993-731-69	Sequence 69, Appl
c	36	20	0.8	20	1	US-09-993-731-70	Sequence 70, Appl
c	37	20	0.8	20	1	US-09-993-731-71	Sequence 71, Appl
c	38	20	0.8	20	1	US-09-993-731-72	Sequence 72, Appl
c	39	20	0.8	20	1	US-09-993-731-73	Sequence 73, Appl
c	40	20	0.8	20	1	US-09-993-731-74	Sequence 74, Appl
c	41	20	0.8	20	1	US-09-993-731-75	Sequence 75, Appl
c	42	20	0.8	20	1	US-09-993-731-76	Sequence 76, Appl
c	43	20	0.8	20	1	US-09-993-731-77	Sequence 77, Appl
c	44	20	0.8	20	1	US-09-993-731-78	Sequence 78, Appl
c	45	20	0.8	20	1	US-09-993-731-79	Sequence 79, Appl
c	46	20	0.8	20	1	US-09-993-731-80	Sequence 80, Appl
c	47	20	0.8	20	1	US-09-993-731-81	Sequence 81, Appl
c	48	20	0.8	20	1	US-09-993-731-82	Sequence 82, Appl
c	49	20	0.8	20	1	US-09-993-731-83	Sequence 83, Appl
c	50	20	0.8	20	1	US-09-993-731-84	Sequence 84, Appl
c	51	18.4	0.7	21	1	US-09-828-034-9	Sequence 9, Appli
	52	18.4	0.7	23	1	US-10-005-626A-70	Sequence 70, Appl
c	53	17.8	0.7	21	1	US-10-418-182-126	Sequence 126, App
c	54	17.4	0.7	20	1	US-10-181-846-153	Sequence 153, App
	55	17.4	0.7	20	1	US-10-032-585-4054	Sequence 4054, Ap
	56	17.4	0.7	20	1	US-10-388-329-9	Sequence 9, Appli
c	57	16.4	0.6	18	1	US-09-733-444-22	Sequence 22, Appl
c	58	16.4	0.6	18	1	US-10-279-454-22	Sequence 22, Appl
c	59	16.4	0.6	20	1	US-10-199-199-70	Sequence 70, Appl
	60	16.4	0.6	20	1	US-10-199-199-135	Sequence 135, App
c	61	16	0.6	20	1	US-10-181-846-155	Sequence 155, App
	62	15.4	0.6	17	1	US-09-866-108-929	Sequence 929, App
	63	15.4	0.6	17	1	US-09-866-108-8659	Sequence 8659, Ap
	64	15.4	0.6	17	1	US-09-780-533A-2359	Sequence 2359, Ap
	65	15.4	0.6	17	1	US-10-060-756A-171	Sequence 171, App
	66	15.4	0.6	18	1	US-09-969-373-3292	Sequence 3292, Ap
	67	14.8	0.6	18	1	US-10-314-405-44	Sequence 44, Appl
	68	14.8	0.6	18	1	US-10-253-967-39	Sequence 39, Appl
c	69	14.8	0.6	18	1	US-10-178-325-107	Sequence 107, App
	70	14.8	0.6	20	1	US-10-199-199-70	Sequence 70, Appl
c	71	14.8	0.6	20	1	US-10-199-199-135	Sequence 135, App
	72	14.4	0.6	17	1	US-09-866-108-928	Sequence 928, App
	73	14.4	0.6	17	1	US-09-866-108-930	Sequence 930, App
	74	14.4	0.6	17	1	US-09-866-108-2617	Sequence 2617, Ap
	75	14.4	0.6	17	1	US-09-866-108-2618	Sequence 2618, Ap
	76	14.4	0.6	17	1	US-09-866-108-6391	Sequence 6391, Ap
	77	14.4	0.6	17	1	US-09-866-108-6392	Sequence 6392, Ap
	78	14.4	0.6	17	1	US-09-866-108-8658	Sequence 8658, Ap
	79	14.4	0.6	17	1	US-09-866-108-8660	Sequence 8660, Ap
c	80	14.4	0.6	17	1	US-09-825-805-668	Sequence 668, App
	81	14.4	0.6	17	1	US-09-818-875-915	Sequence 915, App
c	82	14.4	0.6	17	1	US-09-818-875-916	Sequence 916, App
	83	14.4	0.6	17	1	US-09-818-875-923	Sequence 923, App
c	84	14.4	0.6	17	1	US-09-818-875-924	Sequence 924, App
	85	14.4	0.6	17	1	US-09-780-533A-2360	Sequence 2360, Ap
	86	14.4	0.6	17	1	US-09-780-533A-2364	Sequence 2364, Ap
	87	14.4	0.6	17	1	US-10-060-756A-170	Sequence 170, App
	88	14.4	0.6	17	1	US-10-060-756A-172	Sequence 172, App
c	89	14.4	0.6	17	1	US-10-163-552-338	Sequence 338, App
c	90	14.4	0.6	17	1	US-10-156-306-6015	Sequence 6015, Ap
	91	14.4	0.6	17	1	US-10-209-787-915	Sequence 915, App
c	92	14.4	0.6	17	1	US-10-209-787-916	Sequence 916, App
	93	14.4	0.6	17	1	US-10-209-787-923	Sequence 923, App
c	94	14.4	0.6	17	1	US-10-209-787-924	Sequence 924, App
	95	14.4	0.6	17	1	US-10-261-185-915	Sequence 915, App
c	96	14.4	0.6	17	1	US-10-261-185-916	Sequence 916, App
	97	14.4	0.6	17	1	US-10-261-185-923	Sequence 923, App
c	98	14.4	0.6	17	1	US-10-261-185-924	Sequence 924, App
c	99	14.4	0.6	18	1	US-09-969-373-2606	Sequence 2606, Ap
c	100	14.4	0.6	18	1	US-09-969-373-4139	Sequence 4139, Ap
c	101	14.4	0.6	18	1	US-09-969-373-4141	Sequence 4141, Ap
c	102	14.4	0.6	18	1	US-10-005-956-715	Sequence 715, App
c	103	14.4	0.6	18	1	US-10-005-956-779	Sequence 779, App
	104	14.4	0.6	20	1	US-09-993-731-62	Sequence 62, Appl
	105	14.2	0.6	20	1	US-09-993-731-82	Sequence 82, Appl
	106	14	0.6	17	1	US-09-866-108-2615	Sequence 2615, Ap

	107	14	0.6	17	1	US-09-866-108-2616 Sequence 2616, Ap
	108	14	0.6	17	1	US-09-780-533A-2096 Sequence 2096, Ap
	109	14	0.6	17	1	US-09-780-533A-2368 Sequence 2368, Ap
	110	14	0.6	17	1	US-09-780-533A-2369 Sequence 2369, Ap
	111	13.8	0.5	17	1	US-09-866-108-927 Sequence 927, App
	112	13.8	0.5	17	1	US-09-866-108-2593 Sequence 2593, Ap
c	113	13.8	0.5	17	1	US-09-866-108-6611 Sequence 6611, Ap
c	114	13.8	0.5	17	1	US-09-866-108-6612 Sequence 6612, Ap
c	115	13.8	0.5	17	1	US-09-866-108-7854 Sequence 7854, Ap
c	116	13.8	0.5	17	1	US-09-866-108-7855 Sequence 7855, Ap
	117	13.8	0.5	17	1	US-09-866-108-8082 Sequence 8082, Ap
	118	13.8	0.5	17	1	US-09-866-108-8648 Sequence 8648, Ap
c	119	13.8	0.5	17	1	US-09-866-108-10738 Sequence 10738, A
c	120	13.8	0.5	17	1	US-09-866-108-10740 Sequence 10740, A
	121	13.8	0.5	17	1	US-09-860-784-28 Sequence 28, Appl
c	122	13.8	0.5	17	1	US-09-864-785-1560 Sequence 1560, Ap
c	123	13.8	0.5	17	1	US-09-825-805-667 Sequence 667, App
	124	13.8	0.5	17	1	US-09-818-875-927 Sequence 927, App
c	125	13.8	0.5	17	1	US-09-818-875-928 Sequence 928, App
c	126	13.8	0.5	17	1	US-09-780-533A-899 Sequence 899, App
	127	13.8	0.5	17	1	US-09-780-533A-2358 Sequence 2358, Ap
	128	13.8	0.5	17	1	US-09-780-533A-2361 Sequence 2361, Ap
	129	13.8	0.5	17	1	US-09-780-533A-2362 Sequence 2362, Ap
	130	13.8	0.5	17	1	US-09-780-533A-2363 Sequence 2363, Ap
	131	13.8	0.5	17	1	US-09-780-533A-2462 Sequence 2462, Ap
	132	13.8	0.5	17	1	US-09-848-754A-2225 Sequence 2225, Ap
c	133	13.8	0.5	17	1	US-09-930-423-189 Sequence 189, App
c	134	13.8	0.5	17	1	US-09-930-423-795 Sequence 795, App
c	135	13.8	0.5	17	1	US-09-930-423-1533 Sequence 1533, Ap
c	136	13.8	0.5	17	1	US-09-740-332-244 Sequence 244, App
	137	13.8	0.5	17	1	US-09-740-332-1895 Sequence 1895, Ap
c	138	13.8	0.5	17	1	US-09-740-332-2660 Sequence 2660, Ap
	139	13.8	0.5	17	1	US-09-740-332-4311 Sequence 4311, Ap
c	140	13.8	0.5	17	1	US-09-745-237A-189 Sequence 189, App
c	141	13.8	0.5	17	1	US-09-745-237A-795 Sequence 795, App
c	142	13.8	0.5	17	1	US-09-745-237A-1533 Sequence 1533, Ap
c	143	13.8	0.5	17	1	US-09-817-879-244 Sequence 244, App
	144	13.8	0.5	17	1	US-09-817-879-1895 Sequence 1895, Ap
c	145	13.8	0.5	17	1	US-09-817-879-2660 Sequence 2660, Ap
	146	13.8	0.5	17	1	US-09-817-879-4311 Sequence 4311, Ap
c	147	13.8	0.5	17	1	US-10-060-756A-358 Sequence 358, App
c	148	13.8	0.5	17	1	US-10-163-552-337 Sequence 337, App
	149	13.8	0.5	17	1	US-10-156-306-5905 Sequence 5905, Ap
	150	13.8	0.5	17	1	US-10-156-306-5922 Sequence 5922, Ap
c	151	13.8	0.5	17	1	US-10-238-700-3391 Sequence 3391, Ap
c	152	13.8	0.5	17	1	US-10-230-006-721 Sequence 721, App
	153	13.8	0.5	17	1	US-10-209-787-927 Sequence 927, App
c	154	13.8	0.5	17	1	US-10-209-787-928 Sequence 928, App
	155	13.8	0.5	17	1	US-10-261-185-927 Sequence 927, App
c	156	13.8	0.5	17	1	US-10-261-185-928 Sequence 928, App
	157	13.8	0.5	20	1	US-09-993-731-72 Sequence 72, Appl
	158	13.4	0.5	15	1	US-09-880-313A-235 Sequence 235, App
c	159	13.4	0.5	15	1	US-10-056-414-33 Sequence 33, Appl
c	160	13.4	0.5	15	1	US-10-163-552-1980 Sequence 1980, Ap
	161	13.4	0.5	15	1	US-10-314-405-43 Sequence 43, Appl
	162	13.4	0.5	15	1	US-10-156-306-7867 Sequence 7867, Ap
c	163	13.4	0.5	15	1	US-10-156-306-7883 Sequence 7883, Ap
	164	13.4	0.5	15	1	US-10-428-826-171 Sequence 171, App
c	165	13	0.5	15	1	US-10-043-875-406 Sequence 406, App
	166	13	0.5	15	1	US-10-108-732-58 Sequence 58, Appl
c	167	13	0.5	16	1	US-10-043-875-407 Sequence 407, App
	168	12.8	0.5	16	1	US-09-999-031A-3 Sequence 3, Appli
	169	12.8	0.5	16	1	US-10-150-510-3 Sequence 3, Appli
	170	12.8	0.5	16	1	US-10-308-503-110 Sequence 110, App
c	171	12.8	0.5	17	1	US-09-866-108-8648 Sequence 8648, Ap
	172	12.8	0.5	20	1	US-09-993-731-61 Sequence 61, Appl
	173	12.6	0.5	20	1	US-09-993-731-63 Sequence 63, Appl
	174	12.6	0.5	20	1	US-09-993-731-74 Sequence 74, Appl
	175	12.6	0.5	20	1	US-09-993-731-77 Sequence 77, Appl

ALIGNMENTS

RESULT 1
US-10-275-071-18/c
; Sequence 18, Application US/10275071
; Publication No. US20030186268A1
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; TITLE OF INVENTION: IMMOBILIZED OLIGONUCLEOTIDE
; FILE REFERENCE: 08888.0138-02
; CURRENT APPLICATION NUMBER: US/10/275,071
; CURRENT FILING DATE: 2003-04-07
; PRIOR APPLICATION NUMBER: 09/580,923
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; PRIOR FILING DATE: 1995-11-08
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide
US-10-275-071-18

Query Match 0.8%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 6.8;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1771 AGGAGGAGGAGGCGGAGGAGGC 1792
              |||||||||||| |||||||||
Db         25 AGGAGGAGGAGGAGGAGGAGGC 4
```

RESULT 2
US-09-993-731-36/c
; Sequence 36, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-36

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        840 CTGAATGAGATGAGGACCCG 859
              ||||||||||||||||||||
Db         20 CTGAATGAGATGAGGACCCG 1
```

RESULT 3
US-09-993-731-37/c

; Sequence 37, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-37

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 896 GCAGCAGACAGCCCTGTGCA 915
||||||||||||||||||||
Db 20 GCAGCAGACAGCCCTGTGCA 1

RESULT 4
US-09-993-731-38/c
; Sequence 38, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-38

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 909 CTGTGCAACGATTACTTCAG 928
||||||||||||||||||||
Db 20 CTGTGCAACGATTACTTCAG 1

RESULT 5
US-09-993-731-39/c
; Sequence 39, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-39

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 940 TCCTTGCGGAGCAGAACCAC 959
||||||||||||||||||||
Db 20 TCCTTGCGGAGCAGAACCAC 1

RESULT 6
US-09-993-731-40/c
; Sequence 40, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-40

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 947 GGAGCAGAACCACCTTTACG 966
||||||||||||||||||||
Db 20 GGAGCAGAACCACCTTTACG 1

RESULT 7
US-09-993-731-41/c
; Sequence 41, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-41

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 960 CTTTACGAGGACCTATTCCG 979
||||||||||||||||||||
Db 20 CTTTACGAGGACCTATTCCG 1

RESULT 8
US-09-993-731-42/c
; Sequence 42, Application US/09993731

```
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 42
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-42

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        981 GCCCGCTACAACCTGGGCAC 1000
              ||||||||||||||||||||
Db         20 GCCCGCTACAACCTGGGCAC 1


RESULT 9
US-09-993-731-43/c
; Sequence 43, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 43
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-43

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1023 CACTCCCAGGCTATGCGCTG 1042
              ||||||||||||||||||||
Db         20 CACTCCCAGGCTATGCGCTG 1


RESULT 10
US-09-993-731-44/c
; Sequence 44, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 44
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-44

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1035 ATGCGCTGCTTGGAGGGTGC 1054
              ||||||||||||||||||||
Db         20 ATGCGCTGCTTGGAGGGTGC 1


RESULT 11
US-09-993-731-45/c
; Sequence 45, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 45
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-45

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1061 GTGTGCGCACACCATGAGGA 1080
              ||||||||||||||||||||
Db         20 GTGTGCGCACACCATGAGGA 1


RESULT 12
US-09-993-731-46/c
; Sequence 46, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 46
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-46

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1072 CCATGAGGAAGCGGTTCATG 1091
              ||||||||||||||||||||
Db         20 CCATGAGGAAGCGGTTCATG 1


RESULT 13
US-09-993-731-47/c
; Sequence 47, Application US/09993731
; Publication No. US20030105040A1
```

; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-47

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1085 GTTCATGGAGAGCGAGTGCT 1104
||||||||||||||||||||
Db 20 GTTCATGGAGAGCGAGTGCT 1

RESULT 14
US-09-993-731-48/c
; Sequence 48, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-48

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1099 AGTGCTGCGTGGTTATTGCA 1118
||||||||||||||||||||
Db 20 AGTGCTGCGTGGTTATTGCA 1

RESULT 15
US-09-993-731-49/c
; Sequence 49, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-49

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1112 TATTGCACAGGTCCTCCAAG 1131
||||||||||||||||||||
Db 20 TATTGCACAGGTCCTCCAAG 1

RESULT 16
US-09-993-731-50/c
; Sequence 50, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-50

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1182 CTGGGCTCCCAGAAGCCTGT 1201
||||||||||||||||||||
Db 20 CTGGGCTCCCAGAAGCCTGT 1

RESULT 17
US-09-993-731-51/c
; Sequence 51, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-51

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1194 AAGCCTGTGCAGAGGGCAGC 1213
||||||||||||||||||||
Db 20 AAGCCTGTGCAGAGGGCAGC 1

RESULT 18
US-09-993-731-52/c
; Sequence 52, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:

```
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 52
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-52

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1213 CCATCTGTCAGAACCTCCAG 1232
             ||||||||||||||||||||
Db         20 CCATCTGTCAGAACCTCCAG 1


RESULT 19
US-09-993-731-53/c
; Sequence 53, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 53
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-53

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1223 GAACCTCCAGCATGTGCTGG 1242
             ||||||||||||||||||||
Db         20 GAACCTCCAGCATGTGCTGG 1


RESULT 20
US-09-993-731-54/c
; Sequence 54, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 54
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-54

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1234 ATGTGCTGGCAGTGGTCCGG 1253
             ||||||||||||||||||||
Db         20 ATGTGCTGGCAGTGGTCCGG 1


RESULT 21
US-09-993-731-55/c
; Sequence 55, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-55

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1238 GCTGGCAGTGGTCCGGCTGC 1257
             ||||||||||||||||||||
Db         20 GCTGGCAGTGGTCCGGCTGC 1


RESULT 22
US-09-993-731-56/c
; Sequence 56, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 56
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-56

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AGCAACAGCTGGAAGAGGCT 1277
             ||||||||||||||||||||
Db         20 AGCAACAGCTGGAAGAGGCT 1


RESULT 23
US-09-993-731-57/c
; Sequence 57, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
```

; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-57

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1289 CCCTCAGGGTGCCATGGTCA 1308
||||||||||||||||||||
Db 20 CCCTCAGGGTGCCATGGTCA 1

RESULT 24
US-09-993-731-58/c
; Sequence 58, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-58

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1297 GTGCCATGGTCATCTGTGAG 1316
||||||||||||||||||||
Db 20 GTGCCATGGTCATCTGTGAG 1

RESULT 25
US-09-993-731-59/c
; Sequence 59, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-59

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1300 CCATGGTCATCTGTGAGCAG 1319
||||||||||||||||||||
Db 20 CCATGGTCATCTGTGAGCAG 1

RESULT 26
US-09-993-731-60/c
; Sequence 60, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-60

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1310 CTGTGAGCAGCTAGGGGACC 1329
||||||||||||||||||||
Db 20 CTGTGAGCAGCTAGGGGACC 1

RESULT 27
US-09-993-731-61/c
; Sequence 61, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-61

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1323 GGGGACCTCTTCTCCAAGGC 1342
||||||||||||||||||||
Db 20 GGGGACCTCTTCTCCAAGGC 1

RESULT 28
US-09-993-731-62/c
; Sequence 62, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt

```
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-62

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1328 CCTCTTCTCCAAGGCAGGAG 1347
             ||||||||||||||||||||
Db         20 CCTCTTCTCCAAGGCAGGAG 1


RESULT 29
US-09-993-731-63/c
; Sequence 63, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 63
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-63

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1342 CAGGAGACTTTCCCAGGGCA 1361
             ||||||||||||||||||||
Db         20 CAGGAGACTTTCCCAGGGCA 1


RESULT 30
US-09-993-731-64/c
; Sequence 64, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 64
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-64

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1347 GACTTTCCCAGGGCAGCTGA 1366
             ||||||||||||||||||||
Db         20 GACTTTCCCAGGGCAGCTGA 1


RESULT 31
US-09-993-731-65/c
; Sequence 65, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-65

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1373 CCAGAAGCAGCTGCGTTTTG 1392
             ||||||||||||||||||||
Db         20 CCAGAAGCAGCTGCGTTTTG 1


RESULT 32
US-09-993-731-66/c
; Sequence 66, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 66
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-66

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1392 GCTGAGCTGCTGGACAGACC 1411
             ||||||||||||||||||||
Db         20 GCTGAGCTGCTGGACAGACC 1


RESULT 33
US-09-993-731-67/c
; Sequence 67, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
```

; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-67

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1414 GTGCTGAGCGGGCCATCATC 1433
||||||||||||||||||||
Db 20 GTGCTGAGCGGGCCATCATC 1

RESULT 34
US-09-993-731-68/c
; Sequence 68, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-68

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 CATGAAGGACCACCATGGGG 1482
||||||||||||||||||||
Db 20 CATGAAGGACCACCATGGGG 1

RESULT 35
US-09-993-731-69/c
; Sequence 69, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-69

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1485 GTGCGCCACTATGAGGAGGA 1504
||||||||||||||||||||
Db 20 GTGCGCCACTATGAGGAGGA 1

RESULT 36
US-09-993-731-70/c
; Sequence 70, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-70

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1488 CGCCACTATGAGGAGGAACT 1507
||||||||||||||||||||
Db 20 CGCCACTATGAGGAGGAACT 1

RESULT 37
US-09-993-731-71/c
; Sequence 71, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-71

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1494 TATGAGGAGGAACTGAGGCT 1513
||||||||||||||||||||
Db 20 TATGAGGAGGAACTGAGGCT 1

RESULT 38
US-09-993-731-72/c
; Sequence 72, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302

```
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 72
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-72

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1526 CGTGCTGGAGGAGGCCAAGA 1545
             ||||||||||||||||||||
Db         20 CGTGCTGGAGGAGGCCAAGA 1


RESULT 39
US-09-993-731-73/c
; Sequence 73, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 73
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-73

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1530 CTGGAGGAGGCCAAGACCTG 1549
             ||||||||||||||||||||
Db         20 CTGGAGGAGGCCAAGACCTG 1


RESULT 40
US-09-993-731-74/c
; Sequence 74, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 74
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-74

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1532 GGAGGAGGCCAAGACCTGGC 1551
             ||||||||||||||||||||
Db         20 GGAGGAGGCCAAGACCTGGC 1


RESULT 41
US-09-993-731-75/c
; Sequence 75, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 75
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-75

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1583 CGATGCCTACGAGCTGCTGG 1602
             ||||||||||||||||||||
Db         20 CGATGCCTACGAGCTGCTGG 1


RESULT 42
US-09-993-731-76/c
; Sequence 76, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-76

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1621 CGCTCAGCTGTGCTCAGCAG 1640
             ||||||||||||||||||||
Db         20 CGCTCAGCTGTGCTCAGCAG 1


RESULT 43
US-09-993-731-77/c
; Sequence 77, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
```

; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-77

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1652 CCAGCTGCAGAGGCAGGTCT 1671
||||||||||||||||||||
Db 20 CCAGCTGCAGAGGCAGGTCT 1

RESULT 44
US-09-993-731-78/c
; Sequence 78, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-78

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1658 GCAGAGGCAGGTCTTGCAGC 1677
||||||||||||||||||||
Db 20 GCAGAGGCAGGTCTTGCAGC 1

RESULT 45
US-09-993-731-79/c
; Sequence 79, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-79

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1662 AGGCAGGTCTTGCAGCATCT 1681
||||||||||||||||||||
Db 20 AGGCAGGTCTTGCAGCATCT 1

RESULT 46
US-09-993-731-80/c
; Sequence 80, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-80

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1664 GCAGGTCTTGCAGCATCTCC 1683
||||||||||||||||||||
Db 20 GCAGGTCTTGCAGCATCTCC 1

RESULT 47
US-09-993-731-81/c
; Sequence 81, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-81

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1680 CTCCATACCGTGCAGCTGAG 1699
||||||||||||||||||||
Db 20 CTCCATACCGTGCAGCTGAG 1

RESULT 48
US-09-993-731-82/c
; Sequence 82, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13

```
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 82
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-82

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1690 TGCAGCTGAGGCTGCAGCCC 1709
              ||||||||||||||||||||
Db         20 TGCAGCTGAGGCTGCAGCCC 1


RESULT 49
US-09-993-731-83/c
; Sequence 83, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-83

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1730 AACCAGACTGCGGGAGCTCA 1749
              ||||||||||||||||||||
Db         20 AACCAGACTGCGGGAGCTCA 1


RESULT 50
US-09-993-731-84/c
; Sequence 84, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 84
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-84

  Query Match             0.8%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1842 TCAGAGAGCGAGGACGACAC 1861
              ||||||||||||||||||||
Db         20 TCAGAGAGCGAGGACGACAC 1


RESULT 51
US-09-828-034-9/c
; Sequence 9, Application US/09828034
; Patent No. US20020064771A1
; GENERAL INFORMATION:
;  APPLICANT: Zhong, Weidong
;  APPLICANT:  Hong, Zhi
;  APPLICANT:  Ferrari, Eric
;  TITLE OF INVENTION: HCV REPLICASE COMPLEXES
;  FILE REFERENCE: IN01165
;  CURRENT APPLICATION NUMBER: US/09/828,034
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: U.S. 60/195,852
;  PRIOR FILING DATE: 2000-04-06
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic RNA
US-09-828-034-9

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 11;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
              ||||||||||| ||||||||
Db         21 GGAGGAGGAGGAGGAGGAGG 2


RESULT 52
US-10-005-626A-70
; Sequence 70, Application US/10005626A
; Publication No. US20030119003A1
; GENERAL INFORMATION:
;  APPLICANT: GeneType A.G.
;  APPLICANT:  Michael, Simons J.
;  TITLE OF INVENTION: Intron Sequence Analysis Method for Detection of Adjacent and Rem
;  TITLE OF INVENTION:  Locus Alleles as Haplotypes
;  FILE REFERENCE: 21401-7002
;  CURRENT APPLICATION NUMBER: US/10/005,626A
;  CURRENT FILING DATE:  2001-12-03
;  PRIOR APPLICATION NUMBER: US 10/005,626
;  PRIOR FILING DATE: 2001-12-03
;  PRIOR APPLICATION NUMBER: US 09/070,497
;  PRIOR FILING DATE: 1998-04-30
;  PRIOR APPLICATION NUMBER: US 08/682,054
;  PRIOR FILING DATE: 1996-07-16
;  PRIOR APPLICATION NUMBER: US 07/949,652
;  PRIOR FILING DATE: 1992-09-23
;  PRIOR APPLICATION NUMBER: US 07/551,239
;  PRIOR FILING DATE: 1990-07-11
;  PRIOR APPLICATION NUMBER: US 07/465,863
;  PRIOR FILING DATE: 1990-01-16
;  PRIOR APPLICATION NUMBER: US 07/405,499
;  PRIOR FILING DATE: 1989-09-11
;  PRIOR APPLICATION NUMBER: US 07/398,217
;  PRIOR FILING DATE: 1989-08-25
;  NUMBER OF SEQ ID NOS: 78
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 70
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-005-626A-70

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 23;
```

Best Local Similarity 95.0%; Pred. No. 15;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1274 GGCTGAGGGCAGAGACCCTC 1293
              |||||||||||||||||| |||
Db          2 GGCTGAGGGCAGAGACTCTC 21
```

RESULT 53
US-10-418-182-126/c
; Sequence 126, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551.2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: 60/373,558
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 423
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 126
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-418-182-126

Query Match 0.7%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 15;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1771 AGGAGGAGGAGGCGGAGGAGG 1791
              ||||||||| || ||||||||
Db         21 AGGAGGAGGGGGAGGAGGAGG 1
```

RESULT 54
US-10-181-846-153/c
; Sequence 153, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTSP-0363
; CURRENT APPLICATION NUMBER: US/10/181,846
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-153

Query Match 0.7%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 16;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1769 TGAGGAGGAGGAGGCGGAG 1787
              |||||||||||||| ||||
Db         19 TGAGGAGGAGGAGGAGGAG 1
```

RESULT 55
US-10-032-585-4054
; Sequence 4054, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4054
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-4054

Query Match 0.7%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 16;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1772 GGAGGAGGAGGCGGAGGAG 1790
              |||||||||| |||||||
Db          2 GGAGGAGGAGGAGGAGGAG 20
```

RESULT 56
US-10-388-329-9
; Sequence 9, Application US/10388329
; Publication No. US20040002093A1
; GENERAL INFORMATION:
; APPLICANT: SHI, LIANG
; TITLE OF INVENTION: NUCLEIC ACID DETECTION METHOD
; FILE REFERENCE: 109845.191US2; TMRI-020US
; CURRENT APPLICATION NUMBER: US/10/388,329
; CURRENT FILING DATE: 2003-03-13
; PRIOR APPLICATION NUMBER: 60/364,230
; PRIOR FILING DATE: 2002-03-13
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-388-329-9

Query Match 0.7%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 16;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1772 GGAGGAGGAGGCGGAGGAG 1790
              |||||||||| |||||||
Db          1 GGAGGAGGAGGAGGAGGAG 19
```

RESULT 57
US-09-733-444-22/c
; Sequence 22, Application US/09733444
; Patent No. US20020150894A1
; GENERAL INFORMATION:
; APPLICANT: Batra, Surinder K.
; APPLICANT: Brandt, Randall E.
; APPLICANT: Ringel, J"erg
; APPLICANT: Faulmann, Grit
; APPLICANT: L"hr, Matthias
; APPLICANT: Varshney, Grish C.
; APPLICANT: University of Nebraska Board of Regents

```
;  TITLE OF INVENTION: Specific Mucin Expression as a Marker
;  TITLE OF INVENTION:  for Pancreatic Cancer
;  FILE REFERENCE: UNMC 63155
;  CURRENT APPLICATION NUMBER: US/09/733,444
;  CURRENT FILING DATE:  2000-12-08
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-733-444-22

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        894 CTGCAGCAGACAGCCCTG 911
              ||||||||| ||||||||
Db         18 CTGCAGCAGGCAGCCCTG 1


RESULT 58
US-10-279-454-22/c
; Sequence 22, Application US/10279454
; Publication No. US20030134343A1
; GENERAL INFORMATION:
;  APPLICANT: Batra, Surinder K.
;  APPLICANT:  Brandt, Randall E.
;  APPLICANT:  Ringel, J"erg
;  APPLICANT:  Faulmann, Grit
;  APPLICANT:  L"hr, Matthias
;  APPLICANT:  Varshney, Grish C.
;  APPLICANT:  University of Nebraska Board of Regents
;  TITLE OF INVENTION: Specific Mucin Expression as a Marker
;  TITLE OF INVENTION:  for Pancreatic Cancer
;  FILE REFERENCE: UNMC 63155
;  CURRENT APPLICATION NUMBER: US/10/279,454
;  CURRENT FILING DATE:  2002-10-24
;  PRIOR APPLICATION NUMBER: US/09/733,444
;  PRIOR FILING DATE: 2000-12-08
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-279-454-22

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        894 CTGCAGCAGACAGCCCTG 911
              ||||||||| ||||||||
Db         18 CTGCAGCAGGCAGCCCTG 1


RESULT 59
US-10-199-199-70/c
; Sequence 70, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
;  FILE REFERENCE: RTS-0375
;  CURRENT APPLICATION NUMBER: US/10/199,199
;  CURRENT FILING DATE:  2002-07-18
;  NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-199-70

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 27;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1251 CGGCTGCAGCAACAGCTG 1268
              |||||||||| ||||||
Db         19 CGGCTGCAGCAGCAGCTG 2


RESULT 60
US-10-199-199-135
; Sequence 135, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
;  FILE REFERENCE: RTS-0375
;  CURRENT APPLICATION NUMBER: US/10/199,199
;  CURRENT FILING DATE:  2002-07-18
;  NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 135
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-199-199-135

  Query Match             0.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 27;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1251 CGGCTGCAGCAACAGCTG 1268
              |||||||||| ||||||
Db          2 CGGCTGCAGCAGCAGCTG 19


RESULT 61
US-10-181-846-155/c
; Sequence 155, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
;  FILE REFERENCE: RTSP-0363
;  CURRENT APPLICATION NUMBER: US/10/181,846
;  CURRENT FILING DATE:  2002-07-17
;  PRIOR APPLICATION NUMBER: PCT/US01/01416
;  PRIOR FILING DATE: 2001-01-16
;  PRIOR APPLICATION NUMBER: 09/490,692
;  PRIOR FILING DATE: 2000-01-24
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 155
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-155

  Query Match             0.6%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1756 CTGAAGATGAAGATGA 1771
              ||||||||||||||||
Db         16 CTGAAGATGAAGATGA 1


RESULT 62
US-09-866-108-929
; Sequence 929, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 929
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-929

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 28;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1264 AGCTGGAAGAGGCTGAG 1280
              ||||| ||||||||||
Db          1 AGCTGAAAGAGGCTGAG 17


RESULT 63
US-09-866-108-8659
; Sequence 8659, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8659
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8659

  Query Match             0.6%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 28;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GCTGGAGGAGGCCAAGA 1545
              ||||||||| |||||||
Db          1 GCTGGAGGAAGCCAAGA 17


RESULT 64
US-09-780-533A-2359
; Sequence 2359, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
```

; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2359
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2359

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 28;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1764 GAAGATGAGGAGGAGGA 1780
||||| ||||||||||
Db 1 GAAGAAGAGGAGGAGGA 17

RESULT 65
US-10-060-756A-171
; Sequence 171, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 171
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-171

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 28;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2120 CCACGGGGCCGCAGTGG 2136
|||| ||||||||||||
Db 1 CCACCGGGCCGCAGTGG 17

RESULT 66
US-09-969-373-3292
; Sequence 3292, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3292
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3292

Query Match 0.6%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 33;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1764 GAAGATGAGGAGGAGGA 1780
||||| ||||||||||
Db 2 GAAGAAGAGGAGGAGGA 18

RESULT 67
US-10-314-405-44
; Sequence 44, Application US/10314405
; Publication No. US20030108940A1
; GENERAL INFORMATION:
; APPLICANT: Hidetoshi, Inoko
; APPLICANT: Gen, Tamiya
; APPLICANT: Yasunari, Matsuzaka
; TITLE OF INVENTION: NOVEL POLYMORPHIC MICROSATELLITE MARKERS IN THE HUMAN MHC CLASS I
; FILE REFERENCE: 06501-069001
; CURRENT APPLICATION NUMBER: US/10/314,405
; CURRENT FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: US/09/713,616
; PRIOR FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 44
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-314-405-44

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1770 GAGGAGGAGGAGGCGGAG 1787
|||||||| |||| ||||
Db 1 GAGGAGGAAGAGGAGGAG 18

RESULT 68
US-10-253-967-39
; Sequence 39, Application US/10253967
; Publication No. US20030165925A1
; GENERAL INFORMATION:
; APPLICANT: SAITO et al.
; TITLE OF INVENTION: DIAGNOSTIC PROBE DETECTION SYSTEM
; FILE REFERENCE: 27978/37504A
; CURRENT APPLICATION NUMBER: US/10/253,967
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: US 60/324,421
; PRIOR FILING DATE: 2001-09-24
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 39
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Probe, DQ33

US-10-253-967-39

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1045 TGGAGGGTGCCCGGGAGT 1062
              ||||||| ||||||| ||
Db          1 TGGAGGGGGCCCGGGCGT 18
```

RESULT 69
US-10-178-325-107/c
; Sequence 107, Application US/10178325
; Publication No. US20030199467A1
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsert, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/10/178,325
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/387,341
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 09/156,424
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,979
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,807
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/161,015
; PRIOR FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 107
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-10-178-325-107

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1251 CGGCTGCAGCAACAGCTG 1268
              |||||||| |||| ||||
Db         18 CGGCTGCATCAACTGCTG 1
```

RESULT 70
US-10-199-199-70
; Sequence 70, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsert
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0375
; CURRENT APPLICATION NUMBER: US/10/199,199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-199-70

Query Match 0.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1691 GCAGCTGAGGCTGCAGCC 1708
              ||||||| |||||||||
Db          1 GCAGCTGCTGCTGCAGCC 18
```

RESULT 71
US-10-199-199-135/c
; Sequence 135, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsert
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0375
; CURRENT APPLICATION NUMBER: US/10/199,199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-199-199-135

Query Match 0.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1691 GCAGCTGAGGCTGCAGCC 1708
              ||||||| |||||||||
Db         20 GCAGCTGCTGCTGCAGCC 3
```

RESULT 72
US-09-866-108-928
; Sequence 928, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-928

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGA 1279
||||| ||||||||||
Db 2 AGCTGAAAGAGGCTGA 17

RESULT 73
US-09-866-108-930
; Sequence 930, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 930
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-930

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1265 GCTGGAAGAGGCTGAG 1280
|||| ||||||||||
Db 1 GCTGAAAGAGGCTGAG 16

RESULT 74
US-09-866-108-2617
; Sequence 2617, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2617
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2617

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1840 TCTCAGAGAGCGAGGA 1855
              ||||||||||||||| |
Db          2 TCTCAGAGAGCGAGCA 17


RESULT 75
US-09-866-108-2618
; Sequence 2618, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2618
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2618

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAGGA 1855
              ||||||||||||||| |
Db          1 TCTCAGAGAGCGAGCA 16


RESULT 76
US-09-866-108-6391
; Sequence 6391, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6391
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-6391

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 GCCCCGTGCTTCCAGA 1617
              |||||||||| |||||
Db          2 GCCCCGTGCTCCCAGA 17


RESULT 77
US-09-866-108-6392
; Sequence 6392, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
```

```
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6392
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-6392

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 GCCCCGTGCTTCCAGA 1617
                ||||||||||  |||||
Db          1 GCCCCGTGCTCCCAGA 16


RESULT 78
US-09-866-108-8658
; Sequence 8658, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8658
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8658

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GCTGGAGGAGGCCAAG 1544
                ||||||||| ||||||
Db          2 GCTGGAGGAAGCCAAG 17


RESULT 79
US-09-866-108-8660
; Sequence 8660, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8660
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8660

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1530 CTGGAGGAGGCCAAGA 1545
              ||||||| |||||||
Db          1 CTGGAGGAAGCCAAGA 16


RESULT 80
US-09-825-805-668/c
; Sequence 668, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-F (400/009)
;  CURRENT APPLICATION NUMBER: US/09/825,805
;  CURRENT FILING DATE:  2001-09-27
;  PRIOR APPLICATION NUMBER: 09/578,223
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 09/476,387
;  PRIOR FILING DATE: 1999-12-30
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1558
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 668
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-825-805-668

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1266 CTGGAAGAGGCTGAGG 1281
              ||||||| |||||||
Db          17 CTGGAAGACGCTGAGG 2


RESULT 81
US-09-818-875-915
; Sequence 915, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 915
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-915

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
              | ||||||||||||||
Db          2 GGAGCAACAGCTGGAA 17


RESULT 82
US-09-818-875-916/c
; Sequence 916, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 916
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-916

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1256 GCAGCAACAGCTGGAA 1271
             |||||||||||||||
Db         16 GGAGCAACAGCTGGAA 1
```

RESULT 83
US-09-818-875-923
; Sequence 923, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 923
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-923

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1256 GCAGCAACAGCTGGAA 1271
             |||||||||||||||
Db          2 GGAGCAACAGCTGGAA 17
```

RESULT 84
US-09-818-875-924/c
; Sequence 924, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 924
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-924

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1256 GCAGCAACAGCTGGAA 1271
             |||||||||||||||
Db         16 GGAGCAACAGCTGGAA 1
```

RESULT 85
US-09-780-533A-2360
; Sequence 2360, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2360

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1765 AAGATGAGGAGGAGGA 1780
             |||| ||||||||||||
Db          1 AAGAAGAGGAGGAGGA 16
```

RESULT 86
US-09-780-533A-2364
; Sequence 2364, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2364
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2364

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1883 GGAGGAGGACGAGGAG 1898
             ||||||||| ||||||
Db          2 GGAGGAGGAAGAGGAG 17
```

```
RESULT 87
US-10-060-756A-170
; Sequence 170, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 170
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-170

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGCAGTG 2135
             |||| ||||||||||
Db          2 CCACCGGGCCGCAGTG 17


RESULT 88
US-10-060-756A-172
; Sequence 172, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 172
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-172

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2121 CACGGGGCCGCAGTGG 2136
             ||| ||||||||||||
Db          1 CACCGGGCCGCAGTGG 16


RESULT 89
US-10-163-552-338/c
; Sequence 338, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 338
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-163-552-338

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1266 CTGGAAGAGGCTGAGG 1281
             |||||||| |||||||
Db         17 CTGGAAGACGCTGAGG 2


RESULT 90
US-10-156-306-6015/c
; Sequence 6015, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6015
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-6015

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1017 GGCCAGCACTCCCAGG 1032
             || ||||||||||||||
Db         17 GGGCAGCACTCCCAGG 2
```

RESULT 91
US-10-209-787-915
; Sequence 915, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 915
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-915

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAA 1271
|||||||||||||||
Db 2 GGAGCAACAGCTGGAA 17

RESULT 92
US-10-209-787-916/c
; Sequence 916, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 916
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-916

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAA 1271
|||||||||||||||
Db 16 GGAGCAACAGCTGGAA 1

RESULT 93
US-10-209-787-923
; Sequence 923, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 923
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-923

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAA 1271
|||||||||||||||
Db 2 GGAGCAACAGCTGGAA 17

RESULT 94
US-10-209-787-924/c
; Sequence 924, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 924

```
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-924

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
             | ||||||||||||||
Db         16 GGAGCAACAGCTGGAA 1


RESULT 95
US-10-261-185-915
; Sequence 915, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 915
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-915

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
             | ||||||||||||||
Db          2 GGAGCAACAGCTGGAA 17


RESULT 96
US-10-261-185-916/c
; Sequence 916, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 916
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-916

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
             | ||||||||||||||
Db         16 GGAGCAACAGCTGGAA 1


RESULT 97
US-10-261-185-923
; Sequence 923, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 923
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-923

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
             | ||||||||||||||
Db          2 GGAGCAACAGCTGGAA 17


RESULT 98
US-10-261-185-924/c
; Sequence 924, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
```

```
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 924
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-924

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1256 GCAGCAACAGCTGGAA 1271
             | ||||||||||||||
Db         16 GGAGCAACAGCTGGAA 1


RESULT 99
US-09-969-373-2606/c
; Sequence 2606, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2606
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-2606

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 AAGATGAGGAGGAGGA 1780
             |||| ||||||||||||
Db         16 AAGAGGAGGAGGAGGA 1


RESULT 100
US-09-969-373-4139/c
; Sequence 4139, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 4139
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-4139

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1670 CTTGCAGCATCTCCAT 1685
             |||||||||||| ||||
Db         17 CTTGCAGCATCACCAT 2


RESULT 101
US-09-969-373-4141/c
; Sequence 4141, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 4141
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-4141

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1670 CTTGCAGCATCTCCAT 1685
             |||||||||||| ||||
Db         17 CTTGCAGCATCACCAT 2


RESULT 102
US-10-005-956-715/c
; Sequence 715, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
;  APPLICANT: Bristol-Myers Squibb Company
;  TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
;  FILE REFERENCE: D0053NP
;  CURRENT APPLICATION NUMBER: US/10/005,956
;  CURRENT FILING DATE:  2001-12-03
;  PRIOR APPLICATION NUMBER: 60/251,015
;  PRIOR FILING DATE: 2000-12-04
;  PRIOR APPLICATION NUMBER: 60/263,678
;  PRIOR FILING DATE: 2001-01-23
;  PRIOR APPLICATION NUMBER: 60/273,037
;  PRIOR FILING DATE: 2001-03-02
;  NUMBER OF SEQ ID NOS: 1579
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 715
```

```
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-005-956-715

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1800 ACAGCGGAGAGCGAAG 1815
              |||||||||||||||
Db         18 AGAGCGGAGAGCGAAG 3


RESULT 103
US-10-005-956-779/c
; Sequence 779, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
;  APPLICANT: Bristol-Myers Squibb Company
;  TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
;  FILE REFERENCE: D0053NP
;  CURRENT APPLICATION NUMBER: US/10/005,956
;  CURRENT FILING DATE:  2001-12-03
;  PRIOR APPLICATION NUMBER: 60/251,015
;  PRIOR FILING DATE: 2000-12-04
;  PRIOR APPLICATION NUMBER: 60/263,678
;  PRIOR FILING DATE: 2001-01-23
;  PRIOR APPLICATION NUMBER: 60/273,037
;  PRIOR FILING DATE: 2001-03-02
;  NUMBER OF SEQ ID NOS: 1579
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 779
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-005-956-779

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1800 ACAGCGGAGAGCGAAG 1815
              |||||||||||||||
Db         18 AGAGCGGAGAGCGAAG 3


RESULT 104
US-09-993-731-62
; Sequence 62, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-62

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        775 CTGCCTTTGAGAAGAG 790
              ||||||| ||||||||
Db          4 CTGCCTTGGAGAAGAG 19


RESULT 105
US-09-993-731-82
; Sequence 82, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 82
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-82

  Query Match             0.6%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 80;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1252 GGCTGCAGCAACAGCTGGA 1270
              |||||||||  |||||| |
Db          2 GGCTGCAGCCTCAGCTGCA 20


RESULT 106
US-09-866-108-2615
; Sequence 2615, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2615
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2615

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 56;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAG 1853
              ||||||||||||||
Db          4 TCTCAGAGAGCGAG 17


RESULT 107
US-09-866-108-2616
; Sequence 2616, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2616
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2616

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 56;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1840 TCTCAGAGAGCGAG 1853
              ||||||||||||||
Db          3 TCTCAGAGAGCGAG 16


RESULT 108
US-09-780-533A-2096
; Sequence 2096, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2096
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2096

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 56;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
              ||||||||||||||
Db          2 GAGGAGGACGAGGA 15


RESULT 109
US-09-780-533A-2368
; Sequence 2368, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2368
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2368

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 56;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1884 GAGGAGGACGAGGA 1897
             ||||||||||||||
Db          4 GAGGAGGACGAGGA 17


RESULT 110
US-09-780-533A-2369
; Sequence 2369, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2369
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2369

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 56;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1884 GAGGAGGACGAGGA 1897
             ||||||||||||||
Db          3 GAGGAGGACGAGGA 16


RESULT 111
US-09-866-108-927
; Sequence 927, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 927
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-927

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1262 ACAGCTGGAAGAGGCTG 1278
              | ||||| |||||||||
Db          1 AGAGCTGAAAGAGGCTG 17


RESULT 112
US-09-866-108-2593
; Sequence 2593, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
```

; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2593
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2593

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1293 CAGGGTGCCATGGTCAT 1309
||||||||||||| ||
Db 1 CAGGGTGCCATGGAGAT 17

RESULT 113
US-09-866-108-6611/c
; Sequence 6611, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6611
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6611

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1222 AGAACCTCCAGCATGTG 1238
||| ||||||| |||||
Db 17 AGAGCCTCCAGGATGTG 1

RESULT 114
US-09-866-108-6612/c
; Sequence 6612, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6612
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6612

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1221 CAGAACCTCCAGCATGT 1237
|||| ||||||| ||||
Db 17 CAGAGCCTCCAGGATGT 1

RESULT 115
US-09-866-108-7854/c

; Sequence 7854, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7854
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7854

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 GTCTTGCAGCATCTCCA 1684
||| || ||||||||||
Db 17 GTCCTGTAGCATCTCCA 1

RESULT 116
US-09-866-108-7855/c
; Sequence 7855, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7855
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7855

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1667 GGTCTTGCAGCATCTCC 1683
|||| || |||||||||
Db 17 GGTCCTGTAGCATCTCC 1

RESULT 117
US-09-866-108-8082
; Sequence 8082, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8082
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8082

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1492 ACTATGAGGAGGAACTG 1508
              || | ||||||||||||
Db          1 ACCAGGAGGAGGAACTG 17


RESULT 118
US-09-866-108-8648
; Sequence 8648, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8648
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8648

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1254 CTGCAGCAACAGCTGGA 1270
              ||||||| ||||||||
Db          1 CTGCAGCTGCAGCTGGA 17


RESULT 119
US-09-866-108-10738/c
; Sequence 10738, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10738
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10738

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1447 CCACCACACTGGGAGAC 1463
|| ||||||||||||| |
Db 17 CAACCACACTGGGAGCC 1

RESULT 120
US-09-866-108-10740/c
; Sequence 10740, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10740
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10740

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1445 GGCCACCACACTGGGAG 1461
| | ||||||||||||||
Db 17 GCCAACCACACTGGGAG 1

RESULT 121
US-09-860-784-28
; Sequence 28, Application US/09860784
; Patent No. US20020151512A1
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/860,784
; FILING DATE: 21-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE: 04-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-860-784-28

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1775 GGAGGAGGCGGAGGAGG 1791
|||||| || |||||||
Db 1 GGAGGATGCTGAGGAGG 17

RESULT 122
US-09-864-785-1560/c
; Sequence 1560, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken

; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1560
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1560

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1538 GGCCAAGACCTGGCTGA 1554
|||| || |||||||||
Db 17 GGCCGAGGCCTGGCTGA 1

RESULT 123
US-09-825-805-667/c
; Sequence 667, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 667
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-667

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1268 GGAAGAGGCTGAGGGCA 1284
|||||| ||||||| ||
Db 17 GGAAGACGCTGAGGTCA 1

RESULT 124
US-09-818-875-927
; Sequence 927, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 927
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-927

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGAG 1280
||||||||||| ||| |
Db 1 AGCTGGAAGAGTCTGGG 17

RESULT 125
US-09-818-875-928/c
; Sequence 928, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-928

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGAG 1280
||||||||||| ||| |
Db 17 AGCTGGAAGAGTCTGGG 1

RESULT 126
US-09-780-533A-899/c
; Sequence 899, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-899

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1772 GGAGGAGGAGGCGGAGG 1788
|| |||||||| |||||
Db 17 GGGGGAGGAGGGGGAGG 1

RESULT 127
US-09-780-533A-2358
; Sequence 2358, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2358
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2358

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1762 ATGAAGATGAGGAGGAG 1778
| ||||| |||||||||
Db 1 AGGAAGAAGAGGAGGAG 17

RESULT 128
US-09-780-533A-2361
; Sequence 2361, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2361
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2361

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1764 GAAGATGAGGAGGAGGA 1780
||||| |||||||| ||
Db 1 GAAGAGGAGGAGGAAGA 17

RESULT 129
US-09-780-533A-2362
; Sequence 2362, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2362

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1765 AAGATGAGGAGGAGGAG 1781
|||| |||||||| |||
Db 1 AAGAGGAGGAGGAAGAG 17

RESULT 130
US-09-780-533A-2363
; Sequence 2363, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)

```
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2363
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2363

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGA 1786
              ||||||||||| | |||
Db          1 GAGGAGGAGGAAGAGGA 17


RESULT 131
US-09-780-533A-2462
; Sequence 2462, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2462
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2462

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 62;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1759 AAGATGAAGATGAGGAG 1775
              ||||:||||| ||| ||
Db          1 AAGAUGAAGAAGAGAAG 17


RESULT 132
US-09-848-754A-2225
; Sequence 2225, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2225
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-2225

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 62;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1624 TCAGCTGTGCTCAGCAG 1640
              :|| |:|:|| ||||||
Db          1 UCAUCUGUGCCCAGCAG 17


RESULT 133
US-09-930-423-189/c
; Sequence 189, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 189
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-189

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 CACACCATGAGGAAGCG 1084
              ||||||||||| || |
Db         17 CACACCATGAGGCAGAG 1


RESULT 134
US-09-930-423-795/c
; Sequence 795, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 795
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-795

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1200 GTGCAGAGGGCAGCCAT 1216
              | ||||| |||||||||
Db         17 GCGCAGATGGCAGCCAT 1


RESULT 135
US-09-930-423-1533/c
; Sequence 1533, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1533
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-1533

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1700 GCTGCAGCCCCAGGAGG 1716
              || |||||||||| ||
Db         17 GCCGCAGCCCCAGGGGG 1


RESULT 136
US-09-740-332-244/c
; Sequence 244, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 244
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-244

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1873 CCCCGCAGCTGGAGGAG 1889
              ||| ||||| |||||||
Db         17 CCCAGCAGCGGGAGGAG 1


RESULT 137
US-09-740-332-1895
; Sequence 1895, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1895
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1895

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 62;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        881 CACCTTTGAGAGCCTGC 897
              ||||:::|| || |:||
Db          1 CACCUUUGACAGACUGC 17


RESULT 138
US-09-740-332-2660/c
; Sequence 2660, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2660
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2660

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        882 ACCTTTGAGAGCCTGCA 898
              |||||||| || |||||
Db         17 ACCTTTGACAGACTGCA 1


RESULT 139
US-09-740-332-4311
; Sequence 4311, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4311
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4311

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1872 ACCCCGCAGCTGGAGGA 1888
              |||| ||||| ||||||
Db          1 ACCCAGCAGCGGGAGGA 17


RESULT 140
US-09-745-237A-189/c
; Sequence 189, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 189
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-189

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 CACACCATGAGGAAGCG 1084
              ||||||||||||| || |
Db         17 CACACCATGAGGCAGAG 1


RESULT 141
US-09-745-237A-795/c
; Sequence 795, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 795
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-795

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1200 GTGCAGAGGGCAGCCAT 1216
              | ||||| |||||||||
Db         17 GCGCAGATGGCAGCCAT 1


RESULT 142
US-09-745-237A-1533/c
; Sequence 1533, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1533
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-1533

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1700 GCTGCAGCCCCAGGAGG 1716
              || |||||||||||  ||
Db         17 GCCGCAGCCCCAGGGGG 1


RESULT 143
US-09-817-879-244/c
; Sequence 244, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 244
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-244

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1873 CCCCGCAGCTGGAGGAG 1889
              ||| ||||| |||||||
Db         17 CCCAGCAGCGGGAGGAG 1


RESULT 144
US-09-817-879-1895
; Sequence 1895, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1895
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1895
```

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 62;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```
Qy        881 CACCTTTGAGAGCCTGC 897
              ||||:::|| || |:||
Db          1 CACCUUUGACAGACUGC 17
```

RESULT 145
US-09-817-879-2660/c
; Sequence 2660, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2660
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2660

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        882 ACCTTTGAGAGCCTGCA 898
              ||||||||  || |||||
Db         17 ACCTTTGACAGACTGCA 1
```

RESULT 146
US-09-817-879-4311
; Sequence 4311, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4311
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4311

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1872 ACCCCGCAGCTGGAGGA 1888
              |||| ||||| ||||||
Db          1 ACCCAGCAGCGGGAGGA 17
```

RESULT 147
US-10-060-756A-358/c
; Sequence 358, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 358
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-358

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1652 CCAGCTGCAGAGGCAGG 1668
              |||||| ||| ||||||
Db         17 CCAGCTCCAGCGGCAGG 1
```

RESULT 148
US-10-163-552-337/c
; Sequence 337, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 337
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-337

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1268 GGAAGAGGCTGAGGGCA 1284
              |||||| ||||||| ||
Db         17 GGAAGACGCTGAGGTCA 1
```

```
RESULT 149
US-10-156-306-5905
; Sequence 5905, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5905
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-156-306-5905

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 AGGAGGAGGCGGAGGAG 1790
              ||||||||||.|||.||
Db          1 AGGAGGAGGCCGAGCAG 17


RESULT 150
US-10-156-306-5922
; Sequence 5922, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5922
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-156-306-5922

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 62;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1254 CTGCAGCAACAGCTGGA 1270
              |:|||| | ||||:|||
Db          1 CUGCAGGAGCAGCUGGA 17


RESULT 151
US-10-238-700-3391/c
; Sequence 3391, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3391
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-238-700-3391

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2019 AGGCAGGGCCACCCCCT 2035
              |||||||||.|.|||||
Db         17 AGGCAGGGCAAGCCCCT 1


RESULT 152
US-10-230-006-721/c
; Sequence 721, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 721
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-230-006-721

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 62;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1985 CGAGGGCCAGCTGCGCC 2001
              |||||.|||||.|||||
Db         17 CGAGGACCAGCAGCGCC 1


RESULT 153
US-10-209-787-927
; Sequence 927, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
```

; SEQ ID NO 927
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-927

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGAG 1280
||||||||||| ||| |
Db 1 AGCTGGAAGAGTCTGGG 17

RESULT 154
US-10-209-787-928/c
; Sequence 928, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-928

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGAG 1280
||||||||||| ||| |
Db 17 AGCTGGAAGAGTCTGGG 1

RESULT 155
US-10-261-185-927
; Sequence 927, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: NaPro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 927
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-927

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGAG 1280
||||||||||| ||| |
Db 1 AGCTGGAAGAGTCTGGG 17

RESULT 156
US-10-261-185-928/c
; Sequence 928, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: NaPro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 928
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-928

Query Match 0.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGGAAGAGGCTGAG 1280
||||||||||| ||| |
Db 17 AGCTGGAAGAGTCTGGG 1

RESULT 157
US-09-993-731-72
; Sequence 72, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13

```
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 72
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-72

  Query Match             0.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         93 TGGCCTCGTCCAGCCCG 109
              ||||||| ||||||  ||
Db          4 TGGCCTCCTCCAGCACG 20


RESULT 158
US-09-880-313A-235
; Sequence 235, Application US/09880313A
; Publication No. US20030044791A1
; GENERAL INFORMATION:
;  APPLICANT: Flemington, Erik K
;  TITLE OF INVENTION: Adaptors and Methods of Use
;  FILE REFERENCE: 9397/1000
;  CURRENT APPLICATION NUMBER: US/09/880,313A
;  CURRENT FILING DATE:  2001-06-13
;  NUMBER OF SEQ ID NOS: 276
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 235
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-09-880-313A-235

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 52;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1247 GGTCCGGCTGCAGCA 1261
              | |||||||||||||
Db          1 GATCCGGCTGCAGCA 15


RESULT 159
US-10-056-414-33/c
; Sequence 33, Application US/10056414
; Publication No. US20030003469A1
;   GENERAL INFORMATION:
;        APPLICANT: Stinchcomb, Dan T.
;                   Draper, Kenneth G.
;                   McSwiggen, James
;        TITLE OF INVENTION: RIBOZYME TREATMENT OF
;                            DISEASES OR CONDITIONS
;                            RELATED TO LEVELS OF
;                            NF-KB
;        NUMBER OF SEQUENCES: 830
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Lyon & Lyon
;             STREET: 633 West Fifth Street
;                     Suite 4700
;             CITY: Los Angeles
;             STATE: California
;             COUNTRY: U.S.A.
;             ZIP: 90071-2066
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;                          storage
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: IBM P.C. DOS 5.0
;             SOFTWARE: Word Perfect 5.1
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/056,414
;             FILING DATE: 23-Jan-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/291,932A
;             FILING DATE: August 15, 1994
;             APPLICATION NUMBER: 08/245,466
;             FILING DATE: May 18, 1994
;             APPLICATION NUMBER: 07/987,132
;             FILING DATE: December 7, 1992
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Warburg, Richard J.
;             REGISTRATION NUMBER: 32,327
;             REFERENCE/DOCKET NUMBER: 208/157
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (213) 489-1600
;             TELEFAX: (213) 955-0440
;             TELEX: 67-3510
;   INFORMATION FOR SEQ ID NO: 33:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-056-414-33

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 52;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 GGCCGGCGAGGTGGA 1837
              |||||| ||||||||
Db         15 GGCCGGTGAGGTGGA 1


RESULT 160
US-10-163-552-1980/c
; Sequence 1980, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1980
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-163-552-1980

  Query Match             0.5%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 52;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1267 TGGAAGAGGCTGAGG 1281
              ||||||| |||||||
Db         15 TGGAAGACGCTGAGG 1


RESULT 161
US-10-314-405-43
; Sequence 43, Application US/10314405
; Publication No. US20030108940A1
; GENERAL INFORMATION:
;  APPLICANT: Hidetoshi, Inoko
```

; APPLICANT: Gen, Tamiya
; APPLICANT: Yasunari, Matsuzaka
; TITLE OF INVENTION: NOVEL POLYMORPHIC MICROSATELLITE MARKERS IN THE HUMAN MHC CLASS I
; FILE REFERENCE: 06501-069001
; CURRENT APPLICATION NUMBER: US/10/314,405
; CURRENT FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: US/09/713,616
; PRIOR FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-314-405-43

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1767 GATGAGGAGGAGGAG 1781
|| |||||||||||
Db 1 GAGGAGGAGGAGGAG 15

RESULT 162
US-10-156-306-7867
; Sequence 7867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7867
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7867

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 52;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1653 CAGCTGCAGAGGCAG 1667
||||:||||||| ||
Db 1 CAGCUGCAGAGGGAG 15

RESULT 163
US-10-156-306-7883/c
; Sequence 7883, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7883
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7883

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1018 GCCAGCACTCCCAGG 1032
| |||||||||||||
Db 15 GGCAGCACTCCCAGG 1

RESULT 164
US-10-428-826-171
; Sequence 171, Application US/10428826
; Publication No. US20030186225A1
; GENERAL INFORMATION:
; APPLICANT: PAUL DR, PREM S
; APPLICANT: ZHANG, YANJIN
; TITLE OF INVENTION: PROTEINS ENCODED BY POLYNUCLEIC ACIDS OF PORCINE
; TITLE OF INVENTION: REPRODUCTIVE AND REPIRATORY SYNDROME VIRUS (PPRSV)
; FILE REFERENCE: 8199-0005-55XCIP WO
; CURRENT APPLICATION NUMBER: US/10/428,826
; CURRENT FILING DATE: 2003-05-05
; PRIOR APPLICATION NUMBER: US/09/601,326
; PRIOR FILING DATE: 2000-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/02630
; PRIOR FILING DATE: 1999-04-19
; PRIOR APPLICATION NUMBER: US 09/019,793
; PRIOR FILING DATE: 1998-02-06
; PRIOR APPLICATION NUMBER: US 08/478,316
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: US 08/301,435
; PRIOR FILING DATE: 1994-09-01
; PRIOR APPLICATION NUMBER: US 08/131,625
; PRIOR FILING DATE: 1993-10-05
; PRIOR APPLICATION NUMBER: US 07/969,071
; PRIOR FILING DATE: 1992-10-30
; NUMBER OF SEQ ID NOS: 175
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 171
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-10-428-826-171

Query Match 0.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 52;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2027 CCACCCCCTTAACCC 2041
||||||||||||| ||
Db 1 CCACCCCCTTAAACC 15

RESULT 165
US-10-043-875-406/c
; Sequence 406, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; TITLE OF INVENTION: Transcriptase Gene
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11

```
;  NUMBER OF SEQ ID NOS: 884
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 406
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Human immunodeficiency virus
US-10-043-875-406

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1426 CCATCATCCACGT 1438
              |||||||||||||
Db         15 CCATCATCCACGT 3


RESULT 166
US-10-108-732-58
; Sequence 58, Application US/10108732
; Publication No. US20030175721A1
; GENERAL INFORMATION:
;  APPLICANT: Box, Neil F
;  APPLICANT:  Duffy, David L
;  APPLICANT:  Hayward, Nicholas K
;  APPLICANT:  Martin, Nicholas G
;  APPLICANT:  Sturm, Richard A
;  APPLICANT:  Gruis, Nelleke A
;  APPLICANT:  Van Der Velden, Pieter
;  APPLICANT:  Bergman, Wilma
;  APPLICANT:  Frants, Rune R
;  TITLE OF INVENTION: MELANOMA RISK DETECTION
;  FILE REFERENCE: 8795-27U1
;  CURRENT APPLICATION NUMBER: US/10/108,732
;  CURRENT FILING DATE:  2002-03-28
;  PRIOR APPLICATION NUMBER: US 60/279,515
;  PRIOR FILING DATE: 2001-03-28
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 58
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: V92M Val probe
US-10-108-732-58

  Query Match             0.5%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 64;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1522 GCAACGTGCTGGA 1534
              |||||||||||||
Db          3 GCAACGTGCTGGA 15


RESULT 167
US-10-043-875-407/c
; Sequence 407, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
;  APPLICANT: De Smet, Koenraad
;  APPLICANT:  Stuyver, Lieven
;  TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
;  TITLE OF INVENTION:  Transcriptase Gene
;  FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
;  CURRENT APPLICATION NUMBER: US/10/043,875
;  CURRENT FILING DATE:  2002-04-03
;  PRIOR APPLICATION NUMBER: 60/286,102
;  PRIOR FILING DATE: 2001-04-24
;  PRIOR APPLICATION NUMBER: EP 01870085.6
;  PRIOR FILING DATE: 2001-04-20
;  PRIOR APPLICATION NUMBER: EP 01870005.4
;  PRIOR FILING DATE: 2001-01-11
;  NUMBER OF SEQ ID NOS: 884
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 407
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Human immunodeficiency virus
US-10-043-875-407

  Query Match             0.5%;  Score 13;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1426 CCATCATCCACGT 1438
              |||||||||||||
Db         16 CCATCATCCACGT 4


RESULT 168
US-09-999-031A-3
; Sequence 3, Application US/09999031A
; Patent No. US20020164608A1
; GENERAL INFORMATION:
;  APPLICANT: Garchon, Henri-Jean
;  TITLE OF INVENTION: DIAGNOSIS OF GLAUCOMA
;  FILE REFERENCE: 2702.1001-004
;  CURRENT APPLICATION NUMBER: US/09/999,031A
;  CURRENT FILING DATE:  2002-04-11
;  PRIOR APPLICATION NUMBER: PCT/US00/12179
;  PRIOR FILING DATE: 2000-05-04
;  PRIOR APPLICATION NUMBER: 60/133,224
;  PRIOR FILING DATE: 1999-05-07
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_binding
;   LOCATION: (1)...(16)
;   OTHER INFORMATION: Oligonucleotide
US-09-999-031A-3

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1116 GCACAGGTCCTCCAAG 1131
              ||||| |||||||| |
Db          1 GCACACGTCCTCCATG 16


RESULT 169
US-10-150-510-3
; Sequence 3, Application US/10150510
; Publication No. US20030068632A1
; GENERAL INFORMATION:
;  APPLICANT: Garchon, Henri-Jean
;  TITLE OF INVENTION: DIAGNOSIS OF GLAUCOMA
;  FILE REFERENCE: 2702.1001-011
;  CURRENT APPLICATION NUMBER: US/10/150,510
;  CURRENT FILING DATE:  2002-08-23
;  PRIOR APPLICATION NUMBER: 09/999,031
;  PRIOR FILING DATE: 2001-11-01
;  PRIOR APPLICATION NUMBER: PCT/US00/12179
;  PRIOR FILING DATE: 2000-05-04
;  PRIOR APPLICATION NUMBER: 60/133,224
;  PRIOR FILING DATE: 1999-05-07
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 16
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_binding
;   LOCATION: (1)...(16)
;   OTHER INFORMATION: Oligonucleotide
US-10-150-510-3

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1116 GCACAGGTCCTCCAAG 1131
                ||||| |||||||| |
Db          1 GCACACGTCCTCCATG 16


RESULT 170
US-10-308-503-110
; Sequence 110, Application US/10308503
; Publication No. US20030191080A1
; GENERAL INFORMATION:
;  APPLICANT: PHILLIPS, M. IAN
;  APPLICANT:  ZHANG, YUAN
;  TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
;  TITLE OF INVENTION:  METHODS OF USE
;  FILE REFERENCE: 4300.013900
;  CURRENT APPLICATION NUMBER: US/10/308,503
;  CURRENT FILING DATE:  2003-12-03
;  PRIOR APPLICATION NUMBER: US/09/614,034
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 09/152,717
;  PRIOR FILING DATE: 1998-09-14
;  PRIOR APPLICATION NUMBER: PCT/US99/21007
;  PRIOR FILING DATE: 1999-09-14
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 110
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-10-308-503-110

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1649 TGCCCAGCTGCAGAGG 1664
                |||| |||||| ||||
Db          1 TGCCGAGCTGCGGAGG 16


RESULT 171
US-09-866-108-8648/c
; Sequence 8648, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8648
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8648

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 99;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1652 CCAGCTGCAGAGGCAG 1667
                ||||||||||  ||||
Db         16 CCAGCTGCAGCTGCAG 1


RESULT 172
US-09-993-731-61
; Sequence 61, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-61

  Query Match             0.5%;  Score 12.8;  DB 1;  Length 20;
  Best Local Similarity   87.5%;  Pred. No. 1.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        777 GCCTTTGAGAAGAGCT 792
                ||||| |||||||| |
Db          1 GCCTTGGAGAAGAGGT 16
```

```
RESULT 173
US-09-993-731-63
; Sequence 63, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 63
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-63

  Query Match             0.5%;  Score 12.6;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        212 GCCCCGGGCCAGTCTCCGG 230
              |||| |||  ||||||| |
Db          2 GCCCTGGGAAAGTCTCCTG 20


RESULT 174
US-09-993-731-74
; Sequence 74, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 74
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-74

  Query Match             0.5%;  Score 12.6;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        498 GTCTGGCCTTGGCCTGCTC 516
              | | || |||||||| |||
Db          1 GCCAGGTCTTGGCCTCCTC 19


RESULT 175
US-09-993-731-77
; Sequence 77, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
;  FILE REFERENCE: RTS-0302
;  CURRENT APPLICATION NUMBER: US/09/993,731
;  CURRENT FILING DATE:  2001-11-13
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-77

  Query Match             0.5%;  Score 12.6;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1866 GGCCTGACCCCGCAGCTGG 1884
              | |||| | | ||||||||
Db          2 GACCTGCCTCTGCAGCTGG 20


Search completed: April  7, 2004, 16:18:25
Job time : 5 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 7, 2004, 16:19:56 ; Search time 1 Seconds
(without alignments)
0.798 Million cell updates/sec

Title: us-09-993-731-10
Perfect score: 2525
Sequence: 1 ctctgggctgtgccgtggcc.....cgcattctctctcccacaga 2525

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 9 seqs, 158 residues

Total number of hits satisfying chosen parameters: 18

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 18 summaries

Database : rstdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		21.8	0.9	27	1	AZ345323	ACCESSION:AZ345323
2		18.4	0.7	21	1	AZ321746	ACCESSION:AZ321746
3	c	18.4	0.7	23	1	AZ610186	ACCESSION:AZ610186
4		17.4	0.7	19	1	AZ775540	ACCESSION:AZ775540
5	c	14.4	0.6	16	1	AI564678	ACCESSION:AI564678
6	c	11.6	0.5	27	1	AZ345323	ACCESSION:AZ345323
7		11.4	0.5	13	1	CF306647	ACCESSION:CF306647
8	c	11.4	0.5	14	1	BM400150	ACCESSION:BM400150
9		10.4	0.4	12	1	CF332055	ACCESSION:CF332055
10		10.4	0.4	13	1	BQ593629	ACCESSION:BQ593629
11		9.2	0.4	23	1	AZ610186	ACCESSION:AZ610186
12		8.8	0.3	14	1	BM400150	ACCESSION:BM400150
13		8.8	0.3	16	1	AI564678	ACCESSION:AI564678
14	c	8.8	0.3	21	1	AZ321746	ACCESSION:AZ321746
15	c	8.4	0.3	19	1	AZ775540	ACCESSION:AZ775540
16	c	8.2	0.3	13	1	CF306647	ACCESSION:CF306647
17	c	8.2	0.3	13	1	BQ593629	ACCESSION:BQ593629
18	c	7.8	0.3	12	1	CF332055	ACCESSION:CF332055

ALIGNMENTS

RESULT 1
AZ345323
LOCUS AZ345323 27 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0079M16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0079M16 R, genomic survey sequence.
ACCESSION AZ345323
VERSION AZ345323.1 GI:10424560
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 27)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0079 row: M column: 16
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 27.
FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0079M16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.9%; Score 21.8; DB 1; Length 27;
Best Local Similarity 92.0%; Pred. No. 0.64;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1767 GATGAGGAGGAGGAGGCGGAGGAGG 1791
             || |||||||||||| ||||||||
Db          2 GAGGAGGAGGAGGAGGAGGAGGAGG 26
```

RESULT 2
AZ321746
LOCUS AZ321746 21 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0042N20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0042N20 F, genomic survey sequence.
ACCESSION AZ321746
VERSION AZ321746.1 GI:10374795
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0042  row: N  column: 20
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0042N20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold,* T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 1.2;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1772 GGAGGAGGAGGCGGAGGAGG 1791
              |||||||||||  ||||||||
Db             1 GGAGGAGGAGGAGGAGGAGG 20


RESULT 3
AZ610186/c
LOCUS       AZ610186                 23 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0435A21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0435A21 F, genomic survey sequence.
ACCESSION   AZ610186
VERSION     AZ610186.1  GI:11732376
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0435  row: A  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0435A21"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             0.7%;  Score 18.4;  DB 1;  Length 23;
  Best Local Similarity   95.0%;  Pred. No. 1.5;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 GAGGAGGAGGAGGCGGAGGA 1789
              ||||||||||||| ||||||
Db         23 GAGGAGGAGGAGGAGGAGGA 4


RESULT 4
AZ775540
LOCUS       AZ775540                 19 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0008H15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0008H15 F, genomic survey sequence.
ACCESSION   AZ775540
VERSION     AZ775540.1  GI:12902183
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
```

```
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0008  row: H  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC2M0008H15"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             0.7%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 1.4;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 AGGAGGAGGAGGCGGAGGA 1789
              ||||||||||| ||||||
Db          1 AGGAGGAGGAGGAGGAGGA 19


RESULT 5
AI564678/c
LOCUS       AI564678                  16 bp    mRNA    linear   EST 14-MAY-1999
DEFINITION  tq78g03.x1 NCI_CGAP_Ut1 Homo sapiens cDNA clone IMAGE:2214964 3'
            similar to TR:Q15214 Q15214 SALIVARY PROLINE-RICH PROTEIN 1
            ;contains element MSR1 repetitive element ;, mRNA sequence.
ACCESSION   AI564678
VERSION     AI564678.1  GI:4523135
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
             cDNA Library Preparation: Life Technologies, Inc.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html

            Trace considered overall poor quality
            Insert Length: 1719   Std Error: 0.00
            Seq primer: -40UP from Gibco
            High quality sequence stop: 1
            POLYA=No.
FEATURES              Location/Qualifiers
     source           1. .16
                      /organism="Homo sapiens"
                      /mol_type="mRNA"
                      /db_xref="taxon:9606"
                      /clone="IMAGE:2214964"
                      /tissue_type="well-differentiated endometrial
                      adenocarcinoma, 7 pooled tumors"
                      /lab_host="DH10B"
                      /clone_lib="NCI_CGAP_Ut1"
                      /note="Organ: uterus; Vector: pCMV-SPORT6; Site_1: SalI;
                      Site_2: NotI; Cloned unidirectionally.  Primer: Oligo dT.
                      Average insert size 1.75 kb. Life Technologies catalog #:
                      11538-014"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 2.8;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1780 AGGCGGAGGAGGCGGC 1795
              ||||||||| ||||||
Db         16 AGGCGGAGGGGGCGGC 1


RESULT 6
AZ345323/c
LOCUS       AZ345323                  27 bp    DNA     linear   GSS 29-SEP-2000
DEFINITION  1M0079M16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0079M16 R, genomic survey sequence.
ACCESSION   AZ345323
VERSION     AZ345323.1  GI:10424560
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 27)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
```

Plate: 0079 row: M column: 16
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 27.

FEATURES Location/Qualifiers
source 1. .27
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0079M16"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 11.6; DB 1; Length 27;
Best Local Similarity 65.4%; Pred. No. 11;
Matches 17; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 856 CCCGCCTCTATCTCAACCTGGGCCTC 881
||| |||| ||| ||| ||||
Db 27 CCCTCCTCCTCCTCCTCCTCCTCC 2

RESULT 7
CF306647
LOCUS CF306647 13 bp mRNA linear EST 15-AUG-2003
DEFINITION HDA1--04-H13.g1 OsHDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDA1) Oryza sativa cDNA clone HDA1--04-H13, mRNA sequence.
ACCESSION CF306647
VERSION CF306647.1 GI:33678408
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 13)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES Location/Qualifiers
source 1. .13
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="HDA1--04-H13"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OsHDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDA1)"
/note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2: XhoI; Callus was treated with ABA(20um) for 1hour. cDNA was inserted into lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end with XhoI site. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 5;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2069 GCACGAGGCCTGC 2081
|||||||| ||||
Db 1 GCACGAGGGCTGC 13

RESULT 8
BM400150/c
LOCUS BM400150 14 bp mRNA linear EST 17-JAN-2002
DEFINITION 5009-0-68-B01.t.1 Chilcoat/Turkewitz cDNA (large fraction) Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION BM400150
VERSION BM400150.1 GI:18200203
KEYWORDS EST.
SOURCE Tetrahymena thermophila
ORGANISM Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea; Hymenostomatida; Tetrahymenina; Tetrahymena.
REFERENCE 1 (bases 1 to 14)
AUTHORS Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E., Frankel,J. and Klobutcher,L.
TITLE EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.

FEATURES Location/Qualifiers
source 1. .14
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/note="Vector: BlueScript2 SK+; Details on library preparation can be found in Chilcoat and Turkewitz (2001) Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 0.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 5.8;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1739 GCGGGAGCTCAGT 1751
||| |||||||||
Db 13 GCGTGAGCTCAGT 1

RESULT 9
CF332055
LOCUS CF332055 12 bp mRNA linear EST 18-AUG-2003
DEFINITION NACL--08-G14.g1 Rice callus plasmid cDNA library (NACL) Oryza sativa cDNA clone NACL--08-G14, mRNA sequence.

```
ACCESSION   CF332055
VERSION     CF332055.1  GI:33812331
KEYWORDS    EST.
SOURCE      Oryza sativa
  ORGANISM  Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Oryza sativa"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:4530"
                     /clone="NACL--08-G14"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.4%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 5.9;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1885 AGGAGGACGAGG 1896
              ||||| ||||||
Db          1 AGGAGCACGAGG 12


RESULT 10
BQ593629
LOCUS       BQ593629                 13 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012766-024-026-N02-SP6 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-026-N02 5-PRIME, mRNA sequence.
ACCESSION   BQ593629
VERSION     BQ593629.1  GI:26123212
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 13   Std Error: 0.00
            Plate: 26  row: N  column: 02
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:193221"
                     /db_xref="taxon:161934"
                     /clone="024-026-N02"
                     /tissue_type="developing root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-developing root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.4%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 6.9;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 CCACGGGGCCGC 2131
              ||||| ||||||
Db          2 CCACGCGGCCGC 13


RESULT 11
AZ610186
LOCUS       AZ610186                 23 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0435A21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0435A21 F, genomic survey sequence.
ACCESSION   AZ610186
VERSION     AZ610186.1  GI:11732376
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0435  row: A  column: 21
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
```

/clone="UUGC1M0435A21"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.4%; Score 9.2; DB 1; Length 23;
Best Local Similarity 63.6%; Pred. No. 13;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```
Qy       2102 TGTCCGCTTCCTGCTGGACCAC 2123
              |||| | |||| ||  || | |
Db          2 TTTCCTCCTCCTCCTCCTCCTC 23
```

RESULT 12
BM400150
LOCUS BM400150 14 bp mRNA linear EST 17-JAN-2002
DEFINITION 5009-0-68-B01.t.1 Chilcoat/Turkewitz cDNA (large fraction) Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION BM400150
VERSION BM400150.1 GI:18200203
KEYWORDS EST.
SOURCE Tetrahymena thermophila
ORGANISM Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea; Hymenostomatida; Tetrahymenina; Tetrahymena.
REFERENCE 1 (bases 1 to 14)
AUTHORS Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E., Frankel,J. and Klobutcher,L.
TITLE EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.
FEATURES Location/Qualifiers
source 1. .14
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/note="Vector: BlueScript2 SK+; Details on library preparation can be found in Chilcoat and Turkewitz (2001) Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 0.3%; Score 8.8; DB 1; Length 14;
Best Local Similarity 83.3%; Pred. No. 12;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        185 CTGACCTGACGC 196
              |||| || ||||
Db          2 CTGAGCTCACGC 13
```

RESULT 13
AI564678
LOCUS AI564678 16 bp mRNA linear EST 14-MAY-1999
DEFINITION tq78g03.x1 NCI_CGAP_Ut1 Homo sapiens cDNA clone IMAGE:2214964 3' similar to TR:Q15214 Q15214 SALIVARY PROLINE-RICH PROTEIN 1 ;contains element MSR1 repetitive element ;, mRNA sequence.
ACCESSION AI564678
VERSION AI564678.1 GI:4523135
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 16)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Insert Length: 1719 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 1
POLYA=No.
FEATURES Location/Qualifiers
source 1. .16
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2214964"
/tissue_type="well-differentiated endometrial adenocarcinoma, 7 pooled tumors"
/lab_host="DH10B"
/clone_lib="NCI_CGAP_Ut1"
/note="Organ: uterus; Vector: pCMV-SPORT6; Site_1: SalI; Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.75 kb. Life Technologies catalog #: 11538-014"

Query Match 0.3%; Score 8.8; DB 1; Length 16;
Best Local Similarity 83.3%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        712 GCCGCACCCACC 723
              ||||| ||| ||
Db          1 GCCGCCCCCTCC 12
```

RESULT 14
AZ321746/c
LOCUS AZ321746 21 bp DNA linear GSS 29-SEP-2000
DEFINITION 1M0042N20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0042N20 F, genomic survey sequence.
ACCESSION AZ321746
VERSION AZ321746.1 GI:10374795
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 21)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0042 row: N column: 20
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
FEATURES Location/Qualifiers
source 1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0042N20"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 8.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 14;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```
Qy       2104 TCCGCTTCCTGCTGGACCAC 2123
              ||| | |||| ||   || |
Db         21 TCCTCCTCCTCCTCCTCCTC 2
```

RESULT 15
AZ775540/c
LOCUS AZ775540 19 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0008H15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0008H15 F, genomic survey sequence.
ACCESSION AZ775540
VERSION AZ775540.1 GI:12902183
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 19)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0008 row: H column: 15
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 19.
FEATURES Location/Qualifiers
source 1. .19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0008H15"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.3%; Score 8.4; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 15;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```
Qy       2104 TCCGCTTCCTGCTGGACC 2121
              ||| | |||| ||   ||
Db         19 TCCTCCTCCTCCTCCTCC 2
```

RESULT 16
CF306647/c
LOCUS CF306647 13 bp mRNA linear EST 15-AUG-2003
DEFINITION HDA1--04-H13.g1 OsHDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDA1) Oryza sativa cDNA clone HDA1--04-H13, mRNA sequence.
ACCESSION CF306647
VERSION CF306647.1 GI:33678408
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

```
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .13
                      /organism="Oryza sativa"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:4530"
                      /clone="HDA1--04-H13"
                      /tissue_type="callus"
                      /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                      /lab_host="E.coli SOLR"
                      /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                      phage cDNA library I (HDA1)"
                      /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                      XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                      was inserted into lambda Uni-ZAP XR vector at 5' end with
                      EcoRI and 3' end with XhoI site. mRNA was derived from
                      rice Histone Deacetylase overexpression line."

  Query Match             0.3%;  Score 8.2;  DB 1;  Length 13;
  Best Local Similarity   76.9%;  Pred. No. 13;
  Matches   10;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 GCTGGCCCCGTGC 1610
              || | || |||||
Db         13 GCAGCCCTCGTGC 1


RESULT 17
BQ593629/c
LOCUS       BQ593629                 13 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012766-024-026-N02-SP6 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-026-N02 5-PRIME, mRNA sequence.
ACCESSION   BQ593629
VERSION     BQ593629.1  GI:26123212
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 13   Std Error: 0.00
            Plate: 26  row: N  column: 02
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES              Location/Qualifiers
     source           1. .13
                      /organism="Beta vulgaris"
                      /mol_type="mRNA"
                      /cultivar="KWS2320 (double haploid, monogerm breeding
                      line)"
                      /db_xref="GABI:193221"
                      /db_xref="taxon:161934"
                      /clone="024-026-N02"
                      /tissue_type="developing root"
                      /lab_host="EMDH10B"
                      /clone_lib="MPIZ-ADIS-024-developing root"
                      /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                      cDNA library from sugar beet, library provided by KWS
                      Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                      b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                      orientation:
                      SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                      Sequencing granted in the context of the GABI-Beet
                      project, local PI: Dr. Katharina Schneider, coordinator:
                      Prof. Christian Jung;  Sequence submission managed by
                      RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.3%;  Score 8.2;  DB 1;  Length 13;
  Best Local Similarity   76.9%;  Pred. No. 13;
  Matches   10;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2367 GCGGCTGCCTCGG 2379
              ||||| || | ||
Db         13 GCGGCCGCGTGGG 1


RESULT 18
CF332055/c
LOCUS       CF332055                 12 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--08-G14.g1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa cDNA clone NACL--08-G14, mRNA sequence.
ACCESSION   CF332055
VERSION     CF332055.1  GI:33812331
KEYWORDS    EST.
SOURCE      Oryza sativa
  ORGANISM  Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .12
                      /organism="Oryza sativa"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:4530"
                      /clone="NACL--08-G14"
                      /tissue_type="callus"
                      /dev_stage="proliferated callus on 2N6 media for 30 days"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice callus plasmid cDNA library (NACL)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             0.3%;  Score 7.8;  DB 1;  Length 12;
  Best Local Similarity   81.8%;  Pred. No. 13;
```

Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1603 CCCCGTGCTTC 1613
              || |||||| |
Db         12 CCTCGTGCTCC 2
```

Search completed: April 7, 2004, 16:19:57
Job time : 1 secs